Psychosocial Stress and Addison's Disease: A new approach to evaluate the relevance of endocrine stress responses for health and disease by Wolf, Jutta Manuela
  
PSYCHOSOCIAL STRESS AND ADDISON’S DISEASE 
 
A NEW APPROACH TO EVALUATE THE RELEVANCE OF 
ENDOCRINE STRESS RESPONSES FOR HEALTH AND DISEASE 
 
 
 
 
DISSERTATIONSSCHRIFT 
 
 
 
zur Erlangung des akademischen Grades 
 
Doctor rerum naturalium 
(Dr. rer nat.) 
 
 
 
 
vorgelegt 
 
der Fakultät Mathematik und Naturwissenschaften 
der Technischen Universität Dresden 
 
 
von 
 
 
Dipl. Psych. Wolf, Jutta Manuela 
 
geboren am 23.05.1974 in Waldshut-Tiengen 
 
 
 
 
Gutachter: Prof. Dr. C. Kirschbaum 
Prof. Dr. S. Bornstein 
Prof. Dr. O. T. Wolf 
 
 
 
Eingereicht am:  19.01.2006 
 
Tag der Verteidigung: 06.03.2006 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to Nic 
 
 
 
to my and Nic’s family 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I would like to thank Prof. Dr. C. Kirschbaum and Prof. Dr. O. T. Wolf. Without their ongoing 
support and their scientific advice during the conception and conduction of the experiments, 
this work would not have been possible. 
 
Thanks go to my coworkers in Düsseldorf and Dresden, especially to Serkan Het, Gudrun 
Ramlow, Stefanie Holdmann, and Marcel Piel for their assistance in data acquisition, and to 
Simone M. Kern, Denise Dörfel, Johannes Müller, Tilman Hensch, Sirko Rabe, and Anke 
Karl for being there at work and after work. 
 
I am very grateful to Gregory E. Miller and Edith Chen for comments on the English language 
in this thesis. 
 
Finally, I would like to thank Nicolas Rohleder for providing the emotional framework during 
completion of this thesis. Thank you for everything! 
  
 
CONTENTS I 
CONTENTS 
1 INTRODUCTION 1 
2 THEORETICAL BACKGROUND 3 
2.1 THE NEUROENDOCRINE STRESS RESPONSE 3 
2.1.1 STRESS CONCEPTS: HISTORICAL DEVELOPMENT 3 
2.1.1.1 Claude Bernard 4 
2.1.1.2 Walter Bradford Cannon 4 
2.1.1.3 Hans Selye 4 
2.1.1.4 John W. Mason 5 
2.1.1.5 Richard S. Lazarus 6 
2.1.1.6 Seymour Levine and Holger Ursin 7 
2.1.1.7 Summary 9 
2.1.2 CENTRAL AND PERIPHERAL STRESS SYSTEMS 9 
2.1.2.1 HPA Axis 9 
2.1.2.2 Sympathetic Nervous System 18 
2.1.3 ACTIVATION OF STRESS SYSTEMS 22 
2.1.3.1 Laboratory Stressors 22 
2.1.3.2 Real-Life Stressors 23 
2.1.3.3 Physical Exercise 23 
2.1.4 PROTECTIVE EFFECTS OF STRESS MEDIATORS 24 
2.1.4.1 Cardiovascular Effects 28 
2.1.4.2 Metabolic Effects 28 
2.1.4.3 Neurobiological Effects 30 
2.1.4.4 Effects on Immunity and Inflammation 32 
2.1.5 DAMAGING EFFECTS OF STRESS MEDIATORS 33 
2.1.6 SUMMARY 39 
2.2 ADDISON’S DISEASE 40 
2.2.1 DEFINITION 41 
2.2.2 PREVALENCE 42 
2.2.3 SIGNS, SYMPTOMS, DISEASE PROGRESSION 42 
2.2.4 LABORATORY ASSESSMENT OF PRIMARY ADRENAL INSUFFICIENCY 43 
2.2.4.1 Basal Hormone Measurements 43 
2.2.4.2 Pharmacological Stimulation tests 43 
2.2.4.3 Radiologic Evaluation 45 
2.2.4.4 Adrenal Autoantibody Tests 45 
2.2.5 TREATMENT 45 
2.2.6 ETIOLOGY OF ADDISON’S DISEASE 46 
2.2.6.1 Infectious Addison’s Disease 47 
2.2.6.2 Autoimmune Adrenalitis 48 
2.2.7 SUMMARY 64 
CONTENTS II 
2.3 PSYCHONEUROIMMUNOLOGY 66 
2.3.1 THE IMMUNE RESPONSE 67 
2.3.1.1 First Line of Defense 67 
2.3.1.2 Second Line of Defense: Innate immunity 68 
2.3.1.3 Third Line of Defense: Adaptive Immunity 73 
2.3.2 PSYCHONEUROIMMUNOLOGY: BRAIN – TO – IMMUNE SYSTEM COMMUNICATION 81 
2.3.3 ROLE OF STRESS MEDIATORS 85 
2.3.3.1 Effects of Glucocorticoids on Immune Functions 85 
2.3.3.2 Effects of Catecholamines on Immune Functions 91 
2.3.3.3 Immune System – to – Brain Communication 97 
2.3.4 MECHANISMS AND MODULATION OF HORMONE-TO-IMMUNE SYSTEM SIGNALING 97 
2.3.4.1 Mechanisms of Hormone-to-Immune System Signaling 97 
2.3.4.2 Modulation of Hormone-to-Immune System Signaling 104 
3 PROBLEM FORMULATIONS 110 
3.1 ADDISON’S DISEASE: A METHOD 111 
3.2 PROBLEM FORMULATIONS 112 
3.2.1 STUDY 1: BASAL ENDOCRINE STATE 112 
3.2.2 STUDY 2: STRESS EFFECTS IN ADDISON’S DISEASE 112 
3.2.2.1 Psychosocial Stress: Endocrine and Cardiovascular Response 112 
3.2.2.2 Psychosocial Stress: Immunological Consequences 113 
3.2.2.3 Psychoneuroimmunology: Mediative Role of NF-B 114 
4 RESULTS 115 
4.1 ADDISON’S DISEASE: BASAL ENDOCRINE STATE 115 
4.1.1 ABSTRACT 115 
4.1.2 INTRODUCTION 116 
4.1.3 METHODS 119 
4.1.3.1 Subjects 119 
4.1.3.2 Experimental Protocol 120 
4.1.3.3 Biochemical Analysis 120 
4.1.3.4 Statistical Analysis 120 
4.1.4 RESULTS 121 
4.1.4.1 Courses of Salivary Cortisol Levels 121 
4.1.4.2 Salivary Cortisol Levels: Etiology, Gender, and Time Interval 122 
4.1.4.3 Salivary Cortisol Levels: Glucocorticoid Replacement 122 
4.1.5 DISCUSSION 124 
4.2 ADDISON’S DISEASE: ENDOCRINOLOGICAL RESPONSE TO PSYCHOSOCIAL 
 STRESS 127 
4.2.1 ABSTRACT 127 
CONTENTS III 
4.2.2 INTRODUCTION 127 
4.2.2.1 Stress Response in Healthy Subjects 127 
4.2.2.2 Stress Response in Patients with Addison’s Disease 129 
4.2.2.3 Aim of the Study 131 
4.2.3 METHODS 131 
4.2.3.1 Subjects 131 
4.2.3.2 Experimental Protocol 132 
4.2.3.3 Fatigue Assessment 132 
4.2.3.4 Biochemical Analyses 133 
4.2.3.5 Statistical Analysis 133 
4.2.4 RESULTS 133 
4.2.4.1 Fatigue Assessment 133 
4.2.4.2 Baseline Differences 134 
4.2.4.3 Salivary Free Cortisol Stress Response 134 
4.2.4.4 Effects of Treatment on Salivary Free Cortisol Levels 135 
4.2.4.5 Catecholamine Stress Response 135 
4.2.4.6 Cardiovascular Stress Response 136 
4.2.5 DISCUSSION 137 
4.3 ADDISON’S DISEASE: PSYCHOSOCIAL STRESS AND IMMUNOLOGICAL 
 CONSEQUENCES 140 
4.3.1 ABSTRACT 140 
4.3.2 INTRODUCTION 141 
4.3.2.1 Aim of the Study 142 
4.3.3 METHODS 144 
4.3.3.1 Subjects 144 
4.3.3.2 Experimental Protocol 144 
4.3.3.3 Biochemical Analyses 145 
4.3.3.4 Statistical Analysis 146 
4.3.4 RESULTS 147 
4.3.4.1 Stress Effects in Healthy Subjects 147 
4.3.4.2 Baseline Differences (AD vs. HS) 148 
4.3.4.3 Stress-Induced Changes in Blood Cell Counts 149 
4.3.4.4 Stress-Induced Changes in LPS-Stimulated IL-6 Production and Glucocorticoid 
 Sensitivity of LPS-Stimulated IL-6 Production 150 
4.3.4.5 Stress-Induced Changes in PHA-Stimulated Cell Proliferation and Glucocorticoid 
 Sensitivity of PHA-Stimulated Cell Proliferation 153 
4.3.4.6 Summary of Results 154 
4.3.5 DISCUSSION 154 
4.3.5.1 Blood Cell Counts 155 
4.3.5.2 LPS-Stimulated IL-6 Production 156 
4.3.5.3 PHA-Stimulated Cell Proliferation 159 
4.3.5.4 Conclusion and Outlook 160 
4.4 ADDISON’S DISEASE: PSYCHONEUROIMMUNOLOGY AND THE MEDIATIVE 
 ROLE OF NF-B 162 
4.4.1 ABSTRACT 162 
CONTENTS IV 
4.4.2 INTRODUCTION 163 
4.4.2.1 NF-B is Central to Immune System Activation 163 
4.4.2.2 Glucocorticoid Effects are Mediated by Inhibition of NF-B Activity 164 
4.4.2.3 Catecholamines Interfere with NF-B Activity 166 
4.4.2.4 Aim of the Present Study 167 
4.4.3 METHODS 167 
4.4.3.1 Subjects 167 
4.4.3.2 Experimental Protocol 168 
4.4.3.3 Biochemical Analyses 169 
4.4.3.4 Statistical Analysis 170 
4.4.4 RESULTS 172 
4.4.4.1 Baseline Differences 172 
4.4.4.2 Salivary Free Cortisol Levels: Effects of Stress and Treatment 172 
4.4.4.3 Catecholamine Levels: Effects of Stress 172 
4.4.4.4 NF-B Binding Activity: Effects of Stress, Disease, and Treatment 173 
4.4.4.5 Endocrine Variables: Indices of Variation 174 
4.4.4.6 Regression Analyses: Predictors of NF-B Binding Activity Variations 175 
4.4.5 CONCLUSION 176 
5 SUMMARY, GENERAL DISCUSSION, AND OUTLOOK 179 
5.1 SUMMARY OF RESULTS 179 
5.1.1 INITIAL ENDOCRINOLOGICAL CONDITIONS IN ADDISON’S DISEASE 179 
5.1.2 EFFECTS OF ALTERED ENDOCRINE STRESS RESPONSES ON THE IMMUNE SYSTEM 181 
5.1.2.1 Blood Cell Counts 182 
5.1.2.2 LPS-Stimulated IL-6 Production and its Glucocorticoid Sensitivity 182 
5.1.2.3 PHA-Stimulated Cell Proliferation and its Glucocorticoid Sensitivity 183 
5.1.2.4 NF-B Activity 184 
5.2 GENERAL DISCUSSION 185 
5.2.1 INITIAL ENDOCRINOLOGICAL CONDITIONS 185 
5.2.1.1 Initial Basal Conditions 185 
5.2.1.2 Initial Stress-Related Conditions 187 
5.2.1.3 Summary 190 
5.2.2 EFFECTS OF ALTERED ENDOCRINE STRESS RESPONSES ON THE IMMUNE SYSTEM 191 
5.2.2.1 Baseline Differences 191 
5.2.2.2 Stress-Related Differences 192 
5.2.3 SUMMARY OF GENERAL DISCUSSION 195 
5.3 OUTLOOK 196 
6 REFERENCES 198 
 
 
FIGURE AND TABLE INDEX V 
FIGURE INDEX 
 
Fig. 2-1: Localization of the hypothalamus and the pituitary gland in the human brain (sagittal 
section). ................................................................................................................10 
Fig. 2.2: Hypothalamic nuclei (A: frontal section; B: sagittal section). ...................................11 
Fig. 2-3: Detailed view of the anterior pituitary gland and its regulation by hypothalamic 
neurons.................................................................................................................13 
Fig. 2-4: Localization of the adrenal glands (A; source: Carlyn Iverson) and anatomy of the 
adrenal cortex (B; modified from Gray, 1918)........................................................14 
Fig. 2-5: Preganglionic and postganglionic neurons of sympathetic and parasympathetic 
divisions of the autonomic nervous system and their targets.................................19 
Fig. 2-6: The stress response and development of allostatic load (taken from McEwen and 
Seeman, 1999). ....................................................................................................35 
Fig. 2-7: Characteristics of different forms of adrenal insufficiency, compared with a healthy 
HPA-axis (PAI: primary adrenal insufficiency; SAI: secondary adrenal insufficiency, 
caused at the level of the pituitary=SAI1, or at the level of the hypothalamus=SAI2).
.............................................................................................................................41 
Fig. 2-8: Steroid hormone synthesis pathways (scc: side chain cleavage; 17-OH: 17-alpha-
hydroxylase; 21-OH: 21-hydroxylase; 11-OH: 11-hydroxylase; 17-HDS: 17-beta-
hydroxysteroiddehydrogenase; aldo: aldosterone synthase; aro: aromatase), white 
on black: steroid synthesis limiting enzymes in Addison’s disease. .......................50 
Fig. 2-9: Schematic representation of chromosome 21 showing the map of the APS-1 region 
(APECED) and the structure of the AIRE gene with the main mutations associated 
with the presence of APS-1 (Betterle and Zanchetta, 2003). .................................60 
Fig. 2-10: Location and organization of the HLA complex on chromosome 6 (modified from 
Klein and Sato, 2000a). ........................................................................................62 
Fig. 2-11: Schematic view of the Th1-Th2 concept (Th: T-helper cell; APC: antigen 
presenting cell; CTL: cytotoxic T lymphocyte; M: macrophage; B: B-cell; Ab: 
antibody; modified from Mosmann and Sad, 1996). ..............................................79 
Fig. 2-12: Mechanism of monocyte activation by LPS (taken from Rohleder, 2003). NF-B is 
depicted in the most frequently occurring heterodimeric complex between the p50 
and p65 subunits. .................................................................................................99 
Fig. 2-13: Mechanisms of glucocorticoid inhibition of monocyte activation via IB- 
FIGURE AND TABLE INDEX VI 
upregulation and negative GR-NF-B interaction (modified from Rohleder, 2003).
...........................................................................................................................103 
Fig. 4-1: Means and standard errors (SE) of salivary cortisol levels at day1 and day2 (day2: 
patients were asked to skip dose2 (d2); dose1 and dose2 indicated by grey bars; 
d1 +1h: one hour after dose1, appr. 8a.m.; betw. 1+3: between sample 1 and 
sample 3, appr. 11a.m.; d2 +1min: immediately before dose2, appr. 2p.m.; d2 +1h, 
d2 +2h, and d2 +4h: one, two, and four hour after dose2, resp., appr. 3p.m., 4p.m. 
6p.m.) compared to normal values and standard errors (grey line with shaded area 
under the curve; timepoints: at awakening, awakening +30min, awakening +45min, 
awakening +60min, 11a.m., 3p.m., and 8p.m.; Wust et al., 2000; Westermann et 
al., 2004).............................................................................................................121 
Fig. 4-2: Salivary cortisol levels at day1 for groups hydrocortisone and cortisone (means and 
SE). ....................................................................................................................122 
Fig. 4-3: Salivary cortisol levels broken down by replacement doses (left side: mean cortisol 
levels and SE averaged for day1 and day2; please note that for the sake of clarity, 
no SE are shown; right side: mean cortisol levels and SE of day1). ....................123 
Fig. 4-4: General and physical fatigue (means and standard errors (SE)) in patients with 
Addison’s disease (AD, n=30) and healthy subjects (HS, n=17), measured by the 
Multidimensional Fatigue Inventory. ....................................................................134 
Fig. 4-5: Effects of TSST, group (AD vs. HS) and treatment (HC vs. NaCl) on salivary free 
cortisol levels (mean, SE). ..................................................................................134 
Fig. 4-6: Group differences in salivary free cortisol levels at time-point +10 (cort+10; left side; 
mean, SE) and in increases from time-point -1 to +10 (incr_cort1>3; right side; 
mean, SE)...........................................................................................................135 
Fig. 4-7: Effects of TSST and group (AD vs. HS) on plasma norepinephrine (top) and 
epinephrine (bottom) levels (mean, SE). .............................................................136 
Fig. 4-8: Effects of TSST, group (AD vs. HS) and treatment (HC vs. NaCl) on systolic (top) 
and diastolic (bottom) blood pressure (mean, SE)...............................................136 
Fig. 4-9: Effects of TSST, group (AD vs. HS) and treatment (HC vs. NaCl) on heart rate 
(mean, SE). ........................................................................................................137 
Fig. 4-10: Decisions on direction, underlying mechanisms and relevance of associations 
between stress response and health in humans can be reached based on results 
originating from other approaches like adrenalectomy, use of receptor-antagonists 
or -agonists, and in vitro studies..........................................................................142 
FIGURE AND TABLE INDEX VII
Fig.4-11: Effects of TSST, disease, and treatment on white blood cells counts (mean and 
standard errors (SE), given in % change to baseline). ........................................150 
Fig. 4-12: Lymphocytes and granulocytes (in % of white blood cells; mean and SE) for 
placebo treated healthy subjects and patients with Addison’s disease. ...............150 
Fig. 4-13: Inhibition of LPS-stimulated IL-6 production (mean and SE) by increasing doses of 
dexamethasone for groups AD-HC, AD-NaCl, and HS-NaCl broken down by four 
time-points (TSST -1, +10, +60, and +120 minutes)............................................151 
Fig. 4-14: Stress, group, and treatment effects on LPS-stimulated IL-6 production (mean and 
SE). ....................................................................................................................152 
Fig. 4-15: Stress, group, and treatment effects on glucocorticoid sensitivity of LPS-stimulated 
IL-6 production (IC50, in 10
-8 M DEX; mean and SE). Glucocorticoid sensitivity is 
inversely related to IC50 levels.............................................................................152 
Fig. 4-16: Stress, group, and treatment effects on PHA-stimulated proliferation and IC50 
levels (*10-8M DEX).............................................................................................154 
Fig. 4-17: NF-B-DNA binding activity (signal intensity) before and repeatedly after stress in 
patients (with and without hydrocortisone treatment) and healthy subjects. ........173 
Fig. 4-18: NF-B-DNA binding activity (% change to baseline) before and repeatedly after 
stress in patients (with and without hydrocortisone treatment) and healthy subjects.
...........................................................................................................................174 
Fig. 4-19: Means and standard errors of stress-induced increases in cortisol levels from pre-
TSST to +10min (incr. 1>3), decreases from +10min to +60min (decr. 3>7), and 
decreases from +10min to +120min (decr. 3>9) in healthy subjects and patients 
with Addison’s disease with and without hydrocortisone treatment. ....................174 
Fig. 4-20: Means and standard errors of stress-induced changes in norepinephrine (NE, left) 
and epinephrine (E, right) levels from pre-TSST to +1min (incr. 1>2) and from 
+1min to +10min (decr. 2>3) in patients with Addison’s disease and healthy 
subjects. .............................................................................................................175 
Fig. 2-21: Scatterplots summarizing the significant regression models regarding variations in 
NF-B binding activity. ........................................................................................176 
Fig. 5-1: Summary of endocrine (cortisol: top row, norepinephrine and epinephrine: middle 
row) and blood pressure (bottom row) results. Data from healthy subjects are 
depicted in the left column, from patients with Addison’s disease in the middle 
column, and from patients treated with hydrocortisone in the right column. Please 
note that catecholamine responses in patients were not divided according to 
FIGURE AND TABLE INDEX VIII 
treatment vs. no treatment. .................................................................................180 
Fig. 5-2: Summary of immune (white blood cells: top row, LPS-stimulated IL-6 production: 2nd 
row, PHA-stimulated cell proliferation: 3rd row) and NF-B (bottom row) results. 
Data from healthy subjects are depicted in the left column, from patients with 
Addison’s disease in the middle column, and from patients treated with 
hydrocortisone in the right column. .....................................................................181 
 
FIGURE AND TABLE INDEX IX 
TABLE INDEX 
 
Tab. 2-1: Behavioral and physiological adaptation during acute stress (Chrousos, 1998a)...26 
Tab. 2-2: States associated with altered HPA axis activity and altered regulation or 
dysregulation of behavioral and/or peripheral adaptation (Chrousos, 1998a). .......34 
Tab. 2-3: Etiology of Addison’s disease (modified from Betterle et al., 2002)........................47 
Tab. 2-4: Revisited postulates of Witebsky by Rose & Bona (Rose and Bona, 1993). ..........51 
Tab. 4-1: Patterns of glucocorticoid replacement (HC: hydrocortisone, C: cortisone acetate).
...........................................................................................................................120 
Tab. 4-2: Results of repeated measures ANOVAs regarding effects of TSST on immune 
parameters in healthy subjects. Significant results (p<.05) are highlighted in gray.
...........................................................................................................................148 
Tab. 4-3: Student’s t tests for baseline group differences between patients with Addison’s 
disease and healthy subjects in immune parameters. .........................................148 
Tab. 4-4: Results of repeated measures ANOVAs for blood cell counts (WBC%: white blood 
cells in % change from baseline; LY%, GR%, and MO%: lymphocytes, 
granulocytes and monocytes in % of white blood cells, respectively) with four 
within-group levels representing the four time-points and two between-group levels 
testing for group (column A; AD-NaCl vs. HS-NaCl) and treatment effects (column 
B; AD-HC vs. AD-NaCl), as well as three between-group levels comparing 
changes over time in blood cell counts between all three groups (column C; AD-HC 
vs. AD-NaCl vs. HS-NaCl). Significant results (p<.05) are highlighted in gray, 
trends (p<.10) are indicated by a superscript plus sign (+). ..................................149 
Tab. 4-5: LPS-stimulated IL-6 production – repeated measures ANOVA including groups AD-
HC, AD-NaCl, and HS-NaCl as between-group levels and four time-points and six 
concentrations of dexamethasone as within-group levels. Significant results (p<.05) 
are highlighted in gray.........................................................................................150 
Tab. 4-6: Results of repeated measures ANOVAs for LPS-stimulated IL-6 production and 
glucocorticoid sensitivity of LPS-stimulated IL-6 production (IL-6-IC50) with four 
within-group levels representing the four time-points and two between-group levels 
testing for group (column A; AD-NaCl vs. HS-NaCl) and treatment effects (column 
B;AD-HC vs. AD-NaCl), as well as three between-group levels comparing changes 
over time between all three groups (column C; AD-HC vs. AD-NaCl vs. HS-NaCl). 
The last row (IL-6c-IC50) shows the respective results of an ANCOVA with LPS-
stimulated IL-6 production at time-point +10 minutes as covariate. Significant 
FIGURE AND TABLE INDEX X 
results (p<.05) are highlighted in gray, trends (p<.10) are indicated by a superscript 
plus sign (+). ........................................................................................................153 
Tab. 4-7: PHA-stimulated cell proliferation – repeated measures ANOVA including groups 
AD-HC (n=15), AD-NaCl (n=14), and HS-NaCl (n=14) as between-group levels and 
four time-points and six concentrations of dexamethasone as within-group levels. 
Significant results (p<.05) are highlighted in gray. ...............................................153 
Tab. 4-8: Results of repeated measures ANOVAs for PHA-stimulated cell proliferation (in % 
change of baseline; CP-PHA) and glucocorticoid sensitivity of PHA-stimulated cell 
proliferation (CP-IC50) with four within-group levels representing the four time-
points and two between-group levels testing for group (column A; AD-NaCl vs. HS-
NaCl) and treatment effects (column B;AD-HC vs. AD-NaCl), as well as three 
between-group levels comparing changes over time between all three groups 
(column C; AD-HC vs. AD-NaCl vs. HS-NaCl). Significant results (p<.05) are 
highlighted in gray...............................................................................................154 
Tab. 4-9: Results of repeated measures ANOVAs for NF-B signal intensity (1st row) and NF-
B activity in percent change to baseline (2nd row) with two between-group levels 
testing for group (column A) and treatment effects (column B), and with three 
levels comparing changes over time between all three groups (column C). ........173 
 
 

 
INTRODUCTION 1 
1 INTRODUCTION 
The field of psychoneuroimmunology (PNI) is dedicated to the investigation of stress-
neuroendocrine-immune interactions. Within this field, one area has attracted considerable 
attention: The effects of stress on the immune system and hence on health and disease. To 
date, numerous studies have shown that psychosocial stress leads to an activation of the 
hypothalamus-pituitary-adrenal (HPA) axis resulting in an increased release of its major end 
product cortisol, which in turn has a wide range of effects on the immune system. Thereby, 
these mostly immune-suppressive effects are thought of as protecting the organism against 
an overactive and thus potentially harmful immune response. Thus, contrary to an 
endocrinological response to acute stress, HPA dysfunctions or a missing cortisol stress 
response due to chronic stress are associated with negative health outcomes. 
Although a large number of studies have investigated HPA axis function and 
abnormalities in human diseases, clear-cut evidence for the involvement of glucocorticoids in 
predisposing individuals to the development or exacerbations of specific diseases have so 
far predominantly been derived from animal studies or have been deduced from in vitro 
findings. This work introduces an alternative approach, namely the investigation of patients 
with Addison’s disease, to measure the effects of context-independently long-term altered 
glucocorticoid stress responses on the immune system. Studying such effects in patients 
with Addison’s disease may provide valuable insights in the interplay of endocrine stress 
systems in the human whole organism, the extend to which an organism is able to 
compensate dysregulations in these systems, and the clinical relevance of 
psychoneuroendocrinological and -immunological findings for health and disease. 
For this purpose, first the theoretical background of the three key components – the 
endocrinological stress response, Addison’s disease, and stress-neuroendocrine-immune 
interactions – will be presented in the subsequent chapters. In the first section, the reader will 
find definitions of stress and different stress concepts. Also the endocrinological stress 
response as well as its effects on different body systems will be discussed. The second 
section describes in detail the unique endocrine state ‘Addison’s disease’. In the third 
section, the basic principles of psychoneuroimmunology will be discussed. The reader will 
learn about the components and the functions of the immune system as well as their 
modulation by acute and chronic stress. Also the immune effects of discrete stress mediators 
(i.e., glucocorticoids and catecholamines) as well as mechanisms and modulators of 
glucocorticoid-to-immune system signaling will be presented. 
While the third chapter outlines the specific problem formulations of the present 
thesis, the fourth chapter is divided into four sections, each representing a special set of 
results of two empirical studies. Since so far no data are available on the quality of the 
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pharmacological substitution in Addison’s disease patients, specifically the resulting 
concentrations of free cortisol, this basic condition was investigated first (section 4.1). Due to 
the same reason, in a next step the endocrinological stress response in these patients was 
investigated and compared with the respective responses in healthy controls (section 4.2). 
Based on these data, immunological consequences of a missing cortisol stress response 
were analyzed. To distinguish between effects due to the missing stress response and 
effects due to other responses or compensatory mechanisms, in half of the patients a normal 
cortisol stress response was mimicked by hydrocortisone injection (section 4.3). Also one 
intra-cellular mechanism centrally in mediating glucocorticoid effects on the immune system 
– and thus also potentially important in compensating processes – was investigated. These 
results will be presented in the fourth section (section 4.4). 
In the last chapter of this thesis, the results of all studies are summarized, discussed 
in a broader context, and an outlook suggests promising directions for future studies 
employing the investigation of patients with Addison’s disease. 
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2 THEORETICAL BACKGROUND 
In this section the theoretical background for studying the effects of an absent cortisol 
stress response on the immune system will be introduced. This includes a synopsis of the 
three main topics in this regard: (1) the neuroendocrine stress response, including the 
development and current state of stress concepts as well as the components and functions 
of the endocrine stress axes, (2) a detailed description of the exceptional endocrine state 
‘Addison’s disease’, (3) the effects of stress on the immune system, introduced by a short 
overview of the components and functions of the immune system. 
2.1 THE NEUROENDOCRINE STRESS RESPONSE 
Asking ten people if they sometimes feel stressed out, ten will answer yes. On the 
contrary, asking ten people for their own definition of stress, one will get ten different 
answers. But most probably these ten answers will agree in one point, namely that stress is 
to be blamed for being the direct precursor of mental and physical illness. This is, stress has 
predominantly a negative connotation and evokes detrimental and maladaptive physiological 
and behavioral responses. 
Certainly this is a very one-sided and narrow perspective. Therefore, the following 
sections will try to give a more balanced view and also take positive aspects of stress into 
considerations. In this regard, first a historical overview about the development of stress 
concepts will be given (2.1.1). This will be followed by a description of the participating stress 
systems (2.1.2) and their activation (2.1.3). The last two sections will focus on the effects of 
stress mediators, namely the above mentioned damaging (2.1.4) but also the protective 
effects (2.1.3). 
2.1.1 Stress Concepts: Historical Development 
In searching for a definition of stress, closely intertwined psychological and 
physiological processes have to be taken into account. This is, stress is neither something 
we are confronted with helplessly because it is simply an automatic reaction of the organism 
to external stimuli nor is it just an imagination or a train of thought haunting in people’s mind. 
Accordingly, an overview about the historical development of stress concepts will 
show, how different researchers focused on different processes and thus made different but 
for this very reason important contributions. 
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2.1.1.1 Claude Bernard 
The basis for the later development of stress concepts was provided already in the 
middle of the 19th century by Claude Bernard (1813-1878). He emphasized that an animal’s 
life depends on the milieu intérieur that is, “on extracellular fluids, which provide the physico-
chemical conditions for the correct functioning of cells”. He reasoned that if correct cell 
functioning depends on optimal physico-chemical conditions, then these must be constant 
and there have to be mechanisms that allow such conditions to be maintained. This is, he 
recognized that the stability of the milieu intérieur depends on ensembles of compensating 
mechanisms. For Bernard, “the constancy of the internal environment was the element 
conditioning free, independent life” (Bernard, 1878). This new concept entailed the 
overcoming of the concept of physiology as “anatomy in motion” and a radical shift in 
perspective. The “new” life sciences needed to penetrate this internal environment and 
investigate its regulation if they were to study living organisms (Conti, 2001). But for this it 
was necessary to find a broader concept that would allow for linking together the 
mechanisms affecting the regulation of the body. 
2.1.1.2 Walter Bradford Cannon 
This was done fifty years later by Walter Bradford Cannon (1871-1945) in introducing 
and coining the term homeostasis. He suggested this term to describe the dynamic, 
interactive nature of “coordinated physiological processes which maintain most of the steady 
states of the organism” (Cannon, 1929). Cannon identified the sympathetic nervous system 
as an important orchestrator of responses to challenges. He emphasized the role of 
epinephrine secreted from the adrenal glands, “since it is carried everywhere in the body by 
the blood and has the same effects on the internal organs as the sympathetic impulses” 
(Cannon, 1935). These processes restoring a disturbed steady state of the “fluid matrix” he 
also called “fight-or-flight response”. Interestingly, in the article published in 1935, he already 
used the term stress not only in the by then conventional psychiatric context (i.e., to describe 
mental tension) but also as involving physical as well as emotional stimuli. In a physiological 
context he summarized various threats of homeostasis, like cold, lack of oxygen, low blood 
sugar, or loss of blood (Cannon, 1935). 
2.1.1.3 Hans Selye 
However, the cornerstone in the field of stress research was published one year later 
by Hans Selye (1907-1982) as a letter to Nature entitled “A syndrome produced by diverse 
nocuous agents” (Selye, 1936a). In this brief report he summarized several years of 
experimentation, primarily initiated by his search for new hormones in the placenta (Selye, 
1952). In this regard, he injected rats with crude ovarian extracts and observed adrenal 
THEORETICAL BACKGROUND 5 
enlargement and the atrophy of thymus and lymph nodes. Subsequently he tried to purify the 
responsible hormone for this putative specific reactions. But neither was he able to purify the 
sought-after hormone nor did the specificity of the symptoms prove true. Rather it occurred to 
him after further experiments that these symptoms may represent a nonspecific response to 
noxious agents and he published his findings in the above mentioned letter. Herein he 
summarized “that if the organism is severely damaged by acute nonspecific nocuous agents 
(…), a typical syndrome appears, the symptoms of which are independent of the nature of 
the damaging agent or the pharmacological type of the drug employed, and represent rather 
a response to damage as such” (Selye, 1936a). He also suggested to term this syndrome, 
consisting of (1) an enlargement of the adrenal gland, (2) atrophy of the thymus, spleen and 
other lymphoid tissue, and (3) gastric ulcerations, the “general adaptation syndrome”. The 
syndrome develops in three stages of adaptation, an initial “general alarm reaction”, followed 
by a prolonged period of resistance and a terminal stage of exhaustion and death. All these 
processes he regarded as a generalized effort of the organism to adapt itself to new 
conditions (Selye, 1936a). 
Starting from this report, Selye developed a theory of stress that aroused intense 
research. However, the term stress itself does not appear in his publications until 1946 and 
Selye’s definition of stress appeared to vary at different periods, indicating stimulus, 
response, or interaction between stimulus and response (Mason, 1975a). But in 1950, he 
proposed stress as a condition within the organism in response to evocative agents, and 
these evocative agents he termed “stressors” (Selye, 1950). In 1974, he restated “stress is 
the nonspecific response of the body to any demand made upon it” (Selye, 1974). This is, 
while each input may have a unique effect, they all produce a consistent set of responses. 
Over the time, he repeatedly emphasized the key role of the hypothalamus-pituitary-
adrenal axis in the stress response. And while Cannon introduced catecholamines as 
important mediators, Selye shifted attention to glucocorticoids and hence from the adrenal 
medulla to the adrenal cortex (Selye, 1956). 
2.1.1.4 John W. Mason 
In contrast to Selye’s noxious or evocative agents, John W. Mason focused on the 
role of psychological factors in eliciting a physiological stress response. In 1968, he 
published a review summarizing more than 200 publications on this subject and despite the 
wide variety of events and psychological stimuli found to elicit a stress response, he 
identified conditions which tend to elicit responses of unusual intensity. These conditions 
were: novelty, uncertainty or unpredictability, anticipation of something previously 
experienced as unpleasant, ego-involvement, and situations in which long-established rules 
are suddenly changed (Mason, 1968). Thus, a stress response is not solely determined by 
situational criteria. Rather stimuli are processed by the central nervous system and therefore 
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intervening factors such as previous experiential history or coping styles determine the 
endocrine response. Mason also pointed out the marked individual differences in the 
pituitary-adrenal cortical response and regarded the definition of the multiple determinants of 
these individual differences as a major goal in the future development of psychoendocrine 
research, with the organization of psychological defenses as an especially important factor to 
consider (Mason, 1968). 
Mason also suggested that corticosteroid secretion may be a specific response to 
psychological stimuli and not particularly responsive to physiological stimuli such as heat, 
exercise, and hunger. Scrutinizing Selye’s concept of physiological non-specificity of the 
stress response, Mason proposed that elicitation of an emotion such as anxiety or fear 
constituted the basis for similar neuroendocrine responses to different stressors observed by 
Selye (Mason, 1971; Mason, 1975b). In Mason’s opinion “emotional stimuli must be ruled out 
before it can be concluded that a physical stimulus is capable, by itself, of eliciting increased 
adrenal cortical activity” (Mason, 1968). 
2.1.1.5 Richard S. Lazarus 
Over a long period, stress research was implicitly based on stimulus-response (S-R) 
models: Some researchers focused on the stress response, others emphasized 
characteristics of stimuli. But it was not until the 1970s that the cognitive revolution also 
found its way into the stress area and criticism arose. How does a stimulus approach explain 
the wide variability in human responses to ostensibly the same stressor? On the contrary, 
how helpful is an approach that tends to treat all stressors as equivalent if they produce the 
same response? Are exercise, surprise, and passion equivalent because of their identical 
effect on heart rate? Are emotions and fatigue stress responses, stressors or maybe both? 
And how do response-based views of stress explain different responses in different 
individuals? It became more and more apparent that treating the stress stimulus or the stress 
response in a mechanical manner is insufficient, since it ignores the processes that intervene 
between stimulus and response. 
Richard S. Lazarus viewed stress as a relational phenomenon, which only exists in 
the context of a person-environment interaction. In 1986 he stated: “There is simply no way 
to define an event as a stressor without referring to the properties of persons that make their 
well-being in some way vulnerable to that event.” And: “There are no environmental stressors 
without vulnerable people whose agendas and resources influence whether or not there will 
be stress, the form it will take, and its short and long-term outcomes.” (Lazarus and Folkman, 
1986). Already 20 years earlier Lazarus had proposed a “transactional” model based on 
expectancies and appraisals: In a primary appraisal the person evaluates whether the 
stimulus situation is a threat or not. In the case of a threat, the person considers whether this 
threat can be met with the resources he or she has. If in this secondary appraisal the answer 
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is “no” or the person believes that these resources are insufficient, stress occurs (Lazarus, 
1966). This is, Lazarus considered different concepts to describe the stress process 
(Lazarus, 1993): (1) a causal external or internal agent with a strong emphasis on the 
person-environment relationship and (2) an evaluation that distinguishes what is threatening 
or noxious from what is benign (appraisal). The next two steps are (3) coping processes and 
(4) a complex pattern of effects on mind and body (stress reaction). Thereby, coping is 
viewed as a highly contextual process always mediated by appraisal and affecting 
subsequent stress reactions in two main ways. Problem-focused coping changes a person’s 
relationship with the environment, emotion-focused coping changes the way a person 
attends to or interprets what is happening. Both actions aim for changing the conditions of 
psychological stress for the better. 
With introducing processes like person-environment interaction, appraisal and coping, 
stress research moved away from S-R to stimulus-organism-response (S-O-R) models. Now 
individual differences in motivational and cognitive variables, which intervene between the 
stressor and the reaction, had to be taken into account. 
2.1.1.6 Seymour Levine and Holger Ursin 
Another approach based on a S-O-R model came from Seymour Levine and Holger 
Ursin (Levine and Ursin, 1991) and at first glance does not differ widely from the approach 
presented by Lazarus. Levine and Ursin also view stress as a multidimensional concept and 
identified three main interacting subclasses: (1) the input or stress stimuli, (2) the processing 
systems, including the subjective experience of stress, and (3) the output or stress 
responses.  
Levine and Ursin considered psychological as well as physiological stimuli as 
potential stressors, but propose to classify all input as “loads”. This has the advantage that a 
load may be of physical nature, however it may act as a stressor through eliciting emotional 
loads. In this regard psychological emotional loads are the most frequently reported stress 
stimuli. 
But no matter what kind of stimuli or load, all-dominant are previous experiences or 
learning. Every input is being evaluated or filtered before it gains access to any response 
systems. Thereby, comparison is the basic principle for the stimulus treatment. Levine and 
Ursin regarded comparisons most simply as expectations and differentiated between the 
stimulus expectancy and the response outcome expectancy. The former refers to the storing 
of information that one stimulus precedes another. In the case of a stimulus signaling an 
aversive event, the stress response occurs. Alternatively, the person may deny the 
relationship between the stimulus and the aversive event and defense may block threat 
signals from producing stress responses. The second filter, response outcome expectancies, 
refers to learning about the consequences of acts. Whether an individual will show a stress 
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response is determined by three classes of response outcome expectancies: coping, 
helplessness, and hopelessness. Here, it is important to differentiate between the use of the 
term coping by Levine and Ursin from Lazarus’. Lazarus used the term coping to refer to 
strategies used to face a challenge or threat. Levine and Ursin pointed out that in this 
denotation coping strategies are independent of the level of stress and offer no possibility to 
predict physiological consequences of the stimuli. Therefore, they defined coping as positive 
response outcome expectancies resulting from learning processes. If an individual can 
control or perceive control in a specific situation, the chosen responses (e.g., escaping, 
avoiding, obtaining reinforcement) result in a positive outcome. This relationship of response 
and outcome will then be stored as positive outcome expectancy. The expectation of a highly 
probable positive outcome reduces stress, the inability to cope, i.e. gaining control, results in 
high levels of stress. In the case of a very low probability that a response will lead to any 
consequences at all, helplessness arises. Whereas hopelessness arises in situations with 
very high probability that all available responses will lead to aversive or negative events. 
Additionally, these learning processes can further be modulated or permanently altered by 
individual differences. Factors, which change such tolerance to stressful events, can be 
prenatal stress, nutritional factors, genetic components but also social factors like the 
availability of social support. 
The stress responses itself are defined as all overt behavioral and physiological 
changes. The existence of physiological stress responses can not necessarily be deduced 
from observed behavior, since the behavior may just indicate coping and thus absence of 
physiological responses may result. Therefore, Levine and Ursin proposed subjective verbal 
reports instead, which seem to follow the physiological state and are reasonably consistent 
and reproducible. Regarding the physiological stress response, which occurs whenever there 
is a discrepancy between what the organism is set for and what really exists, two types can 
be differentiated: The first general and non-specific alarm response occurs even when 
coping has been established and is characterized by epinephrine release, pulse rate 
increases and a modest rise in plasma levels of testosterone. The second response is 
specific to situations and experiences and is seen in noncoping individuals. This later stages 
of the stress response are characterized by the release of slower-reacting hormones such as 
cortisol and are seen as processes aiming at re-establishing physiological balance (i.e., 
homeostasis). 
In his later work regarding the cognitive activation theory of stress (CATS), Ursin also 
emphasized more explicitly than in the above cited paper a fourth aspect of stress, namely 
the feedback from the stress response (Ursin and Eriksen, 2004). This is a very important 
aspect, since feedback from the stress response may alter the stimulus situation and these 
effects will be stored as response outcome expectancies. 
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Concluding, Levine and Ursin hypothesized that stress-inducing stimuli can be 
defined by their lack of information concerning the achievement of positive outcomes or 
avoidance of negative outcomes. Therefore stress is presumed to be the state that is created 
whenever the brain registers this informational discrepancy (Levine and Ursin, 1991). As 
Ursin (Ursin, 1998) pointed out, this definition is closely related to one of the principles of 
Mason, which is that particularly potent stimuli of the stress system are novelty, uncertainty, 
and unpredictability (Mason, 1968). 
2.1.1.7 Summary 
This section aimed at finding a definition of stress. In this regard, the development of 
stress research and stress concepts over almost one century was depicted. Yet, no generally 
accepted definition can be presented. Levine even concluded in 2005: “After the completion 
of our last effort to define stress (Levine and Ursin, 1991), I made myself the promise that I 
would never again engage in what I consider a futile exercise” (Levine, 2005). Despite this 
rather disenchanting statement, the most important fact became apparent nevertheless: In 
stress research, one has to deal with a complex system of physiology, behavior, subjective 
experiences, and cognitive functions, including feedback and control loops between these 
different domains. And if focusing on only one of these domains, for example the 
physiological effects of stress, one has still to be aware of the other major processes 
influencing and being influenced by the domain of interest. 
2.1.2 Central and Peripheral Stress Systems 
One aspect repeatedly appearing in the above depicted stress concepts is the link 
between stress and physiological stress responses. Therefore, the following two sections will 
describe the two systems mainly involved in a physiological stress response: the 
hypothalamus-pituitary-adrenal (HPA) axis (2.1.2.1) and the sympathetic nervous system 
(2.1.2.2). 
2.1.2.1 HPA Axis 
The hypothalamus-pituitary-adrenal axis is an endocrine system not only forming a 
fundamental part of the endocrine stress response but also contributing to the maintenance 
of daily energy balance. The activity of the HPA axis is characterized by a pronounced 
circadian variability (2.1.2.1.2) and a tight modulation by feedback mechanisms (2.1.2.1.3). 
Additionally, a wide variety of inputs play an important role in the stress-related activation of 
the HPA axis (2.1.2.1.4). The following sections will illustrate these aspects in greater detail, 
prefaced by a delineation of the organization of the HPA axis (2.1.2.1.1).  
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2.1.2.1.1 Organization of the HPA axis 
As implicated by its name, the HPA axis is composed of three structures: the 
hypothalamus and the pituitary centrally and the adrenal glands peripherally. The hormones 
involved are corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), 
and glucocorticoids (GC). In the following, each of the three structures as well as the 
corresponding hormone will be described. 
Hypothalamus 
The hypothalamus is a very small structure which comprises less than 1% of our 
brain volume. It is located in the middle of the base of the brain, and encapsulates the ventral 
portion of the third ventricle right above the pituitary (see fig. 2-1).  
 
Fig. 2-1: Localization of the hypothalamus and the pituitary gland in the human brain (sagittal section). 
The hypothalamus consists of distinct nuclei (see fig. 2-2) and is divided into medial 
and lateral regions by the fornix, which is a tract of fibers that runs from the hippocampus to 
the mamillary bodies. At the anterior the hypothalamus is limited by the optic chiasm and 
anterior commissure, at the posterior by the mamillary bodies. 
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Fig. 2.2: Hypothalamic nuclei (A: frontal section; B: sagittal section). 
Regarding the organization of the HPA axis, most important is the hypothalamic 
paraventricular nucleus (PVN). The PVN is a bilateral structure located either side of the third 
ventricle and is an elaboration of the periventricular zone of the hypothalamus. It contains 
two sets of neurons: The dorsal and ventral magnocellular neurons project to the brain stem 
and spinal cord and regulate behavioral and autonomic motor activity. The second set of 
neurons is neuroendocrine in nature and can be further divided in magnocellular (larger) cells 
and parvocellular (smaller) cells. The former secrete either oxytocin or vasopressin, the latter 
are located more medially than the magnocellular neuroendocrine cells and have terminals in 
the median eminence. Via the median eminence they secrete hypothalamic releasing 
hormones into the hypophysial portal vasculature to regulate anterior pituitary function 
(Kupfermann, 1991; McCann, 1988; Watts, 2000). One of these releasing hormones 
secreted by the parvocellular neuroendocrine cells of the PVN is the corticotropin-releasing 
hormone (CRH), the first of three molecules constituting the signal cascade of the HPA axis 
and discovered in the late 1950s. 
CRH is a 41-amino-acid peptide that acts not only as a hormone regulating anterior 
pituitary function, but also centrally as a neurotransmitter. On this account it is often called 
corticotropin-releasing factor (CRF). In addition to the CRF-synthesizing neurons in the PVN, 
other CRF-expressing cell groups are located in the central nucleus of the amygdala, the bed 
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nucleus of the stria terminalis, the lateral hypothalamic area, parabrachial nuclei, and the 
dorsal motor nucleus of the vagus. This suggests that the central CRF system regulates not 
only the neuroendocrine, but also autonomic and behavioral responses to stressors (Dallman 
et al., 2000). 
Pituitary gland 
The pituitary gland can be divided into two distinct parts. One part is the posterior 
pituitary or neurohypophysis, which consists of the median eminence, the infundibular stalk, 
and the neural lobe of the pituitary gland. Axons from magnocellular cells in the PVN and 
supraoptic nucleus pass through the infundibular stalk and synapse on the capillaries of the 
posterior pituitary. When an action potential arrives at a terminal, oxytocin or vasopressin is 
released from the terminal directly into the bloodstream. 
The other part is the anterior pituitary or adenohypophysis. In contrast to the 
neurohypophysis, the adenohypophysis is non-neural tissue and has three parts: pars 
distalis, tuberalis, and intermedia. Pars tuberalis makes up approximately 75% of the 
adenohypophysis and its cells contain corticotropes. Corticotropes synthesize 
adrenocorticotropin from its precursor proopiomelanocortin (POMC). The decisive signal is 
CRF. Axons of CRF neurons of the PVN end at the median eminence, and CRF secreted 
from these diffuses into the hypophyseal-portal blood supply and travels to the anterior 
pituitary. Through its action on CRF-recepor-1, CRF regulates the synthesis of POMC and 
eventually the secretion of the 39 amino-acid peptide adrenocorticotropin hormone (ACTH) 
into the general circulation. ACTH is the second major HPA axis hormone. 
Interestingly, vasopressin also has a physiological role in the control of ACTH release 
as it can potentiate the action of CRF at both hypothalamic and pituitary levels. Therefore, 
vasopressin and CRH are regarded as hormones closely cooperating in the control of ACTH 
release (McCann, 1988; Watts, 2000). 
Several other tropic hormones are produced in the anterior pituitary and regulated by 
hypothalamic releasing or inhibiting hormones. In the following these hormones are listed 
and the releasing or inhibiting hormones are given in parentheses: Thyroid-stimulating 
hormone (TSH) and prolactin (in both cases thyrotropin-releasing hormone, additionally 
prolactin-releasing factor in the latter); beta-lipotropin (CRF); follicle-stimulating hormone and 
luteinizing hormone (gonadotropin-releasing hormone); melanocyte-stimulating hormone 
(MSH) and beta-endorphin (MSH-releasing factor); and growth hormone (GH; GH-releasing 
hormone). Furthermore, some of these hormones are regulated by hypothalamic inhibiting 
hormones. These are: prolactin (prolactin release-inhibiting hormone and dopamine), GH 
and TSH (GH release-inhibiting hormone), and MSH (MSH release-inhibiting factor) 
(Kupfermann, 1991). Thereby, the successive processes are similarly to that of CRF-ACTH 
described above and are depicted in fig. 2-3. 
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Fig. 2-3: Detailed view of the anterior pituitary gland and its regulation by hypothalamic neurons. 
Adrenal glands 
The adrenal glands are the third structure constituting the HPA axis and the target 
tissue for ACTH released by the anterior pituitary. As shown in the left panel of figure 2-4, the 
adrenal glands are located bilaterally atop the kidneys (ad-renal) and are well supplied with 
arterial blood. The adrenal cortex comprises 90% of the gland, the medulla the remaining 
10%. The medulla synthesizes and secretes catecholamines. Since catecholamines are 
involved in the second major stress response system, they will be discussed in detail in the 
respective section (see. 2.1.2.2). 
The cortex can be subdivided into three anatomical and functional zones (see right 
panel of figure 2-4). Below the fibrous capsule, the outer zona glomerulosa is situated. Here, 
mineralocorticoids, mainly aldosterone, are synthesized. Subsequently follow the middle 
zona fasciculate and the inner zona reticularis. The former secrets glucocorticoids, the latter 
androgens, mainly dehydroepiandrosterone (DHEA). 
All adrenal steroids are derived from cholesterol by various modifications of its 
structure (see figure 2-8 in section 2.2.6.2). The rate-limiting step in steroid biosynthesis is 
the action of the cytochrome P450 side chain cleavage enzyme (scc), which converts 
cholesterol into pregnenolone. Once pregnenolone is available, sequential modifications by 
further enzymes rapidly form the various steroids. 
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Fig. 2-4: Localization of the adrenal glands (A; source: Carlyn Iverson) and anatomy of the adrenal cortex (B; 
modified from Gray, 1918). 
Since cholesterol is found in storage depots in the absence of stimulation, the very 
first step has to be its release. One stimulus is ACTH, which binds to its membrane receptor 
and via the activation of enzymes converts cholesterol esters to free cholesterol. Additionally, 
as all stimuli of steroidogenesis, ACTH increases the interaction of cholesterol with scc 
enzyme, thus starting the biosynthetic cascade to cortisol – the third major hormone of the 
HPA axis (Kaplan, 1988). 
Cortisol, sometimes also referred to as hydrocortisone, is the main glucocorticoid 
(GC) in humans and most mammals, whereas in some rodents corticosterone serves this 
function. Once Cortisol is secreted and in circulation, it is largely bound to corticosteroid-
binding globulin (CBG, synonym: transcortin). Another 15-20% is bound less tightly to 
albumin, leaving only about 5% of circulating cortisol as unbound (Pearson-Murphy, 2000). 
These 5% of unbound or free cortisol are thought of as the biologically active fraction, based 
on the concept known as the “free hormone hypothesis” (Mendel, 1992). Subsequently free 
cortisol is metabolized in the liver and excreted into the urine, accounting for a half-life of 49 
minutes for total cortisol and of 1.8 minutes to 3.5 minutes for free cortisol (Keenan et al., 
2004). 
Cortisol is essential for life and has a wide variety of effects on different tissues. 
These effects can be further differentiated into basal and stress functions, which will be 
discussed in sections 2.1.4 and 2.1.5. Cortisol exerts its effects genomically (for details see 
also section 2.3.4.1.2): The lipophilic hormone passively diffuses through the cellular 
membrane, binds to and activates its intracellular receptor; then this complex translocates to 
the nucleus, where it either interacts with other transcription factors or binds to DNA 
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response elements (GRE) resulting in up- or down-regulation in the expression of various 
genes (Pearson-Murphy, 2000). 
2.1.2.1.2 Circadian variation 
The activity of the HPA axis and thus the secretion of its hormones are subject to a 
pronounced variation, which allows for adaptive response to environmental demands. 
Basically, generation of a baseline ultradian pattern of HPA activity depends on a relatively 
constant oscillation in the activity of parvocellular CRH and vasopressin neurons. Both 
hormones are secreted episodically at a frequencies of 1 to 3 secretory episodes per hour 
(Chrousos, 1998b). Regarding ACTH and cortisol, varying numbers of pulses per day are 
stated, apparently varying with sampling intervals. While van Cauter reports on 
approximately 15 pulses in a 24-hour span (Van Cauter, 1995), Iranmanesh used various 
sampling intervals decreasing from 12 to 2 minutes and found 20 to 80 pulses per day 
(Iranmanesh et al., 1990), which parallels the 1 to 3 secretory episodes per hour given for 
CRH. 
These pulsations are superimposed by several inputs, constituting a circadian rhythm. 
According to Chrousos, these inputs include: (1) positive circadian input(s) from one or more 
pacemakers; (2) tonic positive input from locus coeruleus/norepinephrine and dopaminergic 
mesocorticolimbic systems; (3) tonic negative input from hippocampus and prefrontal cortex; 
and (4) negative feedback input from the arcuate nucleus-POMC-peptidergic system and the 
end-hormone of the HPA axis cortisol (Chrousos, 1998b). One pacemaker and master 
endogenous clock which controls circadian rhythmicity is the paired suprachiasmatic nucleus 
(SCN) of the hypothalamus, mediating the association with the light-dark cycle (Van Cauter, 
1995). All these inputs influence the amplitudes of the baseline pulsation. Thus, the circadian 
pattern results from increases in the amplitude and not from varying frequencies of pulses 
(Iranmanesh et al., 1990). 
The interplay of episodic pulses and superimposed inputs constitute a typical pattern 
of ACTH and cortisol secretion throughout the day. Both hormones show an early morning 
maximum, declining levels throughout daytime, a quiescent period of minimal secretory 
activity at night, and an abrupt elevation during late sleep (Van Cauter, 1995). 
This circadian variation has clear implications for clinical diagnosis and study-design. 
The time of sample collection has to be chosen adequately, so that for example cortisol 
levels allow for discrimination between healthy persons and patients. It has also to be taken 
into consideration that a stimulus response may depend on the timing of stimulus application 
(Van Cauter, 1995). Additionally, age-related changes in the endocrine circadian rhythm 
have been well described: Older persons show dampened rhythms and specific phase points 
of the rhythms occur earlier than in young persons (van Coevorden et al., 1991). 
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2.1.2.1.3 Feedback regulation 
A process is referred to as feedback when the product of an activity in a system 
modifies the factors that produce that product. Applied to the HPA system, cortisol 
suppresses the production and release of its precursors CRH and ACTH, which in turn 
decreases the production and release of cortisol itself. This negative feedback system has to 
control accurately the activity of the HPA axis under circadian and stressful conditions. This 
covers a range of very low cortisol levels during the trough of basal rhythm to up to the 600-
fold at the peak of the circadian rhythm and under stress. It also poses a problem, since 
receptors characteristically bind their hormones over a 100-fold range (Dallman, 2000). 
Therefore, two receptors are used to regulate the HPA activity. These two receptors differ in 
their affinities and their distribution in the central nervous system. The mineralocorticoid 
receptor (MR) is a high affinity receptor (dissociation constant Kd ~ 0.5nM) for aldosterone, 
cortisol, and corticosterone. Since glucocorticoids circulate in higher concentrations and 
enter the brain more easily than the mineralocorticoid aldosterone, brain MRs are 
predominantly occupied by cortisol and corticosterone. MRs are distributed in the entorhinal 
cortex, limbic structures, and in motor output neurons, but only a very low density of MRs is 
found in neurons of the hypothalamus. On the other hand, the glucocorticoid receptor (GR) is 
a lower affinity receptor (Kd ~ 5-30nM) and preferentially binds glucocorticoids in the order 
dexamethasone > cortisol > corticosterone > deoxycorticosterone > aldosterone. GRs are 
virtually ubiquitous in neurons and glia cells and among others found in hippocampus, 
amygdala, hypothalamus and catecholaminergic cell bodies of the brain stem. Comparing 
the distribution of the two receptors, MR and GR expression overlap in the hippocampus, 
more precisely in hippocampal dentate gyrus neurons and CA1 cells (De Kloet et al., 1998). 
Additionally, the hippocampus has numerous projections to the hypothalamus. Hence it is 
considered centrally in negative feedback regulation of the HPA axis. Beside the different 
affinities and largely distinct distribution, also distinct functions are assigned to MRs and 
GRs. MRs are thought to control basal activity of the HPA axis, whereas GRs (in 
coordination with MRs) regulate feedback during the circadian peak or after stress. 
The regulation of HPA activity by feedback inhibition is the result of a highly complex 
interplay of various factors. Feedback processes may be rate-sensitive or dose-sensitive and 
exist in fast, intermediate and slow time domains. Accordingly, they may occur directly or 
trans-synaptically and result in inhibition of CRF and/or ACTH synthesis and/or release. 
Again this depends on how MRs and GRs mediate their actions, via activating or repressing 
gene transcription, or via protein-protein interactions, whereas disproportionate interactions 
may result in resistance or supersensitivity of the receptors (Dallman, 2000; Dallman et al., 
1994; De Kloet et al., 1998; Jacobson and Sapolsky, 1991; Keller-Wood and Dallman, 1984). 
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2.1.2.1.4 Medial parvocellular PVN-projecting afferents 
Like the generation of circadian rhythmicity, generation of stress-related increases in 
HPA activity depends on relatively constant ultradian oscillations of parvocellular CRH and 
vasopressin neurons, and the superimposition of stress-related inputs (Chrousos, 1998b). In 
this regard, limbic afferents play a major role. Specifically, the ventral subiculum, infralimbic 
and prelimbic region of the medial prefrontal cortex, medial and central amygdaloid nucleus, 
lateral septum, and paraventricular thalamus are involved in the regulation of the PVN.  
In general, the parvocellular PVN receives little or no direct innervations from limbic 
stress-regulatory regions. Thus, at least one intervening synapse seems to be necessary to 
relay limbic input to the PVN. These relays are located in the subparaventricular zone, 
subnuclei of the bed nucleus of the stria terminalis, the medial preoptic area, the lateral 
hypothalamic area, the ventrolateral region of the dorsomedial nucleus, and the nucleus of 
the solitary tract. These local neurons contacted by descending limbic projections are mostly 
GABAergic and to a lesser extent glutamatergic and have inhibitory and excitatory influences 
on the HPA axis, respectively. Nevertheless, limbic GABA positive neurons (e.g. neurons in 
the medial amygdala) may excite the PVN through a GABA-GABA disinhibitory process 
(Herman et al., 2004; Herman et al., 2002). 
Other brain regions regulating HPA activity are the SCN and the ventromedial 
hypothalamic nucleus. Additionally, ascending afferents from the brainstem innervate the 
PVN (noradrenergic afferents, excitatory) or the peri-PVN region (cholinergic and 
serotonergic afferents, excitatory) (Herman et al., 2004). CRH and norepinephrine collateral 
fibers inhibit presynaptic CRH and noradrenergic receptors, respectively, constituting ultra-
short negative-feedback loops (Chrousos, 1995). Centrally secreted substance P in turn 
inhibits hypothalamic CRH neurons but not vasopressin neurons and stimulates the central 
noradrenergic system (Chrousos, 1998b). 
In summary, various interactions of the parvocellular PVN with neuronal systems 
subserving homeostasis, memory and emotionality exist. Inputs concerned with homeostasis 
emanate predominantly from a circumscribed set of medial parvocellular PVN-projecting 
afferents resident in the brainstem, hypothalamus and basal forebrain (Herman et al., 2002). 
They integrate circulatory stress signals from changes in blood volume or pressure through 
vagal afferent nerves, osmotic and chemical signals sensed humorally and through vagal 
afferent signals, as well as inflammatory and pain inputs, also sensed humorally and 
neurally, through vagal and sensory afferent nerves (Chrousos, 1998b). Furthermore, 
mnemonic and emotive processes affect parvocellular PVN neurons predominantly via limbic 
circuits (Herman et al., 2004; Herman et al., 2002). 
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2.1.2.2 Sympathetic Nervous System 
The sympathetic nervous system is the second system involved in physiological 
stress responses and one of three divisions of the autonomic nervous system (ANS). 
2.1.2.2.1 Autonomic nervous system compared to the somatic motor system 
In contrast to the somatic motor system that controls voluntary movement, the ANS 
regulates internal organs and the eyes (Lovallo and Sollers, 2000) and is often referred to as 
autonomic (or visceral) motor system or involuntary motor system (Dodd and Role, 1991). 
Beside the extent of voluntary control, the two systems also differ in the anatomical 
organization. Somatic motor neurons project directly to target skeletal muscles from the 
central nervous system, i.e., the efferent pathway to skeletal muscle is monosynaptic. 
Whereas autonomic preganglionic motor neurons project to autonomic postganglionic motor 
neurons, which in turn synapse on their visceral targets. Thus, in the ANS the efferent 
pathway to the target is disynaptic. Further, all somatic motor neurons are excitatory and 
inhibition is exerted indirectly by inhibiting the motor neurons in the spinal cord that excite the 
muscle. In contrast, the ANS is able to excite and inhibit targets directly (Dodd and Role, 
1991). 
2.1.2.2.2 Anatomy and neurotransmitters of the autonomic nervous system 
The tree divisions of the ANS – sympathetic, parasympathetic and enteric division – 
in turn differ anatomically in the positions of the preganglionic neurons and in the 
organization of postganglionic neurons: Preganglionic cells of the (1) sympathetic nervous 
system (SNS) extend from the first thoracic spinal segment to lower lumbar segments (T1 to 
L3; see left side of fig. 2-5). The cell bodies are found within the spinal cord, primarily within 
the inter-mediolateral gray matter. The axons of these neurons emerge through the ventral 
root, enter the spinal nerve, project through the white rami communicantes to the 
paravertebral chain ganglia, and synapse with postganglionic neurons. The axons may also 
travel within the ganglionic connective and synapse with postganglionic neurons located in 
other ganglia than the ganglion corresponding to the segmental level at which their cell 
bodies are located. This divergence with a ratio of preganglionic to postganglionic fibers of 
approximately 1:10 permits coordinated activation of sympathetic neurons at several spinal 
levels. Axons of postganglionic neurons then exit through the gray rami communicantes and 
travel along branches of the carotid arteries innervating structures in the head or travel in the 
spinal peripheral nerves innervating autonomic targets like the heart, lungs, or bronchi. Some 
preganglionic fibers do not synapse in the paravertebral chain ganglion but on neurons of the 
prevertebral ganglia (celiac ganglion, superior mesenteric ganglion, and inferior mesenteric 
ganglion) innervating the gastrointestinal system, the kidneys, pancreas, liver, bladder, and 
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external genitalia. A fourth group of preganglionic fibers runs with the thoracic splanchnic 
nerve into the abdomen directly innervating cells of the adrenal medulla, which are 
developmentally and functionally related to postganglionic sympathetic neurons. On the other 
hand, preganglionic neurons of the (2) parasympathetic nervous system (PNS) are located 
within the brain stem in several nuclei and in segments S2 to S4 of the spinal cord and 
project to postganglionic neurons in ganglia that are close to visceral targets or actually 
embedded in them (see right side of fig. 2.5). Neurons of the (3) enteric nervous system 
(ENS) eventually are arranged in interconnected plexuses, situated between the various 
layers of muscle and endothelium and innervating the gastrointestinal tract, pancreas, and 
gall bladder. The ENS is composed of local sensory neurons that register alterations, as well 
as interneurons and motor neurons that control the muscles and the secretory activity of its 
targets. The enteric nervous system is regulated by an extrinsic innervation that is supplied 
by the parasympathetic and sympathetic systems, both of which can override intrinsic enteric 
activity in situations of emergency or stress (Dodd and Role, 1991; Lovallo and Sollers, 
2000). 
 
Fig. 2-5: Preganglionic and postganglionic neurons of sympathetic and parasympathetic divisions of the 
autonomic nervous system and their targets. 
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Synapses of the ANS use two neurotransmitters, acetylcholine (ACh) and 
norepinephrine (NE). All preganglionic neurons communicate to their postganglionic neurons 
using ACh and all postganglionic parasympathetic neurons secrete ACh at their 
neuroeffector junctions. In contrast to the PNS, sympathetic fibers secrete NE at their 
effectors (see fig. 2-5). However, there are two exceptions: (1) Specialized sweat glands of 
the palms of the hands and soles of the feet and (2) the medulla of the adrenal gland are 
activated by ACh. Additionally, small neurons that communicate directly between the larger 
pre- and postganglionic neurons secrete dopamine, which inhibits the ganglionic neurons 
(Lovallo and Sollers, 2000). 
2.1.2.2.3 Regulation of the autonomic nervous system 
The output of the autonomic nervous system is influenced by three control 
mechanisms. First, local ANS regulation is provided by the action of locally released 
peptides, neuromodulators, and metabolites. Second, ganglionic mechanisms regulate the 
output of ANS postganglionic neurons. Third, the brain stem, specifically the nucleus of the 
solitary tract (NTS), and the hypothalamus exert regulation on the entire ANS. Under 
psychological stress, the hypothalamus also integrates information of the cerebral cortex, 
hippocampus, entorhinal cortex, parts of the thalamus, basal ganglia, cerebellum, and the 
reticular formation. These changes originating in the highest centers of the brain can be seen 
as a final layer of control over the ANS. To exert control over the ANS, the hypothalamus not 
only projects to nuclei in the brain stem and the spinal cord that act on preganglionic 
autonomic neurons, but also acts on the endocrine system to release hormones that 
influence autonomic function. On the other hand, many autonomic functions do not require 
continuous monitoring by the hypothalamus. In this regard, sensory fibers project to specific 
subnuclei within the NTS and these neurons project to lower brain stem nuclei that connect 
to autonomic motor neurons controlling effectors, thereby constituting a set of reflex circuits 
by which the NTS controls simple autonomic functions. Elaborate homeostatic adjustments 
are coordinated by transmitting information from autonomic targets to higher and lower brain 
regions. In particular, visceral afferents terminate in the commissural nucleus of the NTS, 
which in turn projects to brain stem and forebrain nuclei, such as amygdala, paraventricular 
hypothalamic nucleus, and bed nucleus of the stria terminalis. These nuclei then project back 
to the NTS and lower brain stem nuclei, the latter again projecting directly to the dorsal vagal 
nucleus and sympathetic preganglionic nuclei (Dodd and Role, 1991; Lovallo and Sollers, 
2000). 
2.1.2.2.4 Role of the sympathetic nervous system in stress 
Sympathetic nervous system activation aims at maintaining homeostasis and is 
prominent in orthostasis, mild to moderate exercise, thermoregulation, and the postprandial 
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state. In response to perceived global, metabolic threats like hemorrhage, hypoglycemia, 
shock, or psychological stress, SNS changes do not suffice and increased neural outflow to 
the adrenal medulla elicits catecholamine secretion from the adrenal medulla. As mentioned 
above, the adrenal medulla is one target organ of the sympathetic nervous system, which in 
addition is innervated directly by preganglionic fibers. The catecholamines secreted are the 
hormones norepinephrine and epinephrine, which are synthesized in adrenal chromaffin cells 
from the amino acid precursor tyrosine. Upon entry into adrenal chromaffin cells, tyrosine is 
converted to L-dihydroxyphenylalanine (DOPA) by the enzyme tyrosine hydroxylase. DOPA 
in turn is converted into dopamine by aromatic-L-amino-acid decarboxylase and dopamine is 
then taken up into storage vesicles and converted into norepinephrine by dopamine--
hydroxylase. The last step in catecholamine biosynthesis is the conversion of norepinephrine 
to epinephrine by phenylethanolamine-N-methyltransferase (PNMT). Norepinephrine and 
epinephrine are stored in granules of separate populations of chromaffin granules and 
released via exocytosis. In contrast to norepinephrine, the adrenal medulla is the sole source 
of circulating epinephrine in all mammalian species, including humans, while norepinephrine 
released from the adrenal medulla makes up to only 35% of levels measured in bloodstream. 
The remaining 65% are a small proportion of norepinephrine released locally from 
sympathetic nerve terminals and reaching the bloodstream (Goldstein, 2000; Kvetnansky 
and McCarty, 2000; Pollard, 2000). 
Accumulating evidence supports an independent regulation of sympathetic nervous 
system and sympathoadrenal system. Each of these two systems can be activated 
independently from the other by distinct stimuli. While cold exposure and postural changes 
primarily affect sympathetic nervous system activity, mental effort and caffeine ingestion are 
considered stimuli for the adrenal medulla. When SNS activity is suppressed by fasting, 
adrenal medullary responses to various stimuli are enhanced. For certain stimuli the SNS 
response is biphasic, with an initial suppression followed by subsequent stimulation. During 
the first phase adrenal medullary secretion is markedly increased (Young et al., 1984). 
Catecholamines and specifically epinephrine have many of the same actions as direct 
sympathetic stimulation, but effects last considerably longer. Additionally, a distinction must 
be made between neural and hormonal effects, since the latter can also reach organs 
without direct sympathetic innervation. In parallel to the HPA axis, the sympathoadrenal 
system is often referred to as sympathetic adrenal medullary (SAM) axis and the SAM 
response with release of predominantly epinephrine “fight or flight” reaction. (Goldstein, 
2000; Kvetnansky and McCarty, 2000; Pollard, 2000). As mentioned above, catecholamines 
further play an important role in the regulation of mpPVN neurons: They stimulate the release 
of CRH and hence the HPA axis. 
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2.1.3 Activation of Stress Systems 
The former sections described two systems mainly involved in physiological stress 
response. To identify the stimuli, which are able to activate the HPA and SAM axes and thus 
to elicit a stress response, numerous studies were conducted and a multitude of situations 
and events inducing elevated HPA and SAM activity were identified. Therefore, the following 
descriptions are mainly based on a publication by Mason, reviewing studies published 
between 1921 and 1968 (Mason, 1968), and on a publication by Biondi and Picardi, 
reviewing studies published between 1979 and 1999 (Biondi and Picardi, 1999). Both 
reviews focused on psychological stress, since – as Mason concluded – psychological stimuli 
are the most potent activators of the HPA axis. Generally, situations and events eliciting a 
physiological stress response can be subdivided into laboratory stressors and real-life 
stressors. 
2.1.3.1 Laboratory Stressors 
Common laboratory stressors are mental arithmetic tasks, mental arithmetic tasks 
combined with a speech test, the Stroop color-word conflict test, videogame playing, 
presentation of films and videotapes, interviews, and various multiple task protocols 
combining several of the aforementioned tasks. These stressors additionally vary in duration 
and general conditions (e.g., with or without time pressure; attitude of the experimenter; 
presence of an audience or a video camera; presence of distractors). Significant increases in 
epinephrine and/or norepinephrine were found in virtually every study, except for studies 
presenting films and videotapes, and appeared to be related to the amount of effort, feelings 
of alertness and action proneness, active coping, and sense of control. This does not apply 
to stress responses in cortisol. Cortisol increases were mainly reported in studies using 
combinations of mental arithmetic tasks and speech tests, including recording of the speech 
ostensibly for a subsequent analysis of the verbal and nonverbal performance or for 
televising to an audience (Biondi and Picardi, 1999). Interestingly, this kind of tasks feature 
characteristics comparable to the domains proposed by Mason, namely novelty, 
unpredictability, anticipation, and ego-involvement (Mason, 1968). Applying the stress 
concept of Levine and Ursin, in these situations positive response outcome expectancies are 
low and therefore the inability to cope, i.e. gaining control, results in high levels of stress 
(Levine and Ursin, 1991). A meta-analysis of 80 laboratory studies by Dickerson and 
Kemeny confirmed these results (Dickerson and Kemeny, 2004): “One important set of 
determinants of cortisol responses appears to consist of (a) a motivated performance task, 
(b) relative uncontrollability of task outcome, and (c) presence of social evaluation”. Studies 
which combined these determinants all used a combination of a mental arithmetic task and a 
speech task in front of an audience and/or a video camera. The presence of others which 
THEORETICAL BACKGROUND 23 
could negatively judge performance can be interpreted as an social-evaluative threat or a 
threat to the goal of maintaining the social self (i.e. one’s social value, esteem, and status, 
largely based on others’ perceptions of one’s worth). Notably, social-evaluative threat also is 
an important element in two domains proposed by Mason. These are the domains ambiguity 
and involvement, situations in which long-established rules are suddenly changed and in 
which one must master a difficult task in order to forestall aversive stimuli (Mason, 1968). On 
the other hand, uncontrollability includes one’s inability to avoid negative consequences or 
succeed despite one’s best efforts, corresponding to hopelessness and helplessness, 
respectively, according to Levine and Ursin (Levine and Ursin, 1991). Dickerson and Kemeny 
also referred to the interweavement of uncontrollability and novelty, which could certainly be 
extended to unpredictability: When a situation is novel or unpredictable, the outcomes are 
less certain and hence less controllable. 
2.1.3.2 Real-Life Stressors 
Looking at the results of studies investigating potential real-life stressors, very often 
the same underlying motives and processes can be proposed. Real-life stressors may be 
loss events (e.g. death of a loved one, loss of employment, or loss of home), academic 
examinations, anticipation of surgical interventions, work demands, or public speaking, but 
also acute battle danger, auto racing, or the first parachute jump. A mother perceives 
hopelessness and helplessness, if the child is dying from leukemia. Academic examinations 
and public speaking are social-evaluative threats and more or less controllable. This may 
also apply to a work position with high levels of psychological demands and low level of 
decision latitude. In situations of acute battle danger, a first parachute jump, or the 
anticipation of surgical interventions another aspect may come into play. Such situations 
inhere threats to the goal of physical self-preservation and already Selye (see above) 
showed the potency of such stimuli to elicit a stress response (Mason, 1968). 
2.1.3.3 Physical Exercise 
Beside psychological stressors, also physical exercise can activate the HPA axis. 
Given an adequate work load (i.e., >70% VO2max), cortisol levels will rise and reflect the 
duration of physical stress (Mason et al., 1973). Similar results are observed e.g. in marathon 
runners (Cook et al., 1992). But despite the work load, several studies also showed the 
importance of psychological factors. Pancheri et al. found increases in cortisol levels before 
the start of a competition only in individual competitors, not in athletes who were members of 
a team (Pancheri et al., 1982). Beulen et al. investigated ballroom dancers during training 
sessions and during an tournament and reported sharp cortisol increases only during the 
tournament. The latter was even more pronounced in pair dancers than in group dancers 
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(Beulen et al., 2005). These studies not only emphasize the role of social-evaluative threat, 
but also the role of social support in modulating hormonal reactivity to stress. 
Nevertheless, large inter-individual variability remains a stable finding. Therefore, it is 
important to consider variables repeatedly observed to modulate cortisol stress responses. 
Among these are genetic predisposition, personality and coping style, age, gender, 
menstrual cycle, oral contraceptives, smoking, and early experiences (Biondi and Picardi, 
1999; Kirschbaum and Hellhammer, 1994; Kirschbaum et al., 1999; Kudielka and 
Kirschbaum, 2005; Levine, 2000). 
2.1.4 Protective Effects of Stress Mediators 
While since 1914 (Cannon, 1914) there was scarcely any disagreement regarding 
effects and biological significance of increases in adrenal medulla hormones (i.e., 
epinephrine and norepinephrine) during stress, this does not hold true for glucocorticoids. 
During the first half of the 20th century, stress-induced secretion of glucocorticoids 
were thought to increase resistance to stress by stimulating defense mechanisms. This view 
was proposed also by Selye in an influential review in 1946, in which he additionally 
proposed the concept of “diseases of adaptation” (Selye, 1946). Such diseases were 
postulated to be caused by excessive or abnormal adaptive reactions to stress and Selye 
listed diffuse collagen disease, allergy, and rheumatic diseases as examples. Despite the 
controversial discussion elicited by his theory that one of the principal causative agents of 
these diseases was excessive secretion of mineralocorticoids in response to stress, another 
event would challenge the traditional view and change the history of glucocorticoid 
endocrinology. In 1949, Phillip S. Hench published – together with Kendall, Slocum, and 
Polley – a paper with the title: “The effect of a hormone of the adrenal cortex (17-hydroxy-11-
dehydrocorticosterone: Compound E) and of pituitary adrenocorticotropic hormone on 
rheumatoid arthritis”, in which he described the relief from symptoms of rheumatoid arthritis 
following treatment with cortisone or ACTH (Hench et al., 1949). Thus, while Selye predicted 
that over-activity of the adrenal cortex was an etiologic factor in diseases as rheumatoid 
arthritis, suddenly hormones of the pituitary-adrenocortical axis exerted the contrary, namely 
suppressive effect. This controversy was resolved without further ado by excluding the anti-
inflammatory effects from physiology. Henceforth, attention moved to the pharmacological 
actions and new clinical applications of these hormones and away from investigating their 
physiological role. 
Notwithstanding this time of change, Dwight J. Ingle investigated the role of adrenal 
cortex hormones in metabolic processes. In 1952, he emphasized the permissive role of 
adrenocortical hormones in stress responses, in that their presence at basal levels is 
necessary but not causative for an adequate metabolic stress response. He reached this 
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conclusion despite his own observation that “adrenalectomized rats which were on a fixed 
intake of adrenocortical extract, an amount which represented full replacement under non-
stress conditions, had insufficient hormone during stress and the glycosuria fell sharply” 
(Ingle, 1952). But although Ingle ignored the relevance of this former finding, he uncovered 
an important and new aspect of glucocorticoid actions in the stress response, i.e. their 
permissive actions. 
About the same time, Marius Tausk published a paper in the periodical of a 
pharmaceutical firm (Organon, The Netherlands), whose German title roughly translates to: 
“Does the adrenal gland actually play a role in defense?” (Tausk, 1951). Unfortunately, this 
paper did not enter the regular literature and hence only quotations by other authors can be 
given. According to De Kloet, Tausk pointed out that glucocorticoids block primary stress 
reactions (De Kloet, 2004), respectively restrain defense reaction to stress, which would 
themselves become damaging if left uncontrolled (De Kloet et al., 1998). According to 
Sapolsky et al., Tausk compared stress to a fire and the role of GCs to that of preventing 
water damage rather than putting out the fire (Sapolsky et al., 2000). Eventually Korte et al. 
wrote about “a somewhat modified version of Tausk’s metaphor of ‘water used by firemen’”, 
based on which they concluded that “just like the fireman’s water stress responses are 
ideally beneficial, they can impose a cost to the body, particularly when they are either 
elicited too often or are inefficiently managed” (Korte et al., 2005). Taken together, already in 
1951, Tausk suggested an important role of glucocorticoids in preventing other stress-
induced responses from overshooting and subsequently damaging the organism. 
Since then, this aspect of glucocorticoid actions has been repeatedly assumed, with 
the difference that these times it also entered the regular literature. Besedovsky and Sorkin, 
for example, argued that in the immune system activation of other cells than highly antigen 
specific cells would lead to a disturbance of the system and hence may be potentially harmful 
to the host. Additionally, an excessive expansion of lymphoid cell mass would raise the 
concentration of soluble mediators to an undesirable or possibly even dangerous extent. In 
this context, “an increase of corticosteroids may well have this very function of suppressing a 
potentially harmful expansion of lymphoid tissue of low or no affinity for the antigen” 
(Besedovsky and Sorkin, 1977). Shortly thereafter, Munck, Guyre and Holbrook 
hypothesized “that (1) the physiological function of stress-induced increases in glucocorticoid 
levels is to protect not against the source of stress itself, but against the normal defense 
reactions that are activated by stress; and (2) the glucocorticoids accomplish this function by 
turning off those defense reactions, thus preventing them from overshooting and themselves 
threatening homeostasis” (Munck et al., 1984). This new perspective and the discovery that a 
single, basic molecular mechanism (i.e., via glucocorticoid receptor) initiates most 
glucocorticoid actions (Munck and Leung, 1977), had an unifying influence on glucocorticoid 
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endocrinology. In his later works, Munck additionally incorporated the permissive effects of 
glucocorticoids proposed by Ingle (Ingle, 1952). In his view, under normal conditions, 
permissive effects prime defenses for action, while after stress the delayed suppressive 
effects of glucocorticoids prevent stress-activated immediate defenses from overshooting 
(Munck, 2000; Munck and Naray-Fejes-Toth, 1992). 
Chrousos does not draw this distinction but rather regards activation of stress 
systems as normally adaptive, improving chances of an individual for survival by leading to 
behavioral and physical changes (Chrousos, 1998a). These changes are listed in table 2-1. 
Tab. 2-1: Behavioral and physiological adaptation during acute stress (Chrousos, 1998a). 
Behavioral adaptation 
adaptive redirection of behavior 
Physical adaptation 
adaptive redirection of energy 
o increased arousal and alertness 
o increased cognition, vigilance, and 
focused attention 
o euphoria or dysphoria 
o heightened analgesia 
o increased temperature 
o suppression of appetite and feeding 
behavior 
o suppression of reproductive behavior 
o containment of the stress response 
o oxygen and nutrients directed to the CNS and 
stressed body site(s) 
o altered cardiovascular tone, increased blood 
pressure and heart rate 
o increased respiratory rate 
o increased gluconeogenesis and lipolysis 
o detoxification from toxic products 
o inhibition of growth and reproductive systems 
inhibition of digestion-increased colonic motility 
o containment of the inflammatory-immune response 
o containment of the stress response 
 
Since Chrousos mainly focused on the clinical implications associated with the stress 
system, especially HPA axis dysfunction (e.g., Chrousos and Gold, 1998; Chrousos, 2000), 
the chronology of stress hormone secretion and differential effects of adrenal medulla and 
adrenal cortex hormones were not considered. 
A new framework, which integrated all the above mentioned views and the large array 
of results on glucocorticoid effects on many different target tissues, was compiled by 
Sapolsky, Romero, and Munck (Sapolsky et al., 2000). In this regard, they first considered 
recent findings and, based on them, generated criteria for determining the appropriate 
glucocorticoid action on target tissues. In doing so, they accounted for the different time-
courses of stress mediators as well as the time-courses of their physiological consequences. 
Basically, changes in hormone secretory patterns in response to a stressor can be 
divided into two consecutive but distinct responses, the so-called first wave and the second 
wave. In the first wave, occurring within seconds, an enhanced secretion of catecholamines 
from the sympathetic nervous system, the hypothalamic release of CRH, and (approximately 
10 seconds later) enhanced secretion of pituitary ACTH, a decreased hypothalamic release 
of GnRH, and (shortly thereafter) a decreased secretion of pituitary gonadotropins, the 
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pituitary secretion of prolactin and growth hormone, and the pancreatic secretion of glucagon 
can be observed. Minutes later, the second wave involves the stimulation of glucocorticoid 
release and declines in gonadal steroid secretion. The immediate physiological 
consequences of a stress-response – attributable to catecholamines and CRF – include 
increased cardiovascular tone, immune activation, energy mobilization, loss of proceptive 
and receptive sexual behavior, loss of appetite, increased cerebral blood flow and cerebral 
glucose utilization, and enhanced memory consolidation (Sapolsky et al., 2000). 
What are glucocorticoids doing then? To answer this question, Sapolsky et al. 
distinguished in a first step two classes of glucocorticoid actions. Modulating actions alter an 
organism’s first wave response to stress and preparative actions alter the organism’s 
response to a subsequent stressor or aid in adapting to a chronic stressor. The former are 
further divided into three subclasses, resulting in four classes of glucocorticoid actions: 
1) Permissive actions: GCs present before the stressor prime defense mechanisms. In this 
case, consequences occur whether or not there is a stress-induced increase in GC 
concentrations (cp. Ingle, 1952). 
2) Suppressive actions: stress-induced rise in GCs – with an onset of from about 1 hour or 
more after the onset of the stressor – reins in the stress-activated first wave defense 
reactions and prevent them from overshooting (cp. Besedovsky and Sorkin, 1977; Munck 
et al., 1984; Tausk, 1951). 
3) Stimulating actions: stress-induced rise in GCs enhances the effects of the first wave with 
an onset of from about 1 hour or more after the onset of the stressor (cp. protection 
against stress by stress-induced levels of GCs (Selye, 1946). 
4) Preparative actions: GCs do not affect the immediate response but modulate the 
response to a subsequent stressor. This action may be permissive, stimulating or 
suppressive. 
Importantly, labeling an action as permissive, suppressive or stimulating depends on 
the effects of the first wave. If a glucocorticoid action reduces a first wave effect, may that be 
stimulating or suppressive, the glucocorticoid action is termed suppressive. On the other 
hand, if a glucocorticoid action enhances a first wave effect, may that be stimulating or 
suppressive, the glucocorticoid action is labeled stimulating. If the latter effect is due to basal 
levels present before the first wave, it would be termed permissive. 
Beside this so-called criterion of conformity, three further criteria were applied for 
analyzing the role of GCs in the stress response: the criterion of time course (When does an 
GC effect occur?), the criteria of hormone subtraction and replacement (Is a first wave effect 
attenuated or enhanced if there is no stress-induced rise in GC activity, respectively, is it 
attenuated if basal GC actions are eliminated? Does administering of stress or/and basal 
levels of GCs restore the stress response?), and the criterion of homeostasis (Which of the 
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four particular GC actions make more physiological sense in terms of restoring 
homeostasis?). 
In the context of these criteria, Sapolsky et al. reevaluated glucocorticoid actions in 
selected physiological systems and the following four sections are geared to their framework. 
These sections are (1) cardiovascular effects, (2) metabolic effects, (3) neurobiological 
effects, and (4) effects on immunity and inflammation. Since glucocorticoid actions on the 
immune system are a main focus of this thesis, at this point only a very short synopsis will be 
given and effects will be discussed in greater detail in the respective section later in this work 
(2.3.2: brain-to-immune system communication). 
2.1.4.1 Cardiovascular Effects 
As stated above, catecholamines and CRH mediate the rapid activation of the 
cardiovascular system, which involves elevated arterial pressure, heart rate, and cardiac 
output, diversion of blood to muscle via constriction of mesenteric and renal vessels, and 
dilation of vessels supplying skeletal muscles (Galosy et al., 1981). On the other hand, it is 
long known that glucocorticoids also increase blood pressure and cardiac output (Sambhi et 
al., 1965). This narrows the question about GC actions to stimulating or permissive actions. 
In this regard, most findings point to a permissive action. For example Grünfeld et al. found 
that in normal unstressed rats increases in systolic blood pressure due to treatment with the 
GC agonist RU26988 could be prevented by pre- or post-treatment with the GC antagonists 
RU38486 or progesterone (Grunfeld et al., 1985). Three years later, they observed that while 
RU486 did not alter basal cardiac output and renal blood flow, pre-treatment significantly 
attenuated pressor responses to angiotensin II and norepinephrine in Wistar rats (Grunfeld 
and Eloy, 1987). Additionally, decreased blood pressure in Addisonian and adrenalectomized 
individuals were observed in numerous studies. 
Taken together, these result point to a permissive action of glucocorticoids as 
proposed by Ingle (Ingle, 1952). However, stimulatory actions are so far untested and hence 
can not be excluded. Since both permissive and stimulatory actions enhance the first wave 
response to a stressor, Sapolsky et al. referred to them collectively as helping to mediate the 
stress response. In this regard, glucocorticoids can clearly identified as mediating the 
cardiovascular stress response (Sapolsky et al., 2000). 
2.1.4.2 Metabolic Effects 
During acute stress, blood glucose levels are elevated rapidly by mobilization from 
existing stores and by inhibition of further storage through a rapid insulin resistance. This is 
due to catecholamines, glucagon, and GH and makes sure that energy is diverted from 
storage sites to exercise muscle. 
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Glucocorticoids are known for also increasing circulating glucose concentrations. This 
is achieved by several mechanisms: stimulation of glycogenolysis, (hepatic) 
gluconeogenesis, and glycogen deposition, inhibition of peripheral glucose transport and 
utilization, as well as induction of lipolysis, mobilization of amino acids, and stimulation of 
proteolysis (Pearson-Murphy, 2000). Importantly, glucocorticoid actions under basal 
conditions or after injury (reviewed in Dallman et al., 1993) have to be distinguished from 
actions taking place under acute stress. Under basal conditions, glucocorticoid actions 
mostly oppose with those of insulin. Based on these effects and on observations of increases 
in glucocorticoids after insulin administration (De Feo et al., 1989), glucocorticoids can be 
termed counter-regulatory or suppressive as they prevent insulin-induced hypoglycemia from 
overshooting. This corresponds to the view of Munck (Munck et al., 1984). 
On the other hand, Ingle termed the role of glucocorticoids in metabolism “permissive” 
since they permit other hormones to produce normal responses (Ingle, 1952). Since Ingle, 
the interaction of glucocorticoids, glucagon and epinephrine in the control of glucogenolysis, 
gluconeogenesis, and lipolysis was repeatedly demonstrated. For example, Exton et al. 
examined the effects of glucagon and epinephrine on gluconeogenesis and glycogenolysis in 
the liver and of catecholamines and ACTH on lipolysis in adipose tissue in normal and 
adrenalectomized rats (Exton et al., 1972). In adrenalectomized rats, they found markedly 
reduced glucagon or epinephrine stimulation of glucose synthesis from lactate. The 
gluconeogenic response to glucagon was restored when dexamethason was administered 
30 min prior to perfusion. Physiological concentrations of epinephrine and glucagon also did 
not normally activate glucose release and phosphorylase in livers from adrenalectomized 
rats. Furthermore, livers from these rats showed diminished activation of gluconeogenesis. 
Epinephrine stimulation of free fatty acid and glycerol release was impaired, as was the 
activation of lipolysis by norepinephrine and ACTH reduced. 
In integrating results like the above stated into their framework and additionally 
considering time and dose range required for exerting effects on different processes, 
Sapolsky et al. summarized glucocorticoid actions in metabolism as follows: Since 
glucocorticoids synergize with catecholamines and glucagon to stimulate lipolysis and to 
elevate circulating glucose concentrations by stimulating glycogenolysis and 
gluconeogenesis, they can be categorized as permissive, whereas the slower stimulation of 
gluconeogenesis and inhibition of peripheral glucose utilization by stress-induced GCs also 
can be regarded as stimulatory. Finally, the stimulation of liver glycogen deposition takes 
hours and this restoring of glycogen levels is best classified as preparative (Sapolsky et al., 
2000). Again, this re-evaluation is in concert with Ingle’s view (Ingle, 1952) as well as with 
Selye’s view of glucocorticoids increasing stress-resistance (Selye, 1946). 
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2.1.4.3 Neurobiological Effects 
In the evaluation of neurobiological glucocorticoid effects, it will be focused on three 
topics, for there is information as to the effects of the early wave and dose-response 
information regarding glucocorticoid actions. These topics are (1) cerebral glucose transport 
and utilization, (2) appetite and feeding, and (3) memory formation. 
2.1.4.3.1 Cerebral glucose transport and utilization 
Many stressful events are accompanied by increases in cerebral blood flow and 
energy metabolism and appear to have a common adrenergic mechanism (Bryan, 1990). 
Since catecholamines do not easily pass the blood-brain barrier, this effect is most probably 
mediated by the SNS (Sapolsky et al., 2000). On the other hand, glucocorticoids inhibit 
glucose transport. For example, Kadekaro et al. found increased glucose utilization in 
adrenalectomy and prevention of this stimulatory effects on cerebral glucose metabolism by 
additional treatment with dexamethasone (Kadekaro et al., 1988). Horner et al. reported on 
inhibition of glucose transport in cultures containing both neurons and glia cells. These 
effects were dose- and time-dependent and preventable by a GR- but not a MR receptor 
antagonist (Horner et al., 1990). Further, several studies suggested that glucocorticoids may 
decrease glucose transport by causing translocation of glucose transporters from plasma 
membrane to an internal location (Carter-Su and Okamoto, 1985; Carter-Su and Okamoto, 
1987; Horner et al., 1987). The initial suggestion by these authors that glucocorticoids cause 
synthesis of some protein which in turn causes the transporter to shift was replaced by 
findings of Garvey et al., who observed dexamethasone to decrease transporter mRNA 
(Garvey et al., 1989). All these studies yield a clear picture of inhibitory glucocorticoid actions 
in cerebral glucose transport and utilization (Sapolsky et al., 2000). 
2.1.4.3.2 Appetite and feeding 
 During stress, appetite is suppressed by CRH acting as neurotransmitter (Arase et 
al., 1988; Krahn et al., 1986; Morley and Levine, 1982), while on the other hand 
glucocorticoids at basal levels stimulate appetite (Dallman et al., 1993), but at stress 
concentrations decrease appetite (Devenport et al., 1989). This latter effect is attributable to 
inhibitory effects of insulin stimulated by high concentrations of glucocorticoids. When 
preventing this secondary insulin effect, glucocorticoids stimulate appetite over the entire 
dose range (Dallman et al., 1993). In this regard and applying the criteria of Sapolsky et al., 
glucocorticoids can be categorized as suppressive. At first glance this action may not be 
biologically reasonable. But by glucocorticoids stimulating appetite, energy expenditure 
during phases of stress are counterbalanced and the organism is prepared for future 
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demands. Thus, glucocorticoid actions may further be regarded as preparative (Sapolsky, 
2000). 
2.1.4.3.3 Memory formation 
In 1994, Cahill et al. demonstrated nicely the catecholamine-mediated effect on 
memory (Cahill et al., 1994). In this study, subjects were read one of two stories which only 
differed in their emotional content. In both stories a boy and his mother are on a trip through 
town. In the first story they visit the boy’s father in the hospital and the staff demonstrates 
various medical procedures to the boy. In the second story the boy is seriously injured by a 
car, rushed to the hospital, and various medical procedures are carried out on him. Cahill et 
al. found marked enhancement of the memory for the emotionally laden details of the 
accident and subsequent procedures carried out on the boy. This effect was selectively 
eliminated by beta-adrenergic receptor blockade with propranolol. It is suggested that 
catecholamines exert their effect on memory by enhancing delivery of oxygen and glucose to 
the brain, as for example Manning et al. showed that elevation of glucose concentrations 
enhances episodic memory in the elderly as well as in Alzheimer’s patients (Manning et al., 
1993). 
Glucocorticoids exert more complex effects on memory formation. Diamond et al. 
demonstrated that stress-induced levels of glucocorticoids disrupt long-term potentiation 
(LTP) and/or primed burst potentiation (PBP) in hippocampus. However, lower 
concentrations, such as those seen during the diurnal rise, enhance plasticity (Diamond et 
al., 1992; Diamond et al., 1994). This biphasic effect of glucocorticoids on LTP and PBP 
suggests activation of MRs at low levels of glucocorticoids to increase and occupation of 
GRs by high levels of glucocorticoids to suppress hippocampal excitability (Diamond et al., 
1992; Pavlides et al., 1995). This is underlined by findings of adrenalectomy disrupting 
memory process in animals (Vaher et al., 1994), which is restored by occupancy of MRs, 
while MR antagonists again disrupt cognition (Oitzl et al., 1994). This is also true in humans. 
For example, administration of GR agonists to healthy volunteers was shown to disrupt 
memory within a few days (Wolkowitz et al., 1990) and stress-induced levels of 
glucocorticoids were repeatedly found to impair performance in declarative memory tasks 
(Kirschbaum et al., 1996). 
Taken together, glucocorticoids at basal levels can be regarded as permissive, since 
they enhance memory as catecholamines do. However, at stress levels they are 
suppressive, whereas the biological sense of this remains unclear (Sapolsky et al., 2000). 
Cumulating evidence indicates that the latter action has to be further differentiated: while 
glucocorticoids impair processes of memory retrieval and working memory, they dose-
dependently enhance consolidation of long-term memory (for review see Roozendaal et al., 
2005). 
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2.1.4.4 Effects on Immunity and Inflammation 
Classification of glucocorticoid actions regarding the immune system presents itself 
as very complex. The main problem arises from the criterion of conformity, since first wave 
hormones exert both stimulating and inhibitory effects. For example, catecholamines in vitro 
and after lipopolysaccharide injection suppress cytokines like tumor necrosis factor alpha 
(TNF-) and interleukin(IL)-6, and stimulate the anti-inflammatory cytokine IL-10 (van der 
Poll et al., 1994). On the other hand, DeRijk et al. found subcutaneous injection of 
epinephrine to induce a dose-dependent increase in plasma IL-6 concentration. In parallel, 
intravenous infusion of epinephrine resulting in concentrations similar to those observed 
during stress were found to increase IL-6 concentrations (DeRijk et al., 1994). Furthermore, 
Papanicolaou et al. reports on correlations between peak plasma epinephrine or 
norepinephrine and IL-6 levels 15 minutes after the onset of a treadmill exercise test run 
(Papanicolaou et al., 1996). The administration of another first wave hormone, namely CRF, 
seems to decrease T cell proliferation and natural killer cell cytotoxicity (Jain et al., 1991) but 
to enhance B cell proliferation in vitro (McGillis et al., 1989). Sapolsky et al. conclude that 
considering the criterion of conformity “offers little information regarding the classification of 
glucocorticoid actions because there is no consensus as to the effects of that first wave of 
hormones” (Sapolsky et al., 2000). 
However, it is unanimously agreed that various infectious as well as non-infectious 
(e.g., psychological) stressors rapidly activate the immune system and this immune system 
activation with the release of various cytokines in turn can stimulate the adrenocortical axis 
(Besedovsky and Sorkin, 1977). The most general effect of glucocorticoids is in turn to inhibit 
the synthesis, release, and/or efficacy of cytokines and other mediators of immune and 
inflammatory reactions (reviewed in (McEwen et al., 1997). Nevertheless, over the past two 
decades, a large variety of studies have shown that glucocorticoids also exert stimulatory 
actions on immune functions. Especially striking are effects of glucocorticoids on expression 
of cytokine receptors. While inhibiting the mediator (e.g. IL-6), glucocorticoids up-regulate the 
expression of its receptor (Snyers et al., 1990). Wiegers et al. postulated that distinct MR- 
and GR-mediated effects may underlie stimulatory properties of low physiological 
concentrations of glucocorticoids and the immunosuppressive action observed after 
prolonged pre-incubation with high concentrations of corticosteroids (Wiegers et al., 1994). 
Munck and Náray-Fejes-Tóth combined findings like these and proposed that high mediator 
levels, but few receptors at low glucocorticoid concentrations and high receptor levels, but 
little mediator at high glucocorticoid concentrations result in a biphasic or bell-shaped curve 
of mediator activity. Thus, compared to regulating just the mediator or the receptor, via this 
dual regulatory actions glucocorticoids can more effectively and tightly regulate mediator 
activity. By applying this model to basal and stress-induced conditions, Munck and Náray-
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Fejes-Tóth conclude that under normal conditions, permissive effects prime defenses for 
action, while suppressive effects prevent stress-activated defenses from overshooting 
(Munck and Naray-Fejes-Toth, 1992). Based on the criterion of homeostasis, the same 
conclusion is also drawn by Sapolsky et al. (Sapolsky et al., 2000): Glucocorticoids restrain 
defense reactions to stress, which would themselves become damaging if left uncontrolled 
(Besedovsky and del Rey, 1996). This view of glucocorticoid action on immune system 
additionally includes that glucocorticoids are no longer thought to unselectively inhibit all 
immune responses during stress, but rather to “sculpt” the immune response by inhibiting 
superfluous or autoimmune-prone components (Besedovsky et al., 1991). 
 
Taken together, the new analysis by Sapolsky et al. clearly extended and 
differentiated conclusions drawn by Munck et al. 16 years earlier (Munck et al., 1984). In 
applying the criteria of conformity, time course, subtraction, substitution, and homeostasis 
and in succession distinguishing permissive, stimulatory, suppressive and preparative 
actions, Sapolsky et al. point out the complex role of glucocorticoids in a complex interplay of 
different stress mediators. The cardiovascular, immunological, and cognitive effects of 
glucocorticoids as well as their effects on metabolism permissively help mediating the 
pending or ongoing stress-response and can be regarded as advantageous for homeostasis. 
The same is true for the suppressive actions of glucocorticoids on immune parameters, the 
preparative actions on appetite, and the preparative and stimulatory actions on metabolism. 
However, the homeostatic role of suppressive glucocorticoid actions on selected 
neurobiological parameters (i.e., glucose transport and utilization in the brain, appetite, and 
memory formation) remains to be elucidated. 
This analysis perspicuously emphasizes the importance of considering different 
glucocorticoid actions on different physiological systems at different time points and at 
different concentrations. This does not only have a bearing on designing studies, but is also 
of high clinical and therapeutic relevance. Above all, given such a complex interplay, it is 
conceivable to anticipate serious consequences with the utmost probability if only one of the 
stress systems shows malfunctions. Or to quote Sapolsky: “Where the trouble begins is 
when people start excreting those same hormones for reasons of chronic psychological 
stress” (Sapolsky, 2000). These very consequences, namely the damaging effects of stress 
mediators will be discussed in the following section. 
2.1.5 Damaging Effects of Stress Mediators 
Already 70 years ago, Selye recognized that physiologic systems activated by stress 
can not only protect and restore the organism but also damage the body (Selye, 1936a). 
Sapolsky et al. likewise differentiated between the beneficial and the damaging actions of 
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glucocorticoids: “glucocorticoid physiology should be thought of as the salutary responses 
(be they mediating or suppressive) to noxious stimuli, whereas glucocorticoid pathology 
occurs when the natural recovery phase to a noxious stimulus is prevented from occurring”. 
(Sapolsky et al., 2000). With this, Sapolsky already pointed out one potentially harmful 
condition, namely the failure of shutting down a stress response due to chronic stress. These 
opposed properties are also emphasized by Chrousos et al. (Chrousos, 1998a). Stress 
responses and the accompanying responses are normally seen as adaptive and improving 
chances of an individual for survival. But stress system dysfunctions are associated with 
various pathophysiologic states, including psychiatric, endocrine, and inflammatory disorders 
and/or susceptibility to such disorders. In this regard, Chrousos et al. distinguished between 
HPA axis hyperactivity and hypoactivity and summarized states associated with such altered 
HPA axis activities (see table 2-2). 
Tab. 2-2: States associated with altered HPA axis activity and altered regulation or dysregulation of behavioral 
and/or peripheral adaptation (Chrousos, 1998a). 
Increased HPA axis Decreased HPA axis 
Chronic stress 
Melancholic depression 
Anorexia nervosa 
Malnutrition 
Obsessive-compulsive disorder 
Panic disorder 
Excessive exercise 
  (obligate athleticism) 
Chronic active alcoholism 
Alcohol and narcotic withdrawal 
Diabetes mellitus 
Central obesity 
  (metabolic syndrome X) 
Childhood sexual abuse 
Psychosocial short stature 
Attachment disorder of infancy 
Gastrointestinal disease 
Hyperthyroidism 
Premenstrual tension syndrome 
Pregnancy (last trimester) 
Adrenal insufficiency 
Atypical-seasonal depression 
Chronic fatigue syndrome 
Fibromyalgia 
Hypothyroidism 
Nicotine withdrawal 
Post-glucocorticoid therapy 
Post-Cushing syndrome cure 
Postpartum period 
Post-chronic stress 
Rheumatoid arthritis 
 
In summary, all three theories imply that a stress response is basically protective as 
long as all its elements are well coordinated and the processes are executed in the correct 
order. They also name examples of failures (HPA axis hyperactivity or hypoactivity) and their 
consequences. But the main question remains: Under which circumstances and how do 
these normally adaptive responses exert their maladaptive effects and accelerate 
pathophysiology? 
To answer these questions, in 1993 McEwen and Stellar introduced a new theory 
which mainly focused on potentially damaging effects of stress mediators (McEwen and 
Stellar, 1993). And although McEwen et al. repeatedly broadened and further differentiated 
this theory in the following years, the basic framework persisted (McEwen, 2000a; McEwen, 
2000b; McEwen, 2004; McEwen and Seeman, 1999; McEwen and Wingfield, 2003a; 
McEwen and Wingfield, 2003b). The main advantage of this theory is that it provides a new 
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terminology, which recognizes the “housekeeping role” of stress mediators, allows for more 
stress mediators than glucocorticoids, and helps to better understand processes leading to 
disease (McEwen and Wingfield, 2003b). 
The starting point of this theory is the inadequateness of the term homeostasis to 
describe the observed changes in the physiological systems of interest. Homeostasis in the 
authors’ opinion applies strictly to a limited number of systems (e.g., pH or body temperature) 
that are truly essential for life and are therefore maintained within a narrow range (McEwen, 
1998a; McEwen and Stellar, 1993). Physiological responses to potentially stressful 
challenges demand adaptations in broader boundaries. To describe these mechanisms, 
McEwen et al. adopted the term allostasis introduced by Sterling and Eyer (Sterling and 
Eyer, 1988). Allostasis is defined as achieving “stability through change”, and is thus still an 
essential component of maintaining homeostasis. But allostasis applies to systems that 
maintain systems essentially for life (homeostasis) in balance by fluctuating to meet 
demands from external forces (McEwen, 2004; McEwen and Wingfield, 2003a; McEwen and 
Wingfield, 2003b). If and how systems like the HPA axis and/or the SAM axis respond to 
physical or psychological challenge (i.e., to potentially stressful situations) largely depends 
on two factors: The way a person perceives a situation and a person’s general state of 
physical health (McEwen, 1998a; McEwen, 1998b). Thus, the theory emphasizes the 
important role of cognitive mechanisms and incorporates the stress concepts proposed by 
Lazarus (Lazarus, 1993) and Levine & Ursin (Levine and Ursin, 1991). And it also makes 
allowance for influences on physiological responses exerted by personal behaviors like diet, 
smoking, drinking, or exercise, and individual differences due to factors like genes, 
development, or experiences (see fig. 2-6).  
 
Fig. 2-6: The stress response and development of allostatic load (taken from McEwen and Seeman, 1999). 
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Shaped by these factors, a physiologic response elicited by physical or psychological 
challenge is seen principally and in the first place as adaptive. This may even be true if 
responses are altered or sustained for limited periods1. But in the long run, adaptation has a 
price. These costs of adaptation are termed allostatic load and imply pathophysiologic 
consequences. Allostatic load is the converged result of stress, perturbations of the diurnal 
rhythm of stress mediators, genes, early life experiences, living and working environment, 
interpersonal relationships, influences of diet, exercise, sleep and other lifestyle factors which 
all affect body chemistry, structure, and function over a life-time (McEwen, 2000a). 
Four situations are associated with allostatic load2 (McEwen, 1998a; McEwen, 2000a; 
McEwen and Seeman, 1999): 
1. Frequent or chronic stress: the stress response is frequently turned on by novel events. 
For example, in the case of blood pressure, repeated surges can trigger myocardial 
infarction in susceptible persons (Muller et al., 1989). 
2. Lack of adaptation: the stress response fails to habituate to repeated stressors of the 
same kind. A repeated public speaking challenge usually results in habituation of the 
glucocorticoid stress response. But some individuals, who seem to lack self-confidence 
and self-esteem, fail to habituate and subsequently overexpose their bodies to stress 
hormones (Kirschbaum et al., 1995). 
3. Prolonged response: the stress response is not turned of efficiently after the challenge is 
over. One example of this is individuals with two parents who are hypertensive: they 
show prolonged elevation of blood pressure after a physiological stressor (Gerin and 
Pickering, 1995). 
4. Inadequate response: inadequate in this regard stands for lack of a response. Such a 
inadequate response by some allostatic systems in turn triggers compensatory increases 
in others. This is illustrated by the Lewis rat, which has less corticosterone than the 
Fischer rat and is therefore missing suppressive GC actions on secretion of inflammatory 
cytokines. Consequently, Lewis rat are vulnerable to inflammatory and autoimmune 
disturbances, which are not found in Fischer rats (Sternberg et al., 1989). 
                                            
1
 In later publications, McEwen et al. termed these altered and sustained activity levels of 
primary mediators, e.g. of glucocorticoids, ‘allostatic states’ and hypertension is given as an example 
(McEwen and Wingfield, 2003a). 
2
 In later publications, McEwen et al. additionally differentiate between allostatic load and 
allostatic overload. The former can be considered the result of daily and seasonal routines and is still 
seen as an adaptive response. The letter results if one superimposes on this additional load of 
unpredictable events in the environment, disease, human disturbance, and social interactions. 
Allostatic overload serves no useful purpose and predisposes the individual to disease (McEwen and 
Wingfield, 2003a; McEwen, 2004). 
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Importantly, the four given types of allostatic load are not alternative states, since for 
example frequent stress may lead to prolonged or inadequate responses. And particularly 
the fourth type of allostatic load demonstrates the advantage of a distinction between 
homeostatic and allostatic mechanisms as adverse health outcomes may result despite a 
stable milieu interieur. 
Further examples emphasizing the dual role of stress mediators – short-term adaptive 
actions that are protective (allostasis) and long-term effects that can be damaging (allostatic 
load) – are given for cardiovascular system, metabolism, brain and immune system. 
Regarding the cardiovascular system, catecholamines promote adaptation by adjusting heart 
rate and blood pressure to sleeping, waking, and physical exertion. An example for allostasis 
is the increase in blood pressure when we get out of bed. Such an increase maintains blood 
flow, permits an erect posture, and avoids “black-out” (Sterling and Eyer, 1988). Yet, the 
Whitehall II study showed that lack of control on the job may lead to repeated surges of blood 
pressure and thus increase the risk of coronary heart disease (Bosma et al., 1997). Closely 
related to cardiovascular effects is the role of adrenal steroids in metabolism. On the one 
hand they promote allostasis by activating and maintaining energy reserves, on the other 
hand HPA over-activity may lead to insulin resistance, accelerate progression towards type II 
diabetes, abdominal obesity, hypertension, and atherosclerosis (Brindley and Rolland, 1989). 
Regarding the central nervous system, stress mediators promote retention of memories of 
emotionally charged events (Cahill et al., 1994), however, HPA over-activity may lead to 
cognitive dysfunction by mechanisms that involve reduced neuronal excitability, neuronal 
atrophy, and, in extreme cases, death of brain cells, particularly in the hippocampus 
(McEwen, 2000b). Such changes, in turn, have clinical implications for disorders such as 
depression or post-traumatic stress disorder. For the immune system, the importance of 
balanced physiological responses is especially evident. While chronic over-activity of stress 
systems result in immuno-suppression associated with an enhanced risk of infectious 
diseases (McEwen et al., 1997), the absence of glucocorticoids allows other immune 
mediators to overreact and increase the risk of autoimmune and inflammatory disorders 
(Sternberg, 1997). Additionally, a study of Fernandez-Real et al. in 228 apparently healthy 
persons emphasized the interconnectedness of all these systems and the influence of 
confounding variables (Fernandez-Real et al., 2001): Increased concentrations of 
proinflammatory cytokines (i.e., IL-6) due to insufficient glucocorticoid signaling were found to 
be associated with insulin resistance in men (higher in smokers) and hypertension in women, 
thereby increasing the risk of diabetes and atherosclerosis. But proinflammatory cytokines 
also induce a syndrome of “sickness behavior”, which overlaps with stress-related 
neuropsychiatric and physical disorders like major depression and PTSD (Kent et al., 1992). 
Interestingly, cytokine receptors are found in brain regions, such as the hypothalamus and 
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hippocampus (Rothwell et al., 1996), and these cytokines are potent stimulators of CRH 
(Maier and Watkins, 1998). 
These latter examples already give an idea of the difficulty to determine the 
mechanisms leading from allostasis to allostatic load and subsequently to pathology. For 
example, Raison and Miller summarized just the causes for insufficient glucocorticoid 
signaling. Insufficient glucocorticoid signaling could thereby result from (1) decreased 
hormone bioavailability, caused by (1a) decreased production of upstream glucocorticoid 
secretagogues (ACTH, CRH), (1b) a primary deficit in adrenal hormone production and/or 
release, alterations in (1c) binding proteins, (1d) enzymes such as 11-beta-hydroxysteroid 
dehydrogenase, or (1e) the so-called ‘multidrug resistance pump’, which extrudes cortisol but 
not corticosterone from the cell, or from (2) decreased receptor-mediated signal 
transduction/reduced hormone responsiveness, due to alterations in (2a) number of 
receptors, (2b) binding affinity of receptors, (2c) functional capacity of receptors, or (2d) 
combination of alterations in all. Additionally, any HPA axis abnormality my also be a primary 
or a secondary adaptation to alterations elsewhere in the axis (Raison and Miller, 2003). But 
even if the physiologic origin for an altered concentration of a stress mediator is known, the 
question remains, what such a measurement represents in the cascade of events that lead 
from allostasis to allostatic load and finally to disease. For this reason, McEwen and Seeman 
proposed a new way of classifying such measures, which allows for relating what is 
measured to a pathophysiological process and also to incorporate new measures (McEwen 
and Seeman, 1999). For this purpose, the authors introduced a new formulation based on 
primary mediators leading to primary effects and then to secondary outcomes, which lead, 
finally, to tertiary outcomes that represent actual diseases. In this regard, primary mediators 
are chemical messengers, such as cortisol, norepinephrine, or epinephrine that are released 
as part of allostasis. These mediators cause cellular events (i.e. primary effects), like 
glucocorticoids regulating gene expression via interaction with DNA. In many cases, these 
primary effects are organ- and tissue-specific. Additionally, already at this stage pathways of 
different mediators may converge. Thus, secondary outcomes are mostly the result of more 
than one primary mediator. They rather reflect the cumulative outcome of primary effects in 
response to primary mediators (in a tissue- and organ-specific manner). One example for a 
secondary outcome is elevations in blood pressure. Eventually, tertiary outcomes are actual 
diseases or disorders such as cardiovascular disease that result of the allostatic load 
predicted from secondary outcomes. 
 
With this new terminologies, McEwen and coworkers strike a balance between the 
two extremes of “stress mediators are all protective” and the common sense of “stress 
makes people ill”. The concepts of allostasis and allostatic load overcome the ambiguity of 
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the term stress and emphasize the inter-individually varying factors constituting a 
physiological response and hence the resulting susceptibilities. The main advantage of their 
second framework is that it drives to decide, what a measure, for example elevated blood 
pressure, ultimately stands for. Such elevations may be part of the pathophysiological 
pathway of the metabolic syndrome, but they may also be a more primary indication of 
allostatic load that may lead to accelerated atherosclerosis as well as insulin resistance. 
2.1.6 Summary 
The sections above gave an overview of stress concept developments, the 
physiology of central and peripheral stress systems, as well as their activation. Additionally, 
protective and damaging effects of stress mediators were outlined. 
Psychosocial stress was shown to activate the HPA axis as well as the SAM axis. 
Further, their major end products (i.e., cortisol, epinephrine, and norepinephrine) were shown 
to have various and complex effects on many important body systems. Most important to the 
present work, hormones of the endocrine stress response were shown to influence immune 
functions. These interactions will again be discussed in greater detail in a later section (2.3: 
psychoneuroimmunology). 
However, a closely related question and one of the main questions of this thesis is: 
What consequences for health and disease are to be expected, if an endocrine stress 
response is missing permanently and context-independently? In the present work, the 
exceptional endocrine state ‘Addison’s disease’ was chosen as an approach allowing to 
investigate this problem formulation specifically in humans. The subsequent section will 
describe this disease in detail (2.2: Addison’s disease). Given the theoretical background 
regarding neuroendocrine stress responses outlined in the former sections, the exceptionality 
of this disease and its potential as an valuable alternative approach for 
psychoneuroendocrinological and -immunological problem formulations should become 
apparent. 
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2.2 ADDISON’S DISEASE 
In 1849, Thomas Addison (1793-1860), at this time a 56 year old physician at Guy’s 
Hospital, London, described a remarkable form of progressive pernicious anemia in a paper 
before the South London Medical Society, published in The London Medical Gazette, n.s: 8: 
517-518, 1849: 
“Its approach is first indicated by a certain amount of languor and restlessness, to 
which presently succeed a manifest paleness of the countenance, loss of muscular 
strength, general relaxation or feebleness of the whole frame, and indisposition to, 
or incapacity for, bodily or mental exertion. (…) the patient experiences a distressing 
and increasing sense of helplessness and faintness; the heart is excited, or 
rendered tumultuous in its action, the breathing painfully hurried by the slightest 
exertion, whilst the whole surface bears some resemblance to a bad wax figure; the 
patient is no longer able to rise from his bed; slight edema perhaps shows itself 
about the ankles; the feeling of faintness and weakness becomes extreme, and he 
dies either from sheer exhaustion, or death is preceded by signs of passive effusion 
or cerebral oppression.” (Addison, 1849) 
Even more interesting than the detailed description of this “idiopathic” anemia is an 
observation Addison made at the inspections of the bodies of three cases: “In all of them was 
found a diseased condition of the supra-renal capsules” (Addison, 1849). For the first time 
this form of anemia was linked to a diseased state of the adrenals. 
But it was not until six years later that Thomas Addison was convinced that the 
concurring facts he observed were not merely casual coincidences. He published a book with 
the title “On the Constitutional and Local Effects of Disease of the Supra-renal Capsules” 
(Addison, 1855), in which he described the signs and symptoms of “a morbid state”, the 
leading and characteristic features of which are “anemia, general languor and debility, 
remarkable feebleness of the heart’s action, irritability of the stomach” and – this symptom he 
did not mention before – “a peculiar change of color of the skin, occurring in connection with 
a diseased condition of the suprarenal capsules”. He additionally reported on the 
etiopathology and/or the results of post-mortem examinations of 11 cases. 
One year later, it is Armand Trousseau (1801-1867), who first proposed to call the 
suprarenal syndrome “Addison’s disease”, and in 1928, after reviewing the records of many 
cases, Brenner narrowed down the cause of Addison’s disease and concludes that the 
symptoms of this disease occur only when most of the adrenal cortex is destroyed and even 
if the adrenal medulla and the chromaffin tissues are normal (Brenner, 1928). 
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2.2.1 Definition 
Today different forms of adrenocortical insufficiency are distinguished, depending on 
which level of the HPA-axis is affected and thus the cause of the insufficiency: adrenals, 
pituitary, or hypothalamus (see fig. 2-7). 
Addison’s disease or primary adrenal insufficiency (PAI) is caused by bilateral 
destruction or impaired function of the adrenal cortex, whereas adrenal insufficiency 
manifests itself as a clinical disease if the functional adrenal mass falls below 10% (Ten et 
al., 2001). This reduction of adrenocortical cell mass is responsible for the characteristic 
deficiency of glucocorticoids and mineralocorticoids, or more specifically of cortisol and 
aldosterone, respectively. (Marzotti and Falorni, 2004). Due to the resulting missing negative 
feedback, over-secretion of ACTH is another typical symptom of PAI. 
Whereas destruction of the adrenal cortex itself is the cause of PAI, secondary 
adrenal insufficiency (SAI) may occur as a result of pituitary or hypothalamic disease. In both 
cases the cortisol deficiency is accompanied by an under-secretion of ACTH, and, in the 
case of hypothalamic diseases, additionally by an under-secretion of CRH. In SAI, only few 
patients show isolated corticotropin deficiency with adrenal failure (e.g. isolated deficiency of 
CRH or lymphocytic hypophysitis). Often other hormonal axes are also involved. A more 
frequent type of isolated SAI is that induced by glucocorticoid therapy (Oelkers, 1996). 
 
Fig. 2-7: Characteristics of different forms of adrenal insufficiency, compared with a healthy HPA-axis (PAI: 
primary adrenal insufficiency; SAI: secondary adrenal insufficiency, caused at the level of the pituitary=SAI1, or at 
the level of the hypothalamus=SAI2). 
Since this dissertation is focusing on Addison’s disease, SAI will not be described in 
further detail. 
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2.2.2 Prevalence 
Addison’s disease is a relatively rare disease with prevalence rates ranging from 39 
to 60 per million population according to Oelkers (Oelkers, 1996), 10 to 140 cases per million 
inhabitants in Western countries according to Marzotti (Marzotti and Falorni, 2004), or near 
120 per million according to Ten (Ten et al., 2001). These to some extent incongruent 
statements can be partially explained by taking into account that prevalence rates for 
Addison’s disease vary between countries: While in New Zealand 4,5 cases per million 
inhabitants were reported, 50 cases per million are registered in the USA, Northern Europe 
reports on 40 to 110, and Italy even 117 cases per million inhabitants (Betterle et al., 2002). 
Interestingly, Ten et al. point out that a survey of patients with Addison’s disease 
revealed that 60% had sought medical attention from two or more physicians before the 
correct diagnosis was ever considered. Additionally, no figures are available on the number 
of undiagnosed patients succumbing to adrenal insufficiency (Ten et al., 2001), leading to the 
assumption that prevalence rates may be even higher than mentioned above. 
The incidence of primary adrenal insufficiency is 4.7-6.2 per million in white 
populations (Arlt and Allolio, 2003). But while the prevalence is relatively stationary over the 
years (Betterle et al., 2002), the incidence seems to increase due to variation in rates of 
causes (Laureti et al., 1999; Lovas and Husebye, 2002). On average, age at diagnosis peaks 
in the fourth decade of life, with women more frequently affected than men (Arlt and Allolio, 
2003). But gender distribution and mean age at diagnosis vary widely depending on the 
cause of Addison’s disease. 
2.2.3 Signs, Symptoms, Disease Progression 
In Addison’s disease, all symptoms and signs can be attributed to glucocorticoid, 
mineralocorticoid, and/or adrenal androgen deficiency, caused by destroyed adrenals. 
Unfortunately, most of the symptoms of primary adrenal insufficiency are nonspecific and ill-
defined (Betterle et al., 2002). Patients may suffer from fatigue, dizziness, muscular 
weakness, abdominal pain, vomiting, diarrhea, headache, sweating, muscle and joint pain, 
and may show behavior changes. Because of this non-specificity of symptoms, the disease 
may be often misdiagnosed as depression or anorexia nervosa. 
Beside these symptoms, signs can be postural hypotension, weight loss, generalized 
pigmentation, darkened skin creases, pigmented buccal, mucosa, and nail bed, associated 
vitiligo and/or goiter. Biochemical analyses may reveal high plasma renin levels, 
hyponatremia, hyperkalemia, hypoglycemia, eosinophilia, and lymphocytosis (Ten et al., 
2001). The most specific sign of Addison’s disease is the hyperpigmentation of the skin and 
mucosal surfaces and the most specific symptom is salt craving (Betterle et al., 2002). 
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An aggravating factor in terms of diagnosis is the time course of the disease. In most 
cases the destruction of adrenal cells is a rather slow process. A survey, conducted in the 
Netherlands, comes to the conclusion that the time interval between onset of symptoms and 
correct diagnosis was, on average, almost 3 years (Zelissen, 1994). 
In the case of an acute adrenal insufficiency – i.e., a life-threatening adrenal crisis – 
typically severe hypotension or hypovolaemic shock, acute abdominal pain, vomiting, and 
often fever are present. Sometimes these symptoms lead to the wrong diagnosis of an acute 
abdomen (Arlt and Allolio, 2003). Here the survey reveals that in 50% of patients with 
Addison’s disease, it is an adrenal crisis that leads to the initial diagnosis of adrenal 
insufficiency (Zelissen, 1994). 
2.2.4 Laboratory Assessment of Primary Adrenal Insufficiency 
If PAI is suspected, several biochemical test can help to establish the correct 
diagnosis. If not mentioned otherwise, the following specifications are taken from Oelkers 
(Oelkers, 1996). The values given are guiding values and can vary according to the assay 
used. 
2.2.4.1 Basal Hormone Measurements 
In patients in whom adrenal insufficiency is merely to be ruled out, plasma cortisol 
levels measured between 8 and 9 a.m. provide a good first assessment of adrenal function. 
Concentrations of 19μg/dl (525nmol/l) rule out adrenal insufficiency, whereas levels 3μg/dl 
(83nmol/l) are indicative of the disorder. For the interpretation of the results it is important to 
bear in mind that total cortisol levels can be increased as a result of hepatic cortisol-binding 
globulin production due to e.g. oestrogen. Additionally, cortisol concentrations vary 
throughout the day. Therefore, the diagnostic usefulness of random samples is limited. 
Furthermore, hydrocortisone, methylprednisolone, and prednisone cross-react in the cortisol 
assay and should be avoided within 24 hours of testing (Grinspoon and Biller, 1994). 
To localize the cause of insufficiency, ACTH concentrations can be tested. Here 
ACTH levels are supposed to be higher than normal because cortisol feedback inhibition is 
absent. Levels 100pg/ml (22pmol/l) are indicative of PAI, even if plasma cortisol 
concentration is in normal range. In PAI, also aldosterone concentrations are low or at the 
lower end of normal values, whereas the plasma renin activity or concentration is increased 
because of sodium wasting. 
2.2.4.2 Pharmacological Stimulation tests 
The most commonly used pharmacological test for the diagnosis of PAI is the short 
corticotropin stimulation test. 250μg of ACTH1-24 (cosyntropin, tetracosatrin, Cortrosyn, or 
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Synacthen) are given intravenously or intramuscularly before 10a.m., and plasma cortisol 
levels are measured before and 30 and/or 60 minutes after the injection. In the case of PAI, 
no increase in plasma cortisol is to be expected, since the adrenal cortex is maximally 
stimulated by endogenous ACTH. Accordingly, peak cortisol levels of <500nmol/l lead to the 
diagnosis of PAI. 
Since the 250μg ACTH stimulation test induces supraphysiological ACTH 
concentrations, it has been argued that in the case of acute-onset and mild secondary 
adrenal insufficiency, this dose might over-stimulate partially atrophied adrenals and produce 
a deceivingly adequate cortisol response (Oelkers, 1996). Therefore, the 1μg synthetic 
ACTH test has been suggested to be more sensitive (Abdu et al., 1999), especially since the 
cortisol response to 1μg is equivalent to that obtained with 250μg in normal subjects 
(Dickstein et al., 1997). Laureti et al. (Laureti et al., 2000) demonstrated that the sensitivity of 
the low-dose (1μg) ACTH test is similar to that of the high-dose (250μg) ACTH test also for 
pre-clinical primary adrenal dysfunction and concluded that the low-dose ACTH test has a 
high diagnostic value also for PAI. 
To differentiate between primary and secondary adrenal insufficiency, infusions of 
ACTH1-24 iv or im over a period of 48-72h with cortisol measurements the day before and 
repeatedly over the treatment may also be helpful. In PAI, no rises in cortisol levels are to be 
expected, whereas in secondary adrenal insufficiency cortisol levels starts to rise due to the 
slow re-activation of adrenal cortex cells (Grinspoon and Biller, 1994). 
Another widely used pharmacological test for the assessment of the PHA axis is the 
insulin tolerance test (ITT). Insulin (0.1U/kg) is administered iv to induce hypoglycaemia 
(<2.2mmol/l). Hypoglycaemia is an indirect stimulus to cortisol release via activation of 
hypothalamus and pituitary gland. Accordingly, cortisol is measured 15 minutes before, 
immediately before, and 30, 45, 60, 90, and 120 minutes after injection. An absolute cortisol 
increase to circulating values >550nmol/l typically together with a relative increase of >200-
250nmol/l is considered a normal response (Nylen and Muller, 2004). In PAI, but also in SAI, 
no increase in cortisol secretion is to be expected. Due to the adverse side effects of this 
test, it is contraindicated not only in children, elderly, and patients with a history of seizures, 
ischemic heart disease, or epilepsy (Ammari et al., 1996; Rasmuson et al., 1996), but also 
unnecessary in patients already known to have low basal plasma cortisol concentrations. 
The short metyrapone test was developed specifically to assess the pituitary ACTH 
reserve, but may also be valuable to diagnose PAI. In this test, a single dose of 2.0g 
metyrapone is given po at 2400 h and ACTH, 11-deoxycortisol, and cortisol is measured the 
following morning. Metyrapone inhibits the adrenocortical enzyme 11-OH, leading to a 
decrease of circulating cortisol, thereby stimulating ACTH production, which in turn causes 
the cortisol precursor 11-deoxycortisol to accumulate. In PAI, baseline ACTH levels are high 
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and following metyrapone administration, 11-deoxycortisol levels are still low and ACTH 
levels do not change (Berneis et al., 2002). 
2.2.4.3 Radiologic Evaluation 
After an endocrinologic diagnosis is established by hormone tests, abdominal 
computer tomography scans can be helpful for differential diagnosis. Marked enlargement of 
the adrenal glands with or without calcifications in patients with tuberculous adrenal 
insufficiency is usually a sign of active infection and an indication for treatment with anti-
tuberculosis drugs. The adrenal glands are also enlarged in patients with adrenal 
insufficiency caused by fungal infections, metastatic cancer, lymphoma, and AIDS (Oelkers, 
1996). In contrary, in patients with autoimmune AD the adrenal glands are small and often 
weigh only about 1g in end-stage disease (Betterle et al., 2002). 
2.2.4.4 Adrenal Autoantibody Tests 
Adrenal autoantibodies are an important marker of an ongoing adrenal autoimmune 
process and hence adrenal autoantibody tests are valuable for early diagnosis but also for 
differential diagnosis. Therefore, adrenal autoantibodies are discussed in detail in section 
2.4.2.1 (Idiopathic Addison’s Disease as an Autoimmune Disease) and in section 2.4.2.3 
(Serology and Immunogenetics). 
2.2.5 Treatment 
In the late 1920s and early 1930s, growing interest in the role of the adrenals in 
diseases led physicians to start working with adrenal cortex extracts. In most cases weak 
positive effects were observed in adrenalectomized cats and dogs (Stewart, 1929) and 
patients suffering from Addison’s disease (Hartman, 1930). Meanwhile, also the physiologic 
function of the adrenal cortex came into focus, particularly in regard to sodium and water 
metabolism. In 1927, Marine and Baumann reported of increased survival of ADX cats by 
injection of Ringer’s solution or sodium chloride (Marine, 1927). One year later, Rogoff and 
Stewart reported similar results in dogs (Rogoff, 1928), and in 1933, Loeb published the 
effects of sodium chloride treatment in patients with Addison’s disease (Loeb, 1933). In 1937, 
DeFremery reported on the isolation of corticosterone from the adrenal (DeFremery, 1937) 
and Steiger and Reichstein on the synthesis of deoxycorticosterone (Steiger, 1937). First 
reports of treatment of patients with Addison’s disease came from Simpson (Simpson, 1938) 
and Thorn et al. (Thorn, 1939). 
Today, treatment of patients with Addison’s disease accounts for both missing 
glucocorticoids and mineralocorticoids. Glucocorticoid replacement is usually given in two or 
three daily doses, with a half to two-thirds of the daily dose administered in the morning to 
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mimic the circadian secretion pattern of cortisol (Arlt and Allolio, 2003). The dosage is based 
on the normal daily cortisol production rate of 5.7±0.3mg/m2·day (Kerrigan et al., 1993), 
which translates to about 10-20mg/m2·day of oral hydrocortisone (Ten et al., 2001), 
accounting for step-down losses from absorption, hepatic processing, and metabolic 
bioavailability. Initially, the treatment starts with doses of 25mg hydrocortisone (HC, cortisol, 
15 + 10mg) or 37.5mg cortisone acetate (25 + 12.5mg) (Oelkers, 1996). The daily dose may 
be decreased to 20 or 15mg of HC to prevent over-replacement, which can lead to weight 
gain, osteoporosis and impaired glucose tolerance. On the other hand, under-replacement 
bears the risk of incipient crisis and impairment of wellbeing. The goal should be to use the 
smallest dose that relieves the patient’s symptoms (Betterle et al., 2002). Determination of 
the appropriate dose is mainly based on clinical judgment, taking into account signs and 
symptoms potentially suggestive of glucocorticoid over-replacement or under-replacement, 
or relies on urinary cortisol measurements. The latter is suitable as a marker to only a limited 
extent. Since after HC administration cortisol-binding globulins are rapidly saturated, renal 
cortisol excretion is transiently but clearly increased. Urinary cortisol should therefore only be 
used as a marker for HC over-treatment (Peacey et al., 1997). 
Mineralocorticoid replacement consists of oral administration of fludrocortisone in a 
single daily dose of 50-200μg. The dose is guided by measurements of blood pressure, 
serum potassium, and plasma renin activity (Betterle et al., 2002). Additional markers can be 
serum sodium concentrations and appearance of peripheral oedema (Arlt and Allolio, 2003). 
Optional is the replacement of dehydroepiandrosterone (DHEA) to increase well-
being and mood, taken daily as one dose of 25-50mg DHEA in the morning (Arlt and Allolio, 
2003). However, Lovas summarizes that so far the evidence for beneficial effects of DHEA 
replacement is weak and long-term safety requires further consideration (Lovas and 
Husebye, 2003). 
Acute adrenal insufficiency has to be treated immediately with high doses of HC iv. 
Usually, a bolus dose of 100mg is followed by infusion of 100-200mg over a period of 24 
hours (Oelkers, 1996). Large volumes of isotonic saline and glucose iv are also 
recommended to obviate hypovolemia and hyponatremia. In the case of febrile illness or 
injury the dose of HC should be doubled or tripled temporarily and in the case of vomiting 
glucocorticoid suppositories are recommended (Betterle et al., 2002). 
2.2.6 Etiology of Addison’s Disease 
Addison’s disease can have various etiologies. According to Ten et al. (Ten et al., 
2001), they can be grouped into three categories: 1) adrenal dysgenesis; 2) adrenal 
destruction; and 3) impaired steroidogenesis. 
THEORETICAL BACKGROUND 47 
Adrenal dysgenesis may be due to congenital adrenal hypoplasia (AHC), mutations of 
steroidogenic factor-1 (SF-1), or ACTH unresponsiveness. The destruction of the adrenal 
glands can be caused by autoimmune polyglandular syndrome (APS), adrenoleukodystrophy 
(ALD), adrenal hemorrhage, adrenal metastases, infections, or amyloidoses. Impaired 
steroidogenesis may be due to congenital adrenal hyperplasia (CAH), mitochondrial 
disorders, or the Smith-Lemli-Opitz syndrome (SMOS). 
Another classification offers Betterle (Betterle et al., 2002). He distinguishes between 
autoimmune adrenalitis, infectious adrenalitis, Addison’s disease due to neoplastic diseases, 
adrenal hemorrhage, or adrenal thrombosis, drug-induced adrenal insufficiency, neonatal 
causes, and genetic causes of Addison’s disease (see table 2-3). 
Many of the listed causes are very rare. For example, Betterle studied 317 patients 
with PAI and found 9 cases with adrenoleukodystrophy (2.8%), and 3 cases with neoplastic 
diseases (0.9%; Betterle et al., 2002). Therefore, the following sections will focus on the main 
causes of Addison’s disease, which are infectious, or more precisely, tuberculous adrenalitis 
(section 2.4.1), and autoimmune adrenalitis (section 2.4.2). 
Tab. 2-3: Etiology of Addison’s disease (modified from Betterle et al., 2002). 
Autoimmune adrenalitis  
Infectious adrenalitis Tuberculosis, fungal, viral 
Neoplastic diseases adrenal carcinomas, metastasis 
Adrenal hemorrhage Waterhouse-Friderichsen syndrome, anticoagulation therapy, 
traumas 
Adrenal thrombosis Systemic lupus erythematosus, panarteritis nodosa, 
antiphospholipid syndrome, traumas 
Drug-induced adrenolitic therapy, other agents, anticoagulation 
Other causes sarcoidosis, amyloidosis, hemochromatosis, histiocytosis 
Neonatal maternal Cushing’s syndrome, traumas at birth 
Genetic adrenoleukodystrophy, congenital adrenal hypoplasia, familial 
ACTH resistance syndromes (familial glucocorticoid deficiency, 
Triple A syndrome), Kearns-Sayre syndrome, congenital adrenal 
hyperplasia, Smith-Lemli-Opitz syndrome 
 
2.2.6.1 Infectious Addison’s Disease 
On postmortem examination of 11 of his patients, Addison found six cases with 
adrenal tuberculosis. During this times, tuberculous adrenalitis was by far the most prevalent 
cause of adrenal insufficiency. Today, tuberculosis is still a major cause of disease in the 
developing world (Ten et al., 2001). For example, Soule reviewed retrospectively the case 
notes of patients with Addison’s disease admitted to a South African Teaching Hospital from 
1980 to 1997. In 34% of all patients, active or previous tuberculosis was diagnosed (Soule, 
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1999). Moreover, with an incidence of 6%, the adrenal gland is the fifth major organ involved 
in extra-pulmonary tuberculosis (Lam and Lo, 2001) and the most commonly involved 
endocrine organ in tuberculosis (Kelestimur, 2004). Tuberculosis is also the most common 
cause for infectious forms of Addison’s disease and with approximately 74% (Betterle et al., 
2002) the main non autoimmune cause overall. 
In developed countries the prevalence of tuberculous adrenalitis is usually below 10% 
(Zelissen et al., 1995), but it is conceivable that in future studies relatively more cases of 
Addison’s disease of tuberculous origin will be encountered (Rieder, 1992), since the 
incidence of tuberculosis in many industrialized countries recently failed to decline and in 
eastern Europe and the former Soviet Union cases and deaths are even increasing 
(Raviglione et al., 1995). 
Tuberculous Addison’s disease may be characterized by enlarged or atrophied 
adrenal glands. CT scans reveal large glands in a recent and probably active infection, 
whereas small calcified glands represent remote and probably inactive infection. In the case 
of recent or active infection it is unclear, whether the adrenal glands are enlarged as a result 
of direct involvement of the glands by tuberculosis, or as a result of stressful conditions due 
to tuberculosis which increases cortisol requirement (Kelestimur, 2004). 
More uncommon causes in infectious adrenalitis are fungal diseases, such as 
histoplasmosis and coccidioidomycosis (Ten et al., 2001), or viral infections (i.e., 
cytomegalovirus and HIV) (Betterle et al., 2002). Regarding viral infections, specifically HIV 
infections, interdependency between HIV, tuberculosis and Addison’s disease has to be 
considered: in HIV-infected persons the incidence of active tuberculosis is increased (Selwyn 
et al., 1989), and tuberculosis in turn increases the risk for Addison’s disease (Freda et al., 
1994). 
2.2.6.2 Autoimmune Adrenalitis 
In developed countries, autoimmune adrenal destruction is the major cause of 
Addison’s disease, affecting approximately 90% of all patients with primary adrenal 
insufficiency (Winqvist et al., 1996). The following section addresses findings, which led to 
the view of idiopathic Addison’s disease to be an autoimmune disease. Subsequently, the 
association of Addison’s disease with other autoimmune disorders and its role as part of an 
autoimmune polyendocrine syndrome (APS) will be discussed. Additionally, serological and 
immunogenetic findings will be presented. 
2.2.6.2.1 Idiopathic Addison’s disease as an autoimmune disease 
Until 1957, the cause of many cases of Addison’s disease were unknown and hence 
labeled idiopathic. Already Addison reported of one case of adrenal fibrosis of unknown 
origin, which he described as follows: “the two adrenals together weighted 49 grains, they 
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appeared exceedingly small and atrophied, so that the diseased condition did not result as 
usual from a deposit either of a strumous or malignant character, but appears to have been 
occasioned by an actual inflammation that inflammation having destroyed the integrity of the 
organs, and finally led to their contraction and atrophy” (Addison, 1855). With this description 
of adrenals destroyed by inflammation, Addison provided the first indication of the cause of 
idiopathic adrenal insufficiency. 
More than 100 years later, in 1957, Anderson et al. discovered circulating adrenal 
cortex autoantibodies (Anderson et al., 1957) and subsequent reports indicated that 
idiopathic Addison’s disease might be autoimmune in nature: Blizzard & Kyle demonstrated 
the organ specificity of the adrenal antibodies and isolated specific antigens in the adrenal 
cortical microsomes and mitochondria (Blizzard and Kyle, 1963) and Khoury et al. reported 
the presence of surface-reactive autoantibodies to human adrenal cells (Khoury et al., 1981). 
Studies of Furmaniak et al. suggested that autoantibodies in the serum of patients with 
Addison’s disease interact with a 55 kDa adrenal specific protein (Furmaniak et al., 1988). 
Four years later, Krohn et al. identified this 55 kDa adrenal protein as steroid 17 alpha-
hydroxylase (17-OH) (Krohn et al., 1992) and Winqvist et al. reported on a protein with an 
apparent molecular weight of 54 kDa as another major autoantigen in idiopathic Addison’s 
disease, which they identified as 21-hydroxylase (21-OH) (Winqvist et al., 1992). Both 
enzymes are members of the family of P450 cytochromes and key enzymes in the steroid 
hormone synthesis of the human adrenal cortex (see fig. 2-8). Bednarek et al. hypothesized 
that in early onset Addison’s disease, which is most commonly associated with 
hypoparathyroidism and mucocutaneous candidiasis (see below: APS-1), autoantibodies 
seem to be directed against 17-OH, whereas in adult onset Addison’s disease 
autoantibodies are directed against 21-hydroxylase (Bednarek et al., 1992). In 1993, 
Winqvist et al. revised the findings of Krohn et al. regarding 17-OH and stated that P450 
side chain cleavage (P450scc), an enzyme located in the mitochondria, is the major adrenal 
autoantigen identified by sera of patients with early onset Addison’s disease (Winqvist et al., 
1993). Yet, as Winqvist et al. pointed out, the role of autoantibodies in the pathogenesis of 
Addison’s disease is still unknown, since it is hard to imagine that autoantibodies can react 
with their intracellular autoantigens in intact cells, and the antigens in turn has not been 
convincingly shown to be present on the cell surface (Winqvist et al., 1996). 
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Fig. 2-8: Steroid hormone synthesis pathways (scc: side chain cleavage; 17-OH: 17-alpha-hydroxylase; 21-OH: 
21-hydroxylase; 11-OH: 11-hydroxylase; 17-HDS: 17-beta-hydroxysteroiddehydrogenase; aldo: aldosterone 
synthase; aro: aromatase), white on black: steroid synthesis limiting enzymes in Addison’s disease. 
On the other hand, there is evidence suggesting that also cellular immunity plays a 
critical role in the pathogenesis of Addison’s disease: In 1958, Colover and Glynn observed 
lesions in the adrenal gland and infiltrating cells with irregular basophilic nuclei after 
injections of Freund’s adjuvant (i.e., homologous guinea pig adrenal gland with heat-
inactivated human tubercle bacillus residues) in guinea pigs and hypothesized that this 
experimental adrenalitis may be of immunological nature (Colover and Glynn, 1958). Post-
mortem examinations of adrenals from patients with Addison’s disease revealed infiltrating 
lymphocytes and Fujii et al. observed infiltrations with polymorphonuclear leukocytes in the 
cortex regions of the adrenal glands in mice after repeated injection of adrenal extract (mixed 
with KO3 LPS), which were later replaced by mononuclear cells, such as small lymphocytes 
and macrophages (Fujii et al., 1992). Furthermore, the repeated immunization caused a 
delayed type hypersensitivity to adrenal antigens and Fujii et al. were able to produce 
adrenalitis in normal mice by transfer of spleen cells from hyper-immunized mice. Freeman 
and Weetman showed a proliferative T-cell response to an adrenal-specific protein fraction in 
the molecular weight range of 18-24 kDa (Freeman and Weetman, 1992). These results 
point to a possible interaction of B- and T-cell response in Addison’s disease, in which 
peptides derived from the B-cell autoantigen 21-OH may be involved in the T-cell-mediated 
autoimmunity of Addison’s disease (Winqvist et al., 1996). Additionally, Partanen et al. 
showed that patients with isolated Addison’s disease or Addison’s disease in association with 
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autoimmune hypothyroidism, Graves’ disease, and/or type 1 diabetes share highly similar 
major histocompatibility complex (MHC) class II and class III alleles (Partanen et al., 1994). 
But although the genes encoding 21-OH enzyme are located within the MHC-III region, the 
presence of autoantibodies against 21-OH was not found to be directly determined by the 
MHC alleles, as patients with identical markers but different clinical forms of Addison’s 
disease had different reactivity against 21-OH. 
Altogether, these studies give proof of the autoimmune nature of idiopathic Addison’s 
disease according to the revisited postulates of Witebsky by Rose & Bona (Rose and Bona, 
1993) (see table 2-4) and Betterle et al. summarized these evidences as follows: 1) 
histopathological findings of a diffuse mononuclear cell infiltration progressing to atrophy of 
all the three layers of the adrenal cortex; 2) demonstration of a cell-mediated immunity to 
adrenal cortex antigens; 3) ability to induce the disease in animal models by immunization 
with adrenal cortex extracts; 4) identification of steroidogenic enzymes expressed in adrenals 
as self-antigens; 5) association with other organ-specific autoimmune diseases; 6) 
association with antigens of the major histocompatibility complex (Betterle et al., 2002). 
Retrospectively, the case of adrenal fibrosis of unknown origin described by Addison 
turns out to be the very first description of an autoimmune adrenalitis in the literature. 
Tab. 2-4: Revisited postulates of Witebsky by Rose & Bona (Rose and Bona, 1993). 
 
2.2.6.2.2 APS: autoimmune polyendocrine syndrome 
Starting in the mid seventies, numbers of records were increasing, which show that 
patients with autoimmune Addison’s disease also have a higher prevalence of other 
autoimmune disorders (Irvine, 1975). In 1981, Neufeld, Maclaren and Blizzard distinguished 
two types of autoimmune Addison’s disease, which are associated with different 
polyglandular autoimmune (PGA) syndromes (Neufeld et al., 1981). 
direct proof: based on 
a) production of the disease by human-to-human transfer of autoantibodies, 
b) production of the disease by human-to-animal transfer of autoantibodies, 
c) production of the disease by transfer of autoreactive T cells to SCID mice, or 
d) in vitro destruction of cells carrying the corresponding antigen by autoantibodies) 
indirect evidence: based on 
e) reproduction of the autoimmune disease in experimental animal models, 
f) genetically induced disease models, isolation of autoantibodies, or 
g) isolation of self reactive T cells form organs representing the major target of autoimmune 
disease 
circumstantial evidence: based on distinctive clinical clues 
a) association with other autoimmune diseases in the same individual / the same family, 
b) lymphocytic infiltration of target organs, 
c) statistical association with a particular MHC haplotype or aberrant expression of MHC class II 
antigens on the affected organ, or 
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The following sections introduce these two types of polyglandular autoimmune 
syndromes, also called autoimmune polyendocrine syndromes (APS-1 and APS-2) as well 
as a third and a fourth type, namely APS-3 and APS-4. Isolated autoimmune Addison’s 
disease will be discussed in the last section. 
APS-1 
The first description of an association between hypoparathyroidism and candidiasis 
was published in 1929 (Thorpe and Handley, 1929), and the association of these two 
diseases with idiopathic adrenal insufficiency was reported in 1946 (Leonard, 1946). Since 
then, the autoimmune polyglandular syndrome type 1 (APS-1) has been described under 
varying names, such as Whitaker’s syndrome (Esselborn et al., 1956), polyglandular 
autoimmune disease type 1 (Neufeld et al., 1981), or autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED; Ahonen et al., 1990). Independent of the label, 
its major components are chronic mucocutaneous candidiasis, chronic hypoparathyroidism, 
and autoimmune adrenal insufficiency. To define this syndrome, at least two of these 
diseases have to be present in one individual, while the three main components of APS-1 are 
present together in only about one third to one half of the cases (Betterle et al., 1998). 
APS-1 is inherited in an autosomal-recessive mode and a very rare disorder. The 
highest numbers of patients are found among Finns, Sardinians, and Iranian Jews, with 
estimated prevalence rates of 1 in 25.000, 14.000 and 9.000 inhabitants, respectively, 
whereas only limited numbers of cases are found in other parts of the world (Peterson et al., 
2000). It is generally thought that due to the autosomal recessive mode of inheritance males 
and females are equally affected. Nevertheless, the female/male ratio varies widely between 
0.8 in Finland (Ahonen et al., 1990) and 2.4 in Italy (Betterle et al., 1998). 
Chronic mucocutaneous candidiasis is generally the first disease and the most 
frequent of the three main diseases of APS-1. It can appear at the first month after birth and 
up to 21 year of age, but usually does before the age of 5 (Betterle et al., 1998). It is present 
in 73-100% of all patients and affects nails, dermis, and oral, vaginal, and esophageal 
mucous membranes (Betterle et al., 1998). The disease is accompanied by a normal B-cell 
response of serum antibodies to candidal antigens, which may be responsible for preventing 
the systemic spread of infection (Peterson et al., 1996). However, the cause of this disease 
is considered to be a defective suppressor T-cell function to the antigen Candida albicans 
(Arulanantham et al., 1979). For this reason, the World Health Organization (WHO) classified 
APS-1 in 1995 as an acquired immunodeficiency (WHO, 1995). 
Hypoparathyroidism usually occurs after chronic mucocutaneous candidiasis and 
before Addison’s disease at an age between 3 months to 44 years. It is present in 73-90% of 
the cases of APS-1 (Betterle et al., 1998). Due to the autoimmune destruction of the 
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parathyroid gland, a common symptom in APS-1 is hypocalcaemia, since the parathyroid 
gland is one of the major organs involved in CA2+ homeostasis (Winqvist et al., 1996). 
Autoimmune Addison’s disease is the third disease to appear, usually between 6 
months and 41 year of age, and occurs in 60-100% of cases of APS-1. 
Diseases less frequently associated with APS-1 are summarized according to 
Betterle, Greggio, and Volpato, including details on frequencies, where given (Betterle et al., 
1998): other autoimmune endocrinopathies (hypergonadotropic hypogonadism: 17-50%; 
insulin-dependent diabetes mellitus: 1.2-12%; autoimmune thyroid diseases: 2-13%; and 
pituitary defects), autoimmune or immuno-mediated gastrointestinal diseases (chronic 
atrophic gastritis: 13-15%; pernicious anemia: 11-13%; and malabsorption), chronic active 
hepatitis (8-26%), autoimmune skin diseases (vitiligo: 8-13%; alopecia: 29-32%), ectodermal 
dystrophy (77-82%), keratoconjunctivitis (8-41%), immunological defects (cellular and 
humoral), asplenia, and cholelithiasis. 
In summary, APS-1 is associated with a broad clinical spectrum with the majority of 
patients having three to five manifestations, some of which may not appear until the fifth 
decade. Therefore, Ahonen et al. pointed out that all patients need lifelong follow-up for 
detection of new components of the disease (Ahonen et al., 1990). 
APS-2 
In 1926, Schmidt described two patients with nontuberculous Addison’s disease and 
chronic lymphocytic thyroiditis (Schmidt, 1926), a syndrome later called Schmidt’s syndrome. 
Five years later, the first case of Addison’s disease with hyperthyroidism and diabetes 
mellitus was described (Rowntree and Snell, 1931), and in 1932 Gowen reported on a 
patient affected by Addison’s disease, hypothyroidism and diabetes mellitus (Gowen, 1932). 
Since then reported cases increased every decade. Today, the autoimmune polyglandular 
syndrome type 2 (APS-2) is defined as a combination of autoimmune Addison’s disease, 
which must always be present, and autoimmune thyroid disease and/or type 1 diabetes 
mellitus (Betterle et al., 2002). APS-2 is also termed Carpenter’s syndrome (Betterle et al., 
2004). In the vast majority of cases, the thyroid autoimmune disease is Hashimoto’s 
thyroiditis or idiopathic myxedema (i.e., hypothyroidism), and in the remaining cases Graves’ 
disease (i.e., hyperthyroidism) (Carpenter et al., 1964). 
However, the complete triad can be observed only in approximately 11% of all cases 
(Betterle et al., 2002) and approximately 28% of patients with autoimmune Addison’s disease 
are also diagnosed APS-2 (Zelissen et al., 1995). APS-2 is therefore a rare condition with 
1.4-4.5 cases per 100.000 inhabitants (Betterle et al., 2004). The clinical onset of APS-2 
usually starts in early adulthood with peak age at onset between 30 and 40 years (Zelissen 
et al., 1995). The majority of patients with APS-2 are females, with a female/male ration of 2-
3.7 (Betterle et al., 2002). 
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The components of APS-2 tend to develop in a specific sequence. Based on data of 
sixty patients with APS-2, Betterle et al. summarized that type 1 diabetes mellitus develops in 
general before autoimmune Addison’s disease, whereas autoimmune thyroid diseases 
develop before, contemporary with, or after Addison’s disease (Betterle et al., 1996). Eight 
years later, now based on data of 146 patients with APS-2, Betterle, Lazzarotto, and Presotto 
reported on mean ages at disease onset of 28.4 (range: 2-63) in type 1 diabetes mellitus, 
34.6 (range: 1-85) in Addison’s disease, and 40.2 (range: 12-80) in chronic thyroiditis. 
Among thyroid disorders, Graves’ disease usually precedes (mean age at disease onset: 
33.4; range: 7-58), whereas Hashimoto’s thyroiditis follows Addison’s disease (Betterle et al., 
2004). 
Beside the three main diseases, several minor diseases are reported in APS-2. 
Among these, the more frequently diagnosed are vitiligo (12% of cases) and 
hypergonadotropic hypogonadism (10% of cases). Less than 5% of patients with APS-2 
additionally suffer from chronic autoimmune hepatitis (3%), alopecia (4%), pernicious 
anaemia (2%), or seronegative arthritis (2%; Betterle et al., 2004). 
Since hardly ever the syndrome emerges with two or three main autoimmune 
diseases simultaneously, it is of considerable importance to identify among patients with only 
one main or minor disease those at risk for future development of fully expressed APS-2. For 
example, Zelissen, Bast and Croughs found in 58% of patients with isolated Addison’s 
disease autoantibodies to the thyroid gland (Zelissen et al., 1995), putting these patients at a 
~50% risk for future development of thyroiditis. On the other hand, patients suffering from 
thyroid autoimmune diseases or type 1 diabetes mellitus, who are also tested positive for 
autoantibodies to the adrenal cortex or 21-OH have a 30% risk for future development of 
Addison’s disease (Betterle et al., 2004). 
In this context, Betterle, Lazzarotto and Presotto consider the clinically overt 
syndrome (i.e., APS-2) as only the ‘tip of an iceberg’, since latent or incomplete forms are 
much more frequent. Therefore, early identification and treatment of other autoimmune 
endocrine diseases may be critical and even life-saving (Betterle et al., 2004). 
APS-3 and APS-4 
In addition to the above described two types of autoimmune polyglandular 
syndromes, Neufeld and Blizzard distinguished in their publication in 1980 two additional 
types (Neufeld et al., 1980): Type 3 is classified as thyroid autoimmune diseases (TAD) 
associated with other autoimmune diseases, excluding Addison’s disease and/or 
hypoparathyroidism. Type 4 is classified as combination of organ-specific autoimmune 
diseases not included in the previous types. 
Unfortunately, there is no general agreement regarding the syndrome classification, 
i.e., the number of APS types. Eisenbarth and Gottlieb summarized the ongoing controversy 
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and contrasted the “splitters” and the “lumpers” (Eisenbarth and Gottlieb, 2004). The former 
group discriminates the four already mentioned types of syndromes and additionally 
subdivides APS-3 in the four groups 3A (TAD + type 1 diabetes mellitus), 3B (TAD + chronic 
atrophic gastritis and pernicious anemia), 3C (TAD + vitiligo, alopecia, miastenia gravis), and 
3D (TAD + other unspecified diseases), according to Neufeld (Neufeld et al., 1980). Betterle 
and Zanchetta suggested even a revision of the original classification by Neufeld and 
proposed a new classification of the 4 subgroups of APS-3 (Betterle and Zanchetta, 2003). 
They differentiate between endocrine diseases (3A), diseases affecting the gastrointestinal 
apparatus (3B), diseases affecting the skin / hemopoietic system / nervous system (3C), and 
collagen diseases/vasculitis (3D). 
On the other hand, the “lumpers” consider all the combinations of APS type 2, 3, and 
4 as APS-2. For example, Dittmar and Kahaly argue that no clinical differences between 
APS-2 and APS-3 have been described (Dittmar and Kahaly, 2003). Accordingly, they do not 
differentiate between them and also Eisenbarth and Gottlieb annotate that they tend to agree 
with this group of “lumpers” (Eisenbarth and Gottlieb, 2004). 
Since there is no definite time-point at which one specific disease of the various 
diseases constituting the syndrome has to appear, as well as no definite specific sequence in 
which the different diseases have to develop, there is always the possibility that a patient 
diagnosed with APS-3 or APS-4 will later in his life develop the necessary additional disorder 
(i.e., Addison’s disease) and therefore “qualify” for APS-2. Therefore, in the following 
sections it will be distinguished only between APS-1 and APS-2. 
Isolated autoimmune Addison’s disease 
Isolated autoimmune Addison’s disease is characterized by Addison’s disease in 
absence of any other above described diseases. Here, a very similar problem appears: It is 
not clear what distinguishes a patient with a single disorder, such as isolated Addison’s 
disease, from a patient with multiple additional autoimmune disorders. Comparing the age at 
disease onset, isolated Addison’s disease is possibly just the first manifestation of diseases 
constituting APS-2 (Eisenbarth and Gottlieb, 2004). Especially, since in both cases a HLA-
association as well as thyroid, gastric and islet-cell autoantibodies can be found. This points 
to a common etiology and suggests that isolated Addison’s disease is in fact a variant of 
APS-2 (Peterson et al., 2000). Winqvist et al. likewise concluded that isolated Addison’s 
disease and Addison’s disease as part of APS-2 may be regarded as the same entity 
(Winqvist et al., 1996). The only difference between isolated autoimmune Addison’s disease 
and APS-2 may simply be time (Eisenbarth and Gottlieb, 2004). 
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2.2.6.2.3 Serology and immunogenetics of Addison’s disease 
In all above described forms of autoimmune Addison’s disease, whether isolated or 
as part of an APS, distinctive serological and immunogenetic features can be observed. The 
first reports in this regard were already described above. 
These distinctive features are not only important for differential diagnosis, but also 
may help to uncover the diverse underlying immunological mechanisms. Hence, in the 
following sections the serological as well as the genetic background of autoimmune 
Addison’s disease will be discussed in greater detail and current theories regarding the 
underlying mechanisms will be quoted. 
Serology of Addison’s disease 
In 50-90% of all patients with Addison’s disease adrenocortical autoantibodies (ACAs) 
can be detected (Peterson et al., 2000). The target autoantigens thereby are P450 
cytochromes, more precisely the enzymes 17alpha-hydroxylase (17-OH), 21-hydroxylase 
(21-OH), and cholesterol side chain-cleaving enzyme (scc; see figure 2.8). 
Immunofluorescence studies showed that both 21-OH and scc antigens are found in all three 
layers of the adrenal cortex, while sera reacting with the antigen 17-OH do not stain the 
zona glomerulosa (Uibo et al., 1994). 
While 21-OH is present in the adrenal glands only, the antigens 17-OH and scc are 
found in all steroid-producing organs, such as the Theca interna and corpus luteum of the 
ovary, Leydig and Sertoli cells of the testis, and in placental trophoblasts (in the latter scc 
only; Peterson et al., 2000). To distinguish such antibodies from ACAs, they have generally 
been named steroid cell antibodies (StCA) and the presence of StCAs correlates with a high 
risk of gonadal failure in Addison’s disease patients (Peterson et al., 2000). Here, the major 
antigen seems to be scc, but not 17-OH, at least in APS-1 (Soderbergh et al., 2004). 
Interestingly, in isolated Addison’s disease and in APS-2, predominantly antibodies 
against 21-OH are found with prevalence rates of 25-94% and 78-96%, respectively. 
Autoantibodies to 17-OH and scc are rare in isolated Addison’s, but in APS-2 they can be 
detected in up to a third of patients studied (Peterson et al., 2000). In APS-1, the literature is 
not unanimous as to which of these three types of antibodies is predominant. Martorell et al. 
summarize that 17-OH and scc seem to be the antigens most often involved (Martorell et 
al., 2002). This is in contrast to findings of Söderbergh et al., who performed a multivariate 
logistic regression analysis for the presence of ten autoantibodies as independent predictors 
for different disease manifestations in 90 APS-1 patients from Finland, Norway, and Sweden. 
Here, all three autoantibodies were associated with Addison’s disease, but only 21-OH and 
scc autoantibodies were independent markers and thus Söderbergh et al. concluded that 
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these enzymes constitute the major adrenal cortex autoantigens in APS-1 (Soderbergh et al., 
2004). 
Beside P450 enzymes as the major antigens in Addison’s disease, additionally 
autoantibodies to other organs and cells can be found, especially in the context of APS-1. 
Klemetti et al. as well as Velloso et al. described high autoantibody titers and T-cell-mediated 
responses to the 65-kDa isoform of glutamic acid decarboxylase (GAD65), the major 
autoantigen in type 1 diabetes (Klemetti et al., 2000; Velloso et al., 1994). Autoantibodies to 
GAD65 were also detected in 14% of patients with idiopathic AD (Laureti et al., 1998a). 
Rorsman et al. demonstrated autoantibodies against another pancreatic -cell antigen, 
aromatic l-amino acid decarboxylase (AADC), in APS-1 patients (Rorsman et al., 1995), 
which have been found recently also in a small subgroup of patients with isolated Addison’s 
disease and APS-2 (Soderbergh et al., 2000). Since APS-1 is often associated with 
autoimmune hepatitis, Clemente et al. were interested in liver P450 cytochrome 
autoantibodies. They found autoantibody reactivity with P4501A1, P4501A2, P4502A6, and 
P4502B6 cytochromes, but none of the APS-1 patients had autoantibodies to P4502D6, the 
major target in autoimmune hepatitis (Clemente et al., 1998). Hypoparathyroidism has in one 
study been suggested to result from an autoimmune reaction directed against the 
extracellular domain of the Ca2+-sensing receptor (CaSR), a parathyroid gland-specific 
protein (Li et al., 1996). Ekwall et al. and Hedstrand et al. identified the enzymes tryptophan 
hydroxylase (TPF) and tyrosine hydroxylase (TH) as autoantigens associated with 
gastrointestinal dysfunction and alopecia, respectively, in APS-1 (Ekwall et al., 1998; 
Hedstrand et al., 2000). Additionally, an association between vitiligo and autoantibodies 
against melanocytes was found in APS-1 patients (Song et al., 1994). Regarding 
mucocutaneous candidiasis as one of the major disease components in APS-1, the glycolytic 
enzyme enolase seems to be the immunodominant antigen (Peterson et al., 1996). 
In isolated Addison’s disease and APS-2, thyroperoxidase autoantibodies, 
thyroglobulin autoantibodies, H+/K(+)-ATPase autoantibodies, and GAD65 autoantibodies 
are frequently detected (Falorni et al., 2002), demonstrating again the close relationship 
between isolated Addison’s disease and APS-2. 
Nevertheless, P450 enzymes and ACAs as well as StCAs are still of major interest in 
Addison’s disease, since high correlations between ACAs and 21-OH autoantibodies exist 
also in patients with pre-Addison’s disease and both are good predictive markers for AD, 
especially in children (Peterson et al., 2000). ACAs and 21-OH autoantibodies further 
correlate with the degree of adrenal dysfunction and the presence of high-levels of 21-OH 
antibodies strongly signals the destructive phase of the autoimmune process (Laureti et al., 
1998b). In this regard, the central and the C-terminal regions of 21-OH seem to be the 
important site for autoantibody binding (Volpato et al., 1998). 
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Still, a good serological marker not equates with a pathogenic agent. And despite the 
fact that several authors found 21-OH autoantibodies to inhibit 21-OH activity in vitro, studies 
by Boscaro et al. were not able to confirm these results in vivo (Boscaro et al., 1996). 
Therefore and since there are no data demonstrating that these autoantibodies can enter 
living cells, they argue that 21-OH autoantibodies cannot be considered pathogenic agents of 
adrenal failure, but do represent the best serological markers of progressive autoimmune 
adrenalitis. Again, this raises the question of the direct pathogenic mechanisms and the role 
of cellular immunity in Addison’s disease. Since despite the various autoantibodies and 
autoantigens detected, the direct pathogenic mechanism by which the adrenal cortex is 
destroyed is probably cell mediated. 
One possible mechanism is delineated by Peterson et al. (Peterson et al., 2000): It is 
thought that T cells reactive to adrenal cortex antigens escape antigen-presenting cells in the 
thymus, maybe due to missing presentation of organ-specific, non-circulating antigens. 
These auto-reactive T cells subsequently recognize and destroy adrenocortical cells and 
stimulate auto-reactive B cells, which start producing autoantibodies specific to steroidogenic 
enzymes. Unfortunately, attempts to demonstrate a cell-mediated immune response towards 
adrenal cortical cells have been unsuccessful, yet. 
Another mechanism is proposed by Bøe et al. based on their finding that 
autoantibodies against 21-OH and scc enzyme in autoimmune Addison’s disease are mainly 
of the IgG1 subclass (Boe et al., 2004): In humans, IgG1 and IgG3 indicate Th1 responses 
and are primarily produced in response to protein antigens. The antibody isotypes stimulated 
by Th1 cells have high affinity for Fc receptors and are strong inducers of complement 
activation and antibody-mediated antigen uptake, i.e. IgG1 and IgG3 support antibody-
dependent cellular cytotoxicity and complement-dependent cellular cytotoxicity towards 
membrane-associated antigens. Therefore, the predominance of autoantibodies of the IgG1 
subclass may indicate that the CD4+ T-cell response in Addison’s disease is dominated by 
Th1 cells, a finding that is consistent with the clinical findings of inflammation in the adrenal 
glands of Addison’s patients. 
Dittmar and Kahaly summarized two theories of the immunopathogenesis of 
Addison’s disease/APS: the viral infection theory and the suppressor effect theory (Dittmar 
and Kahaly, 2003). The viral infection theory is based on an immune response to an 
environmental agent that cross-reacts with a host antigen, resulting in disease. For example, 
it was shown by Onodera et al. that reovirus type 1 (that produces diabetes in animals) also 
triggers an autoimmune response and infected mice develop an autoimmune 
polyendocrinopathy (Onodera et al., 1981). Regarding the suppressor effect theory, 
Sakaguchi and Sakaguchi demonstrated that administration of the immunosuppressive drug 
cyclosporine A to newborn BALB/c mice causes a selective defect of the regulatory T 
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suppressor cells normally responsible for down-regulation of the expansion of self-reactive 
lymphocyte clones. Additional removal of the thymus immediately after neonatal cyclosporine 
A treatment permanently sustained the T-cell-deficient state and produced autoimmune 
diseases with a higher incidence and in a wider spectrum of organs, e.g., thyroiditis, gastritis, 
insulitis, and adrenalitis (Sakaguchi and Sakaguchi, 1989). These pathological processes led 
to the preclinical phase of APS, with production of organ-specific antibodies and progressive 
immune-mediated destruction of endocrine tissues, characterized by chronic inflammatory 
infiltration of lymphocytes. 
Immunogenetics of Addison’s disease 
Beside serological markers, also distinctive immunogenetic features can be observed 
in Addison’s disease. These immunogenetic features differ in APS-1 and APS-2. 
Immunogenetics of APS-1 
As mentioned above, APS-1 has an autosomal recessive form of inheritance, 
suggesting a possible role of immunogenetic mutations in the pathogenesis of Addison’s 
disease. Accordingly, Aaltonen et al. found in a study investigating 14 Finnish families an 
association between APS-1 and the chromosome 21q22.3 (Aaltonen et al., 1994). Nagamine 
et al. isolated a novel gene from this region, AIRE (autoimmune regulator), which encodes a 
protein containing motifs suggestive of a transcription factor (Nagamine et al., 1997). Two 
mutations were found in Swiss and Finnish APS-1 patients. One of these, a CT substitution 
that changes the Arg 257 to a stop codon (R257X, a nonsense mutation) is the predominant 
mutation in Finnish APS-1 patients (Nagamine et al., 1997). In the same year, Aaltonen et al. 
also isolated the AIRE gene but reported of already five mutations (Aaltonen et al., 1997). 
These data demonstrated APS-1 being the first autoimmune disease caused by the mutation 
of a single gene. However, clinical disease expression depends on the presence of 
mutations in both alleles of the AIRE gene (Betterle and Zanchetta, 2003). 
AIRE encodes a 58-kDa protein having two plant homeodomain (PHD) zinc fingers, a 
nuclear localization signal, a proline-rich region, four LXXLL motifs, a SAND (after nuclear 
proteins Sp100, AIRE-1, NucP41/75 and DEAF-1/suppressin) and a HSR (homogenously 
staining region-locating) domain (Peterson et al., 2000). It is predominantly expressed in 
thymic epithelial cells but also in some monocyte-derived cells of the thymus, and in a subset 
of cells in lymph nodes, the spleen and in fetal liver (Pitkanen and Peterson, 2003). AIRE is 
thought to be involved in negative selection of self-reactive T-cell clones in the thymus, 
hence in maintaining normal self-tolerance (Ten et al., 2001). 
Over the last eight years, the number of AIRE gene mutations steadily increased from 
more than 20 in 2001 (Ten et al., 2001) to 45 in 2002 (Vogel et al., 2002) and to at least 50 at 
present (Villasenor et al., 2005), whereas most are frameshift or nonsense mutations 
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(Peterson et al., 2000). Betterle and Zanchetta summarized the incidences of the four main 
mutations (see fig. 2-9): The R257X mutation in exon 6 is present in 82% of the alleles of the 
Finnish with APS-1. The del13 in exon 8 is the most common mutation in Caucasian 
American, while the R139X in exon 3 is the most common in patients from Sardinia. Y85C in 
exon 2 is the only one identified in Jewish Persians (Betterle and Zanchetta, 2003). 
 
Fig. 2-9: Schematic representation of chromosome 21 showing the map of the APS-1 region (APECED) and the 
structure of the AIRE gene with the main mutations associated with the presence of APS-1 (Betterle and 
Zanchetta, 2003). 
Despite these interesting associations, the precise molecular mechanism by which 
AIRE exerts its influence remains unknown. It is also not known at what level AIRE functions. 
One possibility is that it operates on individual promoters or enhancers, another scenario 
involves broad regulatory processes at the gene or chromatin level, such as DNA 
methylation or chromatin remodeling. It is also not unlikely that AIRE complexes with and 
influences the activity of multiple other transcription factors, acting as a transcriptional 
regulator. The presence of a SAND domain in AIRE has been interpreted as an important 
clue to its transcriptional function (Gibson et al., 1998), but evidence for the direct binding of 
AIRE DNA remains sparse, confined to only one in vitro study (Kumar et al., 2001). On the 
other hand, several studies show that AIRE has the potential to activate transcription. For 
example, the finding of Pitkanens et al. that AIRE in vitro is associated with cyclic adenosine 
monophosphate-responsive element-binding protein (CREB-binding protein, CBP), a 
transcriptional co-activator, lend further support towards its involvement in transcriptional 
regulation (Pitkanen et al., 2000). Furthermore, Anderson et al. demonstrated in AIRE-
deficient mice a requirement for AIRE expression in the thymic stroma for the induction of 
tolerance to tissue-specific antigens and for the prevention of APS-1. DNA-microarray 
analyses showed that medullary epithelial cells (MEC) of the thymus lacking AIRE exhibited 
down-regulation of a subset of peripheral tissue antigens, strongly implicating this molecule 
being involved in regulation of peripheral tissue antigen expression in MECs and in 
imposition of T-cell tolerance centrally (Anderson et al., 2002). 
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Taken together, it seems rather unlikely that each of the several hundred genes 
specifically in MECs has an AIRE-binding site. More likely, AIRE is acting as a transcriptional 
regulator and/or is involved in broad regulatory processes. There is less uncertainty 
regarding AIRE’s role in the immune system. It is generally agreed that AIRE is involved in 
negative selection of self-reactive T-cell clones in the thymus, thus playing a central role in 
maintenance of normal immune tolerance. Hence, in APS-1, mutations in AIRE may be 
responsible for biased Th2 immune responses to self-antigens and defective protective Th1 
responses (Ten et al., 2001). 
Beside the role of AIRE mutations in APS-1, also the role of particular human 
leukocyte antigen (HLA) haplotypes is discussed. Here, some data lend support to the view 
that there is no such association in APS-1 (Peterson et al., 2000), while others, for example 
Ahonen et al., found HLA-A28 to be more frequent in patients with APS-1 and HLA-A3 to be 
more frequent in those with APS-1 and ovarian failure than in those with normal ovarian 
function (Ahonen et al., 1988). Currently, a general agreement on the role of specific HLA 
haplotypes in APS-1 has to be awaited. 
Immunogenetics of isolated Addison’s disease and APS-2 
Despite the histological picture of adrenalitis, which favors the view that the primary 
pathogenetic mechanism – a cell-mediated immune response leading to the destruction of 
the adrenal cortex – is similar whether AD occurs alone, as part of APS-2 or as a component 
of APS-1, the mechanisms of tolerance breakdown in these conditions are different. While in 
APS-1 the failure of AIRE expression in the thymic medulla is the distinctive finding, in 
isolated Addison’s disease and APS-2 it is a strong association with HLA system (Peterson 
et al., 2000). 
The HLA system is the human version of the major histocompatibility complex (MHC). 
The HLA complex on chromosome 6 contains over 200 genes, more than 40 of which 
encode leukocyte antigens (see fig. 2-10). The HLA genes that are involved in immune 
responses fall into two classes, I and II, which are structurally and functionally different. In 
the HLA region there are some 20 class I genes, three of these, HLA-A, B, and C, are the 
classic, or class Ia genes. The class II genes are classified according to the class (D), the 
family (M, O, P, Q, or R), the encoded chain (A or B for  or  chain, respectively), the 
individual gene (Arabic number), and the allelic variant of the gene (e.g., *0401). For 
example, HLA-DRB1*0401 stands for allelic variant 0401 of gene 1, which encodes the  
chain of a class II molecule belonging to the R family. Class I genes are expressed by most 
somatic cells, class II genes normally by a subgroup of immune cells that includes B cells, 
activated T cells, macrophages, dendritic cells, and thymic epithelial cells. The function of 
both class I and class II molecules is the presentation of short, pathogen-derived peptides to 
T cells, a process that initiates the adaptive immune response (Klein and Sato, 2000a). 
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Fig. 2-10: Location and organization of the HLA complex on chromosome 6 (modified from Klein and Sato, 
2000a). 
Various HLA alleles have been shown to be associate with T cell-mediated 
autoimmune disorders (Klein and Sato, 2000b). In APS-2 and isolated Addison’s disease, 
strong associations between Addison’s disease and alleles within the HLA-DR3 and HLA-
DQ2 carrying haplotype are found, including DRB1*0301 and DQA1*0501–DQB1*0201, 
respectively (Partanen et al., 1994). For example, Partanen et al. found these alleles in 83-
92% of the patients, but only in 20-29% of the healthy controls (Partanen et al., 1994). Huang 
et al. showed that the subtype DQB1*0302 was increased in those patients with Addison’s 
disease and type 1 diabetes mellitus. However, the presence of type 1 diabetes mellitus 
entirely explained this association (Huang et al., 1996). In Italian patients, in addition to HLA-
DR3, also the prevalence of HLA-DR5 was increased in those with both Addison’s disease 
and thyroid autoimmunity (Betterle et al., 1996). In addition, the DRB1*0301 haplotype 
seems to be associated stronger with APS-2 than with isolated Addison’s disease (Partanen 
et al., 1994). Beside this exception, no difference in HLA class II alleles has been found 
between the two clinical subgroups, which further suggests that both forms of Addison’s 
disease, isolated and associated with APS-2, have a similar genetic background and 
etiology. 
Patients with Addison’s disease also show certain variations of genes in the HLA 
class III and I region. Regarding genes in the HLA class III region, patients with Addison’s 
disease show deletion of the complement C4 and CYP21A (a pseudogene for cytochrome 
P450c21) genes, and the tumor necrosis factor  (TNF-) allele TNFB*1 (Peterson et al., 
2000). Interestingly, Partanen et al. found notably similar class II and class III gene markers 
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in healthy controls and patients, if matched for HLA-DRB1*0301. Therefore, they argue that 
none of the class III markers are specific to Addison’s disease (Partanen et al., 1994). 
The same may be true for HLA class I polymorphisms. Here, the HLA-B8 allele and 
MIC-A (MHC class I chain-related gene A) and MIC-B gene polymorphisms (MHC class I 
chain-related gene A) are associated with Addison’s disease (Gambelunghe et al., 1999). 
With regard to the HLA-B8 allele, the association with HLA-DR3-DQ2 seems to be stronger, 
and the B8 allele is only associated with Addison’s disease when part of the HLA-B8-DR3 
haplotype. Thus suggesting strongly that the HLA-B8 allele is also not a marker specific to 
Addison’s disease. 
Other results are observed regarding the MICA and MICB gene polymorphism. The 
exon 5 microsatellite polymorphism of the MIC-A gene consists of five alleles based on the 
number of GCT triplet repeat units (alleles A4, A5, A6, and A9) and the presence of an 
additional nucleotide insertion (allele A5.1; Ota et al., 1997). The intron 1 microsatellite 
polymorphism of the MIC-B gene consist of 13 alleles based on the number of CA/TG repeat 
units (Tamiya et al., 1998). In APS-2 and isolated Addison’s disease, the polymorphisms 
MIC-A5.1 and MICB-CA-25 are of special interest. Gambelunghe et al. observed an 
increased risk for Addison’s disease in the presence of MICB-CA-25 in subjects carrying also 
the MIC-A5.1 allele. Furthermore, they were able to show that both MIC-A5.1 and HLA-
DR3/DQ2 are necessary to confer increased genetic risk for Addison’s disease. Therefore, 
they conclude that this combination is now to be seen as the most important genetic marker 
for isolated Addison’s disease and APS-2 (Gambelunghe et al., 1999). Nevertheless, to date 
there is no proof that this association is a primary association, and not also a result of linkage 
disequilibrium (i.e., a non-random association of alleles at two or more loci on a 
chromosome) as in the case of the HLA-B8 allele or the HLA class III polymorphisms. 
The role of other genomic loci beside HLA genes in Addison’s disease is still unclear. 
One other candidate region is located on chromosome 2q33, where a susceptibility gene has 
been mapped for type 1 diabetes mellitus (Nistico et al., 1996). This region contains the 
cytotoxic T lymphocyte antigen 4 (CTLA-4) gene that encodes a receptor on T cells. CTLA-4 
is a key regulatory element in the interaction with antigen-presenting cells, since T cell 
activation requires two signals: the first signal is provided by antigen–T-cell receptor (TCR) 
engagement and the second co-stimulatory signal is mainly provided by the interaction of the 
co-stimulatory molecule CD28 with its ligands B7.1/B7.2 (CD80/CD86) on antigen-presenting 
cells. Importantly, CTLA-4 also binds to B7.1/B7.2 but in contrast to CD28, it provides a 
negative signal to T cell activation and is only expressed on activated T cells (Vaidya and 
Pearce, 2004). 
In the context of Addison’s disease, isolated or as part of APS-2, two CTLA-4 gene 
polymorphisms are of special interest: (1) an A to G transition at position 49, which results in 
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a threonine to alanine substitution at codon 17 in exon 1 of the CTLA-4 gene (CTLA-4 Ala17) 
and (2) a microsatellite polymorphism (variant lengths of a dinucleotide [AT]n repeat) lying in 
exon 3 of the CTLA-4 gene, specifically a 106 base pair (106-bp) allele. In this regard, 
Donner et al. found patients with Addison’s disease carrying significantly more often at least 
one CTLA-4 Ala17 allele. In their study, increased genetic susceptibility applied only to the 
subgroup of DQA1*0501 positive patients (Donner et al., 1997). Vaidya et al. reported on 
similar findings but without the HLA restriction. They suggested that the effect observed by 
Donner et al. may reflect the presence of an excess of HLA DQA1*0501-associated 
autoimmune thyroid diseases and type 1 diabetes mellitus in this subgroup of patients. 
Further, Vaidya et al. found a stronger association of the CTLA-4 Ala17 allele in patients with 
Addison’s disease as a component of APS-2 than in patients with isolated Addison’s disease 
(Vaidya et al., 2000). Regarding the microsatellite polymorphism, results of Kemp et al. 
indicate an association between the 106-bp allele and Addison’s disease. Interestingly, this 
was true only in the English patients but not in Norwegian, Finnish or Estonian patients 
(Kemp et al., 1998). 
The consistency of allelic associations between the CTLA-4 gene polymorphisms and 
different autoimmune diseases suggests that at least one of these two polymorphisms may 
have a functional role in the pathogenesis of autoimmunity. In this regard, Yanagawa et al. 
hypothesized that the larger size of the 106-bp allele compared to the more common 88-bp 
allele could adversely affect the stability of the messenger RNA (mRNA) transcript, leading to 
reduced levels of cell-surface CTLA-4. But they also point out that there is no evidence that a 
mRNA of 106-bp allele is more stable or less stable than others (Yanagawa et al., 1995). A 
functional role of the CTLA-4 Ala17 allele is generally discounted, and CTLA-4 Ala17 is thought 
simply to be in linkage disequilibrium with the true susceptibility polymorphism. However, it is 
also possible that this polymorphism determines a subtle alteration in the subcellular 
localization or a functionally important difference in the folding of the mature CTLA-4 protein 
(Vaidya et al., 2000). Additional investigations will be necessary to clarify the functional role 
of CTLA-4 gene polymorphisms and their significance in Addison’s disease. 
2.2.7 Summary 
The outline of Addison’s disease given above emphasized the etiological complexity 
of the disease. However, this rare endocrinological state ultimately and invariably is caused 
by the destruction of the adrenal cortex. Thus, no glucocorticoids and mineralocorticoids are 
synthesized and – due to lacking glucocorticoids – also no epinephrine. This lack of vitally 
important hormones is counterbalanced by pharmacological therapy providing basal cortisol 
(and aldosterone) concentrations. Nevertheless, in states of stress this disease does not 
allow for an adequate endocrine response. 
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The combination of existing basal cortisol concentrations but lacking endocrine stress 
response predispose ‘Addison’s disease’ towards an valuable approach to gain new insights 
into the interaction between stress and the immune system. Unfortunately, so far the initial 
endocrinological conditions are unknown in that no experimental data are available 
describing how closely the circadian rhythm of cortisol is mimicked by pharmacological 
therapy. Further, no data are available concerning hormone concentrations during stress. 
Hence, one aim of the present thesis was to first of all determine experimentally these initial 
conditions (see section 4.1 and 4.2). 
However, the second aim of this work was to investigate the effects of a missing 
endocrine stress response on the immune system. Thus, first the third main topic in this 
regard, namely the immune system (2.3.1) will be introduced. Subsequently, studies 
investigating the effects of stress (2.3.2) and stress mediators (2.3.3) on immune functions 
as well as mechanisms and modulators of hormone-to-immune system signaling (2.3.4) will 
be described. 
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2.3 PSYCHONEUROIMMUNOLOGY 
In 1993, Dr. George Freeman Solomon cited in the Normal Cousins Lecture delivered 
at the conference on research perspectives in psychoneuroimmunology the Transylvanian 
physician Papai Pariz Ferenc (1980), who in turn reiterated the famous Greek philosopher, 
natural scientist and influential thinker Aristotle: “When the parts of the body and its humors 
are not in harmony, then the mind is unbalanced and melancholy ensues, but on the other 
hand, a quiet and happy mind makes the whole body healthy” (Solomon, 1993). 
This demonstrates that on the one hand already the ancient Greeks knew about the 
mutual mind-body influences (see also the monography by (Sternberg, 2000). On the other 
hand, a long time this knowledge was opposed by a view of the immune system as 
autonomous, reactive only to antigen, and self-regulatory (Solomon, 1993) – two positions 
apparently incompatible. Hence it was not until Metal’nikov and Chorine demonstrated in 
1926 that the Pavlovian rules of conditioning also apply to the immune system (Metal'nikov 
and Chorine, 1926) that this paradox was resolved. In the following 50 years, indications of 
brain-immune system connectedness accumulated. Five years earlier, Hammar had already 
observed that emotional factors and hormonal alterations have a major influence on the size 
of the thymus (Hammar, 1921). Selye then provided the link of shrinkage of the thymus and 
of lymphoid organs to HPA axis activity (Selye, 1936a; Selye, 1936b). In 1949, Szentivanyi 
and colleagues discovered that the hypothalamus regulates the anaphylactic response in 
guinea pigs, demonstrating that the nervous system has a dominant regulatory power over 
immune reactivity (Filipp and Szentivanyi, 1958; Szentivanyi and Filipp, 1958; Szentivanyi 
and Szekely, 1958). In 1975, the taste-aversion conditioned immunosuppression 
experiments by Bob Ader and Nick Cohen eventually put psychoneuroimmunology (PNI) on 
the map (Ader and Cohen, 1975). 
Twenty-four years later, Bruce Rabin defined psychoneuroimmunology (PNI) as “the 
study of how (1) psychological factors that an individual experiences and that activate 
neurons in the brain (2) modify the production and release of neuropeptides and endocrine 
hormones that (3) alter the function of the immune system, which then (4) increases the 
susceptibility of an individual to diseases that are normally prevented by a healthy functioning 
immunes system” (Rabin, 1999). But this brain-immune system connection is not one-way. 
During the eighties of the 20th century, experiments of several laboratories, for example from 
Besedovsky and colleagues, clearly showed that the immune systems also signals back to 
the central nervous system (Besedovsky et al., 1981) see also (Blalock, 1989). Therefore, a 
definition of PNI should emphasize that this field addresses the way in which nervous system 
and immune system interact with each other, and how these interactions influence the state 
of health of an individual. In their editorial to volume I of the “Neuroimmune Biology Book 
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Series”, Berczi and Szentivanyi pointed out that there is even much more to this interaction 
than ‘bi-directional’. It is a “truly multi-directional, all-inclusive systemic regulatory network 
formed by the nervous-, endocrine- and immune systems, which controls all bodily functions 
of higher animals and man” (Berczi and Szentivanyi, 2001). 
Since it is not within the scope of this thesis to account for the whole complexity of 
this multi-directional network, the outline of the following sections is geared to selected 
questions: How does the immune system protect an organism against disease (2.3.1: the 
immune response)? What effects have psychological and emotional states on the immune 
system (2.3.2: brain-immune system communication)? What particular role play 
glucocorticoids and catecholamines in these interactions? (2.3.3: role of stress mediators)? 
How and influenced by which modulators do glucocorticoids exert their effects on the 
immune system (2.3.4: mechanisms and modulation of glucocorticoid-to-immune system 
signaling)? In the context of the last question, a parameter potentially important in 
compensating missing glucocorticoid signaling will be introduced: The transcription factor 
nuclear factor-kappaB. 
2.3.1 The Immune Response 
Day-to-day an organism is exposed to a wide variety of pathogens. In most cases, 
this does not cause any major symptoms of disease. Once in a while, an acute infection can 
cause a temporary state of disease and in very rare cases, this infection can gain the upper 
hand, leading to death or chronic disease. In the following, the mechanisms accounting for 
these different outcomes are discussed. 
2.3.1.1 First Line of Defense 
Generally, the best defense is not allowing a pathogen to enter the organism at all. 
These external barriers against infections are therefore also called first line of defense and 
include skin, mucous membranes, body fluids, and normal bacterial flora. Normal skin 
protects an organism by a low pH, which is lethal to most pathogens. Mucous membranes in 
the respiratory, gastrointestinal, and genitourinary tracts block adherence of microorganisms 
to epithelial cells by trapping them in the adhesive mucus. Body fluids, such as tears, nasal 
secretions, saliva, gastric juice, semen, and breast milk include important enzymes and 
bactericidal elements (e.g., lysozyme in tears, nasal secretions, and saliva; acid in gastric 
juice; zinc in semen; lactoperoxidase in breast milk). Finally, normal bacterial flora present in 
the gastrointestinal, respiratory, and genital tracts is protective by competing for principal 
nutrients and/or by production of substances capable of inhibiting other microorganisms 
(Uthaisangsook et al., 2002). 
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2.3.1.2 Second Line of Defense: Innate immunity 
What happens, if the first line of defense fails? The second line of defense – or as 
Parham puts it: “The unsung heroes” – come into play (Parham, 2003). It is also Parham who 
stated that “the fact that most people are not perpetually sick is testament to innate immunity 
squelching most of the infections that we contract” (Parham, 2003). This innate immunity is 
the organism’s second line of defense. 
But why ‘unsung heroes’? Contrary to, for example, dendritic cells or complement 
system, virtually everybody heard of antibodies or immune memory and has an idea what 
they stand for. From vaccination or from the last flu, it is also known that an immune 
response is very specific and takes its time to be mounted. As a start, all this does not deal 
with innate immunity. Innate immunity is rather the direct opposite: It is nonspecific and it has 
no memory – but it is fast. And exactly these properties are responsible for the fact that we 
are not perpetually sick. 
As the name implies, the innate immune system is present since birth and a 
phylogenetically ancient defense mechanism found in all multicellular organisms. And 
although nonspecific, it is capable of differentiating between self and non-self perfectly, i.e., 
the innate immunity has the ability to recognize invading microorganisms (i.e., antigens) 
despite their immense molecular heterogeneity and variability. 
2.3.1.2.1 The cellular components of the innate immune system 
A major component of the innate immune system are white blood cells or leukocytes 
(for review see Janeway et al., 2001; Rabin, 1999). These cellular components include 
granulocytes, monocytes, immature dendritic cells, natural killer (NK) cells, / T cells, and B-
1 cells (Uthaisangsook et al., 2002). All these cell types originate from pluripotent 
hematopoietic stem cells in the bone marrow, which then differentiate into myeloid or 
lymphoid stem cells. The former are progenitors for granulocytes, monocytes, and immature 
dendritic cells, the latter for B lymphocytes (B-cells) and T lymphocytes (T-cells) – and 
regarding innate immunity – specifically for NK cells, / T-cells, and B-1 cells (Janeway et 
al., 2001). 
The term granulocytes thereby stands for several types of granular leukocytes, also 
sometimes called polymorphonuclear leukocytes because of their oddly shaped nuclei: They 
include neutrophils, eosinophils, and basophils, labeled according to their staining 
capabilities (Rabin, 1999). Granulocytes are all relatively short lived and produced in 
increased numbers during immune responses. Neutrophils have the capability of binding 
foreign particles, such as bacteria, to their surface and subsequently ingest (phagocytosis) 
and kill them. Eosinophils help to protect against infections with parasites, like worms, by 
releasing toxic proteins. The function of basophils is unknown, but they have granules 
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containing histamine and surface receptors for the Fc portion of the immune globulin (Ig) E 
antibody molecule. Primarily, all these different cells circulate in the blood, but, with the 
exception of basophils, they also enter tissues. Other cells first differentiate in tissues: As 
monocytes subsequently enter tissue, they enlarge in size and this mature form is then called 
macrophages. Like neutrophils, macrophages are phagocytes. But they also have another 
major effector function, namely the presentation of peptides derived from a pathogen on their 
surface via class I and class II major histocompatibility complex (MHC-I and MHC-II) 
molecules. Mast cells are cells with a similar morphology like basophils, but they mature in 
tissues and are mainly found near small blood vessels. Upon activation, they release 
chemical factors like histamine and mediate many allergic reactions. Likewise, immature 
dendritic cells migrate from the blood to reside in secondary lymphoid organs, the skin and 
all tissues of the body. But it is not until they encounter a pathogen that they rapidly mature, 
i.e., dendritic cells uptake the antigen in peripheral sites, migrate to lymph nodes and there 
present the antigen via MHC-I and MHC-II molecules to other cells. Therefore, dendritic cells 
are one of the major so called antigen-presenting cells (APCs). Depending on their location, 
dendritic cells have a variety of other names. In the skin they are called Langerhans cells, 
interstitial dendritic cells in the heart, kidney, intestine, or lung, dendritic cells in the blood, 
and veiled cells in the afferent lymphatics. 
NK cells are the third lineage of lymphoid cells beneath T- and B-cells. They are large 
granular lymphocytes circulating in the blood and have the ability to kill target cells by using 
perforins and granzymes present in cytoplasmic granules. Located in the paracellular space 
between epithelial cells, mostly among the epithelial cells of the colon and small intestine, / 
T cells directly recognize unprocessed target antigens. They have cytolytic activity and 
produce cytokine-inducing growth factors. B-1 cells are a lineage of conventional B-cells 
which express CD5 (CD: cluster of differentiation) on their surface and are therefore also 
called CD5+ B-cells. Their receptors and the antibodies (predominantly immunoglobulin (Ig) 
M) produced by them bind many different ligands with low affinity. Contrary to B-cells, B-1 
cells recognize antigens without the help from antigen-specific T-cells and therefore mount a 
response much faster than usual for B-cells (Uthaisangsook et al., 2002). 
2.3.1.2.2 Recognition of pathogens: PAMPs and PRRs/PRMs 
But how do these cells “know” where to go, what to do, and, most importantly, what is 
self and what is foreign? To accomplish the latter, the innate immunity uses some kind of 
“trick”: Innate immune cells do not recognize specific antigens, but nonspecific molecules, 
called pathogen-associated molecular patterns (PAMPs; Medzhitov and Janeway, 1997a; 
Medzhitov and Janeway, 1997b; Uthaisangsook et al., 2002). These PAMPs are shared by 
large groups of pathogens, conserved products of microbial metabolism, essential for the 
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survival or pathogenicity of the microorganism, and absolutely distinct from self-antigens 
(Medzhitov and Janeway, 1997a). For example, instead of recognizing an antigen as 
Escherichia (E.) coli, cells of innate immunity recognize a component of the bacterial cell 
wall, namely lipopolysaccharide (LPS), shared by most gram-negative bacteria, which E. coli 
is just one of. Other PAMPs are lipoteichoic acids (LTA) present in numerous gram-positive 
bacterial cell walls, peptidoglycan (PGN) in the cell-wall of gram-positive, gram-negative and 
mycobacteria, the unmethylated cytosine phosphate guanine (CpG) motif characteristically 
for bacterial DNA, double-stranded RNA in RNA virus, or mannan components of yeast cell 
walls (Medzhitov and Janeway, 1997a; Uthaisangsook et al., 2002). PAMPs in turn are 
recognized by a set of molecules as well as receptors (cell-surface, transmembrane, 
intracellular, or soluble receptors) referred to as pattern-recognition molecules (PRMs) and 
pattern-recognition receptors (PRRs). They represent different functional classes: endocytic 
receptors like the macrophage mannose receptor, secreted proteins like mannose-binding 
lectin (MBL) or C-reactive protein (CRP), and signaling receptors like the Toll receptor family 
(Uthaisangsook et al., 2002). The specificities of PRMs and PRRs are germline encoded, 
i.e., they arise over evolutionary time due to selection by pathogens at the populational levels 
(Medzhitov and Janeway, 1997a). Given these prerequisites, the cells of the innate immunity 
are able to recognize a great variety of molecular structures associated with pathogens with 
only a limited number of germline-encoded receptors and molecules. And binding of PAMPs 
to PRRs or PRMs (with subsequent binding of these complexes to PRRs) is the first step in 
activating these cells to exert their respective above described functions. 
2.3.1.2.3 The complement system 
Another essential but often underestimated role in immune system activation plays 
the complement system. The complement system consists of at least 20 different proteins 
(C1, C2, C3…), which act in a cascade-like fashion. Activation of a complement component 
(e.g., C3) results in splitting it into fragments, usually designated by the suffixes “a” for the 
smaller fragment released into body fluid (C3a) and “b” for larger membrane-bound fragment 
(C3b). Three cascades or pathways are known: The classical, the alternative, and the MBL 
(mannose-binding lectin) pathway. The latter depends on an above mentioned PRM, namely 
MBL, which recognizes carbohydrate patterns on cell wall of bacteria, yeast, parasites, 
mycobacteria, and certain viruses. Binding of MBL to carbohydrates on the pathogen surface 
is followed by a sequence of reactions resulting in generation of a protease called C3 
convertase formed from C2b bound to C4b. The classical pathway initiates complement 
activation in the same way as the MBL pathway. It just uses a protein very similar to MBL, 
called C1q, which is part of the C1 complex. C1 can also bind directly to pathogens, but it is 
primarily activated by antigen-antibody interactions and thus generally provides a later 
immune response. But again, a C3 convertase is generated. The alternative pathway of 
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complement activation is initiated by the third component of complement, C3. C3 is 
constantly activated by spontaneous hydrolysis into the activated C3 protein, C3(H2O), which 
interacts with serum complement components to form a C3 convertase. Contrary to 
pathogens, host cells have complement regulatory proteins on their cell surface, which 
protect them from the consequences of spontaneous activation of C3 molecules. The 
alternative pathway can also act as an amplification loop for all three pathways. However, the 
production of a C3 convertase is the point at which all three pathways converge and the main 
effector functions of complement are generated. The most important activity of a C3 
convertase is to cleave large numbers of C3 molecules to produce C3b and C3a molecules. 
C3b molecules coat the pathogen surface, a process called opsonization. Simultaneously, 
C3b binds to complement receptors on phagocytic cells and this induces the phagocytic cell 
to ingest the bacteria. C3b may also bind to the convertase resulting from the MBL pathway 
(C4b,C2b) or the alternative pathway (C3b, Bb) to form a C5 convertase complex, which 
cleaves C5 to form C5b and C5a. C5b then initiates the forming of a membrane-attack 
complex. For this, C5b triggers the assembly of a complex of one molecule each of C6, C7, 
and C8. C8 inserts into the cell membrane and up to 16 molecules of C9 are then added to 
the assembly to generate a channel in the membrane of the pathogen. This channel disrupts 
the pathogen cell membrane, thereby killing the pathogen. This second function of 
complement is called lysis. But also the smaller fragments released into body fluid, C3a and 
C5a, have a biological function. These small peptides attract inflammatory cells to the 
location at which the complement is being activated, a process called chemotaxis. 
Additionally, C5a is an important signal to ultimately activate phagocytes to ingest opsonized 
pathogens, if only C3b binds to the complement receptor CR1 on their surface. Taken 
together, activation of the complement system may result in lysis, opsonization, and 
chemotaxis: It not only kills pathogens without any involvement of immune cells, but also 
provides an alternative mechanism for phagozytic cells, beneath PAMPs, to recognize a 
pathogen and above all directs them to the side of action (Janeway et al., 2001; Rabin, 
1999). 
2.3.1.2.4 Communication and “traffic management”: cytokines and adhesion molecules 
Beneath recognition of pathogens, immune cells also have to communicate to each 
other to act in concert and eventually mount an effective and coordinated immune response 
against invading pathogens. The way this communication is accomplished is by mediators 
called cytokines and chemokines (Janeway et al., 2001; Rabin, 1999; Uthaisangsook et al., 
2002). Cytokines are small proteins that are released by various cells, usually in response to 
an activating stimulus like binding to PAMPs, and induce responses through binding to 
specific receptors. Cytokines are in most cases designated as IL (for interleukin) followed by 
a number (e.g., IL-1). Their actions are very complex: Individual cytokines may act on many 
THEORETICAL BACKGROUND 72 
different cell types (ambiguity), while different cytokines may have similar actions 
(redundancy). Several cytokines may also act on one cell synergistically or antagonistically 
and one cytokine may increase or decrease both the production of another and the 
expression of receptors for another. For example, activated macrophages may secrete the 
cytokines IL-1, IL-6, IL-8, IL-12 and TNF-. IL-1 activates vascular endothelium and 
lymphocytes and increases adhesiveness of leukocytes. IL-8 is a chemotactic factor 
recruiting neutrophils, basophils, and T cells to site of infection. TNF- like IL-1 activates 
vascular endothelium and increases vascular permeability, leading to accumulation of 
immune globulin and complement in infected tissues. IL-6 induces B-cell terminal 
differentiation into immune globulin-producing plasma cells. IL-1, IL-6, and TNF- all have 
additionally systemic effects in that they induce an acute-phase response in the liver and 
induce fever. Finally, IL-12 activates NK cells. But NK cells are also activated by the 
interferons (IFN) IFN- and IFN-, which are produced by viral-infected cells and strongly 
upregulate the expression of MHC-I molecules on these infected cells. 
As already mentioned – and in parallel to LPS and by-products of complement 
activation – certain mediators (e.g., IL-1, TNF-) induce the activation of endothelial cells and 
enhance leukocyte adhesion. These processes are important as they are responsible for the 
recruitment and migration of leukocytes out of the blood vessels into the infection site. 
Centrally to this is the induced expression of cell adhesion molecules (CAM) on endothelial 
cells and leukocytes. CAM are used by cells to grip onto each other, to haul themselves by 
one another and to travel to injured tissues. Based on their structure, there are three major 
types of CAM: selectins, integrins and the immunoglobulin superfamily. Selectins are 
expressed on endothelial cells within a few minutes of exposure to – among others – C5a or 
histamine (P selectin), or within a few hours after exposure to LPS and TNF- (E selectin). 
These selectins interact with carbohydrate epitopes on leukocytes and allow them to roll 
along and reversibly attach to the vascular endothelial surface. This process is termed 
rolling. The next step depends on tighter adhesion, i.e. a stronger attachment of leukocytes 
to endothelium and is supported by IL-8. Adhesion involves integrins on leukocyte (e.g., 
leukocyte functional antigens-1 (LFA-1) and complement receptor-3) which interact with 
members of the immunoglobulin superfamily on endothelial cells, mostly intercellular 
adhesion molecules (ICAMs). As a result, the leukocytes attach and adhere firmly to the 
endothelium. The subsequent process is known as diapedesis and represents the 
extravasation of leukocytes through the vessel wall. It additionally involves an Ig-related 
molecule that is called PECAM or CD31 on both, the leukocyte and the intercellular junctions 
of endothelial cells. These interactions enable the leukocytes to squeeze between the 
endothelial cells. Finally in the tissue, the leukocytes just have to be directed to the site of 
infection, a process called migration. Thereby, chemokines, like IL-8 released by the 
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macrophages that first encounter a pathogen, form a concentration gradient along which the 
leukocyte can migrate to the focus of infection (Janeway et al., 2001; Rabin, 1999; 
Uthaisangsook et al., 2002). This migration of leukocytes to tissue and their accumulation in 
tissue also constitutes the so-called inflammatory response (Rabin, 1999). 
2.3.1.2.5 Inflammation 
As already mentioned above, cytokines may have long-range effects that contribute 
to host defense. In this regard, the pro-inflammatory cytokines TNF-, IL-1, and IL-6 
produced by macrophages communicate an infection to the central nervous system and may 
cause fever. Additionally, they may initiate an acute phase response (APR) in the liver, 
thereby amplifying the local immune response by recruiting more phagocytic cells to the site 
of infection (see above). Several of the acute phase proteins (APPs) produced by the liver 
upon activation mimic the action of antibodies, but contrary to antibodies, they have a broad 
specificity for PAMPs. APPs (e.g., SAP: serum amyloid protein, CRP: C-reactive protein, or 
MBL) bind to bacteria, acting as an opsonin but also activating the classical complement 
pathway of the complement system, thus facilitating phagocytosis. These processes of cells 
and soluble substances involved in attracting and activating cells to accumulate at the site of 
an infectious agent are called inflammatory response (Janeway et al., 2001; Rabin, 1999). 
An acute inflammation can be initiated within minutes upon entry of a bacterium into 
the body. Hence, it is a rapid and efficient response to an infectious agent and will frequently 
lead to resolution. The characteristics of an inflammation are well known by everybody: (1) 
redness (erythema) caused by vasodilation, (2) swelling (edema) caused by leakage of fluids 
from enlarged and more permeable blood vessels, (3) local warmth caused by increased 
blood flow (fever) and systemic fever caused by the release of cytokines from macrophages 
acting in the brain, and (4) pain resulting from heat and swelling acting on local nerves. Just 
in an overwhelming infection or cases of an impaired acute inflammatory response, further 
steps are necessary resulting in chronic inflammation (Janeway et al., 2001; Rabin, 1999). 
In some case, all these efforts may not be sufficient or even be too efficient. For this 
reason, immune cell of the innate immune system also present peptides derived from a 
pathogen on their cell surface via MHC-I or MHC-II molecules. Antigen presentation is the 
fourth major property of innate immunity, beneath recognition of a pathogen, its clearance, 
and cytokine production. And in combination with specific cytokine profiles, via this fourth 
property the innate immunity can initiate, direct and control the third line of defense. 
2.3.1.3 Third Line of Defense: Adaptive Immunity 
In contrary to the innate immunity, the adaptive immunity is very specific and has a 
memory. However, this comes at the expense of speed: An adaptive or specific immune 
response may take several days or weeks to develop. 
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Centrally to the adaptive immunity are its cellular components, T lymphocytes and B 
lymphocytes, which develop from progenitor cells within the bone marrow. T-cells migrate to 
the thymus at an early stage as thymocytes, while B cells remain within the marrow for the 
duration of their development. Early in the development of the cells, antigen-specific 
receptors occur. The specificity of adaptive immune responses is due to these antigen-
specific receptors on both cell types. Instead of being germline-encoded, these receptors are 
the result of a random rearrangement and splicing together of multiple DNA segments that 
code for the antigen-binding areas of the receptors. Arstila et al. estimated the repertoire of 
T-cell receptors and B-cell antibody specificities of over 108 and 1010, respectively (Arstila et 
al., 1999). This diversity is achieved by a mechanism quite similar for both cell types and will 
be described exemplarily for the B-cell receptor: Despite a constant region, three segments 
of genes are involved in receptor formation, 25-100 genes for the variable (V) region, 
approximately 25 genes for the diversity (D) region, and circa 50 genes for the joining (J) 
region. Any combination of the genes of these three regions may eventually form the final 
VDJ region of the receptor. Additionally, splicing may be inaccurate and frameshift in 
basepairs leads to production of a different aminoacid (junctional diversity). Third, the 
sequence may be altered by the enzyme deoxyribonucleotidyl-transferase inserting 
nucleotides. The greater repertoire of B-cell receptors is due to further immunoglobulin gene 
rearrangement occurring during B-cell division after antigen stimulation, called somatic 
hyper-mutation (Parkin and Cohen, 2001). As a result, every T-cell and every B-cell has its 
own unique receptor. But this receptor is the product of random processes, hence it may as 
well bind to a self-antigen, an incident to be prevented in any circumstances. Consequently, 
several “safety nets” are build in. 
The first safety net is the selection of cells taking place in the bone marrow in the 
case of B-cells and in the thymus in the case of T-cells. Centrally to T-cell selection are 
APCs, which have MHC-I and MHC-II molecules on their surface occupied with peptides 
derived from self-antigens. In positive selection, either the CD4 or the CD8 molecule on the 
T-cell surface has to bind to the appropriate receptor on a MHC-II or MHC-I molecule, 
respectively. If the T-cell has bound onto a MHC-I molecule, the CD8 molecule will bind to 
the CD8 receptor on MHC-I and synthesis of CD4 will cease. At the same time, the unique T-
cell receptor (TCR) has to fit into the MHC molecule but not bind tightly to the peptide in the 
MHC groove. Only this combination will positively select the T-cell for survival. This first 
testing will result in CD8+ or CD4+ cells, which are able to recognize MHC molecules. Without 
recognizing the body’s own MHC molecules, T-cells would not be able to mount any immune 
response at all against an antigen. In negative selection, useless or autoreactive cells are 
sorted out. Useless T-cells are cells which TCRs do not fit into MHC molecules and thus 
cannot recognize a peptide in a MHC molecule. Without fitting into the MHC molecule, also 
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the CD4 or CD8 will not bind to the receptor on the MHC molecule. Without any signal 
provided by binding, these immature T-cells will die by apoptosis. Apoptosis is the death of a 
cell that occurs when a trigger mechanism instructs the cell to kill itself and is therefore also 
often termed programmed cell death. On the other hand, autoreactive cells not only bind to a 
CD4 or CD8 receptor on a MHC molecule, but also the TCR binds tightly to the self-antigen 
in the MHC groove. A combination which again results in T-cell death by apoptosis. Taken 
together, via these selection processes it is ensured that only T-cells recognizing MHC 
molecules but not self-antigens will survive (Rabin, 1999). B-cell undergo negative selection 
in the bone marrow instead of the thymus. In this case, immature B cells which bind to self 
cell-surface antigens are removed from the repertoire. The unique receptor of B-cells thereby 
is an immunoglobulin, more precisely an IgM molecule expressed on the cell surface 
(Janeway et al., 2001). 
But these mechanisms are just the first safety net. Several other precautions are 
taken with regard to activation of now mature but so far naïve B- and T-cells. These 
precautions are closely intertwined with innate immune responses and will be discussed with 
regard to the three phases of an effective adaptive immune response: The (1) induction 
phase, in which the presence of a pathogen is detected and relevant antigens are presented 
to T-cells; an (2) activation or expansion phase, which includes the proliferation and 
mobilization of immune cells important for the eradication of the pathogen; and an (3) effector 
phase in which the pathogen is neutralized and eliminated by so-called humoral or cellular 
elements or by an interaction of both (McEwen et al., 1997). Additionally, the (4) formation of 
immunological memory as one of the most important consequences of the adaptive immune 
response will be presented. 
2.3.1.3.1 Induction phase 
One major property of innate immunity is the presentation of antigen in MHC-I or 
MHC-II molecules on their surface. Which MHC molecule will be presented depends on the 
antigen. Among others, macrophages digest exogenous pathogens, like bacteria. Once 
recognized, macrophages engulf these pathogens into cytoplasmic phagosomes 
(membrane-bounded vacuoles) and the phagosomes fuse with cytoplasmic granules, in 
which enzymes and antimicrobial peptides inactivate and degrade the pathogen. In the 
endoplasmatic reticulum, pathogen peptides then are loaded on MHC-II molecules and the 
antigen-MHC-II complex will be presented on the cell surface. Another cell expressing an 
antigen-MHC-II complex is the B-cell of the adaptive immunity. B cells internalize soluble 
antigens, which cannot be taken up efficiently by macrophages. Binding of antigens to a 
specific surface immunoglobulin receptor results in internalization and processing of the 
antigen-immunoglobulin complex (Janeway et al., 2001; Medzhitov and Janeway, 1997a; 
Uthaisangsook et al., 2002). On the other hand, endogenous pathogens like viruses are 
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already found inside the cell, since they use the cell to replicate. Via proteasomes, the virus 
is also degraded. But in this case, peptides derived from the virus will be loaded on MHC-I 
molecules, hence an antigen-MHC-I complex will be presented on the surface (Chaplin, 
2003). This is also one important signal to activate NK cells, which then kill the infected cell 
(Uthaisangsook et al., 2002). 
The processing and presentation of a pathogen further results in expression of a co-
stimulatory signal. This co-stimulatory signal is another safety net. To activate T-cells of 
adaptive immunity, they not only have to bind to the antigen-MHC complex, but they also 
have to receive this co-stimulatory signal (e.g., B7 molecules on the APC binds to CD28 on 
the T-cell). And since an adaptive immune response is only appropriate when it is specific to 
pathogen-derived antigens, co-stimulators – which are only expressed in the presence of a 
pathogen – ensure that an immune response is not directed against a host antigen (Janeway 
et al., 2001; Medzhitov and Janeway, 1997a; Uthaisangsook et al., 2002). 
2.3.1.3.2 Activation phase 
So far, innate immunity played the major role and in most cases no involvement of the 
adaptive immunity is needed. Just when the innate immunity is not able to bring an infection 
under control, an adaptive immune response is initiated. The link between innate and 
adaptive immunity is the presentation of antigens by professional APCs (macrophages, 
dendritic cells, and B-cells). Cells recognizing this signal are T-cells, more precisely CD8+ 
and CD4+ cells. CD8+ cells only recognize antigens presented with MHC-I and CD4+ cells 
only antigens presented with MHC-II. Upon activation by binding to the respective antigen-
MHC complex and a co-stimulator, CD8+ cells differentiate to cytotoxic T-lymphocytes (CTL) 
and CD4+ cells to T-helper 1 (Th1) or T-helper 2 (Th2) cells (Janeway et al., 2001). 
Since MHC-I molecules are expressed by all nucleated cells, CD8+ cells can be 
activated by cells infected with a virus, cells infected with other intracellular pathogens, or 
cells producing abnormal tumor antigen. Upon receiving the two signals (binding to antigen-
MHC-I complex and to co-stimulator), CD8+ cells immediately secret the cytokine IL-2 and at 
the same time express a high affinity receptor for IL-2. Binding of IL-2 to its receptor is the 
last signal necessary for transition of a naïve CD8+ cell to an armed effector cell. In this 
regard, activated CD8+ cells first proliferate and after 4-5 days of rapid growth they 
differentiate to CTLs (Janeway et al., 2001). 
CD4+ cells are activated by APCs presenting antigens in the groove of MHC-II 
molecules and expressing the co-stimulatory signal. Depending on the pathogen, APCs 
additionally release different cytokines. This cytokine profile determines, whether a CD4+ cell 
will proliferate and differentiate into a Th1 or a Th2 cell. An APC secreting the pro-
inflammatory cytokines IL-12 or TNF- supports differentiation into a Th1 cell, while the anti-
THEORETICAL BACKGROUND 77 
inflammatory cytokine IL-10 or IL-4 support differentiation into Th2 cells. Via this mechanism, 
APCs of the innate immunity are able to direct the subsequent adaptive immune response 
(Fearon and Locksley, 1996). 
2.3.1.3.3 Effector phase 
As the name implies, T-helper cells assist other cells in exerting their effector 
function. But the name does not reveal how centrally their function in adaptive immunity 
actually is. Depending on the type of T-helper cell induced, the following adaptive immune 
response will be a predominantly cell-mediated (Th1) or a predominantly humoral (Th2) 
immune response. 
Cell-mediated immunity 
Cell-mediated or cellular immunity includes processes induced by intracellular 
infectious agents. Principally, once CD8+ cells are activated and differentiated to CTLs, they 
are able to kill every cell on which they recognize the specific pathogen initially triggering the 
differentiation without further co-stimulatory signals. This killing is achieved either by 
secretion of specific mediators or by inducing apoptosis: Perforin-1 perforates the cell 
membrane, granzymes have proteolytic properties, and IFN- inhibits viral proliferation. 
Further, binding of the Fas-ligand on CTLs to the Fas receptor of an infected cell induces its 
self-destruction. 
Cells other than APCs do not express the initial co-stimulatory molecule, hence a 
CD8+ cell, although specific for the presented antigen, still will not become activated. The 
missing second signal has therefore to be provided by another mechanism. This is done by 
Th1 cells: The Th1 cell specific for an antigen presented by the infected cell binds to it in 
parallel to the CD8+ cell specific for an antigen of the same pathogen. Subsequently, the Th1 
cell either induces the expression of the required co-stimulatory signal or secretes IL-2, thus 
activating the CD8+ cell to differentiate into a CTL even in the absence of co-stimulation. 
The second major task of Th1 cells deals with phagocytes not able to remove an 
infectious agent, because it inhibits the fusion of lysosomes to the phagosmones or prevents 
the acidification of the vesicles, which is required to activate lysosomal proteases. Therefore, 
such infectious agents may resist and even proliferate inside the phagocytic cell. To activate 
these phagocytes, Th1 cells recognizing the antigen-MHC-I complex produce IL-2, IFN- and 
TNF-. Especially IFN- is important in that it induces antimicrobial mechanisms in 
macrophages known as macrophage activation. These cytokines further stimulate the 
macrophage to produce IL-1, IL-6, and TNF-, which in turn activate an inflammatory 
response as described for the innate immune response. The result of Th1 action is a more 
effective activation and coordination of inflammatory mechanisms, as well as the activation of 
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macrophages enabling them to suppress the growth of intracellular pathogens. Whereas the 
latter is regarded as the principal effector action of Th1 cells (Janeway et al., 2001). 
Humoral immunity 
While the cell-mediated immune response protects intracellular spaces, extracellular 
spaces are protected by the humoral immune response, in which antibodies produced by B-
cells exert the major effects. But before becoming an antibody-secreting plasma cell, once 
more first the B-cell has to be activated. And B-cell activation is dependent on Th2 cells, i.e. 
B-cells as well as CD4+ cells have to respond to the same antigen, a process called linked 
recognition. Just when a CD4+ cell recognized an antigen and differentiated to a Th2 cell and 
at the same time a B-cell recognized the same pathogen and presents peptides in complex 
with a MHC-II molecule, the basis for B-cell activation is provided. The Th2 cell will now bind 
via its specific TCR to the antigen-MHC-II complex expressed on the B-cell. This triggers the 
Th2 cell to synthesize cell-bound and secreted effector molecules. One particularly important 
Th2 effector molecule is the CD40 ligand, which binds to the B-cell surface molecule CD40. 
Additionally, Th2 cells synthesize the cytokine IL-4, which binds to the respective receptor on 
the B-cell. These two signals along with other signals synergize in driving the proliferation of 
the B-cell. After several rounds of proliferation and with the help of the cytokines IL-5 and IL-
6 secreted by Th2 cells, B-cells further differentiate into antibody-secreting plasma cells. The 
fact that B-cell activation requires Th2 cells represents another safety net protecting an 
organism from harmful immune responses to host antigen. 
The antibodies secreted by plasma cells, which resemble the specificity of the initial 
immunoglobulin receptor of the resting B-cell, mediate the humoral immune response in 
three main ways. First, they may bind to pathogens like viruses and intracellular bacteria. 
These pathogens have to bind to specific molecules on the target cell surface to enter the 
cell, a mechanism prevented by antibodies bound to the pathogen. Additionally, antibodies 
may prevent bacterial toxins from entering cells. These properties of antibodies are labelled 
neutralization. Second, antibodies may bind to the surface of a pathogen and thus enhance 
phagocytosis. This property is termed opsonization. Phagocytic cells recognize the constant 
C region of antibodies bound to a pathogen by their Fc receptors and subsequently engulf 
and phagocyte the opsonized pathogen. Third, antibodies may bind to the surface of a 
pathogen and thereby activate the complement proteins, resulting in the above described 
effects of enhanced phagocytosis, lysis and chemotaxis. 
Which mechanisms are engaged in a particular response is determined by the class 
of antibodies produced. The expression of this class or so-called Ig isotype (i.e., IgG, IgM, 
IgD, IgE, or IgA) is again regulated by cytokines released by T-helper cells (Janeway et al., 
2001). 
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Taken together, while Th1 cells secrete the cytokines IFN-, IL-2 and TNF- and 
mediate phagocyte activation and cellular immune responses, Th2 cells produce IL-4, IL-5, 
IL-6, IL-10 and IL-13, which primarily act as growth or differentiation factors for B cells and 
thus evoke strong antibody responses. Beyond that, Th1 and Th2 responses are mutually 
inhibitory (see fig. 2-11). This is, Th1 cytokines, such as IL-2 and IFN-, inhibit Th2 cells and 
therefore humoral immune responses and Th2 cytokines, such as IL-4 and IL-10, inhibit Th1 
cells, hence macrophage activation and activation of CD8+ cell (Mosmann and Sad, 1996; 
Romagnani, 2000). Consequently, prevalent Th1 or Th2 responses are linked to conditions 
like organ-specific autoimmune disorders or atopic diseases, respectively (Romagnani, 
2000). 
 
Fig. 2-11: Schematic view of the Th1-Th2 concept (Th: T-helper cell; APC: antigen presenting cell; CTL: cytotoxic 
T lymphocyte; M: macrophage; B: B-cell; Ab: antibody; modified from Mosmann and Sad, 1996). 
However, it should be noted that the classification of activated CD4+ T-cells (Th0 
cells) into Th1 and Th2 cells presented in the above sections is based primarily on the 
cytokines they produce. This circumstance led to some controversy. For example, it was 
argued that synthesis of any cytokine is a continuously distributed function, hence 
classification of cells as Th1 or Th2 cells is strongly determined by assay sensitivity (Kelso, 
1995). Further, since cytokine genes are independently regulated, T-helper cells may 
express diverse assortments of cytokine, not just the described two phenotypes (Kelso, 
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1995). Additionally, at least at present, no specific markers for the two cell types exist. Just 
some surface molecules – all chemokine receptors – show preferential expression. Of these, 
more selectively associated with Th1 or Th2 cells are the receptors CCR5 and CRTH2, 
respectively (Romagnani, 2000). Nevertheless, even if the classification in two types of Th 
cells may be an oversimplification, the concept has proven helpful in explaining most 
functions and diseases involving the adaptive immune system. 
2.3.1.3.4 Memory formation 
After an adaptive immune response is mounted and subsequently the infection 
effectively repelled, as a next step tissue integrity has to be restored. This includes the 
removal of most of the effector cells. Since the stimulus, which originally recruited the 
effector cells is now absent, most cells undergo ‘death by neglect’, i.e. the cells remove 
themselves by apoptosis (Janeway et al., 2001). This activation-induced cell death depends 
on up-regulation of CD95 which interacts with the Fas receptor and eliminates Fas-
expressing T-cells. Another mechanism works via gradual up-regulation and stimulation of 
inhibitory receptors, such as CTL antigen-4, which also down-regulates the immune 
response (Alam and Gorska, 2003). The dying cells are then rapidly cleared by macrophages 
(Janeway et al., 2001). As a result, the infection is ended but additionally most of the 
pathogen-specific effector cells are lost. 
However, one key characteristic of adaptive immunity is its memory. This memory is 
based on some of the effector cells retained and thus providing the “raw material for memory 
T-cell and B-cell responses” (Janeway et al., 2001). The factors determining which cells die 
or survive to become memory cells are still unclear. The former hypothesis of lymphocytes 
being under perpetual stimulation below the threshold for activation by residual antigen has 
been replaced by the hypothesis of specific memory being maintained by distinct populations 
of long-lived memory cells that can persist without residual antigen (Janeway et al., 2001). In 
the case of T-cells, memory T-cell population either can be formed directly from the effector 
cells themselves or without passing through an effector-cell stage, then referred to as central 
memory T-cells (Kaech et al., 2002). These memory cells have a lifespan of 10 years or 
more and react more quickly on subsequent exposure to pathogen (Parkin and Cohen, 
2001). B-cell memory on the other hand is strongly associated with isotype switching (see 
above) and somatic mutations in antigen-binding domains of antibodies (Chaplin, 2003). 
While encountering a pathogen for the first time, B-cells produce predominantly IgM 
antibodies. The secondary response is characterized by larger amounts of IgG antibodies, 
with some IgA and IgE. Additionally, repeated exposure to the pathogen progressively 
increases the affinity as well as the amount of antibody. It has to be noted that the 
proliferation of memory B-cells still is driven by antigen-specific T-helper cells (Janeway et 
al., 2001). 
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Thus both – memory T-cells as well as memory B-cells – are responsible for 
mounting a faster and even more effective response to a second or third infection with the 
same antigen than the primary infection. This so-called protective immunity can also be 
induced artificially by vaccination. Vaccination results in long-lived immunological protection 
by “remembering” the first encounter and hence leading to enhanced memory responses that 
either completely prevent re-infection or greatly reduces the severity of disease (Kaech et al., 
2002). The important role in reducing the mortality and morbidity caused by infectious 
diseases is evident. Therefore, Janeway et al. concluded that vaccination is the most 
outstanding accomplishment of immunology in the field of medicine (Janeway et al., 2001). 
 
The previous section aimed at giving an overview of the different immune system 
components and how they function in protecting an organism against invading pathogens. 
Further, it should have become apparent that a harmonious communication between all 
these immune system components is imperative for a successful eradication of pathogens. 
But then, this also implies that at the other hand a dysfunction occurring at one or more 
levels may impair an effective immune response. Such changes in immune functions are in 
the focus of PNI research, which is dedicated to stress-neuroendocrine-immune interactions 
and their consequences for health and disease. In this regard as mentioned before, 
especially the phenomenon of stress-related immune changes and its clinical significance 
has attracted considerable attention. This phenomenon is also central to the present work. 
Therefore, and before focusing on the effects of a missing endocrine stress response, first 
the effects of acute and chronic psychosocial stress on immune functions will be presented 
(section 2.3.2). In a next step, this more phenomenological view will be specified by 
discussing the isolated effects of glucocorticoid and catecholamines on immune parameters 
(section 2.3.3). The chapter will then be secluded by an overview of mechanisms and 
modulators of glucocorticoid-to-immune system signaling (section 2.3.4). 
2.3.2 Psychoneuroimmunology: Brain – to – Immune System Communication 
Since the taste-aversion experiments by Ader and Cohen in 1975 (Ader and Cohen, 
1975), numerous studies investigating the effects of psychological stress on immune function 
have been published. The models deduced from findings regarding the association between 
stress and immune parameters changed over time. Initially, studies investigating forms of 
stress like bereavement (Schleifer et al., 1983), marital discord (Kiecolt-Glaser et al., 1987), 
caregiving for a relative with a chronic disease (Esterling et al., 1994; Kiecolt-Glaser et al., 
1991; Kiecolt-Glaser et al., 1996; Pariante et al., 1997), living with a cancer diagnosis 
(Andersen et al., 1998), or taking school examinations (Dobbin et al., 1991; Glaser et al., 
1993) consistently found stress to be associated with suppression of NK-cell cytotoxicity and 
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lymphocyte proliferation as well as a blunted humoral response to immunization (for review 
see (Cohen et al., 2001; Herbert and Cohen, 1993). These observations and the broad 
clinical use of glucocorticoids as an immunosuppressive drug led to the conclusion that 
stress generally was immunosuppressive (Elenkov and Chrousos, 1999). 
However, as Dhabhar and McEwen pointed out, a generalized suppression of 
immune function under all stress conditions is not an adaptive characteristic (Dhabhar and 
McEwen, 1997). Evolutionarily, an organism may be injured or infected under conditions of 
stress, for example when being chased by a predator. Hence, it is quite likely to require an 
active, instead of a suppressed immune response. Additionally, it seems paradoxical that on 
the one hand stress is thought to exacerbate inflammatory diseases like psoriasis (Farber et 
al., 1990), asthma (Joachim et al., 2003), and arthritis (Thomason et al., 1992), while on the 
other such diseases should be in fact ameliorated by a suppression of immune function. 
Therefore, Dhabhar and McEwen proposed that the decreases in absolute numbers of 
peripheral blood T-cells, B-cells, NK-cells and monocytes during acute stress represent a 
redistribution of these cells from blood to organs, such as bone marrow, lymph nodes and 
skin (Dhabhar et al., 1996). Such a redistribution appears evolutionarily reasonable, since it 
may serve to enhance immune function in compartments where it is most likely needed (e.g., 
when the skin is wounded during fight). But Dhabhar and McEwen also found chronic stress 
to attenuate this redistribution. Thus, they proposed a biphasic model in which acute stress 
enhances and chronic stress suppresses cell-mediated immunity (Dhabhar and McEwen, 
1997). This biphasic model became modified based on the premise that short-term changes 
in all components of the immune system (i.e., innate and adaptive) would expend too much 
energy to be adaptive. Instead, stress should shift the balance of the immune response 
towards activating innate processes and diminishing adaptive processes, since the former 
can unfold much more rapidly and require less energy rather needed in other bodily systems 
to support the fight-or-flight response (Dopp et al., 2000; Segerstrom and Miller, 2004). 
However, all above mentioned models do not resolve the paradox of stress to be 
associated with both, inadequate immunity (i.e., infectious disease) and excessive immune 
activity (i.e., allergic and autoimmune disease). Therefore, a new model had to be found 
which consolidates such contradictory stress effects. This model is the so-called cytokine or 
Th1/Th2 shift model. As already described above (see fig. 2.11), Th1-cells and their 
cytokines activate phagocyte activation and cellular immune responses, therefore providing 
defense against infection and neoplastic diseases. Contrary, Th2-cells and the respective 
Th2-cytokines evoke a strong humoral immune response (Mosmann and Sad, 1996; 
Romagnani, 2000). Since Th1 and Th2 responses are mutually inhibitory, suppression of one 
response has permissive effects on the other – a shift in the Th1/Th2 balance occurs. Thus, 
a diminished Th1 response not only increases the vulnerability to infectious and neoplastic 
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diseases, it also results in an enhanced Th2 response, which in turn increases the 
vulnerability to autoimmune and allergic diseases. Exactly such a shift has been shown to be 
associated with stress (Marshall et al., 1998). 
Independently of their validity, the different models point out two facts: When studying 
the effects of psychological stress on immune functions, it is necessary to consider (1) the 
duration an organism is exposed to stress (acute vs. chronic stress), as well as (2) the type 
of immunity affected (innate, cellular, or humoral immunity). 
Both considerations were accounted for in a meta-analysis including over 300 
empirical articles investigating the relationship between psychological stress and immune 
system parameters recently published by Segerstrom and Miller (Segerstrom and Miller, 
2004). With regard to the duration of stress, the authors adopted the taxonomy of Elliot and 
Eisdorfer (Elliot and Eisdorfer, 1982) to characterize the stressors used in the studies 
selected for the meta-analysis. They differentiated five types of stressors: Acute time-limited 
stressors (e.g., laboratory challenges), brief naturalistic stressors (e.g., academic 
examinations), stressful event sequences (e.g., the loss of a spouse and the series of related 
challenges), chronic stressors (e.g., caregiving for a relative with a chronic disease), and 
distant stressors (e.g., having been sexually assaulted as a child). Next, Segerstrom and 
Miller related these five categories to immune parameters. They accounted for different types 
of immunity and distinguishing between enumerative and functional measures3. 
Acute laboratory stressors were most commonly utilized, constituting 29% (n=85) of 
the articles considered. The meta-analysis revealed an up-regulation of innate immunity 
accompanied by a potential down-regulation of adaptive immunity in response to time-limited 
laboratory stressors. In detail, increased numbers of NK-cells and neutrophils, as well as an 
increased production of the pro-inflammatory cytokine IL-6 and the interferon IFN- , which 
stimulates macrophages and NK-cells, were indicators of an up-regulated innate immunity. 
On the other hand, lymphocyte proliferation was found to be decreased, thus suggesting a 
down-regulation of adaptive immunity. Taken together, these data are consistent with the 
modified biphasic model described above, proposing a shift towards activating innate 
processes and diminishing adaptive processes (Dopp et al., 2000; Segerstrom and Miller, 
2004). 
                                            
3
 Generally, laboratory assays measuring immune parameters can be differentiated in those 
quantifying cell numbers or concentrations of antibody or cytokine, and those quantifying cell 
functions. Cell numbers are detected most easily by counting the numbers of specific subsets of 
peripheral blood mononuclear cells (PBMCs) by fluorescence activated cell sorting (FACS) or by direct 
counting of cells under the microscope. Cytokine and antibody concentrations can be measured either 
in vivo in plasma or serum, or in vitro by stimulating cells to produce these proteins. To quantify 
immune functions, mostly the ability of NK-cells to lyse target cells (NK cytotoxicity) and the ability of 
lymphocytes to proliferate if stimulated (lymphocyte proliferation) are assessed in vitro. Additionally, 
immune responses to vaccination or intra-dermal antigen application (delayed type hypersensitivity 
(DTH) test) may be measured (for review see Vedhara et al., 1999). 
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Brief naturalistic stressors mostly involved academic examinations and made up 
21,5% (n=63) of the articles. Here, data support the Th1/Th2 shift model: Functional 
measures showed decreases in T-cell proliferation with brief stressors, consistent with a 
suppression of cellular (Th1) immune responses. Further, the production of the Th1 cytokine 
IFN- was attenuated. On the contrary, the production of the Th2 cytokines IL-6 and IL-10 
was increased, as was the antibody production to latent virus. 
Regarding the third category – stressful event sequences - Segerstrom and Miller did 
not find reliable immune changes. Therefore, studies were further divided into three 
subcategories according to the stressor utilized: loss of a spouse, trauma (disasters), and 
positive biopsy for breast cancer. Loss of a spouse was associated only with decreases in 
the cytotoxicity of NK-cells. No changes were found in lymphocyte proliferation and in 
numbers of Th-cells or CTLs (depending on the parameter, the analysis was based on four to 
seven studies). In subjects exposed to a natural disaster (n=2-4), on the one hand increases 
in NK-cell cytotoxicity and lymphocyte proliferation, on the other hand decreases in Th-cell 
and CTL numbers were found. However, none of these changes were statistically significant. 
The three studies on women with a positive initial biopsy for breast cancer also did not yield 
a consistent pattern of immune changes. These inconsistent findings of declines in innate 
immune responses (loss), increases in innate and adaptive immune responses (trauma) and 
no immune alterations (breast biopsy) may well be due to the small numbers of studies 
involved and hence should be considered with caution. But these results also point out that 
stressors comparable on the fist glance still may be distinct and thus have distinct effects. 
This is underlined by the different endocrine consequences of loss and trauma. While loss is 
mostly associated with increases in cortisol (Irwin et al., 1988), trauma is rather associated 
with decreases in cortisol (Yehuda, 2001). 
Chronic stressors also were very heterogeneously and included dementia caregiving, 
being handicapped, and unemployment (7,8%; n=23). Nevertheless, the effects on immune 
parameters were quite consistently. While no systematic changes in leukocyte subset 
numbers were found, NK-cell cytotoxicity, lymphocyte proliferation, and production of IL-2 all 
were negatively associated with chronic stress. These immuno-suppressive effects of chronic 
stress on both, innate and adaptive immune parameters, are consistent with the second part 
of the biphasic model proposed by Dhabhar and McEwen (Dhabhar and McEwen, 1997) or 
the global immunosuppressive model. 
A total of nine studies (3,1%) contributed to the fifth category: distant stressors, such 
as abuse in childhood or combat exposure. In these studies, only NK-cell cytotoxicity was 
examined regularly. However, this immune outcome was not reliable associated with stress. 
In conclusion, this meta-analysis exemplarily reveals a basic phenomenon: 
psychological stress not only is reliably associated with immune changes, but these immune 
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changes are also determined by the characteristics of the stressor. In short, acute time-
limited stressors were found to up-regulate innate immunity, brief naturalistic stressors to 
trigger a Th1/Th2 shift, and chronic stressors to be associated with global immuno-
suppression (Segerstrom and Miller, 2004). 
2.3.3 Role of Stress Mediators 
At this point, the question arises on how these stress effects on immune system are 
mediated. Since psychological stress is associated with an activation of two stress systems, 
namely the SAM and the HPA axis (see section 2.1.2), it stands to reason that the immune 
changes described above are influenced in large part by the hormones epinephrine, 
norepinephrine, and cortisol. Further, depending on intensity and duration of a psychological 
stressor, these hormones are secreted in varying concentrations and combinations. 
Accordingly, they may influence immune parameters differently. Therefore, in the next two 
sections the effects of the stress mediators themselves on immune functions will be 
reviewed. 
2.3.3.1 Effects of Glucocorticoids on Immune Functions 
As described in section 2.1.2.1.3 (feedback regulation), two receptors are used to 
regulate the HPA activity and mediate cortisol signals: the mineralocorticoid receptor (MR) 
and the glucocorticoid receptor (GR). These two receptors differ in their affinities and their 
distribution. The MR is a high affinity receptor for endogenous cortisol and is occupied and 
activated at lower concentrations than the GR, which is a receptor with 10-fold lower affinity 
for cortisol but a high affinity for the synthetic glucocorticoid dexamethasone (DEX) (Spencer 
et al., 1990). As shown above, these two receptors are differentially distributed in the central 
nervous system (De Kloet et al., 1998). But for glucocorticoids to exert effects on the immune 
system, these receptors also have to be expressed in immune cells and tissues. 
In fact, this was repeatedly described for both MR and GR (e.g., Armanini et al., 1985; 
Lowy, 1989; McEwen et al., 1997). And as in the central nervous system, the expression of 
receptor subtypes is considerable heterogeneously. Miller et al. assessed GR protein levels 
using multiple techniques and found different distributions: The whole thymus and thymus 
derived T-cells (mostly CD4+CD8+ double-positive cells) had higher levels of GR than more 
mature T-cells isolated from the spleen. Neutrophils in turn had fewer GRs than lymphocytes 
and also than monocytes (Miller et al., 1998). While MRs are not detected in the thymus, 
both receptors are expressed in the spleen, although MR protein in the spleen is low (Miller 
et al., 1990). 
These data show that basically glucocorticoids effects upon the immune system can 
be mediated classically by binding to their respective receptors. But they also suggest that 
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different immune compartments and cell types may have different responses or sensitivity to 
glucocorticoid hormones. Therefore, in the following glucocorticoid actions already 
summarized in section 2.1.4.4 according to Sapolsky et al. (Sapolsky et al., 2000) will be 
reviewed in more detail. Since at least GRs are found in all immune components, 
glucocorticoids affect virtually every immune function and all immune processes. This 
includes the development, maturation and death of immune cells, immune cell trafficking, 
antigen presentation by APCs, cytokine production, secretion and signaling, regulation of the 
class of immune response and effector functions. 
2.3.3.1.1 Development, maturation and death of immune cells 
Glucocorticoids modulate the immune system by intervening already at early stages 
of precursor cell differentiation. Shezen et al. found that glucocorticoids in vitro on the one 
hand enhance the formation of granulocyte colonies, on the other hand they suppress the 
formation of macrophage colonies, thus causing a shift in the balance of granulocyte vs. 
macrophage formation (Shezen et al., 1985). Furthermore, glucocorticoids attenuate the 
differentiation of monocytes (Baybutt and Holsboer, 1990). Chronically elevated levels of 
glucocorticoids were also shown to cause a rapid depletion of developing B-lineage cells in 
the bone marrow of mice by reducing the number of cycling precursor B-cells and inducing 
apoptosis (Garvy et al., 1993). However, glucocorticoids are not simply suppressive in all 
circumstances. For thymocyte survival and differentiation they are rather necessary, in that 
T-cell hybridomas and thymocytes are rescued only by the simultaneous stimulation through 
both the T-cell receptor (TCR) and the GR (Iwata et al., 1991; Zacharchuk et al., 1990). 
Vacchio et al. showed that absence of stimulation through the GR not only inhibits the 
progression from double negative CD4-CD8- to double positive CD4+CD8+ cells and 
augments negative selection, but also results in death of thymocytes that would have 
otherwise undergone positive selection (Vacchio et al., 1998). Therefore, in antagonizing 
TCR-mediated death signals and allowing positive selection to occur, glucocorticoids at 
physiological levels play a critical supportive role in thymocyte development. None the less, 
Vacchio et al. also showed that beside having the highest numbers of GRs, the thymus also 
is able to make its own steroids (Vacchio et al., 1994). It is therefore unclear, if stress-
induced changes in glucocorticoid concentrations play a role in thymocyte development or if 
these effects are due to locally produced glucocorticoids only. Furthermore, Weiss 
demonstrated that glucocorticoids at concentrations found at the diurnal peak are capable of 
inducing cell death in thymocytes in vitro (Weiss, 1971). These conflicting results of 
glucocorticoids mediating positive and negative effects in the thymus are summarized in an 
overview by Jondal et al. (Jondal et al., 2004). They suggested that the effects depend on 
the local hormonal concentration, with basal glucocorticoid levels promoting growth of early 
thymocytes and increased levels due to stress inducing apoptosis in these cells. Principally, 
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it has been known for the last decade that glucocorticoids are capable of inducing apoptosis 
in most nucleated cells. But again, the associations are quite complex. First, the effect of 
glucocorticoids on apoptosis depends on the cell lineage. Cells of hematopoietic origin (e.g., 
monocytes, macrophages, lymphocytes) are very sensitive to glucocorticoid stimulation of 
apoptosis. In contrast, cells of epithelial origin (e.g., mammary gland, ovarian follicular cells, 
hepatocytes) are protected by glucocorticoids against various stimuli for apoptosis 
(Amsterdam and Sasson, 2002). Second, as Evans-Storms and Cidlowski pointed out, anti-
proliferative and apoptotic effects of glucocorticoids may have the same net result, but these 
effects are mediated by different pathways. Hence, it is important to separate them (Evans-
Storms and Cidlowski, 1995). 
2.3.3.1.2 Immune cell trafficking 
Glucocorticoids also play an important role in regulation of immune cell distribution or 
trafficking. Numerous investigators demonstrated that pharmacological glucocorticoid 
application as well as stress-induced changes in glucocorticoids induce a pronounced 
decrease in lymphocyte, monocyte, and eosinophil numbers in the blood, accompanied by 
an increase in numbers of neutrophils (e.g., Fauci and Dale, 1974). These effects are 
mediated via the GR (Dhabhar et al., 1996) and interpreted as a redistribution of the cells out 
of circulation into other body compartment (Fauci and Dale, 1974) or to “battle-stations” 
(Dhabhar et al., 1996), rather than a glucocorticoid-induced cell death. This redistribution of 
cells is probably due largely to alterations in cell adhesion molecules (Sapolsky et al., 2000). 
Glucocorticoids can induce down-regulation of cell adhesion molecules in endothelial and 
polymorphonuclear cells and regulate the expression of cell adhesion molecules in 
lymphocytes and monocytes, thus alter cell trafficking and hence cell infiltration at sites of 
inflammation (Cronstein et al., 1992; for review see Pitzalis et al., 2002). 
2.3.3.1.3 Antigen presentation by APCs 
The induction of an immune response largely depends on the ability and 
effectiveness of MHC molecules to bind and present antigens. Glucocorticoids interfere with 
this response not only by altering the effectiveness of antigen presentation, but also at very 
early stages of the adaptive immune response by modulating differentiation, maturation and 
function of antigen-presenting cells, specifically of dendritic cells (Kitajima et al., 1996; 
Tuckermann et al., 2005). For example, glucocorticoids have been shown to down-regulate 
MHC-II antigens on macrophages and to reduce IFN--induced increases in MHC-II 
expression in rats (Leszczynski et al., 1986). With regard to APCs, glucocorticoids can 
suppress the accumulation of dendritic cells in the spleen and bronchial mucosae, where 
immature dendritic cells reside that have not yet taken up antigen (Moser et al., 1995). In this 
regard, the finding that glucocorticoids suppress dendritic cell maturation is interpreted as a 
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positive mechanism, since it promotes the tolerance of dendritic cells to self antigens 
(Tuckermann et al., 2005). Once activated, APCs migrate into the draining lymph nodes, a 
process which for Langerhans cells has been shown to be inhibited by glucocorticoids 
(Cumberbatch et al., 1999). Cumberbatch et al. further found that this effect results from 
glucocorticoid regulation of synthesis and/or release of TNF-, which provides one important 
signal for Langerhans cells to traffic from skin into lymph nodes (Cumberbatch et al., 1999). 
2.3.3.1.4 Cytokine production, secretion and signaling 
The latter finding emphasized an important mechanism by which glucocorticoids 
influence the immune system, namely by interfering with the production, secretion and 
signaling of cytokines. One of the most well-established and important effects of 
glucocorticoids is the inhibition of cytokine production. This includes IL-1, IL-2, IL-3, IL-5, IL-
6, IL-12, granulocyte monocyte colony-stimulating factor (GM-CSF), IFN-, TNF-, and 
chemokines like IL-8 (reviewed in Wiegers and Reul, 1998). But again, these glucocorticoid 
effects have to be regarded differentially. As mentioned before, glucocorticoids not only 
influence cytokine expression, but they may also (up-)regulate the expression of receptors 
for these cytokines (see section 2.1.4.4). Via this dual regulatory actions, glucocorticoids 
effectively and tightly regulate mediator activity (Munck and Naray-Fejes-Toth, 1992). For 
example, Wiegers et al. found in in vitro studies that glucocorticoids as expected suppress 
IL-2 production in anti-TCR-stimulated rat splenic lymphocytes, but by increasing the 
expression of IL-2 receptors, glucocorticoids also increase the sensitivity of these cells to IL-
2 during the phase of enhanced proliferation (Wiegers et al., 1995); for glucocorticoid-
dependent stimulation of IL-6 receptor synthesis see (Snyers et al., 1990). These findings 
show that rather than simply suppressing cytokine production, glucocorticoids exert a 
regulatory role in cellular immunity by combining stimulatory components and inhibitory 
properties. It also shows that it is necessary to include the assessment of all primary 
parameters and full-time course analyses to conceptually define the role of glucocorticoids 
(Wiegers and Reul, 1998). 
2.3.3.1.5 Regulation of the class of immune response 
The fact that glucocorticoids influence cytokine synthesis may also have further 
implications. By suppressing cytokines derived from Th1-cells (IL-2, IFN-), dendritic cells, or 
macrophages (IL-12) on the one hand and enhancing the production of IL-4 and IL-10 
derived from Th2-cells, macrophages, dendritic cells and mast cells on the other hand, 
glucocorticoids cause a shift from cellular to humoral immune processes, hence regulate the 
class of immune response (Daynes and Araneo, 1989; Elenkov, 2004; Tuckermann et al., 
2005). In contrast to these findings, glucocorticoids in pharmacological concentrations 
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strongly inhibit the secretion of the Th2 cytokines IL-4, IL-5, and IL-13 by T-cells, thereby 
exerting the immunosuppressive effects being availed clinically in allergic diseases (Barnes, 
2001). 
2.3.3.1.6 Effector functions 
Beside effects on induction and proliferation of immune responses, glucocorticoids 
have been found to directly inhibit a variety of immune effector functions relating to NK-cells, 
CTLs, and B-cells. In the case of NK-cells, it has been reported that glucocorticoids in vitro 
inhibit the cytotoxic activity in a dose-dependent manner and also minimize the enhancement 
of NK cytotoxicity obtainable in the presence of IFN- (Gatti et al., 1987). Furthermore, these 
effects were shown to be due to direct inactivation of cytotoxic function of NK-cells and not 
due to effects on cellular proliferation (Callewaert et al., 1991). Interestingly, in vivo 
administration of glucocorticoids has often been found to facilitate instead of inhibit NK-cell 
responses. This facilitation appears to reflect glucocorticoid effects on cell distribution rather 
than altered cell function (Katz et al., 1984). In the case of cytotoxic T-lymphocytes (CTLs), 
glucocorticoids were also found to be mostly inhibiting. Here, glucocorticoids may act both 
indirectly via effects on IL-2 production and directly on CTLs. For example, Schleimer et al. 
found the inhibitory effects of low but not higher concentrations of dexamethasone to be 
reversible by IL-2 (Schleimer et al., 1984). But glucocorticoids may affect not only CTL 
proliferation, but also CTL apoptosis. The former was shown to be the result of 
glucocorticoids inhibiting IL-2 activity (Redondo et al., 1988), the latter was inhibited by IL-2 
and IL-4 (Migliorati et al., 1994). Furthermore, studies by DeKrey and Kerkvliet suggest 
glucocorticoid effects on CTLs to be dose-dependent (DeKrey and Kerkvliet, 1995): the 
generation of CTL activity in mice was sensitive to high doses of glucocorticoids or 
dexamethasone, but was refractory to stress-like glucocorticoid elevations. In the case of B-
cells, glucocorticoids have been shown to decrease the expression of MHC class II 
molecules on B-cells (Dennis and Mond, 1986; Weiss et al., 1996b) and the number of 
mature B-cells in the spleen (del Rey et al., 1984; Weiss et al., 1996b). Weiss et al. 
emphasized that for the former effect glucocorticoids are necessary and sufficient, but for the 
latter, they are just necessary, i.e., other mediators in addition are required (Weiss et al., 
1996b). Contrary to early (antigen-stimulated activation and proliferation) or later 
(proliferative response to B-cell growth factor) events in the B-cell cycle, glucocorticoids were 
consistently observed to stimulate the immunoglobulin synthesis by cultured B-cells, when 
added early (Cupps et al., 1985; Grayson et al., 1981; Wu et al., 1991). However, as 
described above, some of these effects could be secondary to glucocorticoid modulation of 
cytokine production or activity, such as the shift from Th1 to Th2 cells or the induction of 
cytokine receptors (Sapolsky et al., 2000; Wu et al., 1991). Furthermore, glucocorticoids in 
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vivo were also found to suppress immunoglobulin production (Goldstein et al., 1992). Thus, it 
is difficult to evaluate the physiological role of glucocorticoid influences on B-cell functions. 
Nevertheless, these data point out that endogenous glucocorticoids at least contribute to the 
regulation of B-cell response to antigen (del Rey et al., 1984; McEwen et al., 1997). 
2.3.3.1.7 Summary of glucocorticoid effects on immune function 
In summary, glucocorticoids have been shown to influence virtually every immune 
function, mostly in a suppressive way. However, the outline above also showed that these 
effects have to be interpreted cautiously when it comes to drawing conclusions about the 
physiological role of glucocorticoids in immune function, especially the role of stress-induced 
increases in glucocorticoid concentrations. First of all, many results were obtained using the 
synthetic glucocorticoid dexamethasone, and furthermore, using rather high concentrations 
of it. Therefore, it is subject to controversial discussion, if observed effects may be limited to 
synthetic glucocorticoids or supra-physiological concentration of endogenous glucocorticoids. 
For example, Dhabhar and McEwen pointed out that acute stress and low doses of 
corticosterone in laboratory animals increased, instead of decreased specific components of 
immune function, e.g. cellular immunity in the skin (Dhabhar and McEwen, 2001). Hence, 
questions arise not only regarding the transferability of studies using dexamethasone, but 
also regarding the dependency of glucocorticoid effects on the applied dose. Another point 
concerns the transferability of in vitro data to in vivo situations. As mentioned above, in some 
immune parameter, e.g. in immunoglobulin production, contrary effects of glucocorticoids are 
observable. Additionally, some effects may require other mediators in addition (Weiss et al., 
1996b). Furthermore, the studies by Wiegers et al. showed that glucocorticoids may act in a 
complex manner and exert dual regulatory actions (suppression of IL-2 and stimulation of IL-
2 receptor expression; (Wiegers et al., 1995). Therefore, it is necessary to consider various 
primary parameters and full-time course analyses to reveal such complex interplays. Beside 
these points for further discussion, also species-differences have to be taken into account. 
Some effects seem comparable in rodents and humans, while others, like the greater 
sensitivity of rodent lymphocytes to glucocorticoid-induced apoptosis, differ between species 
(Weiss et al., 1996b). 
Taken together, although many glucocorticoid effects on immune functions seem to 
be suppressive when considered isolated, this may nevertheless serve a positive mechanism 
when related to the whole organism. Therefore, glucocorticoids are not thought of as being 
mostly suppressive and sometimes enhancing, but rather as directing immune reactions in a 
specific and coordinated manner. This position is also held by Besedovsky et al., who stated 
that glucocorticoids are sculpting the immune response by selectively inhibiting specific 
immune processes, while stimulating or not affecting others (Besedovsky et al., 1991). 
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2.3.3.2 Effects of Catecholamines on Immune Functions 
As for glucocorticoids, the immunological effects of catecholamines secreted as a 
stress response is an area of considerable complexity, since epinephrine and norepinephrine 
also have both stimulating and inhibitory effects (Sapolsky et al., 2000). Generally, 
catecholamines exert their effects by binding to adrenoceptors, which are transmembrane 
spanning G-protein coupled cell surface receptors. Adrenoceptors can be classified into 
three major groups, 1-, 2-, and -adrenoceptor types, which can be further subdivided into 
at least three subtypes: 1A, 1B, and 1C, 2A, 2B, and 2C, and 1, 2, and 3 (Hasko 
and Szabo, 1998). Norepinephrine predominantly activates - and 1-adrenoceptors and is a 
weak stimulator of 2-adrenoceptors, whereas epinephrine is a strong stimulator of -
adrenoceptors (Motulsky and Insel, 1982). 
For catecholamines to modulate immune functions, the major requirement is the 
presence of adrenoceptors on immune cells and immune tissues. Until recently, 
adrenoceptor expression on peripheral blood leukocytes (i.e., lymphocytes, macrophages, 
neutrophils, eosinophils, and basophils) was thought to be restricted to 2- and -
adrenoceptors (Bishopric et al., 1980; Hadden et al., 1970; Khan et al., 1986; Pochet et al., 
1979). This was due to the demonstration of Casale and Kaliner that circulating human blood 
cells have no detectable 1-adrenoceptors (Casale and Kaliner, 1984). But Rouppe van der 
Voort et al. showed in 1999 that the expression of 1b- and 1d-adrenoceptors can be 
induced in human monocytes by dexamethasone and the 2-adrenoceptor agonist 
terbutaline (Rouppe van der Voort et al., 1999); see also (Kavelaars, 2002). Beside differing 
in the type of adrenoceptor predominantly expressed, lymphocyte subsets differ also in their 
receptor density, such as NK-cells having the greatest and Th-cells having the lowest 
number of 2-adrenoceptor, while CTLs, B-cells, and monocytes have an intermediate 
number of 2-adrenoceptors (Khan et al., 1986; Maisel et al., 1989). Importantly, 2-
adrenoceptors seem to be selectively expressed on Th1 cells, while Th2 cells do not express 
any detectable 2-receptors (Sanders et al., 1997). However, high 2-adrenoceptor density 
does not necessarily mean high response after stimulation of these receptors. It was 
demonstrated that NK-cells, CTLs, and monocytes are very responsive to -adrenoceptor 
stimulation, while Th-cells and B-cells show only a modest response (Knudsen et al., 1995; 
Maisel et al., 1989). 
Beside type, density and responsiveness of receptors, also the way of communication 
can be different. Norepinephrine may reach its target cells by (1) neural communication, 
when released at synaptic junctions and acting across a narrow synaptic cleft on the 
postsynaptic cell, by (2) non-synaptic communication, when diffusing in the vicinity of the 
nerve terminal and reaching more distant target cells, and by (3) endocrine communication, 
when released from the adrenal medulla and reaching cells via the circulating blood. 
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However, epinephrine reaches its target cells just by endocrine communication (Hasko and 
Szabo, 1998). 
Despite this complex interplay of receptor types, numbers, and sensitivities and ways 
of communication, the reports of catecholamine effects on immune function rather 
consistently found most effects to be mediated via 2- and -adrenoceptors. As 
glucocorticoids, catecholamines – directly or indirectly – influence virtually every immune 
function and immune process. In this regard, a clear distinction should be made between the 
role of sympathetic nervous system control of immune processes and effects of 
catecholamines on immune functions. For example, specific compartments of the thymus are 
innervated noradrenergically and hence, norepinephrine but not epinephrine effects on 
thymocyte development has been described. However, in the following, an overview of 
catecholamine effects on immune functions will be given. This includes thymocyte 
development; immune cell trafficking; activity and function of cells of the innate immunity; 
production of cytokines and regulation of the class of immune response; and effector 
functions (i.e., lymphocyte proliferation, CTL activity, and antibody production). 
2.3.3.2.1 Thymocyte development 
To differentiate into T-cells, thymocytes have to be under the influence of a specific 
microenvironment, which is created by a number of supporting cells. The major cell type 
involved are supposed to be thymic epithelial cells (TEC) and these TECs synthesize the key 
factors of the thymic microenvironment, e.g., cytokines like IL-1 or IL-6 (Kendall, 1991). 
Furthermore, especially subcapsular/perivascular TECs are in close connection to 
catecholaminergic nerve fibers innervating the thymus and thus exposed to norepinephrine, 
the main catecholamine in the thymus (Kendall et al., 1988). Additionally, TECs have been 
shown to express functionally active 1- and 2-adrenoceptors (Kurz et al., 1997). However, 
von Patay et al. demonstrated that the release of IL-6 from TECs in vitro was stimulated only 
scarcely by catecholamines and moderately by LPS alone, but increased dose-dependently 
when both were added and thus acted synergistically (von Patay et al., 1998). The regulation 
of IL-6 expression in TECs by catecholamines is of particular interest, because IL-6 has 
repeatedly been implicated in T-cell development: In combination with IFN- and IL-2, IL-6 
has been shown to induce the differentiation of CTLs from immature thymocytes (Takai et al., 
1988) and together with IL-2 or IL-4, IL-6 enhances the proliferation of single positive 
thymocytes (Chen et al., 1989; Suda et al., 1990). Additionally, IL-6 acts as an autocrine 
growth factor for TECs themselves (Colic et al., 1992). Therefore, it may be speculated that 
catecholamines play a role in augmenting the production of T-cells. 
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2.3.3.2.2 Lymphocyte trafficking and circulation 
Increases in SNS activity or administration of catecholamines have been shown to 
affect lymphocyte distribution in a time-dependent manner. In the short term, catecholamines 
acutely mobilize NK-cells and granulocytes from depots, whereas in the long term, 
chronically, catecholamines decrease the number of lymphocytes, and particularly of NK-
cells in the peripheral blood (Benschop et al., 1996; Schedlowski et al., 1996), whereas T- 
and B-cell numbers remain relatively unaffected (Benschop et al., 1996). These changes in 
NK-cell numbers were shown to be accompanied neither by alterations in expression of 
adhesion molecules on NK-cells nor by changes in plasma concentration of soluble adhesion 
molecules (Schedlowski et al., 1996). This modulation of NK-cell circulation rather appears to 
be mediated via 2-adrenoceptor mechanisms, whereas the transient increases of 
granulocytes after short term catecholamine administration involve -adrenoceptor 
stimulation (Benschop et al., 1996). In this regard, several mechanisms by which 
catecholamines modulate lymphocyte distribution are discussed. The finding that T- and B-
cells remain relatively unaffected suggests a role of the varying sensitivities of lymphocyte 
subpopulations to catecholamine effects. Alternatively, the SNS, which directly innervates the 
vascular smooth muscle and regulates the regional blood flow, may thereby change the 
delivery of lymphocyte to post-capillary venules of tissues and thus the opportunity for 
lymphocytes to enter tissues (Elenkov et al., 2000). Independently of the mechanisms, 
catecholamines increase the number of circulating NK-cells and granulocytes, i.e., immune 
cells of innate immunity. And because higher numbers of circulating cells also means more 
cells can be attracted in cases of tissue damage, catecholamines may help reducing the risk 
for infections (Benschop et al., 1996). 
2.3.3.2.3 Macrophage activity and neutrophil functions 
The effects of catecholamines on macrophage functions appear to be rather complex. 
Catecholamines are repeatedly reported to stimulate (Spengler et al., 1990) as well as 
suppress (Hasko et al., 1998) the production of TNF- by macrophages. This apparent 
discrepancy may be attributed to the state of activation of macrophage populations. It is 
thought that there is a transient stage of differentiation when monocytes during maturation to 
macrophages lose their -adrenoceptor responsiveness. Naïve cells may thus preferentially 
express -adrenoceptors, which will result in stimulation of macrophage activity (Spengler et 
al., 1990). On the other hand, antigen challenge and activation of macrophages may result in 
an increase in -adrenoceptors and hence a suppression of macrophage activity (Chou et 
al., 1996; Hasko et al., 1998). Despite the state of activation or differentiation of 
macrophages, which may determine the responsiveness and expression of adrenoceptor 
subtypes, also various other factors may modulate the effect of catecholamines on 
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macrophage activity. These are: the presence of mediators, such as substance P, which 
potentiates TNF- production by macrophages (Ho et al., 1998), peripheral CRH as a potent 
mast cell secretagogues (Theoharides et al., 1995), and histamine, which suppresses the 
production of TNF- and is stimulated via - or inhibited by 2-adrenoceptors by 
catecholamines, and the effect of catecholamines on the expression of important co-
stimulatory molecules like B7.2. 
Contrary to the complex effects of catecholamines on macrophage functions, 
functions of neutrophils seem to be generally inhibited by catecholamines. Neutrophil 
phagocytosis, release of lysosomal enzymes (Zurier et al., 1974), respiratory burst of 
neutrophils associated with degranulation (Nielson, 1987), superoxide generation and 
formation of oxygen radicals that play an important microbicidal role (Barnett et al., 1997; 
Weiss et al., 1996a), and chemotaxis of human neutrophils (Harvath et al., 1991) all have 
been shown to be suppressed by catecholamines. Here, stimulation of -adrenoceptors 
seems to play an important role, as for example suppression of superoxide generation and 
formation of oxygen radicals at nanomolar concentrations of epinephrine could be prevented 
by 2-adrenorceptor blockade (Barnett et al., 1997; Weiss et al., 1996a). 
2.3.3.2.4 Cytokine production and regulation of the class of immune response 
In cytokine production, catecholamines appear to have a substantial modulatory role, 
affecting antigen-presenting cells and Th1-cells, mostly by stimulation of -adrenoceptors. As 
for glucocorticoids, most of these effects result in driving a Th2 shift (Agarwal and Marshall, 
2000; Chrousos, 2000; Elenkov and Chrousos, 1999; Hasko and Szabo, 1998), a 
mechanism by which catecholamines affect the class of immune response elicited in 
response to challenge. 
In antigen-presenting cells, norepinephrine and epinephrine has been shown to inhibit 
the production of IL-12 in human whole blood cultures stimulated with lipopolysaccharide 
(LPS) ex vivo via stimulation of -adrenoceptors on monocytes (Elenkov et al., 1996). IL-12 
enhances IFN- and inhibits IL-4 synthesis by T-cells, which results in inhibition of Th1-cell 
development and promotion of Th2-cell differentiation (see figure 2-11). Inhibition of IL-12 
production by catecholamines may thus represent one of the major mechanisms by which 
epinephrine and norepinephrine affect Th1/Th2 balance. Beside IL-12, catecholamines and 
-adrenoceptor agonists inhibit the production of TNF- by LPS-treated monocytes (Severn 
et al., 1992; van der Poll et al., 1994), microglial cells (Hetier et al., 1991), and astrocytes 
(Nakamura et al., 1998) and by human mast cells stimulated with IgE (Bissonnette and 
Befus, 1997). Mostly via this inhibition of TNF-, also the production of IL-1 is suppressed by 
catecholamines (Koff et al., 1986; Van der Poll and Lowry, 1997). This effect is additionally 
potentiated by catecholamines enhancing the production of IL-10 (Elenkov et al., 1996; 
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Siegmund et al., 1998; van der Poll et al., 1996; Van der Poll and Lowry, 1997), a type 2 
cytokine produced by antigen presenting cells. One other cytokine, of which the production is 
also up-regulated by catecholamines is IL-6 (Maimone et al., 1993; Norris and Benveniste, 
1993). IL-6 exerts both pro-and anti-inflammatory effects, but possesses mostly Th2-type 
activities. 
These actions of catecholamines are in close accordance with their effects on type 1 
and type 2 cytokines. Since Th2 cells do not express 2-adrenoceptors (Sanders et al., 
1997), catecholamines are most probable not able to affect the production of type 2 
cytokines by Th2 cell directly. Thus, catecholamines mainly affect Th1 cells. For example, 
2-adrenoceptor agonists have been shown to inhibit IFN- production by Th1 cells, but do 
not affect IL-4 production by Th2 cells (Borger et al., 1998; Sanders et al., 1997). Changes in 
cytokine patterns in turn affect the immunoglobulin-isotype produced by B-cells. In humans, 
IFN- producing Th1 cells induce B cells to produce IgG1, whereas IL-4 producing Th2 cells 
induce B cells to produce IgE and IgG4 (Fearon and Locksley, 1996). 
Taken together, catecholamines on the one hand do not have a direct effect on the 
secretion of cytokines from Th2 cells hand, but facilitate the production of type 2 cytokines by 
antigen presenting cells. On the other hand, they inhibit the production of type 1 cytokines by 
both antigen presenting cells and Th1 cells. Thus, all effects of catecholamines on cytokine 
production of antigen presenting cells aim at attenuating cellular immunity and facilitating 
humoral immunity. 
2.3.3.2.5 Effector functions 
Lymphocyte proliferation: 
T-cell proliferation induced by mitogens has repeatedly been shown to be inhibited by 
catecholamines or -adrenoceptor agonists (Chambers et al., 1993; Hadden et al., 1970). 
Since CD8+ T-cells have a higher number of -adrenoceptors, the proliferative response of 
CD8+ T-cells has been found to be inhibited to a greater extent than CD4+ T-cells (Bartik et 
al., 1993). This anti-proliferative effect of catecholamines has been linked to an increase of 
cyclic adenosine monophosphate (cAMP) in lymphocytes (Carlson et al., 1989). Because 
elevation of cAMP in turn inhibits the secretion of the co-stimulatory cytokine IL-2 by T-cells 
(Bartik et al., 1993), inhibition of T-cell proliferation might at least in part be due to the 
inhibition of the production of IL-2 (Elenkov et al., 2000). 
Cytotoxic T-lymphocyte (CTL) activity: 
Only a few studies are available investigating the effects of catecholamines on CTL 
function. For example, Cook-Mills et al. found anti-MOPC-215 tumor cytotoxicity by mouse 
splenic CTLs to be suppressed by epinephrine, norepinephrine, and isoproterenol (Cook-
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Mills et al., 1995). Dobbs et al. observed restraint stress to induce suppression of herpes 
simplex virus-specific CTL activation in mice, an effect which could be prevented by an 
peripherally acting -adrenoceptor antagonist (Dobbs et al., 1993). Furthermore, in vitro 
development of memory CTL activity in mice was found to be significantly inhibited by 
increasing cAMP via a -adrenoceptor agonist (Cook-Mills et al., 1995). Contrary, Hatfield et 
al. observed increased CTL-mediated cytotoxicity in mixed lymphocyte culture (BALB/c 
mice), but only, when catecholamines or -adrenoceptor agonists were added at the initiation 
of a 5-day sensitization phase (Hatfield et al., 1986). These findings suggest that 
catecholamines on the one hand exert enhancing effects on the initiation of CTL responses, 
while they on the other hand inhibit effector cell function, i.e. CTL cytotoxicity and CTL 
memory development (Elenkov et al., 2000). 
Antibody production / humoral immunity: 
Regarding humoral immunity, norepinephrine is generally known to enhance B-cell 
antibody production via stimulation of 2-adrenoceptors. This effect is achieved by several 
mechanisms. First, catecholamines have been found to induce an increase in the frequency 
of B-cells differentiating into antibody-secreting cells (Sanders, 1998; Sanders, 2006). 
Seconds, agents that elevate cAMP up-regulate the expression of B7 molecules on B-cells, a 
molecule which determines the effectiveness of T-cell-B-cell interaction (Watts et al., 1993). 
Furthermore, for activation of conjugated B-cells, a critical threshold level of intracellular 
cAMP must be given (Pollok et al., 1991). Stimulation of 2-adrenoceptor during Th-2-B-cell 
interaction may help to augment cAMP levels above this critical threshold (Sanders, 1998). 
Third, catecholamines may influence B-cell functions by their effects on type1 and type 2 
cytokine production (see section 2.3.3.2.4). In facilitating IL-4, IL-6, and IL-10 production 
(Coqueret et al., 1994) and inhibiting IFN- production (Coqueret et al., 1995), 
catecholamines selectively inhibit Th1 functions and cellular immunity and mediate a Th2 
shift that potentiates humoral immunity. 
2.3.3.2.6 Summary of catecholamine effects on immune functions 
Taken together, catecholamines modulate lymphocyte trafficking, in that they mobilize 
NK-cells and granulocytes in the short-time, thereby reducing the risk for infections for 
example during acute stress (Benschop et al., 1996). Regarding cytokine production and 
release, catecholamines have been shown to cause a Th1/Th2 shift, resulting in potentiation 
of humoral immunity (Chrousos, 2000; Elenkov and Chrousos, 1999). These effects are 
facilitated by catecholamines inhibiting lymphocyte proliferation and CTL effector functions 
(Elenkov et al., 2000) on the one hand, and enhancing T-cell-B-cell interaction and B-cell 
antibody production on the other (Sanders, 1998). 
THEORETICAL BACKGROUND 97 
2.3.3.3 Immune System – to – Brain Communication 
In 1975, Besedovsky et al. reported that antigenic challenge to the immune system 
causes serum levels of glucocorticoids to increase to levels three times higher than normal 
(Besedovsky et al., 1975). Starting with this observation, evidence accumulated that the 
communication between nervous system and immune system is not unidirectional, but that 
the immune system itself sends signals to the nervous system that alter physiological and 
behavioral states. In the context of PNE and PNI, the activation of the HPA axis with 
subsequent secretion of glucocorticoids by cytokines is of special interest: These cytokine 
actions constitute a negative feedback loop (‘cytokine-HPA axis feedback circuit’), in which 
an activated immune system is finally reset to a state of decreased or baseline activity. 
Therefore, instead of interfering with antigen presentation, clonal expansion of activated 
lymphocytes, or the initial production of cytokines, the rather late phenomenon of increased 
glucocorticoid levels are thought to prevent inappropriate, excessive expansion and activity 
of immune cells and overproduction of cytokines (Besedovsky and del Rey, 1996; 
Besedovsky and del Rey, 2000).4 
2.3.4 Mechanisms and Modulation of Hormone-to-Immune System Signaling 
In the previous sections, effects of stress as well as effects of single stress mediators 
on the immune system were described. As outlined, for glucocorticoids and catecholamines 
to modulate immune functions, the major requirement is the presence of receptors in and on 
immune cells and immune tissues, respectively. In the following sections, the molecular 
mechanisms of how hormone-receptor binding influences immune functions will be 
summarized (2.3.4.1: Mechanisms of hormone-to-immune system signaling). Subsequently, 
potential pathways of modulation of these mechanisms will be described (2.3.4.2: Modulation 
of hormone-to-immune system signaling). 
2.3.4.1 Mechanisms of Hormone-to-Immune System Signaling 
To facilitate insight into possible pathways by which glucocorticoids and 
catecholamines can influence immune cell functions, first the activation of the main effector 
cells of the innate immune response by LPS will be elaborated exemplarily in more detail. 
                                            
4
 As this way of communication is not in the focus of the present thesis, the interested reader 
is referred to Besedovsky and del Rey (1996 and 2000) for further information, such as the different 
proposed pathways of cytokine-to-brain-signaling. 
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2.3.4.1.1 Monocyte activation and cytokine production 
Basically, cells of innate immunity recognize pathogen-associated molecular patterns 
(PAMPs; Medzhitov and Janeway, 1997a; Medzhitov and Janeway, 1997b; Uthaisangsook et 
al., 2002), which are shared by large groups of pathogens. PAMPs are recognized by 
immune cells via a set of molecules as well as receptors referred to as pattern-recognition 
molecules (PRMs) and pattern-recognition receptors (PRRs; (Medzhitov and Janeway, 
1997a). Binding of PRRs or PRMs to PAMPs is the first step in activating functions of innate 
immunity (see also section 2.3.1.2.2: recognition of pathogens: PAMPs and PRRs/PRMs). 
One example for a pathogen-associated molecular pattern is a component of the cell wall of 
gram-negative bacteria, namely lipopolysaccharide (LPS; Kitchens, 2000; Uthaisangsook et 
al., 2002). In more detail, LPS is recognized by the pattern-recognition receptors of the Toll 
receptor family. In humans, at least ten of these so-called Toll-like receptors (TLR) have 
been identified so far (Chuang and Ulevitch, 2001). For LPS recognition by monocytes and 
macrophages, specifically TLR-4 is thought to play an important role (Medzhitov et al., 1997). 
Before the discovery of TLR-4, LPS was only known to complex with soluble receptors (e.g., 
lipopolysaccharide binding protein (LBP) or the soluble form of the monocyte surface protein 
CD14 (sCD14)) and that this complex binds to the surface molecule CD14 of monocytes and 
macrophages. However, as CD14 does not possess a cytoplasmic domain, it could not be 
resolved how LPS could activate the subsequent cascade of effects. But TLRs – as type I 
trans-membrane proteins – consist not only of an extracellular leucine-rich repeat domain, 
but also do have a cytoplasmic domain. This cytoplasmic domain is homologous to the 
cytoplasmic domain of the human IL-1 receptor (IL-1R), hence it is referred to as the Toll/IL-
1R homology (TIR) domain (Kopp and Medzhitov, 1999) and the intracellular cascade 
following activation of monocytes and macrophages by LPS is similar to the cascade 
activated by IL-1 (Muzio and Mantovani, 2000). This cascade is shown in figure 2-12. 
In detail (see Caamano and Hunter, 2002), upon interaction with LPS bound to CD14, 
the intracellular domain of TLR-4 binds to the adaptor protein myeloid differentiation factor-88 
(MyD88). The interaction of the TIR domain of TLR and the TIR domain of MyD88 recruits 
the IL-1R associated kinase (IRAK), which becomes phosphorylated and binds to TNF-
receptor-associated-factor-6 (TRAF6). This binding activates the nuclear factor-kappaB (NF-
B)-inducing kinase (NIK), which next phosphorylates IB kinase (IKK). IKK in turn 
phosphorylates and degrades inhibitory B-. Normally, the protein IB- inhibits activation 
of the transcription factor NF-B by binding to NF-B in the cytoplasm of cells. Upon 
dissociation of NF-B from IB, a nuclear localization signal (NLS) becomes unmasked and 
NF-B translocates to the nucleus, where it binds to B-responsive DNA elements. Binding 
of NF-B to the B-responsive DNA elements then induces the transcription of a large array 
of monocyte and macrophage products, such as TNF- (McKay and Cidlowski, 1999), which 
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is usually the first cytokine to appear at an inflammatory site (Hesse et al., 1988; van 
Deventer et al., 1990).  
 
Fig. 2-12: Mechanism of monocyte activation by LPS (taken from Rohleder, 2003). NF-B is depicted in the most 
frequently occurring heterodimeric complex between the p50 and p65 subunits. 
However, NF-B is found in virtually every cell of the immune system, hence a much 
greater number of genes transcriptionally regulated by NF-B-DNA binding exist. Among 
these are growth factors (relevant cell types: monocytes, macrophages, myeloid cells), such 
as granulocyte/macrophage colony stimulating factor (GM-CSF), pro-inflammatory cytokines 
(B-cells, T-cells, monocytes, macrophages, etc.), especially IL-1, IL-2, IL-6, IL-8, and TNF-, 
cell adhesion molecules (endothelial cells, mucosal cells, megakaryocytes), such as inter-
cellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM), acute 
phase proteins (hepatocytes), for example serum amyloid A precursor protein and 
complement factors B and C4, but also transcriptional regulators including the protein IB- 
(for review see (McKay and Cidlowski, 1999). Such new synthesis of IkB- causes retention 
of NF-B in the cytoplasm and attenuation of NF-B-mediated transcriptional activation 
(Baldwin, 1996), and provides a feedback mechanism for modulating the extent and duration 
of inflammatory responses by a cell. 
In parallel to this pathway, binding of LPS complex to TLR and consecutive binding to 
MyD88 may also activate activator protein 1 (AP-1). The transcription factor AP-1 is a dimeric 
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complex that in mammalian cells most commonly comprises members of the Jun und Fos 
protein. Several cascades of AP-1 activation are known resulting in increased synthesis of 
the AP-1 components Jun and Fos and/or in phosphorylation of these components. Figure 2-
12 depicts exemplarily the activation of the catalytic activities of the Jun N-terminal kinase 
(JNK) via the MAP kinase (MKK) cascade (Karin and Gallagher, 2005; Karin et al., 2001). 
Once activated, AP-1 has similar effects as NF-B, with AP-1 regulating gene expression 
both independently of and synergistically with NF-B (McKay and Cidlowski, 1999). Thus, 
AP-1 is a critical regulator of for example cell proliferation, cell survival, cell death, DNA 
repair and metabolism (Karin and Gallagher, 2005). 
2.3.4.1.2 Glucocorticoid signal transduction 
As shown in the previous chapters, glucocorticoids exert a wide range of effects on 
the immune system and these effects are mediated by glucocorticoid/type-II receptors (GR) 
and mineralocorticoid/type-I receptors (MR). Regarding immune cells and tissues, the former 
appears to be expressed predominantly (Armanini et al., 1985; Lowy, 1989; McEwen et al., 
1997). 
The main mechanism by which glucocorticoids exert their effects on immune 
functions is the inhibition of the NF-B and AP-1 activation cascades described above 
(McKay and Cidlowski, 1999). For a more detailed insight in these mechanisms, the following 
three chapters first describe the activation of glucocorticoid receptors, followed by a 
summary of the so-called classic and alternative mechanism of glucocorticoid receptor 
action. 
Glucocorticoid receptor activation 
The glucocorticoid receptor is found in the cytoplasm as part of an assembly 
consisting of the receptor itself, two molecules of heat shock protein (HSP)90 and one 
molecule each of HSP70 and/or HSP56, as well as other, lesser know proteins, such as p23 
(Pratt, 1993; Smith and Toft, 1993). Interestingly, in this complex of glucocorticoid receptor 
and HSP90, the receptor undergoes simultaneous conversion from a non-steroid binding but 
DNA binding state (transformed receptor) back to the steroid binding, non-DNA binding state 
(untransformed receptor; Scherrer et al., 1990). HSP90 in this regard seems to be required 
for strong ligand binding activity. But once hormone binding has occurred, it can be sustained 
in the absence of HSP90 (Bresnick et al., 1989). 
As lipophilic substances, glucocorticoids (GC) are able to cross the cell membrane 
readily to interact with the intracellular glucocorticoid receptor (GR). Ligand binding induces 
conformational change in the GR molecule that has a number of functional consequences 
(Bamberger et al., 1996). First, the GR-GC complex dissociates from the HSP complex and 
is no longer able to re-associate with it (Hutchison et al., 1994). Furthermore, the partially 
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phosphorylated receptor protein becomes hyper-phosphorylated (Bodwell et al., 1993) and 
finally, now unmasked nuclear localization signals (NLS) within the ligand-binding domain of 
the receptor (Picard and Yamamoto, 1987) cause nuclear translocation of the GR-GC 
complex (Akner et al., 1994). Within the nucleus, the hormone-activated glucocorticoid 
receptor can act in two ways, referred to as classic and alternative mechanism of 
glucocorticoid receptor action. 
Classic mechanism of glucocorticoid receptor action 
The classic mechanism of GR action is characterized by GRs interacting with specific 
DNA sequences. A receptor homodimer binds to short DNA sequences termed 
glucocorticoid response elements (GREs) in the promoter region of glucocorticoid-responsive 
genes. When bound to the GRE, the GR homodimer interacts with components of the basic 
transcription machinery, either directly or indirectly via bridging factors. This interaction is 
sufficient to stabilize the pre-initiation complex on the promoter and thus to enhance 
transcription of GR-regulated genes by RNA polymerase II. In addition, binding of the GR 
homodimer to the GRE can induce a rearrangement of the chromatin structure in the 
respective promoter region, thus allowing other transcription factors to bind to the previously 
inaccessible DNA. Furthermore, in some promoters, binding of the activated GR to so-called 
negative glucocorticoid response elements (nGREs) causes inhibition rather than 
enhancement of transcription (Bamberger et al., 1996; McKay and Cidlowski, 1999). 
Regarding the immune system, GRs are known to repress cytokine genes, for 
example IL-1, IL-2, IL-6, IL-8, and TNF- genes, as well as cell adhesion molecule genes, 
such as ICAM-1 (reviewed in McKay and Cidlowski, 1999). Interestingly, the promoters of 
these (pro-inflammatory) genes do not contain nGREs nor do they have any other GR-
binding site, yet they are repressed by glucocorticoids (Bamberger et al., 1996; Cato and 
Wade, 1996). But what they do carry are sites for NF-B and AP-1. It has therefore been 
proposed that immune suppression is mediated by glucocorticoid-induced expression of the 
inhibitory protein IB-, and in 1995, Scheinman et al. as well as Auphan et al. showed that 
glucocorticoids in fact induce the transcription of the gene encoding IB- and effectively 
down-regulate NF-B associated gene products (Auphan et al., 1995; Scheinman et al., 
1995a). In this regard, an increase in protein synthesis leads to the rapid turnover of IB- 
protein associated with pre-existing NF-B complexes. In the presence of an activator, such 
as LPS, newly released NF-B re-associates with the glucocorticoid induced IB-, thus 
reducing the amount of NF-B translocating to the nucleus. Additionally, newly synthesized 
IB- may enter the nucleus and inhibit NF-B-DNA binding. Both pathways effectively 
down-regulate NF-kB associated gene products (Scheinman et al., 1995a). 
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Alternative mechanism of glucocorticoid receptor action 
The alternative mechanism of glucocorticoid receptor action involves physical 
interaction of the GR with other transcription factors, such as AP-1 and NF-B. Regarding 
NF-B, comparing the genes regulated by GR with NF-B-induced genes (see former 
sections), clearly reveals GR and NF-B to be physiological antagonists. Accumulating 
evidence exists that the activated GR specifically interferes with the trans-activation potential 
of the NF-B p65 subunit (De Bosscher et al., 1997; De Bosscher et al., 2000b; Ray and 
Prefontaine, 1994). The mammalian NF-B/Rel family of proteins consists presently of five 
members, namely, Rel (c-Rel), p65 (Rel A), Rel B, p50 (NFKB1; precursor: p105), and p52 
(NFKB2; precursor: p100). The members p50 and p52 lack transcriptional activation domains 
and their homodimers are thought to act as repressors. In contrast, p65, Rel B, and c-Rel 
carry transcriptional activation domains, and with the exception of Rel B, they are able to 
form homo- and heterodimers with the other members of the protein family. In general, the 
designation NF-B refers to the most frequently occurring and ubiquitously expressed 
heterodimeric complex between the p50 and p65 subunits (Caamano and Hunter, 2002; 
Wulczyn et al., 1996). Another important physical interaction occurs between the GR and 
AP-1. GRs can interact with both Fos and Jun subunits of the AP-1 heterodimer, although it 
appears that Fos may be the preferential target for GRs. This interaction alters in turn the 
interaction of both transcription factors with DNA, resulting in reciprocal repression of AP-1 
and GR transactivation functions (Hsu et al., 1993; Jonat et al., 1990; Kerppola et al., 1993; 
Konig et al., 1992; Schule et al., 1990; Yang-Yen et al., 1990). As NF-B and AP-1 can 
synergize in the pro-inflammatory pathway, GR repression of AP-1 may be an additional and 
important indirect mechanism for suppressing NF-B-mediated immune responses. Figure 2-
13 summarizes the classic and alternative mechanism of glucocorticoid actions by means of 
IB- upregulation and negative GR-NF-B interaction. 
Beside the two outlined mechanisms, also labelled the IB- upregulatory model and 
the protein-protein interaction model, a third model of glucocorticoid-mediated repression of 
NF-B- and AP-1-driven genes is discussed, namely the cofactor squelching or competition 
model (De Bosscher et al., 2000a; McKay and Cidlowski, 1999). Cofactors are essential 
coactivators of transcription and the competition model proposes that transcription factors 
have to compete for limiting amounts of such essential coactivators. At present, specifically 
the cofactor CREB-binding protein (CBP)/p300 is being examined as a potential candidate, 
but so far the findings are contradictory and some laboratories report data supporting (Lee et 
al., 1998; Sheppard et al., 1998), others data countering the competition model (De Bosscher 
et al., 2000b; Pfitzner et al., 1998). 
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Fig. 2-13: Mechanisms of glucocorticoid inhibition of monocyte activation via IB- upregulation and negative GR-
NF-B interaction (modified from Rohleder, 2003). 
2.3.4.1.3 Catecholamine signal transduction 
Norepinephrine and epinephrine transduce their biological information through 
stimulation of adrenoceptors. Adrenoceptors directly activate G-proteins, which consist of 
three distinct classes of subunits, , , and , with the -subunit conferring the effector 
specificity. The different -subunit genes have been divided into four major subfamilies, Gs, 
Gi, Gq, and G12. Different types of adrenoceptors thereby couple to different G-proteins: -
adrenoceptors couple to Gs protein, 1-adrenoceptor to Gi proteins and 1-adrenoceptors to 
Gq protein. Coupling of -adrenoceptors to Gs proteins activates adenylate cyclase (AC), 
which in turn increases intracellular cAMP. Contrary, coupling of 1-adrenoceptors to Gi 
proteins inhibits AC and thus subsequently the formation of cAMP from ATP. The 1-
adrenoceptor coupling to Gq proteins activates another intracellular effector, namely 
phospholipase C (PLC), which increases inositol triphosphate (IP3) and diacylglycerol (DAG). 
Once these second messengers are generated, cAMP activates protein kinase A (PKA), 
DAG activates protein kinase C (PKC), and IP3 mobilizes Ca
2+ from intracellular stores. The 
latter is further linked to the Ca2+/calmodulin (Ca2+/CaM) pathway, which – like PKA – 
subsequently transfers signals to the nucleus (Elenkov et al., 2000). 
As outlined above (see section 2.3.3.2.4), for example activation of 2-adrenoceptors 
on immune cells has been shown to be associated with increased levels of cAMP (Fedyk et 
al., 1996) as well as the inhibition of TNF- and IL-12 (Elenkov et al., 1996; Severn et al., 
1992; van der Poll et al., 1994) and an increase of IL-10 production (Elenkov et al., 1996; 
Siegmund et al., 1998; van der Poll et al., 1996; Van der Poll and Lowry, 1997). 
see fig. 2-12 
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In parallel to glucocorticoids, several lines of evidence exist of catecholamine signal 
transduction pathways interfering with activity of transcription factors, such as NF-B and 
AP-1. Thereby, Haraguchi et al. suggested that all three pathways, i.e. the cAMP/PKA, the 
PKC, and the Ca2+/CaM pathway, modulate these transcription factors by regulating their 
phosphorylation status (Haraguchi et al., 1995). Regarding NF-B, elevated levels of cAMP 
are generally known to inhibit its activation, for example by cAMP inhibiting the binding of 
NF-B to the NF-B-DNA site (Chen and Rothenberg, 1994; Neumann et al., 1995; Tsuruta 
et al., 1995). Furthermore, the cAMP/PKA pathway induces impaired nuclear translocation 
and DNA binding of p65, probably due to a retarded degradation of IB- (Neumann et al., 
1995; Paliogianni et al., 1993). Alternatively, this pathway may also inhibit NF-B 
transcription by phosphorylating the transcription factor CREB, which then competes with 
p65 for limited amounts of CBP (Parry and Mackman, 1997). Contrary, NF-B activity can 
also be stimulated via the Ca2+/CaM pathway enhancing inactivation of the inhibitory protein 
IB- (Frantz et al., 1994). It is also conceivable that CREB competes with AP-1 for binding 
at the AP-1 site, thus displacing it (Elenkov et al., 2000). This proposed mechanism is 
supported by findings of cAMP to also inhibit the binding of NF-AT (nuclear factor of 
activated T-cell), a nuclear factor that contains AP-1 protein (Paliogianni and Boumpas, 
1996). 
2.3.4.1.4 Summary of mechanisms of hormone-to-immune system signaling 
The former sections clearly showed that glucocorticoids and catecholamines 
modulate the immune system at the transcriptional level. Furthermore, both stress mediators 
exert at least some of their immune effects via interference with other transcription factors, 
such as NF-B and AP-1. In this regard, especially the inhibition of NF-B activity by 
glucocorticoids is instrumental for glucocorticoid receptor anti-inflammatory mechanisms, 
while the inhibition of Th1 cytokines by glucocorticoids is essentially explained by the action 
of AP-1 (Refojo et al., 2001). However, the data presented in the last result section (4.4) of 
this thesis will be on the effects of endocrine stress responses – and specifically of missing 
cortisol stress responses in patients with Addison’s disease – on NF-B activity. 
2.3.4.2 Modulation of Hormone-to-Immune System Signaling 
Given the complexity of glucocorticoid and catecholamine signal transduction 
pathways, it is conceivable to expect various mechanisms and modulators to interfere with 
these pathways at different levels and thus to change the transcriptional output. Among 
these are extracellular and intracellular hormone availability, receptor expression level, 
hormone binding affinity, and repression by other transcription factors (Bamberger et al., 
1996). These and other determinants of hormone sensitivity will be summarized in the 
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following sections exemplarily by means of factors influencing glucocorticoid sensitivity. The 
overview will follow the glucocorticoid-induced cascade of events described above in section 
2.3.4.1.2 leading to modulation of transcription. 
2.3.4.2.1 Extracellular hormone availability 
Glucocorticoid concentrations vary not only due to stress, also other factors influence 
glucocorticoid availability. For example, circadian variation in glucocorticoids has been 
shown to be sufficient to cause a corresponding cyclic variation in lymphocyte function, i.e. 
release of IFN- and proliferative response to challenge, in humans (Hiemke et al., 1995; 
Petrovsky and Harrison, 1995; Petrovsky et al., 1994), a finding supported by the observation 
of diurnal changes in circulating T-cell subsets being comparable to those induced by 
prednisolone (Fukuda et al., 1994). Furthermore, in blood cortisol is largely bound to 
corticosteroid-binding globulin (CBG, synonym: transcortin). Another 15-20% is bound less 
tightly to albumin, leaving only about 5% of circulating cortisol as unbound (Pearson-Murphy, 
2000). These 5% of unbound or free cortisol are thought of as the biologically active fraction, 
based on the concept known as the “free hormone hypothesis” (Mendel, 1992). Free cortisol 
levels may thus vary depending on factors influencing hepatic CBG production, such as 
oestrogen. In this regard, CBG levels have been shown to be increased for example in 
women under oral contraceptive medication (Crook, 1997; Wiegratz et al., 1995). Contrary, 
short-term treatment with IL-6 was shown to induce rapid decreases of CBG levels (Tsigos et 
al., 1998), which would translate into increased availability of glucocorticoids during infection 
and thereby a higher efficacy of immune suppression. 
2.3.4.2.2 Intracellular hormone availability 
Once glucocorticoids have entered a target cell, two enzymes inside this target cell 
catalyze the inter-conversion of active glucocorticoids (cortisol/corticosterone) to inactive 
forms (cortisone, 11-dehydrocorticosterone) and vice versa, interrupting GR-GC binding and 
thus determining glucocorticoid access to the glucocorticoid receptor. These enzymes are 11 
beta-hydroxysteroid dehydrogenase type 1 (11-HSD1) and 11-HSD2, with 11-HSD1 
producing the active and 11-HSD2 producing the inactive form (“cortisol-cortisone shuttle”; 
Rook, 1999). Among other tissues, 11-HSD2 is found in the kidney, where it converts 
cortisol into inactive cortisone to stop the mineralocorticoid receptor from binding cortisol 
(Walker, 1994). As a result, mineralocorticoid functions are almost exclusively mediated by 
aldosterone, although this hormone is present at much lower concentrations. 11-HSD1, 
converting cortisone back to cortisol, is present in essentially all tissues with the liver being 
probably the major site of this conversion (Stewart and Whorwood, 1994). Interestingly, 
exposure of cells expressing both enzymes to IL-1 or TNF- was shown to cause a marked 
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increase in expression of 11-HSD1 (Escher et al., 1997). This finding points to a 
mechanism by which cytokines counterbalance their own pro-inflammatory effect by 
determining the anti-inflammatory action of glucocorticoids. 
Interestingly, Balzi et al. (Balzi et al., 1994) recently identified a yeast transporter 
protein (PDR5P; see also LEM1, STS1, YDR1P) that was shown to actively and specifically 
export glucocorticoids from the cell (Kralli et al., 1995). If a mammalian glucocorticoid-
transporter homolog exists, such a protein would surely represent another important 
regulator of intracellular hormone availability. 
2.3.4.2.3 Glucocorticoid receptor expression level 
Another factor modulating the effect of a given concentration of glucocorticoids is the 
number of glucocorticoid receptors available (Vanderbilt et al., 1987). This expression of GR 
varies between different tissues, with the thymus probably expressing one of the highest 
numbers of receptors per cell (Miller et al., 1990). If this variation in GR numbers also do 
have regulatory consequences, is not known yet. So far the most potent regulator of GR 
expression appears to be glucocorticoids themselves (Burnstein et al., 1991; Silva et al., 
1994). With glucocorticoids down-regulating GR expression – for example by reducing its 
half-life (McIntyre and Samuels, 1985) –, a short-loop feedback mechanism is constituted 
that may protect tissues from excessive glucocorticoid levels (Bamberger et al., 1996). 
Furthermore, a large body of evidence exists of cytokines influencing GR expression. 
With the exception of one study finding TNF- to decrease GR number (Franchimont et al., 
1999), cytokines, i.e. pro-inflammatory and type1 cytokines, are generally found to up-
regulate transcription of the glucocorticoid receptor.5 This findings are contradicted by studies 
differentiating between the two isoforms of glucocorticoid receptors. The human 
glucocorticoid receptor contains a total of 10 exons. By alternative splicing of exon 9, two GR 
isoforms are produced (Encio and Detera-Wadleigh, 1991), the fully functional GR isoform 
and the GR isoform without hormone-binding activity (Hollenberg et al., 1985). These two 
forms are able to form heterodimers, but only GR homodimers are functional. Thus, GR is 
thought to act as an endogenous inhibitor of glucocorticoid action (Bamberger et al., 1995). 
In parallel to these findings, treatment of human peripheral blood mononuclear cells 
(PBMCs) with IL-2 and IL-4 was shown to increase the expression of GR by more than 
100% (Leung et al., 1997), while TNF- and IL-1 causes a relative over-expression of GR 
by increasing GR by 150% and GR by 350% (Webster et al., 2001). While the former data 
                                            
5
 Pariante et al. (1999): IL-1; Costas et al. (1996): TNF-; Verheggen et al. (1996): IL-1, 
TNF-, LPS; Rakasz et al. (1993): IL-1, IL-6, TNF-; Masera et al. (2000): IL-6; Sartori et al. (1998): 
IL-2; Salkowski and Vogel (1992b): LPS; Salkowski and Vogel (1992a): IFN-; Franchimont et al. 
(1999): IL-10, TNF-. 
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point to cytokines increasing GR expression, the latter studies let assume that they 
predominantly increase the negative isoform GR and thus down-regulate glucocorticoid 
sensitivity of target cells. Cytokines may thus counter-regulate actions of glucocorticoids 
themselves on GR. 
2.3.4.2.4 Hormone binding affinity 
Irrespective of the number of GR proteins, glucocorticoid-binding affinity of the GR is 
another factor potentially modulating signal transduction. For example, all point mutations 
within the coding-region for the ligand-binding domain have been found to be associated with 
decreased ligand-binding affinity (Ashraf and Thompson, 1993; Hurley et al., 1991). 
Additionally, factors influencing the assembly of the GR-HSP complex, which serves to keep 
the GR in ligand-friendly high affinity conformation (Pratt, 1993), negatively affected the 
binding affinity of GR. Such factors are ATP/energy depletion (Hu et al., 1994; Orti et al., 
1992), decreased expression of HSP90 (Picard et al., 1990), and mutations of HSP90 
(Cadepond et al., 1994; Nathan and Lindquist, 1995). Contrary, Huizenga et al. reported of 
GR polymorphisms, detected in approximately 6% of 216 volunteers, to be associated with 
an increased glucocorticoid sensitivity (Huizenga et al., 1998) and Ning and Sanchez 
observed stabilized GR-HSP complexes and thus increased hormone-binding affinity in 
response to the immunosuppressive drug FK506, which is also a ligand for HSP56 (Ning and 
Sanchez, 1995). 
Rather complex are the effects of cytokines on hormone binding affinity. While for 
example each of the cytokines IL-1, IL-6, and TNF- were reported to increase binding 
affinities (Falus et al., 1995; Masera et al., 2000; Rakasz et al., 1993), using various 
combinations of these three cytokines were reported to decrease hormone binding affinity 
(Rakasz et al., 1993; Verheggen et al., 1996). As in vivo additionally sequences of events 
(e.g. in inflammation: TNF- > IL-1 > IL-6; (Chrousos, 1995) have to be considered, the 
picture becomes even more complex and no general consequences regarding the effects of 
cytokines on glucocorticoid-binding affinity of GR can be drawn. 
2.3.4.2.5 Glucocorticoid receptor phosphorylation and nuclear translocation 
Before nuclear translocation of the GR-GC complex takes place, the GR becomes 
hyper-phosphorylated. To date it is not clear whether phosphorylation of GR influences its 
activity. Selective mutations of single, multiple, or all phosphorylation site of the mouse 
(Mason and Housley, 1993) as well as the human (Almlof et al., 1995) GR only modestly 
reduced the transcriptional activity of the receptor. Furthermore, when diverse phosphatases, 
phosphatase inhibitors, and kinases were analyzed with regard to their effect on GR function, 
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no consistent pattern of enhancement or inhibition could be established (Kuiper and 
Brinkmann, 1994; Orti et al., 1992). 
In unmasking a nuclear localization signal (NLS), glucocorticoids may accelerate the 
nuclear translocation of the GR-GC complex (Akner et al., 1994). Furthermore, both 
cyclosporin A (Renoir et al., 1995), a binding agent of the immunosuppressive mediator 
immunophilin, and the HSP56-binding drug FK506 (Hutchison et al., 1993; Ning and 
Sanchez, 1993) were shown to enhance glucocorticoid-mediated transcription at low 
hormone concentrations. Contrary, treatment of L929 mouse fibroblasts with IL-1 resulted in 
decreased GR translocation to the nucleus (Pariante et al., 1999). 
2.3.4.2.6 DNA-GRE binding 
Once the GR-GC complex translocated to the nucleus, it will bind to DNA and specific 
GREs or nGREs. Thereby, again various factors may negatively or positively regulate this 
binding and hence attenuate or augment transcription. For example, several proteins, such 
as a promoter present in rat liver cells termed ATP-stimulated GR translocation promoter 
(ASTP; Okamoto et al., 1993), increase GR binding to DNA, but so far none of these proteins 
has been analyzed in terms of their expression pattern and functional relevance in vivo 
(Bamberger et al., 1996). Interestingly, activation of the PKA pathway (see section 2.3.4.1.3: 
catecholamine signal transduction) has been reported to augment transcription initiated by 
glucocorticoids (Espinas et al., 1995; Rangarajan et al., 1992). Findings of PKA activators 
not being correlated with changes in GR phosphorylation suggest the effect of PKA being 
mediated by phosphorylation of factors interacting with the GR (Moyer et al., 1993). 
Regarding immune related parameters, Pariante et al. not only found IL-1 to 
decrease GR translocation to the nucleus, but consequently also to decrease GR-mediated 
gene transcription (Pariante et al., 1999). Contrary but also in L929 cells, Costas et al. 
showed TNF- to increase transcriptional activity (Costas et al., 1996). This latter finding 
may reflect again a mechanism by which cytokines potentiate the counter-regulation of 
inflammatory processes by glucocorticoids. 
2.3.4.2.7 Interaction with other nuclear factors 
It was already outlined above that activated GR interferes with the transcription factor 
NF-B (De Bosscher et al., 1997; De Bosscher et al., 2000b; Ray and Prefontaine, 1994). 
But NF-B may repress the DNA-binding activity of the GR to the same extent. Again, it is 
the p65 subunit, which is involved in this functional antagonism (Caldenhoven et al., 1995; 
McKay and Cidlowski, 1998; Ray and Prefontaine, 1994; Scheinman et al., 1995a). As a 
second mechanism of GR repression by NF-B, NF-B has been shown to increase the 
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expression of the receptor isoform GR, thus increasing the ratio of GR:GR, impairing GR 
transactivation, and eventually causing glucocorticoid resistance (Webster et al., 2001). 
This mutual antagonism of NF-B and the GR as well as the reciprocal repression of 
AP-1 and GR transactivation functions (see section 2.3.4.1.2) imply that during inflammation 
the glucocorticoid sensitivity of the respective tissue should decrease. This conclusion is 
substantiated by findings in steroid-resistant asthmatics of reduced GR-DNA binding due to 
abnormal AP-1-GR interactions (Adcock et al., 1995a; Adcock et al., 1995b). 
2.3.4.2.8 Summary of modulation of hormone-to-immune system signaling 
The previous sections clearly showed that glucocorticoid sensitivity of target tissue 
can be modulated at nearly every level of the glucocorticoid signal transduction pathway. 
Regarding immune related parameters, contradicting results hamper a general conclusion. 
Some evidence points to cytokines counter-regulating their own action by increasing 
glucocorticoid sensitivity (via increasing 11-HSD1 expression, GR transcription, 
glucocorticoid binding affinity, and GR-mediated gene transcription). Contrary, other findings 
suggest that cytokines counter-regulate glucocorticoid effects, as combinations of the 
cytokines IL-1, IL-6, and TNF- decreased binding affinity and IL-1 was associated with 
attenuated GR translocation and GR-mediated gene transcription. This is supported by 
findings of both NF-B and AP-1 to also repress GR-mediated gene transcription. However, 
practically none of the outlined data come from in vivo studies. Therefore it is impossible to 
predict the overall result of different combinations of moderators on glucocorticoid signaling, 
even less so over the course of e.g. an inflammatory or stress response. 
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3 PROBLEM FORMULATIONS 
Especially the last section revealed a general problem in psychoneuroimmunology 
research: Much data comes from approaches scarcely to be linked to the situation in human 
whole organism. But especially if the interest is of clinical nature, it is important to be able to 
decide on the role of endocrine stress responses for health and disease. 
As outlined in section 2.1, an endocrines stress response is basically thought of as 
being primarily protective (Benschop et al., 1996; Besedovsky and del Rey, 1996). Section 
2.3 gave further evidence to this positive role in regard to the immune system. Consequently, 
usually only dysfunctions of stress systems have been associated with negative or 
pathophysiological consequences (Chrousos, 1998a). 
But based on which data are such conclusions drawn? In human research, mostly 
just associations can be revealed between, for example, endocrine dysfunctions and 
distinctive features of the immune system. To decide on direction and above all relevance of 
such associations, results of – in the broadest sense – fundamental research have to be 
consulted. This implies effects of stress mediators being investigated in animals or in vitro. 
Next, a logical set of criteria has to be applied to analyze the role of glucocorticoids and 
catecholamines in the stress response. Sapolsky, Romero, and Munck (Sapolsky et al., 
2000) for example applied the following three criteria: 
1 The criterion of time course 
(When does an effect occur?) 
2 The criteria of hormone subtraction and replacement 
(What happens if a glucocorticoid and/or catecholamine stress response is 
eliminated? Does administering of stress or/and basal levels of the respective 
hormone restore the stress response?) 
3 The criterion of homeostasis 
(Which action, i.e., permissive, suppressive, stimulating, or preparative action, 
makes more physiological sense in terms of restoring homeostasis?) 
 
However, logical reasoning does not overcome the general problem of the arguable 
explanatory power of many of the underlying data regarding the human whole body situation. 
Surely the question, to what extent data from animal research can be assigned to humans, is 
a very common one, but it is nevertheless a legitimate one. Further, in vitro approaches may 
reveal important basic mechanisms and help to interpret in vivo findings. But to what extent 
can they also predict and explain events in this highly complex situation? These open issues 
notwithstanding, the criteria of hormone subtraction and replacement are unquestionably 
essential for gaining insights into how endocrine stress responses affect the immune system. 
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3.1 ADDISON’S DISEASE: A METHOD 
The most evident answer for these problems is to investigate the criteria of hormone 
subtraction and replacement in humans. In this regard, several approaches are conceivable 
and most of them are widely utilized. In parallel to animal and in vitro studies, also human 
subjects may be treated with hormone antagonists and agonist. An example for a 
glucocorticoid antagonist is mifepristone (RU486), which blocks the glucocorticoid receptor. 
The synthetic glucocorticoid dexamethasone in turn is a glucocorticoid agonist, which 
consequently also inhibits glucocorticoid secretion by negative feedback mechanism. To both 
RU486 and dexamethasone several objections may be raised. For example, RU486 does not 
specifically block the glucocorticoid receptor as it also act as an antiprogestin and thus 
blocks the progesterone receptor (Mahajan and London, 1997). Furthermore, though it does 
not evoke a glucocorticoid-like effect, because the RU486-GR complex fails to interact 
properly with the basal transcription machinery (Bamberger and Chrousos, 1995; Chrousos 
et al., 1988; Mao et al., 1992), in some cases the RU486-bound glucocorticoid receptor still 
mediates transrepression of AP-1 and NF-B (Heck et al., 1994; Liu et al., 1995; Scheinman 
et al., 1995b), whereas it has antagonistic effects in others (Caldenhoven et al., 1995; Jonat 
et al., 1990). Dexamethasone on the other hand shows a higher binding affinity to the 
glucocorticoid receptor, does not bind to CBG and is thus retained in high amounts, and 
blocks HPA activity predominantly on the pituitary level (De Kloet et al., 1998). But the most 
prominent objection concerning antagonists and agonists in general is the fact that this kind 
of treatment mostly is limited in duration of time. Hence this approach does not allow for 
considering allostatic processes elicited by longer lasting stress system dysfunctions and 
especially not for considering the extend to which these allostatic processes are capable of 
counter-balancing dysfunctions. Consequently, it is questionable whether such short time 
treatments may allow predictions regarding the clinical relevance of glucocorticoids and 
catecholamines for normal functioning of the immune system. An alternative approach 
should thus account for long-term effects of stress system dysfunctions. In animal research, 
adrenalectomy is a common method in this regard. A similar albeit therapeutically approach 
can be found in patients with adrenocortical adenoma, carcinoma, or dysplasia. Bi-lateral 
adrenalectomy in turn will result in primary adrenal insufficiency or Addison’s disease. As 
outlined in section 2.2, patients with Addison’s disease – independent of etiology – do not 
produce any cortisol due to destroyed (missing) adrenals and therefore have to be treated 
with glucocorticoid replacement (Arlt and Allolio, 2003; Betterle et al., 2002; Oelkers, 1996; 
Ten et al., 2001). The therapy thereby only provides basal cortisol supply, while it does not 
provide for additional doses during stress. This represents an unique physiological situation 
satisfying all prerequisites for an approach investigating the role of stress and stress 
mediators in human health and disease. 
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3.2 PROBLEM FORMULATIONS 
The present thesis was guided by the question of the clinical relevance of regular 
stress responses or more precisely by the question: Is a regular endocrine stress response 
mandatory for physical health or does the organism, at least to a certain extent, compensate 
for it? As outlined above, investigation of patients with Addison’s disease can be seen as the 
most promising approach in this regard. But despite this patient population being obviously 
quite interesting for PNI research, no stress-related endocrine and immune data are 
available so far. Therefore, the aim of the present work had to be to first define the general 
conditions of the ‘method’ Addison’s disease’s. This concerns the hypothesized missing 
cortisol stress response and even more essentially, the basal cortisol levels theoretically 
restored by glucocorticoid replacement therapy. 
3.2.1 Study 1: Basal Endocrine State 
Establishing basal cortisol levels is all the more important as the adequacy of 
replacement therapy to mimic diurnal cortisol rhythm was already repeatedly questioned. In 
most cases, patients with Addison’s disease are reported to be over-treated (Lovas and 
Husebye, 2003; Lovas et al., 2002; Peacey et al., 1997). This is not only of special interest 
from a patients’ point of view as over-treatment has been associated with long-term adverse 
consequences, such as decreases in bone mineral density (Zelissen et al., 1994). Deviations 
in circadian free cortisol rhythm has also been connected repeatedly to various clinical and 
psychiatric diseases (Giubilei et al., 2001; Pruessner et al., 2003). Over-treatment will further 
most probably affect the sensitivity of target tissue to glucocorticoid signals, which is 
important to consider when interpreting stress effects on immune parameter. Unfortunately, 
so far in Addison’s disease the determination of the appropriate dose is mainly based on 
clinical judgement and no objective assessment has proven to be reliable for monitoring 
replacement quality. For this reason, the first study of the present thesis was undertaken not 
only to determine the adequacy of replacement therapy, but at the same time to test the 
usability and reliability of salivary free cortisol measures in patients with Addison’s disease. 
3.2.2 Study 2: Stress Effects in Addison’s Disease 
3.2.2.1 Psychosocial Stress: Endocrine and Cardiovascular Response 
 The second study first of all aimed at establishing endocrine and cardiovascular 
stress responses in Addison’s disease, primarily the missing cortisol response. But missing 
cortisol stress responses are not the sole distinctive feature to be expected. Endogenous and 
locally acting cortisol is critical in the last step of the catecholamine biosynthesis (Bornstein 
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et al., 1995), consequently in Addison’s disease very low epinephrine levels have been 
observed (Bornstein et al., 1995). These findings suggest that beside a missing cortisol 
stress response, patients with Addison’s disease may also not show stress responses in 
epinephrine. This leaves only norepinephrine to regularly respond to stress with an increased 
release. As both catecholamines and glucocorticoids are known to be important activators 
and mediators, respectively, of the cardiovascular stress response (Galosy et al., 1981; 
Sambhi et al., 1965; Sapolsky et al., 2000), investigation of heart rate and blood pressure 
changes during stress in Addison’s disease may provide first evidences of the compensatory 
capacity of the human organism. 
However, physiological changes in response to hormone subtraction just indicate the 
necessity of the respective hormone for these effects. Only subsequent hormone 
replacement will also reveal the sufficiency of the hormone for these effects. Therefore, a 
pilot study in healthy subjects was conducted to determine the dose of hydrocortisone iv best 
mimicking normal stress-induced increases in free cortisol levels (=0.03mg/kg). In the course 
of study 2, this dose was also tested in patients with Addison’s disease regarding its 
adequacy to restore stress levels of free cortisol and their potentially modulatory effects on 
cardiovascular parameters. 
3.2.2.2 Psychosocial Stress: Immunological Consequences 
The second aim of study two was to investigate the immunological consequences of 
missing endocrine stress responses in Addison’s disease. As glucocorticoids show 
pronounced anti-inflammatory actions, missing cortisol stress responses should result in 
facilitated pro-inflammatory processes in patients with Addison’s disease. This hypothesis is 
supported by observations of patients being prone to diseases like bronchial asthma (Green 
and Lim, 1971) and various allergies (Carryer et al., 1960). To gain insight into the 
immunological consequences of endocrine dysfunctions, stress effects on three common 
immune parameters were investigated: Percentages of cell subtypes, which provide general 
information about immune system activation (Dhabhar, 2000), as well as LPS-stimulated IL-6 
production and PHA-stimulated cell proliferation, which provide information about the 
responsiveness of cells of innate immunity and adaptive immunity, respectively (Vedhara et 
al., 1999). 
It may further be hypothesized that glucocorticoid replacement therapy influences the 
sensitivity of target cells to glucocorticoid signaling, even more so if patients with Addison’s 
disease are actually over-treated. Therefore, additionally the sensitivity of LPS-stimulated IL-
6 production and PHA-stimulated cell proliferation to the inhibitory signal of the synthetic 
glucocorticoid dexamethasone was measured. Furthermore, hydrocortisone injections were 
utilized to decide on glucocorticoids being necessary or actually sufficient. 
PROBLEM FORMULATIONS 114 
3.2.2.3 Psychoneuroimmunology: Mediative Role of NF-B 
Beside operationalizing glucocorticoid sensitivity by adding dexamethasone ex vivo to 
stimulated whole blood or peripheral blood mononuclear cells, also measuring NF-B activity 
in patients with Addison’s disease may provide insights into long-term adaptive processes 
regarding glucocorticoid signaling. As outlined above, the transcription factor NF-B is found 
in virtually every cell of the immune system regulating a great number of immune related 
genes. Transcriptional activity of NF-B and glucocorticoid receptors usually leads to the 
production of immune mediators with contrary actions. Furthermore, as promoters of most 
pro-inflammatory genes do not contain negative glucocorticoid response elements 
(Bamberger et al., 1996; Cato and Wade, 1996), it is thought that glucocorticoids exert their 
anti-inflammatory action by activated glucocorticoid receptors interfering with NF-B activity 
(De Bosscher et al., 1997; De Bosscher et al., 2000b; Ray and Prefontaine, 1994). Hence, 
NF-B can be regarded as important mediator of immune-suppressive glucocorticoid actions. 
The fourth aim of the present work was to investigate this mediative role of NF-B by 
measuring NF-B-DNA binding activity before and repeatedly after stress in patients with 
Addison’s disease. 
 
 
In the following chapter (chapter 4), the results of the accomplished studies will be 
presented. Aligned formally to a manuscript, for each of the four problem formulation first a 
short introduction will be given summarizing the respective theoretical background. This is 
followed by information on subjects, study design, and methods. Adjacent to the presentation 
of results, findings will be discussed in the context of the respective problem formulation. 
Subsequent to the result chapter, data will be pulled together and discussed in a greater 
context (chapter 5: Summary, general discussion, and outlook). 
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4 RESULTS 
4.1 ADDISON’S DISEASE: BASAL ENDOCRINE STATE 
Salivary Free Cortisol Measurement in Addison’s Disease – A Reliable Method for 
Glucocorticoid Replacement Therapy Surveillance 
4.1.1 Abstract 
Background: Addison’s disease is caused by bilateral destruction of the adrenal 
cortex. The resulting failure to produce steroid hormones requires life-long replacement 
therapy with mineralocorticoids and glucocorticoids. In both over and under-treated patients 
substantial morbidities develop. While obesity, osteoporosis, and impaired glucose tolerance 
are found in patients over-treated with glucocorticoids, incipient crisis and impairment of 
wellbeing is observed in patients with insufficient steroid replacement regimens. Despite the 
significant iatrogenic consequences, the choice of the appropriate replacement dose is 
mainly based on clinical judgment rather than careful monitoring of steroid levels in the 
patient. The present study therefore investigated whether repeated measurements of free 
cortisol levels in saliva provide a tool for objectively assessing the adequacy of replacement 
therapy in patients with Addison’s disease. 
Methods: In 27 patients with Addison’s disease, salivary cortisol was measured 
repeatedly over two days at time-points related to individual medication intake. 
Results: All patients show markedly elevated free cortisol levels compared to 
reference values. Salivary free cortisol levels in patients taking cortisone showed less 
pronounced fluctuating courses compared to the hydrocortisone group. In the latter, a non-
linear relationship between dose and salivary cortisol levels was found. Salivary cortisol 
levels rose with increasing replacement doses up to 20mg hydrocortisone, while lower 
cortisol levels were found with hydrocortisone doses of 25mg. 
Conclusions: Since salivary free cortisol levels are a valid reflection of free cortisol 
levels in blood, monitoring of salivary cortisol levels provides an easy approach to objectively 
assess the adequacy of replacement therapy in patients with Addison’s disease. The present 
data provide firm evidence that in current replacement regimens, most patients are over-
treated. In order to avoid treatment-induced morbidity, cortisol levels should be monitored 
more closely with non-invasive sampling strategies. 
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4.1.2 Introduction 
Primary adrenal insufficiency, also labeled Addison’s disease, is caused by bilateral 
destruction or impaired function of the adrenal cortex, whereupon adrenal insufficiency 
manifests itself as clinical disease if the functional adrenal mass falls below 10% (Ten et al., 
2001). This reduction of adrenocortical cell mass is responsible for the characteristic 
deficiency of glucocorticoids and mineralocorticoids, more specifically cortisol and 
aldosterone, respectively (Marzotti and Falorni, 2004).  
Addison’s disease is a relatively rare disease with prevalence rates ranging from 10 
to 140 per million population, varying between countries (Marzotti and Falorni, 2004; Oelkers, 
1996; Ten et al., 2001). The incidence is 4.7-6.2 per million in white populations (Arlt and 
Allolio, 2003). On average, the age at diagnosis peaks in the fourth decade of life, with 
women more frequently affected than men (Arlt and Allolio, 2003). 
Addison’s disease can have various etiologies. Betterle et al. (Betterle et al., 2002) 
offer a classification, in which they distinguish between autoimmune adrenalitis, infectious 
adrenalitis, Addison’s disease due to neoplastic diseases, adrenal hemorrhage, or adrenal 
thrombosis, drug-induced adrenal insufficiency, neonatal causes, and genetic causes of 
Addison’s disease. Many of the listed causes are very rare. In non-developed countries, 
infectious diseases (e.g., tuberculosis) are the major cause of Addison’s disease. In 
developed countries, autoimmune adrenal destruction is the major cause, affecting 
approximately 90% of all patients with primary adrenal insufficiency (Winqvist et al., 1996). 
The treatment of patients with Addison’s disease accounts for the missing 
glucocorticoids and mineralocorticoids. Mineralocorticoid replacement consists of oral 
administration of fludrocortisone in a single daily dose of 50-200μg. The dose is guided by 
measurements of blood pressure, serum potassium, and plasma renin activity (Betterle et al., 
2002). Additional markers can be serum sodium concentrations and appearance of 
peripheral oedema (Arlt and Allolio, 2003). Optional is the replacement of 
dehydroepiandrosterone (DHEA) to increase well-being and mood, taken daily as one dose 
of 25-50mg DHEA in the morning (Arlt and Allolio, 2003). Glucocorticoid replacement is 
usually given in two or three daily doses, with a half to two-thirds of the daily dose 
administered in the morning to mimic the circadian secretion pattern of cortisol (Arlt and 
Allolio, 2003). The dosage is based on the normal daily cortisol production rate of 
5.7±0.3mg/m2·day (Kerrigan et al., 1993), which translates to about 10-20mg/m2·day of oral 
hydrocortisone (Ten et al., 2001), accounting for step-down losses from absorption, hepatic 
processing, and metabolic bioavailability. Initially, the treatment starts with doses of 25mg 
hydrocortisone (15 + 10mg) or 37.5mg cortisone acetate (25 + 12.5mg; Oelkers, 1996). The 
daily dose may be decreased to 20 or 15mg of hydrocortisone to prevent over-replacement, 
which was repeatedly shown to be associated to weight gain, osteoporosis and impaired 
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glucose tolerance (al-Shoumer et al., 1995; Florkowski et al., 1994; Zelissen et al., 1994). On 
the other hand, under-replacement bears the risk of incipient crisis and impairment of 
wellbeing. The goal should be to use the smallest dose that relieves the patient’s symptoms 
(Oelkers, 1996). 
In Addison’s disease, the determination of the appropriate dose is mainly based on 
clinical judgment, taking into account signs and symptoms potentially suggestive of 
glucocorticoid over-replacement or under-replacement. So far, no objective assessment has 
proven to be reliable for monitoring replacement quality. Cortisol levels can be measured in 
plasma. But since cortisol concentrations vary throughout the day, the diagnostic usefulness 
of random plasma samples is limited. Measuring cortisol levels repeatedly over the day on 
the other hand is unpleasant for patients as it is associated with repeated venipunctures or 
an in-dwelling catheter. Additionally, some endogenous and synthetical corticosteroids cross-
react in the cortisol assay and should therefore be avoided within 24 hours of testing 
(Grinspoon and Biller, 1994). Taken together, this hampers a close surveillance of 
replacement therapy by plasma samples. Urinary 24 hrs free cortisol excretion has been 
advocated for monitoring replacement. However, since after HC administration cortisol-
binding globulins are rapidly saturated, renal cortisol excretion is transiently but clearly 
increased (Monson, 1997). Urinary cortisol should therefore only be used as a marker for HC 
over-treatment (Peacey et al., 1997). Adrenocorticotropic hormone (ACTH) cannot be used 
as a criterion for dose adjustment, since in primary adrenal insufficiency it is invariably high 
before the morning dose and rapidly declines with increasing cortisol concentrations after 
glucocorticoid ingestion (Feek et al., 1981; Scott et al., 1978). 
Furthermore, in blood cortisol is largely bound to corticosteroid-binding globulin (CBG, 
synonym: transcortin). Another 15-20% is bound less tightly to albumin, leaving only about 
5% of circulating cortisol as unbound (Pearson-Murphy, 2000). These 5% of unbound or free 
cortisol are thought of as the biologically active fraction, based on the concept known as the 
“free hormone hypothesis” (Mendel, 1992). Since only the free cortisol fraction acts upon 
target tissues, leading to the known broad spectrum of physiological effects of cortisol, 
measures of total cortisol levels in plasma have to be interpreted with caution. Not only can 
total cortisol levels be increased as a result of hepatic cortisol-binding globulin production 
due to e.g. oestrogen, but, regarding cortisol effects on target tissues, it is rather debatable 
whether measures of total cortisol levels are conclusive at all. Therefore, in clinical and 
especially endocrinological research the measure of free cortisol is usually preferred. 
Moreover, since almost twenty years, free cortisol can be measured in saliva. The main 
advantage of saliva samples is that they offer a non-invasive method to measure free cortisol 
levels. Thus free cortisol levels can be investigated repeatedly and in short time intervals 
without inconvenience for patients, and even at patients’ homes. Additionally, free cortisol 
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levels are found to be unaffected by conditions which alter the amount of CBG and/or 
albumin (e.g., oestrogens) and hence influence the measurement of total cortisol (Gozansky 
et al., 2005; Kirschbaum and Hellhammer, 1989). Due to the wide-spread usage of free 
cortisol measures in saliva in research, normal values for free cortisol levels over the day 
exists (Westermann et al., 2004; Wust et al., 2000) and different types of assays with low 
cross-reactivity to most endogenous and synthetic corticosteroids are commercially 
available. 
Specifically in patients with Addison’s Disease, the measurement of free cortisol 
levels in saliva would represent a valuable alternative approach in that it allows for closely 
controlling the adequacy of glucocorticoid replacement. This adequacy was repeatedly 
questioned. For example, Peacey et al. found by measuring cortisol in serum and urine, 75% 
of patients on conventional glucocorticoid therapy to be over-treated (Peacey et al., 1997). 
Additionally, Lovas et al. reported of persistent complaints of fatigue, weariness, and reduced 
stress tolerance in many patients with Addison’s disease on standard replacement therapy 
(Lovas et al., 2002). Therefore, Lovas and Husebye concluded that none of the 
glucocorticoid replacement regimes satisfactorily mimic the normal diurnal rhythm of cortisol 
(Lovas and Husebye, 2003). This is of special interest, since not only over-treatment in 
patients with Addison’s Disease has been associated with long-term adverse consequences 
like decreases in bone mineral density (Zelissen et al., 1994). Deviations in circadian free 
cortisol rhythm – far less pronounced than to be expected in patients with Addison’s disease 
due to replacement therapy – has also been connected repeatedly to various clinical and 
psychiatric diseases, like Alzheimer’s disease (Giubilei et al., 2001) or depression (Pruessner 
et al., 2003). 
However, it has been shown that various factors, e.g. gender or health status, 
influence the circadian rhythm of free cortisol in non-Addisonians (Kudielka and Kirschbaum, 
2003; Wust et al., 2000). Beside the dose of glucocorticoid replacement, it is conceivably to 
hypothesize that some of these factors may also influence salivary cortisol levels in patients 
with Addison’s disease. For example, gender may influence the course of cortisol levels as a 
result of hepatic cortisol-binding globulin production due to oestrogen (Grinspoon and Biller, 
1994). Contrary, as outlined above, free cortisol levels are found to be unaffected by 
conditions which alter the amount of CBG and/or albumin (Gozansky et al., 2005; 
Kirschbaum and Hellhammer, 1989). Also the type of medication may influence cortisol 
levels. While hydrocortison is chemically identical to endogenous cortisol, cortisone 
compounds first have to be activated to form cortisol by the hepatic enzyme 11 beta-
hydroxysteroid dehydrogenase type 1 (11-HSD1). Therefore, the absorption curve of 
cortisone is blunted and delayed compared to that of hydrocortisone (Feek et al., 1981), 
which also may result in different salivary cortisol courses. 
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So far, salivary cortisol measurement has already been proven to be a useful method 
in diagnosing Cushing’s syndrome (Trilck et al., 2005). The aim of the present study was to 
apply this method also to patients with Addison’s disease and further, to investigate the 
impact of factors like gender, type and dosage of replacement therapy, which are known to 
influence total cortisol levels in plasma, on free cortisol levels in saliva. 
4.1.3 Methods 
4.1.3.1 Subjects 
A total of thirty-seven patients with Addison’s Disease were recruited at the university 
hospital at Duesseldorf and via advertisement in the journal “Glandula”. Complete endocrine 
data were available for twenty-seven patients. The sample consisted of 17 women and 10 
men between 19 and 63 years of age (mean: 45.11, SD: 10.6). Male and female patients did 
not differ significantly in age (t25=-0.74, p=.46). Disease duration varied between 0.5 and 41.0 
years (mean: 11.05, SD: 10.9) and differed significantly between male (mean: 16.60, SD: 
13.1) and female (mean: 7.78, SD: 8.0) patients (t25=-2.18, p=.039), consistently with 
reported differences in gender distribution and mean age at diagnosis depending on the 
cause of Addison’s disease (Betterle et al., 2002). Of all patients, 18 patients (66,6%) were 
diagnosed with autoimmune Addison’s disease due to the presence of autoantibodies (i.e., 
adrenocortical autoantibodies (ACAs), steroid cell antibodies (StCA); see (Peterson et al., 
2000) and/or according to the criteria for diagnosing APS-1 or APS-2 (Neufeld et al., 1981), 
one patient was diagnosed with infectious Addison’s disease due to tuberculosis, and two 
with adrenal insufficiency due to Cushing’s disease. Six patients (22.2%) could not further 
specify their diagnosis of primary adrenal insufficiency and the co-morbidities did not fulfil 
criteria for classification to autoimmune Addison’s disease. Most patients are prescribed 
hydrocortisone (HC; n=21), six patients took cortisone acetate (cortisone). Glucocorticoid 
replacement was given in two doses in 15 patients and in three doses in 12 patients. The 
pattern of glucocorticoid replacement varied widely between the patients. In 27 patients, 15 
different patterns were found (see table 4-1). Controlling for gender, both weight and body 
mass index (BMI) did not correlate with first dose of hydrocortisone and total daily dose of 
hydrocortisone (dose1 HC: r18=-.06, p=.81; r18=-.03, daily dose of HC: p=.91; r18=-.11, p=.66; 
r18=-.03, p=.92; respectively).  
In further analyses, only the first two doses, independently of the time of day of the 
second dose were included. The mean time interval between dose1 and dose2 was 6h58min 
(standard deviation (SD): 1h56min, range: 4hrs to 11.5hrs). 
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Tab. 4-1: Patterns of glucocorticoid replacement (HC: hydrocortisone, C: cortisone acetate). 
dose 1 (mg) dose 2 (mg) dose 3 (mg) n 
- 2 HC 
10 5 
5 1 HC 
- 1 HC 
5 
5 4 HC 
- 2 HC 
15 
10 
5 3 HC 
- 1 HC 
5 
5 1 HC 
- 3 HC 
20 
10 
10 1 HC 
5 5 1 HC 
25 
10 5 1 HC 
18,75 - 1 C 
25 
12,5 
- 4 C 
37,5 25 - 1 C 
 
4.1.3.2 Experimental Protocol 
Patients were asked to collect six saliva samples at two consecutive days at home 
using the Salivette device (Sarstedt, Nümbrecht, Germany). Because of the widely varying 
patterns of glucocorticoid replacement, time-points at which patients collected saliva samples 
were related to the time-points of medication intake: The first sample (sample 1) had to be 
taken one hour after taking the first substitution dose (dose1), sample 2 between sample 1 
and 3, sample 3 immediately before taking dose2, and samples 4, 5, and 6 at one, two, and 
four hours after taking dose2, respectively. At day 2, patients were asked to skip the second 
dose but collect saliva samples at the same time-points as at day 1. The time interval of one 
hour after medication intake was chosen to avoid contamination of saliva samples with 
residues of the orally taken medication. The patients were further asked not to eat, drink 
(except water) or brush their teeth during a phase of 30 minutes prior to each sampling to 
avoid false high free cortisol concentrations. 
4.1.3.3 Biochemical Analysis 
Free cortisol levels in saliva were measured using a commercially available 
chemiluminescence assay (IBL, Hamburg, Germany). Samples were measured in duplicates 
and averaged for subsequent statistical analyses. Samples with >100nmol/l free cortisol were 
measured again diluted 1:10 in assay buffer and included only if two more measures in 
duplicates yielded identical results. 
4.1.3.4 Statistical Analysis 
Data were analyzed using the Statistical Package for the Social Science Version 
11.0.2 (SPSS Institute, Chicago, IL). Time effects and group differences in free cortisol levels 
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throughout the day(s) were calculated by repeated measures analysis of variance with 
within-group levels representing the time-points of saliva sampling. All data were tested for 
normality prior to statistical analysis using the Kolmogorov-Smirnov test and Greenhouse-
Geisser corrections for repeated measures were calculated where appropriate. Furthermore, 
partial correlations controlling for type of medication and Pearson’s correlations were 
computed. Values of p<0.05 were considered significant. 
4.1.4 Results 
4.1.4.1 Courses of Salivary Cortisol Levels 
At day1, salivary cortisol levels changed significantly over time showing decreases 
from time-point one to three and from four to six, and increases from time-point three to four. 
The overall time effect including all six time-points was significant with F5,130=34.89; p<.001. 
Though at day2 the overall time effect also was significant (F5,130=30,59; p<.001), salivary 
cortisol levels did not show significant changes from sample 3 on (time effect calculated for 
sample 3 to sample 6: F3,78=1.03; p=.34). Thereby, day1 and day2 differed significantly 
(F1,130=6.09, p=.02), but no time-by-day effect was found (F5,130=2.51, p=.11). Figure 4-1 
depicts the course of salivary cortisol levels at day1 and day2 over the six time-points with 
reference to replacement dose1 and dose2 in comparison to normal values. 
 
Fig. 4-1: Means and standard errors (SE) of salivary cortisol levels at day1 and day2 (day2: patients were asked 
to skip dose2 (d2); dose1 and dose2 indicated by grey bars; d1 +1h: one hour after dose1, appr. 8a.m.; betw. 
1+3: between sample 1 and sample 3, appr. 11a.m.; d2 +1min: immediately before dose2, appr. 2p.m.; d2 +1h, 
d2 +2h, and d2 +4h: one, two, and four hour after dose2, resp., appr. 3p.m., 4p.m. 6p.m.) compared to normal 
values and standard errors (grey line with shaded area under the curve; timepoints: at awakening, awakening 
+30min, awakening +45min, awakening +60min, 11a.m., 3p.m., and 8p.m.; Wust et al., 2000; Westermann et al., 
2004). 
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4.1.4.2 Salivary Cortisol Levels: Etiology, Gender, and Time Interval 
With six time-points at two days as within-subjects factors, no significant effects were 
found with between-subjects factors etiology or gender, except significant time effects 
(etiology: group: F3,23=.45, p=.72; day: F1,115=1.13, p=.30; time: F5,115=8.40, p=.005; group-by-
time: F15,115=.77, p=.54; group-by-day: F3,115= 0.22, p=.88; time-by-day: F5,115=.36, p=.61; 
group-by-time-by-day: F15,115=.18, p=.95 – gender: group: F1,25=.68, p=.42; day: F1,125=4.02, 
p=.056; time: F5,125=37.46, p<.001; group-by-time: F5,125=.98, p=.34; group-by-day: F1,125= 
3.73, p=.065; time-by-day: F5,125=2.82, p=.09; group-by-time-by-day: F5,125=1.06, p=.33). 
With increases in time intervals between sample 1 and 2 (time1>2) or between 
sample 1 and 3 (time1>3), salivary cortisol levels decreased (time1>2 x sample 2: r=-.46, 
p=.015; time1>3 x sample 3: r=-.41, p=.033). 
4.1.4.3 Salivary Cortisol Levels: Glucocorticoid Replacement 
Mean salivary cortisol levels did not differ significantly between the hydrocortisone 
and the cortisone group, but showed a trend to attenuated levels in the cortisone group and a 
trend to an interaction between type of medication and time (group: F1,25=3.31, p=.08; 
medication-by-time: F5,125=3.82, p=.05). Mean cortisol levels at day1 and day2 differed 
significantly (day: F1,125=7.69, p=.01), as well as salivary cortisol levels over time (time: 
F5,125=22.14, p<.001). The interactions between day and time as well as day and time and 
type of medication also did not reach statistical significance (day-by-time: F5,125=.87, p=.39; 
day-by-time-by-group: F5,125=1.51, p=.23). Figure 4-2 depicts the course of salivary cortisol 
levels at day1 for the groups hydrocortisone (n=21) and cortisone (n=6). 
 
Fig. 4-2: Salivary cortisol levels at day1 for groups hydrocortisone and cortisone (means and SE). 
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Next, partial correlations between doses and the appropriate indices of the course of 
salivary cortisol levels were computed controlling for type of medication. Generally, the first 
replacement dose did not correlate with salivary cortisol levels at time-points 1, 2, or 3, nor 
with decreases from time-point 1 to 2 (decr1>2) or decr1>3 (averaged for day1 and day2; 
r=.28, p=.17; r=.07, p=.72; r=-.11, p=.59; r=.28, p=.17; r=.30, p=.14; resp.). Dose2 at day1 
did not correlate with salivary cortisol levels at time-points 4, 5, or 6, nor with decr4>5 or 
decr4>6 (r=.20, p=.32; r=.32, p=.11; r=.08, p=.71; r=-.03, p=.90; r=.16, p=.44; resp.), but did 
correlate positively with increases in salivary cortisol levels from sample 3 to 4 (r=.42, 
p=.035), indicating more pronounced increases with higher replacement doses. 
To further test for effects of replacement doses, two separate repeated measures 
ANOVAs were computed for dose1 and dose2. Regarding dose1, salivary cortisol levels of 
samples 1 to 3 were again averaged for day1 and day2. Furthermore, due to the group and 
group-by-time trend in type of medication, four hydrocortisone replacement groups (10mg, 
15mg, 20mg, and 25mg) as well as one cortisone replacement group (mean: 26.04mg, SD: 
6,2) were included as between-subjects factors. Cortisone dosages were not further divided 
into sub-groups due to the low number of cases. Regarding dose2, salivary cortisol levels of 
samples 4 to 6 as within-subjects factors and hydrocortisone replacement doses 5mg and 
10mg and one cortisone group (mean: 14.58mg, SD: 5.1) as between-subjects factors were 
included. Following the first replacement dose, the five groups differed significantly overall 
and in their course of salivary cortisol levels (group: F4,22=2.90, p=.045; time: F2,44=39.54, 
p<.001; group-by-time: F8,44=3.21, p=.028). In salivary cortisol levels following dose2, no 
significant group effects of replacement doses were found (group: F2,24=2.25, p=.13; time: 
F2,48=10.04, p=.001; group-by-time: F4,48=.90, p=.44). Figure 4-3 depicts the course of 
salivary cortisol levels depending on replacement doses. 
 
Fig. 4-3: Salivary cortisol levels broken down by replacement doses (left side: mean cortisol levels and SE 
averaged for day1 and day2; please note that for the sake of clarity, no SE are shown; right side: mean cortisol 
levels and SE of day1). 
RESULTS 124 
4.1.5 Discussion  
The present study shows salivary cortisol levels in patients with Addison’s disease to 
be notably elevated compared to standard values. Furthermore, on average seven hours 
after the first replacement dose, the effect of the replacement medication on salivary cortisol 
levels vanished and cortisol levels did not vary anymore thereafter. Generally, gender and 
etiology did not influence the course of salivary cortisol levels, whereas cortisone acetate 
resulted in less pronounced and less varying salivary cortisol levels compared to 
hydrocortisone. Comparing the dosages of glucocorticoid replacement, increasing morning 
hydrocortisone doses resulted in higher cortisol levels up to 20mg, while two patients taking 
25mg hydrocortisone showed lower levels comparable to 15mg hydrocortisone. Again, 
cortisone produced the lowest levels one hour after medication intake. No effects of the 
second doses on subsequent salivary cortisol levels were found. 
The present findings of salivary cortisol levels clearly point to an over-replacement of 
patients with Addison’s disease. This is in line with prior findings and strengthens the 
skepticisms expressed repeatedly regarding the adequacy of replacement regimes (Howlett, 
1997; Lovas and Husebye, 2003; Peacey et al., 1997), especially because chronic over-
replacement is associated with substantial morbidity, including impaired glucose tolerance, 
obesity, and osteoporosis (al-Shoumer et al., 1995; Florkowski et al., 1994; Zelissen et al., 
1994). 
The results of the present study regarding the effects of type of medication and 
dosage on salivary cortisol levels are in line with previous findings in total plasma cortisol and 
free urinary cortisol. As in plasma cortisol, the salivary cortisol curve of cortisone is blunted 
and delayed compared to that of hydrocortisone (Feek et al., 1981). The missing linear 
association between hydrocortisone doses and resulting salivary cortisol levels supports 
findings showing no beneficial effects of hydrocortisone doses greater than 20mg a day. For 
example, Wichers et al. did not find decreases in well-being in patients taking 15 or 20mg 
hydrocortisone per day, but long-term negative effects of higher replacement doses on bone 
metabolism (Wichers et al., 1999). 
Furthermore, higher hydrocortisone doses just resulted in steeper decreases of 
salivary cortisol levels, while already three hours after medication intake no substantial 
differences in salivary cortisol levels between the various doses can be observed. 
Additionally, comparison of salivary cortisol levels at the second day of investigation with 
normal values shows that on average 7 hours after the first replacement dose, levels of 
patients with Addison’s disease fall below levels of healthy subjects. This is in line with data 
on pharmacokinetics and pharmacodynamics of cortisol: Since plasma half-life of cortisol is 
less than 2 hours, even peak total cortisol levels of 1000nmol/l will result in non-detectable 
levels after approximately eight hours (Howlett, 1997). These results support a change in 
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replacement regimes to smaller doses taken more frequently, which is a conclusion also 
drawn from several other studies. For example, both Howlett and Peacey et al. suggested 
from 24-hour urinary free cortisol and serum cortisol measures that optimal replacement is 
achieved with thrice daily regimes with 10mg/5mg/5mg (rising/lunch/evening; Howlett, 1997; 
Peacey et al., 1997). 
Comparison of salivary cortisol courses between hydrocortisone and cortisone 
suggests that the latter might be preferable due to the less pronounced fluctuations in 
salivary cortisol. However, only six patients took cortisone, therefore these results have to be 
interpreted with caution. Since cortisone has to be activated to form cortisol by 11-HSD1 
and thus variable action of this enzyme could result in variable und unpredictable cortisol 
effects, some authors oppose the use of cortisone. On the other hand, no evidence exists 
that this is a clinical problem, other than in rare cases of 11-HSD1 deficiency (Lovas and 
Husebye, 2003). 
Taken together, the present results clearly circumstantiate the findings by others of 
patients with Addison’s disease to be over-treated. They endorse recommendations of 
replacement regimens which allow for lower but more frequent doses (Howlett, 1997; Peacey 
et al., 1997) or alternatively, a combination of one higher dose of glucocorticoid replacement 
in the morning combined with sustained-release tablets (Lovas and Husebye, 2003). In each 
case, resulting cortisol levels should be under close surveillance to avoid over- and under-
treatment, both being associated with serious health risks. In this regard, the measurement 
of salivary cortisol has been proven to be a useful method to assess the adequacy of 
glucocorticoid replacement therapy. The method is reliable, non-invasive, convenient for the 
patients, inexpensive, without limitations to the number of samples to be collected, and (with 
the exception of prednisolone) cross-reactivities in commercially available assays are under 
2%. It is thus most suitable for a tight treatment surveillance and accomplishes the 
prerequisites for individually adjusted glucocorticoid therapy. 
From a methodological point of view, the present results regarding the over-treatment 
of patients clearly question the comparability of the basal hormonal situation in patients with 
Addison’s disease and healthy persons. As basal glucocorticoid levels exert permissive 
functions in stress responses (Sapolsky et al., 2000), distinctive features in patients with 
Addison’s disease may not be ascribable solely to the missing cortisol stress response but 
rather to glucocorticoid (over-)treatment, which results in non-physiological high ‘basal’ 
glucocorticoid levels and evokes compensatory mechanisms in other bodily systems. 
The straightest implication of the present results for further investigations concerns 
the study design. For studying stress effects in patients with Addison’s disease in 
comparison to healthy controls, patients should avoid ingestion of glucocorticoid replacement 
several hours prior to study. Otherwise patients will show already at baseline cortisol levels 
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far higher than those healthy subjects will show in response to a laboratory stressor. Again, 
this will hamper a comparison of patients and healthy subjects as well as the interpretation of 
results. Futhermore, variations in free cortisol levels between patients also render it 
impossible to utilize a defined dose of hydrocortisone for mimicking cortisol stress responses 
of healthy subjects. 
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4.2 ADDISON’S DISEASE: ENDOCRINOLOGICAL RESPONSE TO   
     PSYCHOSOCIAL STRESS 
Endocrine and Cardiovascular Stress Responses in Addison’s Disease 
4.2.1 Abstract 
Background: Many findings in psychoneuroendocrinology (PNE) and 
psychoneuroimmunology (PNI) raise the question, which consequences for health are to be 
expected if endocrine stress responses in humans are altered permanently and 
independently of context. We see investigation of patients with Addison’s disease as a 
valuable approach in this regard. Since so far no experimental data on endocrine and 
cardiovascular stress response patterns in these patients exist, the present study aims at 
establishing these patterns and additionally, at testing an i.v. injection of 0.03mg/kg 
hydrocortisone (HC) in patients for its appropriateness at mimicking normal free cortisol 
stress responses. 
Methods: 31 patients and 18 healthy subjects were exposed to the “Trier Social 
Stress Test” (TSST). Saliva and blood samples were collected before and repeatedly 
afterwards for determination of salivary cortisol, plasma epinephrine, and plasma 
norepinephrine levels. At the same time-points, blood pressure and heart rate were 
measured. 16 patients were treated with HC after TSST. 
Results: Patients with Addison’s disease did not show stress responses in cortisol 
and epinephrine, while norepinephrine levels did increase in response to TSST. HC injection 
in patients resulted in salivary free cortisol levels comparable to those of healthy subjects. No 
differences between patients and healthy subjects as well as no HC effects were found in 
blood pressure and heart rate stress responses.  
Conclusions: The present data for the first time show experimentally the expected 
dysregulated endocrine stress response patterns in patients with Addison’s disease. These 
findings provide a basis for investigating the effects of permanent and context independent 
alterations of stress response patterns on other bodily systems, such as the immune system. 
This knowledge may further provide valuable insights to what extend an organisms is able to 
compensate dysregulations in these systems. 
4.2.2 Introduction 
4.2.2.1 Stress Response in Healthy Subjects 
Numerous studies have shown that psychosocial stress is associated with an 
increased activity of the hypothalamus-pituitary-adrenal (HPA) axis as well as the 
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sympathetic-adrenal-medullary (SAM) axis (for review see Biondi and Picardi, 1999; Mason, 
1968). Basically, changes in hormone secretory patterns in response to a stressor can be 
divided into two consecutive but distinct responses, the so called first wave and the second 
wave. In the first wave, occurring within seconds after the onset of a stressor, among others 
an enhanced secretion of catecholamines (epinephrine and norepinephrine) from the 
sympathetic nervous system, the hypothalamic release of corticotropin-releasing hormone 
(CRH) and (approximately 10 seconds later) enhanced secretion of pituitary 
adrenocorticotropic hormone (ACTH) can be observed. Minutes later, the second wave 
involves the stimulation of glucocorticoid release (Sapolsky et al., 2000). 
Stress-induced increases in the secretion of glucocorticoids and catecholamines have 
been shown to be associated with a broad range of effects on various bodily systems, 
including metabolic, cardiovascular, immunological, and cognitive effects (for review see 
(Sapolsky et al., 2000). For catecholamines, Cannon coined the term “fight-or-flight 
response” to describe the tasks performed by catecholamines secreted in response to a 
challenge (Cannon, 1935). This term summarizes the major effects of catecholamines, 
namely the rapid activation of the cardiovascular system and the rapid mobilization of 
glucose. Both effects are important in terms of preparing and enabling the organism to fight 
or to flight. Activation of the cardiovascular system involves elevated arterial pressure, heart 
rate, and cardiac output, diversion of blood to muscle via constriction of mesenteric and renal 
vessels and dilation of vessels supplying skeletal muscle (Galosy et al., 1981). Blood glucose 
levels are elevated rapidly by mobilization from existing stores and by inhibition of further 
storage through a rapid insulin resistance. This makes sure that energy is diverted from 
storage sites to the exercising muscle. Additionally, catecholamines have been found to 
markedly enhance memory for emotionally laden details (Cahill et al., 1994), an effect again 
making sense biologically and evolutionarily. Regarding the immune system, catecholamines 
have a wide array of effects. For example, they increase the number of circulating natural 
killer (NK)-cells and granulocytes, i.e., immune cells of innate immunity, and thus help 
reducing the risk for infections in cases of tissue damage (Benschop et al., 1996). 
These stress-induced rapid events are followed by increases in glucocorticoids. 
Consequently, important effects of stress-induced increased glucocorticoid levels include the 
prolongation of catecholamine effects. For example, since glucocorticoids are known to also 
increase blood pressure and cardiac output (Sambhi et al., 1965), they prolong the 
cardiovascular effects prior initiated by catecholamines. This is also the case in energy 
metabolism, where glucocorticoids synergize with catecholamines and glucagon to stimulate 
lipolysis and to elevate circulating glucose concentrations by stimulating glycogenolysis and 
gluconeogenesis. Furthermore, stress-induced glucocortiocoids inhibit peripheral glucose 
utilization and stimulate liver glycogen deposition. Since this restoring of glycogen levels 
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takes hours, glucocorticoids also help preparing the organism for subsequent stressors 
(Sapolsky et al., 2000). The mostly suppressive effects of glucocorticoids on the immune 
system are thought of as restraining defense reactions to stress, which would themselves 
become damaging if left uncontrolled (Besedovsky and del Rey, 1996). In other words, 
glucocorticoids “sculpt” the immune response by inhibiting superfluous or autoimmune-prone 
components (Besedovsky et al., 1991). 
In summary, all of the described actions of stress mediators suggest that an 
endocrine stress response is basically protective, adaptive, and improving chance of the 
individual for survival. On the other hand, given such a complex interplay, it is also 
conceivable to anticipate serious health consequences if stress systems show malfunctions. 
In fact, HPA axis dysfunctions have been associated repeatedly with various 
pathophysiologic states, including psychiatric, endocrine, and inflammatory disorders and/or 
susceptibility to such disorders (for review see Chrousos, 1998a). 
However, one question remains to be answered: What happens in this complex 
network of interactions if parts of the endocrine stress response are missing permanently and 
independently of context? Does the organism compensate for the missing response or is a 
regular endocrine stress response mandatory for health? 
4.2.2.2 Stress Response in Patients with Addison’s Disease 
To answer such questions, mostly adrenalectomized animals were investigated (e.g., 
Jacobson and Sapolsky, 1993; Keller et al., 1983; Rocha, 1985) or receptor blockers were 
administered (e.g., Hermann et al., 1995; Sheridan et al., 1998) in the past. However, both 
approaches hold their specific problems. Approaches like adrenalectomy are only realizable 
in animals, hence transfer of results to humans is limited. On the other hand, in 
pharmacological approaches the treatment is mostly temporary, limited to one hormone, and 
often also affects basal hormone concentrations. Thus, again only limited conclusions 
concerning the effects of a permanently missing endocrine stress response can be drawn. 
We see investigation of patients with Addison’s disease as a valuable alternative 
approach in this regard. To the best of our knowledge no data are available to date which 
describe the endocrine stress responses in these patients. Therefore, the present work aims 
at investigating the endocrine stress responses in these patients, laying the groundwork for 
further studies. 
Generally, Addison’s disease is a primary adrenal insufficiency caused by destroyed 
adrenal cortical cells (for review see Arlt and Allolio, 2003; Betterle et al., 2002; Oelkers, 
1996; Ten et al., 2001). Due to these destroyed steroid producing cells, patients with 
Addison’s disease are no longer able to produce glucocorticoids and mineralocorticoids. 
Consequently, the treatment of these patients accounts for the two mainly missing hormones 
cortisol and aldosterone. However, glucocorticoid replacement therapy only aims at restoring 
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basal cortisol levels and mimicking its circadian rhythm. But theoretically, patients with 
Addison’s disease also can not show a regular cortisol stress response. This is in parallel 
with findings in animal studies, where after adrenalectomy (ADX) whether stress nor ACTH 
induce any changes in corticosterone levels (Desser-Wiest, 1976). Nevertheless, to date it is 
unclear if patients with Addison’s disease show the same response pattern found in ADX 
animals. 
Furthermore, endogenous and locally acting cortisol is critical in the last step of the 
catecholamine biosynthesis, since it has been shown to induce the enzyme 
phenylethanolamine-N-methyl-transferase (PNMT), which converts norepinephrine to 
epinephrine (Bornstein et al., 1995). Without cortisol, norepinephrine will not be converted to 
epinephrine and in contrast to norepinephrine, the adrenal medulla is the sole source of 
circulating epinephrine in all mammalian species, including humans. However, 
norepinephrine released from the adrenal medulla usually makes up to only 35% of the 
levels measured in the bloodstream. The remaining 65% are a small proportion of 
norepinephrine released locally from sympathetic nerve terminals and reaching the 
bloodstream (Goldstein, 2000; Kvetnansky and McCarty, 2000; Pollard, 2000). Hence, in 
Addison’s disease low epinephrine levels accompanied by elevated norepinephrine levels 
have been reported (Bornstein et al., 1995). Therefore, also a low to non-existing 
epinephrine stress response has to be expected in these patients accompanied by – albeit 
generally elevated norepinephrine levels – a regular norepinephrine stress response 
compared to healthy controls. 
Based on the findings outlined above of stress-induced cortisol and catecholamines 
affecting cardiovascular parameters, we were further interested in the effect of the suspected 
altered endocrine stress pattern in patients with Addison’s disease on stress responses in 
blood pressure and heart rate. Postural hypotension is a typically clinical sign in developing 
Addison’s disease (Ten et al., 2001) and of mineralocorticoid under-treatment, since 
mineralocorticoid deficiency leads to dehydration and hypovolaemia, resulting in low blood 
pressure, postural hypotension, and sometimes even in prerenal failure (Arlt and Allolio, 
2003). On the other hand, hypertension, bradycardia, and suppressed renin levels are 
clinical signs of over-treatment with mineralocorticoids (Ten et al., 2001). Nevertheless, 
combined mineralocortioid and glucocorticoid replacement in Addison’s disease has been 
shown to reconstitute the diurnal rhythm of blood pressure (Fallo et al., 1994) and to reverse 
cardiac dysfunction (Fallo et al., 1999). Glucocorticoids contribute to this improvement not 
only by mineralocorticoid receptor binding, but also by permissive effects on catecholamine 
action (Allolio et al., 1994). Therefore, given an adequate glucocorticoid and 
mineralocorticoid replacement therapy, at least no baseline differences before stress in 
patients with Addison’s disease are to be expected. 
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Beside Addison’s disease being a potentially valuable methodological approach, 
endocrine and cardiovascular stress responses in Addison’s disease also are interesting 
from a patients’ point-of-view. Many patients with Addison’s disease on standard 
replacement therapy have persistent complaints of fatigue, wariness, and reduced stress 
tolerance, which in many cases reduce their ability to maintain work (Lovas et al., 2002). We 
were therefore also interested in confirming these findings in regard to fatigue. Primarily, 
these findings may concern mostly the adequacy of replacement therapy, which itself was 
repeatedly questioned (Howlett, 1997; Lovas and Husebye, 2003; Peacey et al., 1997). 
Nevertheless, it is conceivable to hypothesize these complains being at least partly caused 
by dysfunctional endocrine stress responses. 
4.2.2.3 Aim of the Study 
The aim of the present study was to establish endocrine and cardiovascular stress 
response patterns in patients with Addison’s disease. Furthermore, we were interested 
whether an i.v. 0.03mg/kg hydrocortisone in patients with Addison’s disease adequately 
mimics a salivary cortisol stress response usually seen in healthy subjects. This dose was 
chosen based on a pilot study in healthy subjects with various doses of hydrocortisone 
injected in the late afternoon, a time of day characterized by low salivary free cortisol levels. 
Additionally, cardiovascular variables were tested for treatment effects. For catecholamines, 
no effect of treatment was expected, since for conversion of norepinephrine to epinephrine 
cortisol is needed in high concentrations locally in the adrenal medulla (chromaffin cells, 
Bornstein et al., 1995). 
4.2.3 Methods 
4.2.3.1 Subjects 
A total of 36 patients with Addison’s disease (AD) and 21 healthy subjects (HS) were 
investigated. Patients were further subdivided into two age- and gender-matched groups. 
Due to missing endocrine data, the final sample consisted of 31 patients and 18 healthy 
subjects. Of the two patient groups, one group was treated with 0.03mg/kg hydrocortisone 
(HC) i.v. (Sigma, Berlin) after a psychosocial stress test (AD-HC: n=16), while the second 
group as well as all healthy subjects received an injection of 4ml saline (NaCl; AD-NaCl: 
n=15; HS-NaCl: n=18). The AD-HC group consisted of 11 females and five males, the AD-
NaCl group of 12 females and three males, and the HS-NaCl group of 11 females and seven 
males (2=1.38, p=.50). Mean age of all subjects was 44.59 years (standard deviation (SD): 
8.6). The three groups did not differ in age (F2,48=0.10, p=.91; AD-HC: mean=43.81, SD=8.5; 
AD-NaCl: mean=44.87, SD=7.9; HS-NaCl: mean=45.06, SD=9.8) or body mass index (BMI; 
F2,48=0.77, p=.47; AD-HC: mean=23.89, SD=4.3; AD-NaCl: mean=23.98, SD=2.6; HS-NaCl: 
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mean=25.40, SD=4.6). Based on the existence of autoantibodies (i.e., adrenocortical 
autoantibodies (ACAs), steroid cell antibodies (StCA); see Peterson et al., 2000) or co-
morbidities fulfilling criteria for classification to Autoimmune Polyglandular Syndrom (APS) 
type 1 or type 2 (Neufeld et al., 1981), 21 patients were diagnosed with autoimmune 
Addison’s disease (67.7%). In four patients the cause for Addison’s disease was former 
Cushing’s disease (12.9%) and six patients could not provide sufficiently detailed information 
for differential diagnosis (19.4%). 
4.2.3.2 Experimental Protocol 
Subjects reported to the lab at 1p.m. and were examined for past or current health 
problems by a physician. Patients were asked to postpone their second glucocorticoid 
replacement dose usually taken around 2p.m. (mean=13:49h, SD=1h57min) to avoid 
unpredictable and un-physiologically high salivary free cortisol levels (see section 4.1), 
hampering the comparability of patients and healthy subjects. After catheter insertion, 
attaching the ambulatory blood pressure monitoring system (‘Quiet Track’, Welch Allyn/Tycos 
Instruments, Arden, NC) and a resting period of 45 minutes, a first blood (9ml 
ethylenediamine tetraacetic acid (EDTA)-tubes, Sarstedt, Nümbrecht, Germany) and saliva 
(Salivette, Sarstedt, Nümbrecht, Germany) sample was collected and blood pressure and 
heart rate were measured. Subsequently, subjects were exposed to the psychosocial stress 
test “Trier Social Stress Test” (TSST), which consists of a three minute preparation period, a 
five minute free speech and a five minute mental arithmetic task in front of an audience 
(Kirschbaum et al., 1993). Additional blood and saliva samples were collected as well as 
blood pressure and heart rate were obtained 1, 10, 20, 30, 45, 60, 90, and 120 minutes after 
stress exposure. After time-point +1, HC or saline was injected. This time-point was chosen 
since the stress test has a duration of 13 minutes and the maximum cortisol stress response 
is to be expected 15-20 minutes after stress onset. The study protocol was approved by the 
ethics committee of the University of Düsseldorf, and written informed consent was obtained 
from all subjects. 
4.2.3.3 Fatigue Assessment 
During the resting period, all subjects were ask to self-report their fatigue measured 
by the Multidimensional Fatigue Inventory (MFI; Smets et al., 1995). Beside general fatigue, 
the MFI covers the dimensions physical fatigue, mental fatigue, reduced activity, and 
reduced motivation. 
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4.2.3.4 Biochemical Analyses 
Saliva samples: Free cortisol levels in saliva were measured using a commercially 
available chemiluminescence assay (IBL, Hamburg, Germany). Samples were measured in 
duplicates and averaged for subsequent statistical analyses. 
Blood samples: Plasma was separated at 4°C and stored at -80°C. Plasma 
concentrations of norepinephrine and epinephrine were determined by high-performance 
liquid chromatography with electrochemical detection (Smedes et al., 1982). Epinephrine 
levels under detection limit were labeled 5pg/ml representing half of the lowest standard. 
4.2.3.5 Statistical Analysis 
Data were analyzed using the Statistical Package for the Social Science Version 
11.0.2 (SPSS Institute, Chicago, IL). Student’s t tests were applied for comparing the scores 
of the five MFI-scales and baseline (-1min) endocrine and cardiovascular measures between 
patients and healthy subjects (AD vs. HS). For endocrine and cardiovascular parameters, 
time (i.e. TSST) effects and group differences were calculated by repeated measures 
analysis of variance (ANOVA) with within-group levels representing the nine time-points of 
blood/saliva sampling or blood pressure and heart rate measures. For group or group-by-
time effects, two between-group levels for catecholamines (AD vs. HS) and three between-
group levels for cortisol levels and cardiovascular measures (AD-HC, AD-NaCl, and HS-
NaCl) were included. All data were tested for normality prior to statistical analysis using the 
Kolmogorov-Smirnov test and Greenhouse-Geisser corrections for repeated measures were 
calculated where appropriate. To test for effects of treatment, univariate ANOVAs were 
calculated with salivary free cortisol levels at time-point +10 (cort+10) as well as with 
increases in salivary free cortisol levels from time-point -1 to +10 (incr_cort1>3; calculated by 
subtracting salivary free cortisol levels at time-point -1 from levels at +10) as dependent and 
the three groups as independent variables. In cases of significant group effects, additionally 
Scheffé post-hoc tests were computed to specify treatment effects. Values of p<0.05 were 
considered significant. 
4.2.4 Results 
4.2.4.1 Fatigue Assessment 
Student’s t tests revealed significant group differences for the two MFI scales general 
fatigue and physical fatigue (general fatigue: t45=3.23, p=.002; physical fatigue: t45=2.56, 
p=.014, mental fatigue: t45=0.65, p=.52; reduced activity: t45=.43, p=.67, reduced motivation: 
t45=-0.38, p=.70). In both cases, patients showed higher fatigue scores than healthy subjects 
(see figure 4-4). 
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Fig. 4-4: General and physical fatigue (means and standard errors (SE)) in patients with Addison’s disease (AD, 
n=30) and healthy subjects (HS, n=17), measured by the Multidimensional Fatigue Inventory. 
4.2.4.2 Baseline Differences 
At baseline, only salivary free cortisol levels and epinephrine levels differed 
significantly between patients and healthy subjects (cortisol: t47=-3.67, p=.001; 
norepinephrine: t47=1.42, p=.16; epinephrine: t47=-4.81, p<.001; systolic blood pressure: 
t44=0.39, p=.70; diastolic blood pressure: t44=0.07, p=.95, heart rate: t44=0.92, p=.36). 
4.2.4.3 Salivary Free Cortisol Stress Response 
Repeated measures ANOVA with salivary free cortisol levels as within-group levels 
revealed significant group, time, and group-by-time effects (group: F2,46=22.65, p<.001; time: 
F8,368=48.06, p<.001; group-by-time: F16,368=13.98, p<.001). Subsequent Scheffé post-hoc 
tests showed all three groups to differ significantly from each other (HC-AD vs. NaCl-AD: 
meandiff=4.81, SD=1.6, p=.014, HC-AD vs. HS-NaCl: meandiff=-5.47, SD=1.5, p=.003, AD-
NaCl vs. HS-NaCl: meandiff=-10.28, SD=1.5, p<.001). 
  
Fig. 4-5: Effects of TSST, group (AD vs. HS) and treatment (HC vs. NaCl) on salivary free cortisol levels (mean, 
SE). 
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4.2.4.4 Effects of Treatment on Salivary Free Cortisol Levels 
In both, salivary free cortisol levels at time-point +10 as well as increases in salivary 
free cortisol levels from time-point -1 to +10, the AD-NaCl group did differ significantly from 
the two other groups. Hydrocortisone injection resulted in non-significant group differences 
between healthy subjects and patients (cort+10: F2,46=33.50, p<.001 – Scheffé: AD-HC vs. 
AD-NaCl: meandiff=15.34, SD=2.5, p<.001; AD-HC vs. HS-NaCl: meandiff=-3.40, SD=2.4, 
p=.36; AD-NaCl vs. HS-NaCl: meandiff=-18.74, SD=2.4, p<.001; incr_cort1>3: F2,46=30.90, 
p<.001 – Scheffé: AD-HC vs. AD-NaCl: meandiff=17.98, SD=2.5, p<.001; AD-HC vs. HS-
NaCl: meandiff=2.63, SD=2.4, p=.54; AD-NaCl vs. HS-NaCl: meandiff=-17.35, SD=2.4, 
p<.001). 
 
Fig. 4-6: Group differences in salivary free cortisol levels at time-point +10 (cort+10; left side; mean, SE) and in 
increases from time-point -1 to +10 (incr_cort1>3; right side; mean, SE). 
4.2.4.5 Catecholamine Stress Response 
As outlined above, no treatment effects in catecholamine stress responses in patients 
are to be expected for physiological reasons (Bornstein et al., 1995). Regarding 
catecholamines, repeated measures ANOVAs were therefore computed with two between-
group levels representing patients with Addison’s disease (n=31) and healthy subjects 
(n=18). 
Despite higher norepinephrine levels in patients throughout the investigation, no 
significant group or group-by-time effects were found (group: F1,47=2.43, p=.13; group-by-
time: F8,376=1.00, p=.42). Nevertheless, TSST caused increases in norepinephrine levels 
indicated by a significant time effect (time: F8,376=12.36, p<.001). 
For epinephrine, significant group, TSST, and group-by-time effects were found 
(group: F1,47=33.59, p<.001; time: F8,376=10.74, p<.001; group-by-time: F8,376=6.87, p=.002). 
Figure 4-7 depicts norepinephrine and epinephrine levels before and after TSST. 
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Fig. 4-7: Effects of TSST and group (AD vs. HS) on plasma norepinephrine (top) and epinephrine (bottom) levels 
(mean, SE). 
4.2.4.6 Cardiovascular Stress Response 
For blood pressure and heart rate, only significant time effects but no group or group-
by-time effect were found (systolic blood pressure – group: F2,36=0.82, p=.45; time: 
F8,288=5.93, p<.001; group-by-time: F16,288=0.98, p=.47; diasystolic blood pressure – group: 
F2,36=0.14, p=.87; time: F8,288=2.35, p=.036; group-by-time: F16,288=0.62, p=.81; heart rate – 
group: F2,36=1.13, p=.34; time: F8,288=4.97, p<.001; group-by-time: F16,288=0.76, p=.67). Figure 
4-8 depicts the course of systolic and diastolic blood pressure and figure 4-9 the course of 
heart rate over the period of investigation. 
 
Fig. 4-8: Effects of TSST, group (AD vs. HS) and treatment (HC vs. NaCl) on systolic (top) and diastolic (bottom) 
blood pressure (mean, SE). 
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Fig. 4-9: Effects of TSST, group (AD vs. HS) and treatment (HC vs. NaCl) on heart rate (mean, SE). 
4.2.5 Discussion 
In summary, patients with Addison’s disease showed significantly more general and 
physical fatigue compared to healthy subjects. Regarding endocrine and cardiovascular 
parameters, no baseline differences were found in norepinephrine, blood pressure or heart 
rate, but significantly lower salivary free cortisol and epinephrine levels in patients with 
Addison’s disease. The TSST induced significant increases in salivary free cortisol levels in 
healthy subjects, while patients did not show any response. The injection of 0.03mg/kg 
hydrocortisone in patients with Addison’s disease resulted in salivary cortisol increases and 
maximum levels comparable to those found in healthy subjects. No significant differences 
were found in norepinephrine stress responses, despite generally higher norepinephrine 
levels in patients. In epinephrine, healthy subjects showed a typical stress response pattern, 
while patients showed very low levels throughout the investigation period and no stress 
response. Furthermore, no distinctive features were found in blood pressure and heart rate 
responses to the TSST. 
The present findings of elevated general and physical fatigue scores in patients with 
Addison’s disease are in line with former findings (Lovas et al., 2002) and with subjective 
self-reports of patients. Interestingly, contrary to subjective self-reports no differences in 
mental fatigue, activity and motivation were found in patients compared to healthy subjects. 
This may be explained in part by patients’ efforts to master their life despite their disease and 
by a tendency to rather admit physical or unspecific problems than mental or intentional 
problems. 
Regarding salivary free cortisol levels, patients with Addison’s disease showed the 
expected missing stress response. These findings confirm data from studies investigating the 
effects of adrenalectomy on corticosteroid stress response (Desser-Wiest, 1976). Treatment 
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of patients with 0.03mg/kg hydrocortisone resulted in stress-induced cortisol increases and 
maximum salivary cortisol levels mimicking those of healthy subjects. However, patients 
clearly showed a more pronounced decrease in salivary cortisol levels thereafter. Contrary to 
one-time hydrocortisone treatment in patients with Addison’s disease, in healthy subjects, 
HPA-reactivity is adjusted to stress duration and may show several episodes of secretion. 
This demonstrates that treatment of patients with hydrocortisone at one time-point is only to 
a certain extent able to mimic context-dependent HPA-reactivity controlled by negative 
feedback circuit. 
The findings of very low epinephrine levels accompanied by a trend to elevated 
norepinephrine levels are also in line with prior findings and emphasize the role of 
glucocorticoids in normal functioning of chromaffin cells and their capacity at the 
transcriptional level to express PNMT, the enzyme that converts norepinephrine to 
epinephrine (Wong et al., 1995). Our data regarding basal catecholamine levels confirm 
other findings in patients with Addison’s disease (Bornstein et al., 1995), in experimental 
animals with reduced glucocorticoid synthesis (Wurtman, 1966), and after adrenalectomy 
(Eisenhofer et al., 1995; Merke et al., 2000). One study additionally included stress 
stimulation in patients with isolated glucocorticoid deficiency due to unresponsiveness to 
adrenocortiocotropin hormone (ACTH; Zuckerman-Levin et al., 2001). The authors found a 
minimal stress response in epinephrine and slightly increased norepinephrine responses 
compared to healthy subjects. Again, this is in line with the present findings. Plasma 
norepinephrine derives to a high proportion from nerve terminals of the sympathetic nervous 
system and to a lower extend from the adrenal medulla (Goldstein, 2000; Kvetnansky and 
McCarty, 2000; Pollard, 2000). This raises the question where the slightly increased 
norepinephrine levels come from. Based on the data outlined above and on findings of 
decreased norepinephrine in 21-hydroxylase deficient mice (Bornstein et al., 1999), it was 
repeatedly suggested to be more likely an intra-adrenal effect. However, to which extent 
elevated norepinephrine levels may compensate almost missing epinephrine levels is 
unknown. 
As expected, the present study further found no significant differences in resting 
blood pressure or heart rate in patients with Addison’s disease compared to healthy subjects. 
This suggests glucocorticoid and mineralocorticoid replacement therapy to restore cardiac 
functions as demonstrated by Fallo et al. (Fallo et al., 1999; Fallo et al., 1994). Furthermore, 
no differences in stress responses in these parameters as well as no effects of 
hydrocortisone treatment were found. Therefore, it may be speculated that increased 
norepinephrine levels are at least partly able to compensate for missing epinephrine and 
cortisol responses in patients with Addison’s disease. Also permissive actions of cortisol (i.e., 
basal cortisol levels induced by replacement therapy) on catecholamine stress effects may 
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explain these findings to a certain extend (Allolio et al., 1994). The missing effects of 
hydrocortisone treatment in patients may be attributable to dosage and/or frequency being 
too low to exert effects or by effects appearing later than two hours after treatment. Studies 
investigating the role of cortisol in hypertension usually treat subjects with higher doses for 
longer periods of time (e.g., 6-8mg/day intravenously or 50mg every 6h orally over a 5 day 
administration period; (Whitworth et al., 1995) and observe increases in systolic pressure of 
the order of 15mmHg (Kelly et al., 1998). 
Taken together, the present data in patients with Addison’s disease show for the first 
time the dysregulated endocrine stress response pattern expected from literature. No effects 
of missing cortisol and epinephrine stress responses on blood pressure and heart rate were 
found, hinting to mechanisms able to compensate dysregulated endocrine stress responses. 
Treatment of patients with 0.03mg/kg hydrocortisone i.v. proved to adequately mimic 
acute free cortisol stress responses found in healthy subjects. In further investigations, such 
treatment may prove helpful at attributing observed effects to a specific stress mediator. It 
cannot be concluded from these data that patients should be treated with additional doses of 
hydrocortisone during stress. First of all, hydrocortisone was injected in this study and the 
respective dose of orally taken hydrocortisone is unknown and untested. Furthermore, there 
is increasing evidence that patients tend to be over-treated (Howlett, 1997; Lovas and 
Husebye, 2003; Peacey et al., 1997). Chronic over-treatment in turn was repeatedly 
associated with increased risks of impaired glucose tolerance, obesity, and osteoporosis (al-
Shoumer et al., 1995; Florkowski et al., 1994; Zelissen et al., 1994). Increasing the daily 
dose of glucocorticoid replacement might further heighten the risk for such morbidities. 
However, these findings provide a basis for investigating the effects of permanently 
and context independently altered stress response patterns on other bodily systems, such as 
the immune system, in future studies. Studying such effects in patients with Addison’s 
disease may provide valuable insights in the interplay of endocrine stress systems in human 
whole organism and the extend to which an organisms is able to compensate dysregulations 
in these systems. This knowledge may help to further evaluate findings in 
psychoneuroendocrinology and psychoneuroimmunology of altered stress response patterns 
being associated with immunological diseases or psychiatric disorders. 
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4.3 ADDISON’S DISEASE: PSYCHOSOCIAL STRESS AND IMMUNOLOGICAL 
     CONSEQUENCES 
Stress and Addison’s Disease: 
Implications of Dysregulated Stress Systems for Health and Disease in Humans 
4.3.1 Abstract 
Background: Dysfunctions in endocrine stress responses were repeatedly implicated 
with immunological diseases. Studies investigating such interactions between stress and 
immunological diseases usually only reveal associations. To decide on direction and possible 
mechanisms, findings from approaches like adrenalectomy, receptor-(ant)agonists treatment, 
or in vitro studies have to be consulted. Such approaches hold their own restrictions 
regarding the transfer of results to situations in the human whole organism. As an alternative 
approach, we investigated patients with Addison’s disease to gain new insights in the effects 
of permanently and context independently missing cortisol and epinephrine stress 
responses. 
Methods: 31 patients with Addison’s disease and 16 healthy subjects were 
investigated. All subjects were exposed to the psychosocial stress paradigm “Trier Social 
Stress Test” (TSST). Percentages of leukocyte subtypes in peripheral blood, LPS-stimulated 
IL-6 production, PHA-stimulated cell proliferation, as well as the respective glucocorticoid 
sensitivities were measured before and repeatedly after stress (10, 60, and 120 minutes after 
TSST). 16 age- and gender-matched patients were treated with an injection of 0.03mg/kg 
hydrocortisone i.v. after stress, while all other subjects received placebo injection (saline). 
Results: In healthy subjects, stress resulted in significant changes in blood cell 
counts and LPS-stimulated IL-6 production. No baseline differences in immune parameters 
were found between patients with Addison’s disease and healthy subjects. Stress in patients 
with Addison’s disease resulted in courses of blood cell counts and LPS-stimulated IL-6 
productions significantly different from healthy subjects. Treatment with hydrocortisone only 
influenced the course of LPS-stimulated IL-6 production. No influence of disease or 
hydrocortisone treatment were found in cell proliferation parameters. 
Conclusions: Investigation of patients with Addison’s disease proved to be a 
valuable alternative approach for PNI research. The present findings confirm glucocorticoids 
to play an important role in leukocyte migration and stimulated cytokine production, while T-
cell proliferation appeared to be glucocorticoid-independent. The distinctive features in blood 
cell counts and LPS-stimulated IL-6 production point to patients with Addison’s disease being 
at an increased risk for infectious as well as autoimmune diseases. 
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4.3.2 Introduction 
The field of psychoneuroimmunology (PNI) addresses the way in which nervous 
system and immune system interact with each other, and how these interactions influence 
the state of health of an individual. In their editorial to volume I of the “Neuroimmune Biology 
Book Series”, Berczi and Szentivanyi pointed out that there is even much more to this 
interaction than ‘bi-directional’. It is as a “truly multi-directional, all-inclusive systemic 
regulatory network formed by the nervous-, endocrine- and immune systems, which controls 
all bodily functions of higher animals and man” (Berczi and Szentivanyi, 2001). Within the 
field of PNI, one area has attracted considerable attention: The effects of stress on the 
immune system and hence on health and disease. To date, it is well-known that psychosocial 
stress is associated with an increased activity of the hypothalamus-pituitary-adrenal (HPA) 
axis as well as the sympathetic-adrenal-medullary (SAM) axis (for review see Biondi and 
Picardi, 1999; Mason, 1968). The major end products of these two axes are the hormones 
cortisol (HPA axis) and epinephrine and norepinephrine (SAM axis). Stress-induced 
increased release of these mediators was in turn repeatedly demonstrated to have a wide 
range of effects on the immune system. In cases of acute stress, these effects are thought of 
as primarily protective. For example, the fast release of catecholamines (epinephrine and 
norepinephrine), occurring within seconds after onset of a stressor, increases the number of 
circulating natural killer (NK)-cells and granulocytes, i.e., cells of innate immunity, and thus 
helps reducing the risk for infections in cases of tissue damage (Benschop et al., 1996). 
These stress-induced rapid events are followed by increases in glucocorticoids. The mostly 
suppressive effects of glucocorticoids on the immune system are thought of as restraining 
defense reactions to stress, which would themselves become damaging if left uncontrolled 
(Besedovsky and del Rey, 1996). On the other hand, given the complex interplay of 
hormones and immune system, it is also conceivable to anticipate serious health 
consequences if stress systems show malfunctions. In fact, HPA axis dysfunctions have 
been associated repeatedly with various pathophysiologic states, including psychiatric, 
endocrine, and inflammatory disorders and/or susceptibility to such disorders (for review see 
(Chrousos, 1998a). Thus, contrary to an endocrinological response to acute stress, chronic 
stress may result in HPA and SAM axes dysfunctions (e.g., missing cortisol stress 
responses), which in turn are associated with negative health outcomes. 
Such conclusion are usually drawn by combining research results originating from 
different backgrounds. For example, Sapolsky, Romero, and Munck (Sapolsky et al., 2000) 
applied three criteria to analyze the role of glucocorticoids and catecholamines in stress 
response: the criterion of time course (When does an effect occur?), the criteria of hormone 
subtraction and replacement (What happens if a glucocorticoid and/or catecholamine stress 
response is eliminated? Does administration of stress or/and basal levels of the respective 
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hormone restore the stress response?), and the criterion of homeostasis (Which action, i.e., 
permissive, suppressive, stimulating, or preparative action, makes more physiological sense 
in terms of restoring homeostasis?). 
However, independent of applied criteria, combining research results from different 
backgrounds raises three intertwined questions: (1)To what extend can results from animal 
research be combined with results from human research? (2) To what extend can effects of 
hormones per se be combined with effects of hormones secreted due to stress? (3) To what 
extend can results from in vitro approaches be combined with results from studies in whole 
organisms? 
These questions are especially prominent in human research. For example, if 
interests are of clinical nature, patients with immunological diseases may be investigated and 
their endocrine and immunological stress responses compared with responses of healthy 
subjects. Without a longitudinal design, no causal associations can be revealed in such 
cases: Stress may exacerbate already existing immune dysfunctions or immune dysfunctions 
may influence endocrine stress responses. To hypothesize on direction, underlying 
mechanisms, and relevance of association for health and disease, findings from approaches 
like adrenalectomy, usage of receptor-(ant)agonists, or in vitro studies have to be consulted 
(see figure 4-10). By doing that, conclusions are drawn based on findings all limited in terms 
of transferability to the human whole organism situation. 
 
Fig. 4-10: Decisions on direction, underlying mechanisms and relevance of associations between stress response 
and health in humans can be reached based on results originating from other approaches like adrenalectomy, use 
of receptor-antagonists or -agonists, and in vitro studies. 
4.3.2.1 Aim of the Study 
Nevertheless, to define the role or stress hormones for normal functioning of the 
immune system, two important criteria are hormone subtraction and hormone replacement 
(Sapolsky et al., 2000). Therefore and since our focus is on human research, we aimed at 
finding a model for studying these criteria in human whole organism, thereby overcoming the 
shortcomings of alternative approaches like adrenalectomy, use of receptor-(ant)agonists, 
and in vitro studies. Such an approach would then allow for answering important questions in 
PNI research: What happens in the human whole organism, if parts of the endocrine stress 
response are missing permanently and independently of context? Are regular endocrine 
stress responses in fact mandatory for health? Or does the organism compensate for these 
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missing parts? And if compensatory mechanisms exists, to what extend are they able to 
compensate for dysregulations in endocrine stress responses? Answering such questions is 
also of great clinical interest, since it may help to decide on the clinical relevance of 
distinctive features in endocrine stress responses found in patients with immunological 
diseases. 
We see investigation of patients suffering from Addison’s disease as such an 
alternative approach providing valuable new evidences for human PNI research. Patients 
with Addison’s disease do not produce any cortisol due to destroyed adrenals and therefore 
receive glucocorticoid replacement (for review see Arlt and Allolio, 2003; Betterle et al., 2002; 
Oelkers, 1996; Ten et al., 2001). This therapy only provides basal cortisol supply, while no 
provisions are made for additional doses during stress. Despite the apparent advantages 
compared with the above mentioned approaches, to the best of our knowledge no data on 
endocrine stress responses in these patients were available so far. We therefore first 
investigated such responses in patients with Addison’s disease, thereby laying the 
groundwork necessary for answering the questions outlined above (see section 4.2). Our 
studies revealed missing cortisol and epinephrine stress responses and normal to slightly 
elevated norepinephrine levels in these patients. Furthermore, we showed an i.v. injection of 
0.03mg/kg hydrocortisone after a psychosocial stress test of 13 minutes duration to 
accurately mimic the acute stress response in salivary free cortisol levels seen in healthy 
subjects. 
Based on these endocrinological findings, we investigated in the present study the 
effects of missing cortisol and epinephrine stress responses on the immune system in 
patients with Addison’s disease. In this regard we repeatedly measured percentages of 
immune cell subsets, lipopolysaccharide (LPS)-stimulated IL-6 production and 
phytohemagglutinin (PHA)-stimulated cell proliferation, as well as the respective 
glucocorticoid sensitivity in response to a psychosocial stress test in patients with Addison’s 
disease and healthy subjects. Proportion of immune cells in circulation were chosen as an 
estimation of immune system activation, as decreased numbers of cells in peripheral blood 
can point to immune activation due to trafficking of these cells to inflammatory sites 
(Dhabhar, 2000). LPS-stimulated IL-6 production in whole blood (De Groote et al., 1992) and 
PHA-stimulated cell proliferation in peripheral blood mononuclear cells (PBMCs) provide 
information about reactivity of innate immunity and cellular immunity, respectively (Vedhara 
et al., 1999). Since sensitivity to the effects of glucocorticoids differ between individuals and 
even between different tissues of individuals (DeRijk and Sternberg, 1997), both parameters 
were additionally tested for their glucocorticoid sensitivity. To further distinguish between 
effects of missing cortisol from effects of missing epinephrine, the effect of treatment with 
0.03mg/kg hydrocortisone i.v. on these immune measures were tested in patients. 
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4.3.3 Methods 
4.3.3.1 Subjects 
A total of 34 patients with Addison’s disease (AD) and 20 healthy subjects (HS) were 
investigated. Due to missing data, the final sample consisted of 31 patients with Addison’s 
disease and 16 healthy subjects. 16 age- and gender-matched patients were treated with an 
injection of 0.03mg/kg hydrocortisone i.v. (HC; Sigma, Berlin, Germany) after a psychosocial 
stress test, while 15 patients and 16 healthy subjects received a placebo injection (saline, 
NaCl; Sigma, Berlin, Germany). Mean age of subjects was 44.74 years (standard deviation 
(SD)=8.6) and mean body mass index (BMI) 24.11kg/m2 (SD=3.6). Distribution of age and 
BMI did not differ between the three groups (age: F2,46=0.96, p=.39; AD-HC: mean=43.75, 
SD=8.4; AD-NaCl: mean=47.27, SD=8.4; HS-NaCl: mean=43.38, SD=9.0. BMI: F2,46=0.60, 
p=.55; AD-HC: mean=23.54, SD=3.8; AD-NaCl: mean=23.90, SD=2.2; HS-NaCl: 
mean=24.88, SD=4.4). The group AD-HC consisted of 12 females and 4 males, the group 
AD-NaCl of 10 females and 5 males, and the group HS-NaCl of 11 females and 5 males 
(2=0.28, p=.87). 
Of all patients, 22 (71%) were diagnosed with autoimmune Addison’s disease, based 
on the existence of autoantibodies (i.e., adrenocortical autoantibodies (ACAs), steroid cell 
antibodies (StCA); see Peterson et al., 2000) or co-morbidities fulfilling criteria for 
classification to Autoimmune Polyglandular Syndrom (APS) type 1 or type 2 (Neufeld et al., 
1981). One patient suffered from Addison’s disease due to former infection (infectious AD; 
3.2%) and three due to former Cushing’s disease (9,7%). Five patients could not provide 
sufficiently detailed information for differential diagnosis (primary adrenal insufficiency (PAI); 
16.1%). Glucocorticoid replacement was hydrocortisone in 24 patients (mean=26.77mg/day, 
SE=1.2) and cortisone acetate in seven patients (mean=39.58mg/day, SE=5.0). 
4.3.3.2 Experimental Protocol 
Subjects reported to the laboratory at 1p.m. and were examined for past or current 
health problems by a physician. Patients were asked to postpone their second glucocorticoid 
replacement dose usually taken around 2a.m. (mean=13:52h, SD=1h54min) to avoid 
unpredictable and un-physiologically high salivary free cortisol levels (see section 4.1), 
hampering the comparability of patients an healthy subjects. After catheter insertion and a 
resting period of 45 minutes, a first blood sample was collected (5ml heparinized syringe, 
2,7ml ethylenediamine tetraacetic acid (EDTA) Monovette, 9ml citrate Monovette; Sarstedt, 
Nümbrecht, Germany). Subsequently, subjects were expose to the psychosocial stress test 
“Trier Social Stress Test” (TSST), which consists of a three minute preparation period, a five 
minute free speech and a five minute mental arithmetic task in front of an audience 
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(Kirschbaum et al., 1993). Additional blood samples were collected 10, 60, and 120 minutes 
after stress exposure. Immediately after TSST, HC or saline was injected. This time-point 
was chosen since the stress test has a duration of 13 minutes and the maximum cortisol 
stress response is to be expected 15-20 minutes after stress onset. The study protocol was 
approved by the ethics committee of the University of Düsseldorf, and written informed 
consent was obtained from all subjects. 
4.3.3.3 Biochemical Analyses 
4.3.3.3.1 Blood cell counting 
Four blood samples were collected for determination of leukocyte numbers in EDTA-
tubes. A differential blood count was performed measuring absolute numbers of leukocytes, 
as well as number and percentage of monocytes, lymphocytes, and granulocytes. Cell 
counting was performed on a Coulter AcTdiff cell counter (Beckman-Coulter, Krefeld, 
Germany). Each sample was measured five times and results were averaged. 
4.3.3.3.2 LPS-stimulated IL-6 production and glucocorticoid sensitivity 
IL-6 production: Venous blood was collected at four time-points in heparinized sterile 
tubes and diluted 10:1 with saline. Diluted whole blood was then co-incubated with 
lipopolysaccharide (LPS; E. Coli, Difco, Augsburg, Germany) and six different concentrations 
of dexamethasone (DEX; Sigma, Berlin, Germany) on a 24-well plate (Greiner, Nürtingen, 
Germany). 400μl diluted whole blood was added to 50μl of LPS and 50μl of DEX. Final 
concentrations were 30ng/ml LPS and 0, 10-9, 10-8, 5x10-8, 10-7, and 10-6 M DEX, 
respectively. After 18 hours of incubation at 37°C and 5% CO2, plates were centrifuged for 10 
minutes at 2000g at 4°C. Plasma supernatant was collected and stored at -80°C until 
assayed. 
Cytokine assay: IL-6 in plasma supernatant was measured using ELISA employing 
the multiple antibody sandwich principle (BD Pharmingen, San Diego, CA, USA). The 
detection limit of the IL-6 ELISA was 4.7pg/ml. Plates were read by microplate reader 
(Anthos HTII, Anthos Labtec, Salzburg, Austria), and absorbance was transformed to 
cytokine concentration (pg/ml) using a standard curve computed by Anthos Winread 2.3 
software (Anthos Labtec, Salzburg, Austria). 
4.3.3.3.3 PHA-stimulated cell proliferation and glucocorticoid sensitivity 
Cell proliferation: Venous blood was collected at four time-points in sterile citrate 
tubes. Cells were isolated immediately after blood draw by density gradient centrifugation 
(10ml Ficoll, Biochrom, Berlin, Germany). Cells were then transferred to a new 50ml tube 
(Greiner, Nürtingen, Germany), washed three time with PBS (PAA, Coelbe, Germany), and 
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counted on a coulter AcTdiff cell counter (Beckman-Coulter, Krefeld, Germany). Cell 
numbers were adjusted to 1 million cells diluted in 1ml culture medium (RPMI 1640 with 10% 
FCS and 1% Penicillin/Streptomycin; Biochrom, Berlin, Germany). For each subject, the four 
cell suspensions were then co-incubated in triplets with phytohemagglutinin (PHA, Sigma, 
Berlin, Germany) and six different concentrations of dexamethasone (DEX; Sigma, Berlin, 
Germany) on one 96-well plate (Greiner, Nürtingen, Germany). Cell suspension (45μl) was 
added to 45μl of PHA and 10μl of DEX. Final concentrations were 7.5μg/ml PHA and 0, 10-9, 
10-8, 5x10-8, 10-7, and 10-6 M DEX, respectively. Plates were incubated at 37°C and 5% CO2. 
Proliferation assay: After 48 hours of incubation, 10μl of BrdU labeling reagent 
(Roche Diagnostics, Penzberg, Germany) was added and plates were incubated another 12 
hours at 37°C and 5% CO2. Plates were then centrifuged at room temperature for 10 minutes 
at 300g. Supernatant was discarded and cells were dried. Proliferation was measured by a 
colorimetric immunoassay for quantification of cell proliferation, based on the measurement 
of BrdU incorporation during DNA synthesis (cell proliferation ELISA; Roche Diagnostics, 
Penzberg, Germany). Plates were read by a microplate reader giving ODs (optical density) 
as output. Results of each triplet were averaged and blanks (cell suspension without PHA 
and DEX) were subtracted. 
4.3.3.4 Statistical Analysis 
As an index for glucocorticoid sensitivity, inhibitory concentrations 50% (IC50) were 
calculated of each individual dose-response-curve for DEX inhibition of LPS-induced 
cytokine production and DEX inhibition of PHA-induced cell proliferation. The IC50 reflects the 
specific dexamethasone concentration required for 50% inhibition of maximum cytokine 
production observed after LPS-stimulation without DEX and of maximum cell proliferation 
observed after PHA-stimulation without DEX. IC50-values were calculated for each individual 
dose-response curve (i.e., for all four time-points and both variables (LPS-stimulated IL-6 
production and PHA-stimulated cell proliferation) for every individual subject) using 
GraphPad Prism version 4.00c for Macintosh (GraphPad Software, San Diego, USA). 
Data were analyzed using the Statistical Package for the Social Science Version 
11.0.2 (SPSS Institute, Chicago, IL). Student’s t tests were applied for comparing baseline 
immune measures between patients and healthy subjects (AD vs. HS). Immune parameters 
tested are: numbers of white blood cells (WBCs); lymphocytes, granulocytes, and monocytes 
given in percentage of WBCs (LY%, GR%, and MO%, respectively); LPS-stimulated IL-6 
production (IL-6-LPS), glucocorticoid sensitivity of LPS-stimulated IL-6 production (IL-6-IC50), 
PHA-stimulated cell proliferation (CP-PHA), and glucocorticoid sensitivity of PHA-stimulated 
cell proliferation (CP-IC50). 
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To test for time (i.e., TSST) effects in healthy subjects, repeated measures analysis of 
variance (ANOVA) were calculated with within-group levels representing the four time-points 
of blood sampling. To test for effects of Addison’s disease on immune parameters, repeated 
measures ANOVAs were calculated with two between-group levels representing the groups 
AD-NaCl and HS-NaCl (‘disease’). Next, a second set of repeated measures ANOVAs were 
calculated to test for effects of HC-treatment in patients with Addison’s disease with AD-HC 
and AD-NaCl representing the two between-group levels (‘treatment’). Third, repeated 
measures ANOVAs were calculated including all three groups (AD-HC, AD-NaCl, and HS-
NaCl). 
For dose-response curves of LPS-stimulated IL-6 production and PHA-stimulated cell 
proliferation, repeated measures ANOVAs were computed with the two within-group factors 
time (four levels: TSST -1, +10, +60, and +120 minutes) and dexamethasone (six levels: 0, 
10-9, 10-8, 5x10-8, 10-7, and 10-6 M DEX) and the three groups as between-group factor. 
For repeated measures ANOVAs, numbers of white blood cells and ODs of cell 
proliferation were transferred to percent change to baseline. All data were tested for 
normality prior to statistical analysis using the Kolmogorov-Smirnov test and Greenhouse-
Geisser corrections for repeated measures were calculated where appropriate. Values of 
p<0.05 were considered significant. 
4.3.4 Results 
4.3.4.1 Stress Effects in Healthy Subjects 
In a first set of analyses, effects of stress on immune parameter in healthy subjects 
were tested. In numbers of white blood cells, most pronounced changes (i.e., increases) 
were found 2 hours after TSST (see fig. 4-11). The percentage of lymphocytes (LY%, % of 
white blood cells) increased immediately after TSST (+1 min), but decreased below baseline 
during the subsequent two hours. The opposite picture was found for granulocytes (see fig. 
4-11). The percentage of granulocytes (GR%) decreased after TSST, but increased over 
baseline levels during the following 2 hours. No changes could be observed in the 
percentage of monocytes (MO%). 
Regarding LPS-stimulated IL-6 levels, healthy subjects showed decreases after TSST 
(+1 min) and increases over baseline levels thereafter, while the glucocorticoid sensitivity of 
LPS-stimulated IL-6 production did not change over time (see fig. 4-14 and 4-15). Since 
glucocorticoid sensitivity of LPS-stimulated IL-6 production was shown to be dependent on 
gender (Rohleder et al., 2001), the course of IC50 was tested for differences between male 
(n=5) and female (n=11) healthy subjects. No statistically significant effects of gender were 
found (group: F1,14=0.02, p=.90; time: F3,42=2.32, p=.09; group-by-time: F3,42=1.16, p=.31). 
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Furthermore, no effects of TSST were found in PHA-stimulated cell proliferation or 
glucocorticoid sensitivity of PHA-stimulated cell proliferation (see fig. 4-16). Table 4-2 
summarizes the statistics of all results regarding stress effects in healthy subjects. 
Tab. 4-2: Results of repeated measures ANOVAs regarding effects of TSST on immune parameters in healthy 
subjects. Significant results (p<.05) are highlighted in gray. 
Immune parameter  Abbreviation ANOVA 
white blood cells (x10
3
)  WBC F3,45=11.59, p<.001 
lymphocytes (% of white blood cells)  LY% F3,45=7.54, p=.005 
granulocytes (% of white blood cells)  GR% F3,45=6.99, p=.007 
monocytes (% of white blood cells)  MO% F3,45=0.20, p=.87 
LPS-stimulated IL-6 levels  IL-6-LPS F3,45=5.69, p=.003 
glucocorticoid sensitivity of LPS-stimulated IL-6 
production 
 IL-6-IC50 F3,45=1.56, p=.23 
PHA-stimulated cell proliferation  CP-PHA F3,39=0.82, p=.43 
glucocorticoid sensitivity of PHA-stimulated cell 
proliferation 
 CP-IC50 F3,39=0.83, p=.43 
 
4.3.4.2 Baseline Differences (AD vs. HS) 
All immune parameter were tested for baseline differences between healthy subjects 
and patients with Addison’s disease. In none of these parameters, patients with Addison’s 
disease differed significantly from healthy subjects (see table 4-3). 
Tab. 4-3: Student’s t tests for baseline group differences between patients with Addison’s disease and healthy 
subjects in immune parameters. 
Immune parameter  Abbreviation Student’s t tests 
white blood cells (x10
3
)  WBC t43=1.10, p=.28 
lymphocytes (% of white blood cells)  LY% t43=-0.48, p=.63 
granulocytes (% of white blood cells)  GR% t43=0.60, p=.55 
monocytes (% of white blood cells)  MO% t43=-0.75, p=.46 
LPS-stimulated IL-6 levels  IL-6-LPS t45=0.83, p=.41 
glucocorticoid sensitivity of LPS-stimulated IL-6 
production 
 IL-6-IC50 t45=-0.34, p=.74 
PHA-stimulated cell proliferation  CP-PHA t41=0.71, p=.48 
glucocorticoid sensitivity of PHA-stimulated cell 
proliferation 
 CP-IC50 t41=-0.72, p=.47 
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4.3.4.3 Stress-Induced Changes in Blood Cell Counts 
For blood cell counts, three different sets of repeated measures ANOVAs were 
computed. First, stress effects on immune blood cell counts were compared between 
patients and healthy subjects. Significant changes in white blood cells over time were found. 
Additionally, significant group-by-time effects indicated differences in the trajectories of white 
blood cells (see. fig. 4-11), percentage of lymphocytes and percentage of granulocytes. 
Thereby, patients with Addison’s disease did not show the sharp increases in white blood 
cells from time-point +60 min to +120 min as healthy subjects. And contrary to healthy 
subjects, patients with Addison’s disease showed increases in lymphocytes and decreases in 
granulocytes over time (see fig. 4-12). No significant group differences in percentages of 
monocytes were found (see column A in table 4-4). 
Next, effects of treatment in patients with Addison’s disease were investigated. While 
patients with Addison’s disease showed significant changes over time in all four blood cell 
counts, hydrocortisone injection (AD-HC) did not result in different time courses compared to 
placebo (AD-NaCl; see column B in table 4-4). Repeated measures ANOVAs with three 
between-group levels reflected these results (see column C in table 4-4). 
Tab. 4-4: Results of repeated measures ANOVAs for blood cell counts (WBC%: white blood cells in % change 
from baseline; LY%, GR%, and MO%: lymphocytes, granulocytes and monocytes in % of white blood cells, 
respectively) with four within-group levels representing the four time-points and two between-group levels testing 
for group (column A; AD-NaCl vs. HS-NaCl) and treatment effects (column B; AD-HC vs. AD-NaCl), as well as 
three between-group levels comparing changes over time in blood cell counts between all three groups (column 
C; AD-HC vs. AD-NaCl vs. HS-NaCl). Significant results (p<.05) are highlighted in gray, trends (p<.10) are 
indicated by a superscript plus sign (
+
). 
  A: DISEASE 
AD-NaCl (n=14) /  
HS-NaCl (n=16) 
B: TREATMENT 
AD-HC (n=15) /  
AD-NaCl (n=14) 
C: DISEASE x TREAT. 
AD-HC / AD-NaCl / 
HS-NaCl 
group: F1,28=0.11, p=.75 F1,27=0.14, p=.71 F2,42=0.08, p=.92 
time: F3,84=11.74, p<.001 F3,81=5.63, p=.008 F3,126=13.54, p<.001 
WBC% 
group x time: F3,84=4.07, p=.026 F3,81=0.47, p=.61 F6,126=3.57, p=.012 
group: F1,28=1.51, p=.23 F1,27=2.49, p=.13 F2,42=1.26, p=.30 
time: F3,84=1.72, p=.19 F3,81=11.09, p<.001 F3,126=4.92, p=.013 
LY% 
group x time: F3,84=10.74, p<.001 F3,81=1.03, p=.35 F6,126=7.49, p<.001 
group: F1,28=1.90, p=.18 F1,27=2.74, p=.11 F2,42=1.44, p=.25 
time: F3,84=2.14, p=.14 F3,81=17.04, p<.001 F3,126=7.01, p=.003 
GR% 
group x time: F3,84=11.87, p<.001 F3,81=1.19, p=.31 F6,126=8.75, p<.001 
group: F1,28=0.34, p=.57 F1,27=0.44, p=.51 F2,42=0.26, p=.77 
time: F3,84=1.60, p=.21 F3,81=4.83, p=.008 F3,126=3.37, p=.028 
MO% 
group x time: F3,84=2.52, p=.08
+
 F3,81=0.19, p=.86 F6,126=1.35, p=.25 
 
Figure 4-11 depicts the courses of white blood cells (in % change to baseline) for the 
three groups AD-HC, AD-NaCl, and HS-NaCl. Figure 4-12 shows the courses of percentages 
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of lymphocytes and granulocytes for placebo-treated patients with Addison’s disease and 
healthy subjects. 
 
Fig.4-11: Effects of TSST, disease, and treatment on white blood cells counts (mean and standard errors (SE), 
given in % change to baseline). 
 
Fig. 4-12: Lymphocytes and granulocytes (in % of white blood cells; mean and SE) for placebo treated healthy 
subjects and patients with Addison’s disease. 
4.3.4.4 Stress-Induced Changes in LPS-Stimulated IL-6 Production and 
Glucocorticoid Sensitivity of LPS-Stimulated IL-6 Production 
Dose-response-curves for LPS-stimulated IL-6 production were tested with repeated 
measures ANOVA and the three groups (AD-HC: n=16, AD-NaCl: n=15, and HS-NaCl: n=16) 
as between-group levels. Two within-group factors were included (time-points: TSST -1, +10, 
+60, and +60 minutes; dexamethasone: 0, 10-9, 10-8, 5x10-8, 10-7, 10-6 M DEX) resulting in 24 
within-group levels. All effects were highly significant (see table 4-5). 
Tab. 4-5: LPS-stimulated IL-6 production – repeated measures ANOVA including groups AD-HC, AD-NaCl, and 
HS-NaCl as between-group levels and four time-points and six concentrations of dexamethasone as within-group 
levels. Significant results (p<.05) are highlighted in gray. 
effect: F-values p-values  effect: F-values p-values 
group F2,44=5.95 p=.005  group-by-time F6,132=6.85 p<.001 
time F3,132=9.03 p<.001  group-by-DEX F10,220=4.25 p=.012 
DEX F5,220=493.66 p<.001  time-by-DEX F15,660=12.69 p<.001 
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Figure 4-13 depicts the dose-response curves of each group broken down by four 
time-points. LPS-stimulated IL-6 levels without dexamethasone as well as glucocorticoid 
sensitivity can be seen to be influenced by stress, disease and hydrocortisone treatment. 
 
Fig. 4-13: Inhibition of LPS-stimulated IL-6 production (mean and SE) by increasing doses of dexamethasone for 
groups AD-HC, AD-NaCl, and HS-NaCl broken down by four time-points (TSST -1, +10, +60, and +120 minutes). 
Because of the complexity of information contained in dose-response curves, they will 
be described in the following by two indices: LPS-stimulated IL-6 production without inhibition 
by dexamethasone (IL-6-LPS; indicated in figure 4-13 as ‘DEX 0’) as well as glucocorticoid 
sensitivity (IL-6-IC50), representing the specific dexamethasone concentration required for 
50% inhibition of LPS-stimulated IL-6 production without DEX. 
As in blood cell counts, a three step approach was chosen to test the variables IL-6-
LPS and IL-6-IC50 for effects of disease and hydrocortisone treatment. Patients with 
Addison’s disease differed significantly in LPS-stimulated IL-6 levels showing higher levels 
than healthy subjects. No effects of disease on IC50 levels were found (see column A in table 
4-6). Treatment with hydrocortisone in patients with Addison’s disease resulted in significant 
group and group-by-time effects with pronounced decreases in LPS-stimulated IL-6 
production and in a trend to group-by-time interaction with steep increases in IC50 levels 10 
minutes after injection compared to placebo treated patients with Addison’s disease (see 
column B in table 4-6). At time-points +60 and +120min, hydrocortisone treated patients 
showed LPS-stimulated IL-6 levels and IC50 levels comparable to healthy subjects (see figure 
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4-14 and 4-15). Repeated measures ANOVAs with three between-group levels reflected 
these results (see column C in table 4-6). 
 
Fig. 4-14: Stress, group, and treatment effects on LPS-stimulated IL-6 production (mean and SE). 
 
Fig. 4-15: Stress, group, and treatment effects on glucocorticoid sensitivity of LPS-stimulated IL-6 production 
(IC50, in 10
-8
 M DEX; mean and SE). Glucocorticoid sensitivity is inversely related to IC50 levels. 
Since LPS-stimulated IL-6 levels were pronouncedly decreased in hydrocortisone-
treated patients at time-point +10 minutes, thereby affecting IC50 calculation, the set of 
repeated measures ANOVAs for IL-6-IC50 were computed again with IL-6-LPS levels at +10 
minutes as covariate. Only significant time effects remained and formerly significant group-
by-time interaction vanished (see table 4-6, third row). 
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Tab. 4-6: Results of repeated measures ANOVAs for LPS-stimulated IL-6 production and glucocorticoid sensitivity 
of LPS-stimulated IL-6 production (IL-6-IC50) with four within-group levels representing the four time-points and 
two between-group levels testing for group (column A; AD-NaCl vs. HS-NaCl) and treatment effects (column 
B;AD-HC vs. AD-NaCl), as well as three between-group levels comparing changes over time between all three 
groups (column C; AD-HC vs. AD-NaCl vs. HS-NaCl). The last row (IL-6c-IC50) shows the respective results of an 
ANCOVA with LPS-stimulated IL-6 production at time-point +10 minutes as covariate. Significant results (p<.05) 
are highlighted in gray, trends (p<.10) are indicated by a superscript plus sign (
+
). 
  A: DISEASE 
AD-NaCl (n=15) /  
HS-NaCl (n=16) 
B: TREATMENT 
AD-HC (n=16) /  
AD-NaCl (n=15) 
C: DISEASE x TREAT. 
AD-HC / AD-NaCl /  
HS-NaCl 
group: F1,29=5.80, p=.023 F1,29=10.19, p=.003 F2,44=5.77, p=.006 
time: F3,87=3.23, p=.030 F3,87=9.22, p<.001 F3,132=13.42, p<.001 
IL-6-
LPS 
group x time: F3,87=2.45, p=.074
+
 F3,87=9.76, p<.001 F6,132=6.59, p<.001 
group: F1,29=0.95, p=.34 F1,29=2.31, p=.14 F2,44=2.93, p=.064
+
 
time: F3,87=2.42, p=.095
+
 F3,87=4.25, p=.046 F3,132=4.79, p=.032 
IL-6-
IC50 
group x time: F3,87=1.47, p=.24 F3,87=3.59, p=.066
+
 F6,132=3.62, p=.032 
group: F1,28=0.00, p=.96 F1,28=0.00, p=.98 F2,43=1.37, p=.27 
cov: F1,28=3.27, p=.081
+
 F1,28=1.61, p=.22 F2,43=1.23, p=.27 
time: F3,84=0.21, p=.83 F3,84=5.83, p=.021 F3,129=6.19, p=.015 
group x time: F3,84=0.44, p=.66 F3,84=0.02, p=.91 F6,129=1.04, p=.36 
IL-6c-
IC50 
cov x time: F3,84=0.54, p=.60 F3,84=3.30, p=.078
+
 F3,129=3.47, p=.067
+
 
 
4.3.4.5 Stress-Induced Changes in PHA-Stimulated Cell Proliferation and 
Glucocorticoid Sensitivity of PHA-Stimulated Cell Proliferation 
In parallel to LPS-stimulated IL-6 production, dose-response-curves for PHA-
stimulated cell proliferation were tested with repeated measures ANOVA. No significant 
effects of group and no significant interactions were found. Only stress (i.e., TSST -1, +10, 
+60, and +120 minutes) and treatment of cells in vitro with increasing doses of 
dexamethasone (0, 10-9, 10-8, 5x10-8, 10-7, 10-6 M DEX) resulted in significant changes in 
PHA-stimulated cell proliferation (see table 4-7). 
Tab. 4-7: PHA-stimulated cell proliferation – repeated measures ANOVA including groups AD-HC (n=15), AD-
NaCl (n=14), and HS-NaCl (n=14) as between-group levels and four time-points and six concentrations of 
dexamethasone as within-group levels. Significant results (p<.05) are highlighted in gray. 
effect: F-values p-values 
group F2,40=0.35 p=.71 
time F3,120=12.18 p<.001 
DEX F5,200=325.91 p<.001 
group-by-time F6,120=0.52 p=.74 
group-by-DEX F10,200=0.54 p=.70 
time-by-DEX F15,600=1.63 p=.20 
group-by-time-by-DEX F30,600=1.43 p=.23 
 
While TSST resulted in significant increases over time, no effects of disease or 
hydrocortisone treatment were found in PHA-stimulated cell proliferation and glucocorticoid 
sensitivity of PHA-stimulated cell proliferation (see table 4-8). 
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Tab. 4-8: Results of repeated measures ANOVAs for PHA-stimulated cell proliferation (in % change of baseline; 
CP-PHA) and glucocorticoid sensitivity of PHA-stimulated cell proliferation (CP-IC50) with four within-group levels 
representing the four time-points and two between-group levels testing for group (column A; AD-NaCl vs. HS-
NaCl) and treatment effects (column B;AD-HC vs. AD-NaCl), as well as three between-group levels comparing 
changes over time between all three groups (column C; AD-HC vs. AD-NaCl vs. HS-NaCl). Significant results 
(p<.05) are highlighted in gray. 
  A: DISEASE 
AD-NaCl (n=14) /  
HS-NaCl (n=14) 
B: TREATMENT 
AD-HC (n=15) /  
AD-NaCl (n=14) 
C: DISEASE x TREAT. 
AD-HC / AD-NaCl /  
HS-NaCl 
group: F1,26=0.27, p=.61 F1,27=0.00, p=.98 F2,40=0.18, p=.84 
time: F3,78=3.28, p=.041 F3,81=4.34, p=.009 F3,120=4.76, p=.005 
CP-
PHA 
group x time: F3,78=0.23, p=.82 F3,81=0.17, p=.90 F6,120=0.21, p=.96 
group: F1,26=0.37, p=.55 F1,27=0.32, p=.57 F2,40=0.25, p=.78 
time: F3,78=3.23, p=.047 F3,81=5.58, p=.011 F3,120=5.81, p=.004 
CP-IC50 
group x time: F3,78=0.44, p=.65 F3,81=0.48, p=.58 F6,120=0.55, p=.71 
 
Figure 4-16 depicts the courses of PHA-stimulated cell proliferation and glucocorticoid 
sensitivity of PHA-stimulated cell proliferation broken down by group and treatment (AD-HC 
vs. AD-NaCl vs. HS-NaCl). 
 
Fig. 4-16: Stress, group, and treatment effects on PHA-stimulated proliferation and IC50 levels (*10
-8
M DEX). 
4.3.4.6 Summary of Results 
In healthy subjects, stress resulted in significant changes in blood cell counts and 
LPS-stimulated IL-6 production. No baseline differences in immune parameters were found 
between patients with Addison’s disease and healthy subjects. Stress in patients with 
Addison’s disease resulted in courses of blood cell counts and LPS-stimulated IL-6 
production significantly different from healthy subjects. Treatment with hydrocortisone only 
influenced the course of LPS-stimulated IL-6 production. No influences of disease or 
hydrocortisone treatment were found in cell proliferation parameters. 
4.3.5 Discussion 
In the present study, stress responses in three different immune parameters were 
tested and compared between patients with Addison’s disease and healthy subjects. 
Furthermore, treatment of patients with hydrocortisone i.v. were tested for its ability to restore 
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possibly changed immune stress responses. In the following, results will be first discussed 
separately for each of the three immune parameters. 
4.3.5.1 Blood Cell Counts 
Stress resulted in significant changes in numbers of white blood cells over time. 
Patients with Addison’s disease showed slow increases in numbers of white blood cells, 
while healthy subjects showed most pronounced increases between one and two hours after 
stress. Although numbers or percentages of specific subsets of peripheral blood 
mononuclear cells not necessarily correlate with function of the respective cell (Anesi et al., 
1994), blood cell counts provide information about immune system activation, as decreased 
numbers of cells in peripheral blood point to immune activation due to trafficking of these 
cells to inflammatory sites (Dhabhar, 2000). To determine which subsets of cells may have 
caused observed changes in white blood cells, percentages of lymphocytes, granulocytes, 
and monocytes were measured. While healthy subjects showed an increase in percentage of 
lymphocytes in response to stress, percentage of lymphocytes decreased below baseline in 
the following two hours. The opposite trajectory was found in granulocytes. Here, 
percentages decreased in an acute response to stress to subsequently increase over 
baseline levels thereafter. No changes in percentage of monocytes were found. These 
findings reflect patterns found by others, indicating catecholamines being the primary 
mediator of acute stress-induced changes in numbers of cell subtypes, while glucocorticoids 
seem to play a role at later time-points. After catecholamine administration, typically two 
phases are recognized (for review see Benschop et al., 1996): A quick (<30 minutes) 
mobilization of lymphocytes, followed by an increase in granulocyte numbers with decreasing 
lymphocyte numbers. Thereby, changes in lymphocytes seem to be mainly mediated via 
activation of 2-adrenoceptors, whereas granulocytes increases involve -adrenoceptor 
stimulation. Regarding later time-points, studies by Dhabhar et al. showed glucocorticoids to 
play a role in distribution of white blood cells (Dhabhar et al., 1996). The authors observed 
significantly increased lymphocyte numbers in adrenalectomized rats two hours after being 
stressed by a vehicle injection, while intact animals showed significant decreases. Injection 
of corticosterone in adrenalectomized rats resulted in significantly decreased lymphocyte 
numbers two hours later. This redistribution of cells is probably due largely to alterations in 
cell adhesion molecules (Sapolsky et al., 2000), since glucocorticoids can regulate the 
expression of cell adhesion molecules in lymphocytes, thereby altering cell trafficking and 
hence cell infiltration at sites of inflammation (Cronstein et al., 1992; for review see Pitzalis et 
al., 2002). 
As may be expected from these findings, patients with Addison’s disease showed 
early stress responses in lymphocytes and granulocytes comparable to healthy controls, 
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indicating norepinephrine being able to compensate missing epinephrine responses. But at 
one and two hours after stress, differences in trajectories were found between patients and 
healthy subjects, indicating glucocorticoids to play a role at these later time-points. These 
later trajectories seem to be a prolongation or missing termination of earlier events, in that 
lymphocytes continued increasing and granulocytes continued decreasing. Nevertheless, 
hydrocortisone treatment of patients did not restore these patterns, as would have been 
suggested. This may at least in part be due to the dose of 0.03mg/kg being injected as a 
bolus. This treatment resulted in salivary free cortisol levels being comparable between 
patients and healthy controls immediately after stress, but patients showed faster decreases 
in cortisol levels thereafter. Thus, cortisol effects may have been terminated earlier in 
patients than in healthy subjects. Furthermore, patients are treated with glucocorticoid 
replacement two to three times a day with mean doses of 26.77mg hydrocortisone and 
39.58mg cortisone acetate per day. It may therefore be hypothesized that this treatment 
alters the sensitivity of lymphocytes to glucocorticoid regulation of cell adhesion molecule 
expression. Thus, as in untreated patients, lymphocytes are recruited from the marginal pool 
and the spleen by catecholamines (Benschop et al., 1996), but do not exit peripheral blood 
due to missing glucocorticoid induction of cell adhesion molecules. 
In healthy subjects, changes in blood leukocyte distribution are interpreted as 
migration of specific leukocytes to the “battle stations” and “communication stations” 
(Dhabhar et al., 1996), i.e., immune compartments like lymph nodes, lung, skin, and mucosa, 
where they are important for the ability of the immune system to perform its surveillance and 
effector functions. In turn, missing lymphocyte redistribution to other immune compartments, 
as found in patients with Addison’s disease, may attenuate the ability of the immune system 
to respond to infections and thus represent an enhanced health risk. 
4.3.5.2 LPS-Stimulated IL-6 Production 
Cells of innate immunity recognize pathogen-associated molecular patterns (PAMPs; 
Medzhitov and Janeway, 1997a; Medzhitov and Janeway, 1997b; Uthaisangsook et al., 
2002), which are shared by large groups of pathogens, as for example lipopolysaccharide 
(LPS), a component of the bacterial cell wall. PAMPs in turn are recognized by a set of 
molecules as well as receptors referred to as pattern-recognition molecules (PRMs) and 
pattern-recognition receptors (PRRs), which are germline encoded, i.e., they arise over 
evolutionary time due to selection by pathogens at the populational levels (Medzhitov and 
Janeway, 1997a). Binding of PAMPs to PRRs or PRMs is the first step in activating functions 
of innate immunity. Based on these mechanisms, stimulation of immune cells in vitro by LPS 
measures their ability to produce cytokines, if challenged by an infection, and thereby informs 
about “what could be”. In this regard, LPS stimulation of whole blood appears to reproduce 
the natural environment better than stimulation of PBMCs (De Groote et al., 1992). 
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The cytokine IL-6 is one of the major pro-inflammatory cytokines and has a wide 
range of important functions in the immune system. It is produced and released by a variety 
of cells, including lymphoid cells, endothelial cells, and fibroblasts (Heinrich et al., 1990). IL-6 
is known to regulate B and T-cell function, it promotes proliferation and differentiation of 
haematopoietic stem cells (Akira et al., 1990), and has pyrogenic activity (Kluger, 1991). In 
addition, during the acute phase response, IL-6 is thought to be the main regulator of the 
production and release of acute phase proteins by the liver (Heinrich et al., 1990). 
Consequently, stimulation of monocytes and macrophages by LPS has repeatedly been 
shown to increase IL-6 production (Gauldie et al., 1987; May et al., 1988; Northoff et al., 
1987; Ritchie and Fuller, 1983). 
Contrary to LPS, one of the most well-established and important effects of 
glucocorticoids is the inhibition of cytokine production (reviewed in (Wiegers and Reul, 1998). 
This also includes the production of IL-6 and its effects on target tissues (Chrousos, 1995). 
One exception in this regards is the effect of IL-6 on the production of acute-phase reactants 
by the liver, which is potentiated by glucocorticoids (Boumpas et al., 1993; Hirano et al., 
1990). Furthermore, glucocorticoids (Rohleder et al., 2003a) and norepinephrine (van der 
Poll et al., 1994) have repeatedly been shown to suppress IL-6 production ex vivo in LPS-
stimulated whole blood in a dose-dependent manner. Acute stress in turn has been shown to 
increase (Gaab et al., 2005) and decrease LPS-stimulated IL-6 production (Rohleder et al., 
2003a). This contradictory results may in part be due to the sexual hormone status of 
subjects investigated, as Rohleder et al. found IL-6 production to decrease in response to 
acute stress in men (Rohleder et al., 2001) and in women in the luteal phase, while women 
taking oral contraceptives responded to acute stress with increased IL-6 production 
(Rohleder et al., 2003b). 
Nevertheless, no differences between healthy men and women were found in the 
present study in the trajectories of LPS-stimulated IL-6 production6. Healthy subjects showed 
a fast response in LPS-stimulated IL-6 production, in that levels decreased immediately after 
stress. During the subsequent two hours, stimulated IL-6 levels slowly increased and 
reached levels above baseline at two hours after TSST. This trajectory closely reflected the 
course of salivary free cortisol levels (see section 4.2): Ten minutes after TSST, cortisol 
levels reached their maximum and decreased thereafter, with levels close to baseline levels 
60 minutes after TSST and levels below baseline 120 minutes after TSST7. Consequently, 
patients with Addison’s disease – characterized by a missing cortisol stress response – 
                                            
6
 11 females, 5 males; gender: F1,14=0.12, p=.73; time: F3,42=3.99, p=.014; gender-by-time: 
F3,42=0.35, p=.76. 
7
 AD-HC: n=15, HS-NaCl: n=16; salivary free cortisol levels at +10min correlated negatively 
with LPS-stimulated IL-6 production at +10min (p=.08) and at +60min (p=.097). Data not shown. 
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showed increases in LPS-stimulated IL-6 levels in response to stress, with little variations in 
the following two hours. It may be hypothesized that the stress-induced increase in cortisol in 
healthy subjects is associated with a short-time suppressed immune response to challenge 
and that such a response is physiologically advantageous, as during stress no energy is 
wasted on immune system activation. In patients with Addison’s disease, stress immediately 
leads to enhanced immune responsiveness, since no cortisol is secreted. Hence, the 
immune activation is not protracted to times after stress termination. 
Treatment of patients with hydrocortisone in turn resulted in pronouncedly decreased 
IL-6 production ten minutes after TSST with a return to baseline 1 hour after TSST. These 
findings clearly point to a suppressive action of glucocorticoids in immune responses to 
infections. This action seems to be restricted to stress, since no baseline differences in LPS-
stimulated IL-6 production could be found between healthy subjects and patients with 
Addison’s disease. From a patients’ point-of-view the questions arises, which effects on the 
immune system have to be expected in regard to intake of glucocorticoid replacement two to 
three times a day. The pronounced effect of hydrocortisone treatment on LPS-stimulated IL-6 
production in this study does not point to a decreased sensitivity of the immune system to 
glucocorticoid signaling, as may have been expected as an effect of the high doses of 
glucocorticoid replacement. 
In this regard, we also assessed the sensitivity of LPS-stimulated IL-6 production to 
inhibitory glucocorticoid signals, in that we added dexamethasone in increasing doses to the 
whole blood cultures. The amount of dexamethasone needed to suppress LPS-stimulation 
IL-6 production to 50% (IC50) was used as an index of glucocorticoid sensitivity, with higher 
dexamethasone doses/higher IC50 indicating lower sensitivity. The effects of psychosocial 
stress on glucocorticoid sensitivity of LPS-stimulated IL-6 production have so far been 
investigated in just a few studies. For example, Miller et al. (Miller et al., 2002) found parents 
of children suffering from cancer showing a decreased GC sensitivity of LPS-stimulated IL-6 
production in whole blood compared to parents of medically healthy children. In regard to 
acute psychosocial stress, our laboratory did a series of studies and observed glucocorticoid 
sensitivity to decrease in women and older men, to increase in younger men and women 
using oral contraceptives, and to not change in women being in the luteal phase of their 
menstrual cycle (Rohleder et al., 2003a). 
 Interestingly, independent of gender8, no differences between healthy subjects and 
patients with Addison’s disease in courses of IC50s were found. Only hydrocortisone 
treatment resulted in pronounced decreases in glucocorticoid sensitivity, but this effect 
                                            
8
 AD-NaCl: 10 females, 5 males; HS-NaCl: 11 females, 5 males. Gender: F1,27=0.33, p=.57; 
group: F1,27=0.55, p=.47; gender-by-group: F1,27=0.20, p=.66; time: F3,81=3.01, p=.055; gender-by-time: 
F3,81=2.12, p=.13; group-by-time: F3,81=1.18, p=.32; group-by-gender-by-time: F3,81=0.29, p=.76. 
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appeared to be due to LPS-stimulated IL-6 levels being pronouncedly decreased after 
hydrocortisone-treatment, thereby affecting IC50 calculation. Controlling for this LPS-
stimulated IL-6 production revealed patients with Addison’s disease and healthy subjects to 
not differ in their glucocorticoid sensitivity trajectories. Patients thereby show this regular 
responses despite a missing cortisol stress response and taking glucocorticoid replacement 
in high doses several times per day (see section 4.1). 
In summary, a missing cortisol stress response in patients with Addison’s disease is 
associated with increased responsiveness to an infectious stimulus, accompanied by 
unchanged glucocorticoid sensitivity of IL-6 producing cells. Treatment with hydrocortisone 
revealed this effect being due to missing cortisol in patients with Addison’s disease. If 
glucocorticoids are important for protection of the organism against an over-reactive immune 
system, these findings on the one hand point to patients being prone to 
autoimmune/inflammatory diseases. In parallel to this interpretation, individuals with 
Addison’s disease in fact have been found to be prone to diseases like bronchial asthma 
(Green and Lim, 1971) and various allergies (Carryer et al., 1960). Surprisingly, patients 
further responded very sensitive to inhibitory glucocorticoid signals, despite being treated 
with glucocorticoid replacement in supra-physiological concentrations several times a day 
over years (see section 4.1). This still existing and pronounced sensitivity to glucocorticoid 
signaling therefore points on the other hand to an increased risk for infections two to three 
times a day subsequently to the intake of replacement medication. 
4.3.5.3 PHA-Stimulated Cell Proliferation 
One of the most common measures of cell-mediated immunity is the nonspecific 
mitogen-induced lymphocyte proliferation. Therefore, to also receive information on 
effectiveness of cellular immune responses, especially of T-cells, in the present study PHA-
stimulated cell proliferation as well as glucocorticoid sensitivity of cell proliferation were 
measured. 
Despite PHA-stimulated proliferation being a common measure of cell-mediated 
immunity, research results in this regard are rather contradictory. For example, forced swim 
tests were found to suppress PHA-stimulated proliferation in peripheral T-cells (Connor et al., 
1997) as well as in splenocytes (Ferry et al., 1991) in rats. Contrary, a social stressor was 
found to facilitate proliferation in rats (Bohus et al., 1993). Also five weeks of isolation and 
water scheduling enhanced proliferation in rats (Jessop et al., 1987). In humans, reduction in 
proliferation were found in response to a Stroop test (Bachen et al., 1992). No changes in 
proliferation were observed in response to a difficult puzzle task (Brosschot et al., 1992) or in 
response to an electric shock with loud white noise (Weisse et al., 1990). In juvenile squirrel 
monkeys, 3 hours of separation resulted in suppressed proliferation two days later (Friedman 
et al., 1991). In these studies not only different types and durations of stressors, but also 
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different tissues and different PHA concentrations were employed. Therefore, no general 
conclusion can be drawn on the effects of stress on PHA-stimulated cell proliferation. 
A likewise inconsistent picture can be observed in regard to glucocorticoid sensitivity 
of PHA-stimulated cell proliferation. Only a few studies measured sensitivity and found acute 
stress to not induce any significant changes in glucocorticoid sensitivity of PHA-stimulated 
splenocyte and blood lymphocyte proliferation in rats (Bauer et al., 2001), while 
glucocorticoid sensitivity of PHA-stimulated PBMC proliferation significantly decreased on 
days with academic examination stress (Sauer et al., 1995). Contrary, our laboratory found 
acute stress in humans to induce increased glucocorticoid sensitivity (Rohleder et al., 2005). 
Again, conclusions regarding stress-induced changes in PHA-stimulated cell proliferation are 
hampered by the investigation of different species, tissues and stressors. 
In the present study, only significant time effects were found, indicating stress to 
result in increases in PHA-stimulated cell proliferation and decreases in glucocorticoid 
sensitivity. The latter was most pronounced two hours after stress. These findings are in line 
with data from Rohleder et al. (Rohleder et al., 2005) presented above. This consensus may 
be explained by type and duration of stressor (i.e., TSST) as well as concentrations of PHA 
and dexamethasone being identical in both studies. Interestingly, no differences between 
patients with Addison’s disease and healthy subjects and no effect of hydrocortisone 
treatment in patients were found. These findings lead to the same conclusion as drawn by 
Keller et al. (Keller et al., 1983). Keller et al. investigated stress-induced changes in 
lymphocyte stimulation by phytohemagglutinin in isolated lymphocytes and in cultures of 
whole blood from adrenalectomized rats. In parallel to the missing effects of disease and 
hydrocortisone treatment, Keller concluded from his data that corticosteroid independent 
mechanisms participate in stress effects on lymphocyte function. 
Taken together, neither PHA-stimulated cell proliferation nor glucocorticoid sensitivity 
of stimulated T-cells are changed in patients missing a cortisol stress response. Furthermore, 
both parameters are not sensitive to hydrocortisone treatment. These findings clearly point to 
stress-induced changes in cell-mediated immunity being mediated by other mechanisms 
than glucocorticoid signaling. 
4.3.5.4 Conclusion and Outlook 
Investigation of patients with Addison’s disease proved to be a valuable alternative 
approach to verify in humans stress effects on the immune system found in animal research 
or in vitro approaches. In this regard, three commonly used parameters were investigated: 
Percentages of leukocyte subtypes in peripheral blood, stimulated IL-6 production and T-cell 
proliferation. Additionally, sensitivities of the latter two parameters to glucocorticoid signaling 
were measured. As expected from literature, glucocorticoids seem to play an important role 
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in leukocyte migration and stimulated cytokine production, while T-cell proliferation appeared 
to be glucocorticoid-independent. 
While treatment of patients with 0.03mg/kg hydrocortisone did restore the early 
pattern of stimulated IL-6 trajectories, no effects were found in leukocyte trafficking. This may 
be explained by treatment lasting too shortly for measurably affecting leukocyte trafficking, at 
least at the time-points used in the present study. Contrary, in LPS-stimulated IL-6 
production, incubation of whole blood for 18 hours allowed hydrocortisone treatment to exert 
its full effects. 
From a patient’s point-of-view, the findings of the present study may have several 
implications. The distinctive features in blood cell counts may point to an increased health 
risk, as the ability of the immune system to respond to infections is attenuated in response to 
stress. On the other hand, stress responses in cytokine production hint to a hyper-reactive 
innate immune response due to missing suppressive cortisol signals, which in turn points to 
patients having an increased risk for autoimmune diseases. This situation may even be 
exacerbated by the conserved sensitivity to glucocorticoid signaling, seen in the pronounced 
responses to hydrocortisone treatment in stimulated IL-6 production – especially since 
patients receive glucocorticoid replacement several times a day, resulting in morning salivary 
free cortisol levels being up to six fold the levels seen in healthy subjects (see section 4.1). 
The findings of the present study should be extended in future studies investigating 
the effects of missing endocrine stress responses on other parameters of innate and 
adaptive immunity in these patients, as for example on natural killer cells or T-helper cell 1/T-
helper cell 2 balance. Treatment of patients with epinephrine in comparison to or in 
combination with hydrocortisone may further help to reveal the immune regulatory role of 
stress mediators in humans. Additional insights into these interactions may be gained by 
investigating the effects of the daily glucocorticoid replacement regimen on immune 
functions. 
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4.4 ADDISON’S DISEASE: PSYCHONEUROIMMUNOLOGY AND THE  
     MEDIATIVE ROLE OF NF-B 
Stress and Addison’s Disease: 
NF-B as a Mediator of Stress Effects on Immune System? 
4.4.1 Abstract 
Background: The nuclear transcription factor kappaB (NF-B) is central to immune 
system activation. Glucocorticoids in turn are known to suppress most immune functions, an 
effect thought to be mainly mediated by inhibiting the NF-B activation cascade. We 
previously showed psychosocial stress to be associated with increased NF-B activity in 
humans. This effect was inducible in vitro by norepinephrine. To gain deeper insights into the 
intracellular processes in humans in regard to stress, we investigated endocrine stress 
responses in patients with Addison’s disease and their association with changes in NF-B 
activity. 
Methods: 21 patients with Addison’s disease and 11 healthy subjects were exposed 
to a psychosocial stress test. Blood and saliva samples were collected immediately before 
and repeatedly after stress for analyzing cortisol and catecholamine levels as well as NF-B-
DNA binding activity. Half of the patients were treated with hydrocortisone subsequent to the 
stress test to mimic normal cortisol stress responses. 
Results: In healthy subjects, stress induced significant increases in cortisol and 
catecholamines. Patients with Addison’s disease showed stress-induced increases in 
norepinephrine only, while cortisol and epinephrine levels were very low and did not vary in 
response to stress. No significant changes in NF-B activity were found over the course of 
investigation, but in healthy subjects, cortisol levels one minute after stress predicted NF-B 
decrease from pre-stress to 10 minutes post-stress, while in patients with Addison’s disease, 
this NF-B decrease was predicted by the decrease in norepinephrine to baseline levels after 
stress. None of the investigated parameters was found to predict NF-B variation in 
hydrocortisone treated patients. 
Conclusion: The present study shows for the first time that stress-induced 
glucocorticoid concentrations inhibit NF-B activity in humans. Furthermore, findings in 
patients with Addison’s disease suggests that this immune-suppressive action of 
glucocorticoids is accomplishable also by norepinephrine, if glucocorticoid stress responses 
are missing in the long term. These results once more emphasize the need for studying 
complex and interrelated processes also in human whole organism to allow for uncovering 
compensatory mechanisms. 
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4.4.2 Introduction 
The innate immune response to challenge involves secretion of cytokines and other 
mediators leading to an inflammatory process as an immediate host defense reaction. The 
basis of this fast response are phylogenetically conserved signaling mechanisms with cells of 
innate immunity recognizing pathogen-associated molecular patterns (PAMPs) shared by 
large groups of pathogens (Medzhitov and Janeway, 1997a; Medzhitov and Janeway, 1997b; 
Uthaisangsook et al., 2002). Binding of PAMPs to a set of molecules as well as receptors 
referred to as pattern-recognition molecules (PRMs) and pattern-recognition receptors 
(PRRs) is the first step in activating functions of innate immunity (Medzhitov and Janeway, 
1997a). Centrally to this activation and thus to first-line defense is the nuclear transcription 
factor kappaB (NF-B). 
NF-B family members contain a conserved DNA binding and dimerization domain 
called the Rel homology domain. The mammalian NF-B/Rel family of proteins consists 
presently of five members, namely, Rel (c-Rel), p65 (Rel A), Rel B, p50 (NFKB1; precursor: 
p105), and p52 (NFKB2; precursor: p100). The members p50 and p52 lack transcriptional 
activation domains and their homodimers are thought to act as repressors. In contrast, p65, 
Rel B, and c-Rel carry transcriptional activation domains, and with the exception of Rel B, 
they are able to form homo- and heterodimers with the other members of the protein family. 
In general, the designation NF-B refers to the most frequently occurring and ubiquitously 
expressed heterodimeric complex between the p50 and p65 subunits (Caamano and Hunter, 
2002; Wulczyn et al., 1996). 
4.4.2.1 NF-B is Central to Immune System Activation 
NF-B is rapidly activated by a large spectrum of chemically diverse agents and 
cellular stress conditions, including the component of the cell wall of gram-negative bacteria, 
namely lipopolysaccharide (LPS; Kitchens, 2000; Uthaisangsook et al., 2002), microbial and 
viral pathogens, cytokines and growth factors (Baeuerle and Baltimore, 1996). Once 
activated, NF-B transcriptionally regulates a wide variety of important immune-related 
genes by binding to DNA. Among these are growth factors, such as granulocyte/macrophage 
colony stimulating factor (GM-CSF), pro-inflammatory cytokines, especially IL-1, IL-2, IL-6, 
IL-8, and TNF-, cell adhesion molecules, such as inter-cellular adhesion molecule (ICAM)-1 
and vascular cell adhesion molecule (VCAM), acute phase proteins (hepatocytes), for 
example serum amyloid A precursor protein and complement factors B and C4, but also 
transcriptional regulators including the inhibitory protein IB- (McKay and Cidlowski, 1999). 
In addition to its prominent role in innate immunity, NF-B exerts important functions in the 
adaptive immune system, such as lymphocyte activation by controlling proliferation, 
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immunoglobulin isotype switching and expression of cytokines and their receptors (Attar et 
al., 1997; Gerondakis et al., 1998). Furthermore, NF-B serves to protect cells against 
apoptosis and supports cell cycle progression (Baichwal and Baeuerle, 1997; Foo and Nolan, 
1999). 
The central paradigm of NF-B activation involves the removal of inhibitory protein 
IB, which forms a cytoplasmic complex with NF-B, thus retaining NF-B inactive (Baeuerle 
and Baltimore, 1988a; Baeuerle and Baltimore, 1988b). The major pathway used by a wide 
variety of stimuli to activate NF-B involves the phosphorylation of IB- at its regulatory N-
terminus on serines 32 and 36 by the cytokine-responsive IB kinases IKK and , an event 
leading to subsequent conjugation with ubiquitin and proteasome-mediated degradation of 
the inhibitor (Baldwin, 1996; Verma et al., 1995). As already mentioned, NF-B itself 
transcriptionally regulates IB synthesis. Thus, new synthesis of IB-, causing retention of 
NF-B in the cytoplasm and attenuation of NF-B-mediated transcriptional activation, 
provides a feedback mechanism for modulating the extent and duration of inflammatory 
responses by a cell (Baldwin, 1996). 
4.4.2.2 Glucocorticoid Effects are Mediated by Inhibition of NF-B Activity 
Interestingly, NF-B and the glucocorticoid receptor appear to exert antagonistic 
effects regarding the regulation of most immune-related genes. While NF-B up-regulates 
most genes, the glucocorticoid receptor is known to repress cytokine genes, for example IL-
1, IL-2, IL-6, IL-8, and TNF- genes, as well as cell adhesion molecule genes, such as 
ICAM-1 (reviewed in (McKay and Cidlowski, 1999). 
However, the glucocorticoid signaling pathway becomes activated by glucocorticoids 
(GCs) crossing the cell membrane and interacting with the intracellular GR. This ligand 
binding induces conformational changes in the GR molecule (Bamberger et al., 1996). The 
GR-GC complex dissociates from a heat shock protein (HSP) complex (Hutchison et al., 
1994), the partially phosphorylated receptor protein becomes hyper-phosphorylated (Bodwell 
et al., 1993), and now unmasked nuclear localization signals (NLS) within the ligand-binding 
domain of the receptor (Picard and Yamamoto, 1987) cause nuclear translocation of the GR-
GC complex (Akner et al., 1994). Within the nucleus, the hormone-activated glucocorticoid 
receptor can act in two ways, referred to as classic and alternative mechanism of 
glucocorticoid receptor action. 
The classic mechanism of GR action is characterized by GR-binding to specific DNA 
sequences termed glucocorticoid response elements (GREs), thereby interacting with 
components of the basic transcription machinery and eventually enhance transcription of 
glucocorticoid-responsive genes. Furthermore, in some promoters, binding of the activated 
GR to so-called negative glucocorticoid response elements (nGREs) causes inhibition rather 
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than enhancement of transcription (Bamberger et al., 1996; McKay and Cidlowski, 1999). 
Interestingly, the promoters of most genes, which should be repressed by GRs according to 
the well-known anti-inflammatory actions of glucocorticoids, do not contain nGREs nor do 
they have any other GR-binding site (Bamberger et al., 1996; Cato and Wade, 1996). But 
they do carry sites for NF-B. It has therefore been proposed that immune suppression is 
mediated by glucocorticoid-induced expression of the inhibitory protein IB-, a hypothesis 
which was confirmed by studies showing that glucocorticoids in fact induce the transcription 
of the gene encoding IB- (Auphan et al., 1995; Scheinman et al., 1995a). The increase in 
protein synthesis leads to the rapid turnover of IB- protein associated with pre-existing NF-
B complexes and in the presence of an activator, such as LPS, newly released NF-B re-
associates with the glucocorticoid induced IB-, thus reducing the amount of NF-B 
translocating to the nucleus. Additionally, newly snythesized IB- may enter the nucleus 
and inhibit NF-B-DNA binding. Both pathways eventually down-regulate NF-B associated 
gene products (Scheinman et al., 1995a). 
The alternative mechanism of glucocorticoid receptor action involves physical 
interaction of the GR with other transcription factors, such as NF-B. Accumulating evidence 
exists that the activated GR specifically interferes with the trans-activation potential of the 
NF-B p65 subunit (De Bosscher et al., 1997; De Bosscher et al., 2000b; Ray and 
Prefontaine, 1994). Another important physical interaction occurs between the GR and AP-1, 
resulting in reciprocal repression of AP-1 and GR transactivation functions (Hsu et al., 1993; 
Jonat et al., 1990; Kerppola et al., 1993; Konig et al., 1992; Schule et al., 1990; Yang-Yen et 
al., 1990). As NF-B and AP-1 can synergize in the pro-inflammatory pathway, GR 
repression of AP-1 may be an additional and important indirect mechanism for glucocorticoid 
suppression of NF-B-mediated immune responses (McKay and Cidlowski, 1999). 
In summary, it appears that the main mechanism by which glucocorticoids exert their 
anti-inflammatory effects is by inhibition of the NF-B activation cascade (McKay and 
Cidlowski, 1999), while the inhibition of Th1 cytokines by glucocorticoids is essentially 
explained by the action of AP-1 (Refojo et al., 2001). However, it is important to consider that 
the interaction between NF-B and GR is one of mutual antagonism: NF-B represses DNA-
binding activity of the GR to the same extent as GRs repress NF-B activity (Caldenhoven et 
al., 1995; McKay and Cidlowski, 1998; Ray and Prefontaine, 1994; Scheinman et al., 1995a). 
Furthermore, NF-B may repress GR activity by increasing the expression of the non-
functional receptor isoform GR, thus impairing GR transactivation and eventually causing 
glucocorticoid resistance (Webster et al., 2001). 
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4.4.2.3 Catecholamines Interfere with NF-B Activity 
In parallel to glucocorticoids, several lines of evidence exist of catecholamine signal 
transduction pathways interfering with activity of transcription factors, such as NF-B and 
AP-1. Basically, norepinephrine and epinephrine transduce their biological information 
through stimulation of adrenoceptors, which directly activate G-proteins. Basically, coupling 
of -adrenoceptors to Gs protein activates adenylate cyclase (AC), which in turn increases 
intracellular cAMP. Contrary, coupling of 1-adrenoceptors to Gi proteins inhibits AC and 
thus subsequently the formation of cAMP from ATP. The 1-adrenoceptor coupling to Gq 
proteins activates phospholipase C (PLC), which increases inositol triphosphate (IP3) and 
diacylglycerol (DAG). Once these second messengers are generated, cAMP activates 
protein kinase A (PKA), DAG activates protein kinase C (PKC), and IP3 mobilizes Ca
2+ from 
intracellular stores. The latter is further linked to the Ca2+/calmodulin (Ca2+/CaM) pathway, 
which – like PKA – subsequently transfers signals to the nucleus (Elenkov et al., 2000). For 
example, activation of 2-adrenoceptors on immune cells has been shown to result in 
inhibition of TNF- and IL-12 (Elenkov et al., 1996; Severn et al., 1992; van der Poll et al., 
1994) and an increase of IL-10 production (Elenkov et al., 1996; Siegmund et al., 1998; van 
der Poll et al., 1996; Van der Poll and Lowry, 1997). 
All three pathways, i.e. the cAMP/PKA, the PKC, and the Ca2+/CaM pathway, 
modulate transcription factor activity (Haraguchi et al., 1995). Regarding NF-B, elevated 
levels of cAMP are generally known to inhibit its activation, for example by cAMP inhibiting 
the binding of NF-B to the NF-B-DNA site (Chen and Rothenberg, 1994; Neumann et al., 
1995; Tsuruta et al., 1995). Furthermore, the cAMP/PKA pathway induces impaired nuclear 
translocation and DNA binding of p65, probably due to a retarded degradation of IB- 
(Neumann et al., 1995; Paliogianni et al., 1993). Alternatively, this pathway may also inhibit 
NF-B transcription by phosphorylating the transcription factor CREB, which then competes 
with p65 for limited amounts of CREB binding protein (CBP; Parry and Mackman, 1997). 
Contrary, NF-B activity can also be stimulated via the Ca2+/CaM pathway enhancing 
inactivation of the inhibitory protein IB- (Frantz et al., 1994). 
Accumulating evidence exist, including our own data (Bierhaus et al., 2003) that 
norepinephrine may also modulate NF-B (as well as GR activity; Schmidt et al., 2001) by 
the mitogen-activated protein kinase (MAPK) pathway (Choi and Jeong, 2005). This pathway 
seems to be induced by the / subunits of G-proteins instead of the  subunit normally 
regarded as functional subunit and inducing the above described three pathways. In 
particular, the / subunit from inhibitory Gi proteins have been demonstrated to interact with 
specific isoforms of phophoinositide-3 kinase (PI3-K) and to stimulate the MAPK pathway 
(Crespo et al., 1994; Lopez-Ilasaca et al., 1997). 
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Taken together, catecholamines interfere with NF-B activity via several pathways. 
Thereby, pathways involving the  subunit of G-proteins may inhibit (-adrenoceptor coupling 
to Gs with subsequent increase in cAMP) or stimulate NF-B activity (2-adrenoceptor 
coupling to Gi with subsequent decrease in cAMP, Ca
2+/CaM pathway induced by 1-
adrenoceptor coupling to Gq). Additionally, norepinephrine may up-regulate NF-B activity by 
activation of the MAPK pathway via / subunits of G-proteins. 
4.4.2.4 Aim of the Present Study 
The aim of the present study was to test the following assumptions: Based on the 
previous findings, we propose a sequence of stress-induced events, in which first the 
increased release of catecholamines increases NF-B activity, thereby helping to prepare the 
immune system for potential challenges. With some delay, increased release of cortisol 
suppresses immune responses by antagonizing the NF-B activation cascade, thus 
protecting the organism against an over-reacting immune system. 
As almost all of the above cited studies were done in animals or in vitro, our focus 
was explicitly on investigating these processes in humans, since possible compensating 
mechanisms, such as NF-B influencing the sensitivity of immune cells to glucocorticoid 
signaling, may not be detected in in vitro approaches or may vary between species. The 
most promising approach in humans appears to be the investigation of patients with primary 
adrenal insufficiency (for review of disease see Arlt and Allolio, 2003; Betterle et al., 2002; 
Oelkers, 1996; Ten et al., 2001). 
To accept the assumptions outlined above as true, the missing cortisol stress 
response in these patients should result in a missing termination of prior catecholamine 
induced increases in NF-B activity. Substitution of these patients with hydrocortisone in turn 
should result in stress-associated NF-B trajectories comparable to that found in healthy 
subjects. 
4.4.3 Methods 
4.4.3.1 Subjects 
A total of 27 patients with Addison’s disease (AD) and 16 healthy subjects (HS) were 
investigated. Due to missing data, the final sample consisted of 21 patients with Addison’s 
disease and 10 healthy subjects. 10 age- and gender-matched patients were treated with an 
injection of 0.03mg/kg hydrocortisone i.v. (HC; Sigma, Berlin, Germany) after a psychosocial 
stress test, while 11 patients and 11 healthy subjects received a placebo injection (saline, 
NaCl; Sigma, Berlin, Germany). Mean age of subjects was 45.16 years (standard deviation 
(SD)=7.9) and mean body mass index (BMI) 25.74kg/m2 (SD=4.0). Distribution of age and 
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BMI did not differ between the three groups (age: F2,31=0.96, p=.40; AD-HC: mean=43.90, 
SD=8.5; AD-NaCl: mean=43.64, SD=7.3; HS-NaCl: mean=47.82, SD=7.9. BMI: F2,31=1.56, 
p=.23; AD-HC: mean=25.82, SD=4.1; AD-NaCl: mean=24.23, SD=2.7; HS-NaCl: 
mean=27.19, SD=4.7). The group AD-HC consisted of 6 females and 4 males, the group AD-
NaCl of 8 females and 3 males, and the group HS-NaCl of 7 females and 4 males (2=0.41, 
p=.82). 
Of all patients, 13 (61.9%) were diagnosed with autoimmune Addison’s disease, 
based on the existence of autoantibodies (i.e., adrenocortical autoantibodies (ACAs), steroid 
cell antibodies (StCA); see Peterson et al., 2000) or co-morbidities fulfilling criteria for 
classification to Autoimmune Polyglandular Syndrom (APS) type 1 or type 2 (Neufeld et al., 
1981). Two patient suffered from Addison’s disease due to former Cushing’s disease (9,5%). 
Six patients could not provide sufficiently detailed information for differential diagnosis 
(primary adrenal insufficiency (PAI); 28.6%). Glucocorticoid replacement was hydrocortisone 
in 17 patients (mean=27.21mg/day, SE=1.5) and cortisone acetate in four patients 
(mean=41.67mg/day, SE=11.0). 
4.4.3.2 Experimental Protocol 
Subjects reported to the laboratory at 1p.m. and were examined for past or current 
health problems by a physician. Patients were asked to postpone their second glucocorticoid 
replacement dose usually taken around 2a.m. (mean=13:52h, SD=1h54min) to avoid 
unpredictable and un-physiologically high salivary free cortisol levels (see section 4.1), 
hampering the comparability of patients an healthy subjects. After catheter insertion and a 
resting period of 45 minutes, a first blood sample for measure of NF-B activity was collected 
(9ml citrate Monovette; Sarstedt, Nümbrecht, Germany). Subsequently, subjects were 
expose to the psychosocial stress test “Trier Social Stress Test” (TSST), which consists of a 
three minute preparation period, a five minute free speech and a five minute mental 
arithmetic task in front of an audience (Kirschbaum et al., 1993). Additional blood samples 
were collected 10, 60, and 120 minutes after stress exposure. For measure of salivary free 
cortisol and catecholamine levels, additionally saliva samples (Salivettes, Sarstedt, 
Nümbrecht, Germany) and blood samples (9ml ethylenediamine tetraacetic acid (EDTA) 
Monovette, Sarstedt, Nümbrecht, Germany) were collected before (-1 minute) and 1, 10, 20, 
30, 45, 60, 90, and 120 minutes after TSST, respectively. Immediately after TSST, HC or 
saline were injected. This time-point was chosen since the stress test has a duration of 13 
minutes and the maximum cortisol stress response is to be expected 15-20 minutes after 
stress onset. The study protocol was approved by the ethics committee of the University of 
Düsseldorf, and written informed consent was obtained from all subjects. 
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4.4.3.3 Biochemical Analyses 
4.4.3.3.1 Hormone analyses 
Saliva samples: Free cortisol levels in saliva were measured using a commercially 
available chemiluminescence assay (IBL, Hamburg, Germany). Samples were measured in 
duplicates and averaged for subsequent statistical analyses. 
Blood samples: Plasma was separated at 4°C and stored at -80°C. Plasma 
concentrations of norepinephrine and epinephrine were determined by high-performance 
liquid chromatography with electrochemical detection (Smedes et al., 1982). Epinephrine 
levels under detection limit were labeled 5pg/ml representing half of the lowest standard. 
4.4.3.3.2 NF-B-DNA binding activity 
Preparation of nuclear proteins: Immediately after collection peripheral blood 
mononuclear cells (PBMCs) were separated. 10ml whole blood anticoagulated with sodium 
citrate were loaded onto 10ml Ficoll (Biochrom, Berlin, Germany) and centrifuged for 30 
minutes at 500g. The PBMC containing band was aspirated, cells were washed three times 
in PBS (PAA, Coelbe, Germany), and counted on a coulter AcTdiff cell counter (Beckman-
Coulter, Krefeld, Germany). Three million cells were separated for nuclear protein 
preparation and assayed for transcription factor-binding activity by using NF-B consensus 
oligonucleotides (Promega, Mannheim, Germany) as described (Bierhaus et al., 2001; 
Hofmann et al., 1999). In brief, 3x106 PMBCs were lysed in 300μl ice-cold butter A (10mmol/l 
HEPES-KOH, pH 7.9 at 4°C, 1.5mmol/l MgCl2, 10mmol/lKCl, 0.5mmol/l DTT, 0.2mmol/l 
PMSF), incubated on ice and centrifuged for 30 seconds at 4°C and 15.000rpm. Supernatant 
was discarded and the nuclear pellet was resuspended in 100μl ice-cold buffer B (20mmol/l 
HEPES-KOH, pH7.9 at 4°C, 25% glycerol, 1.5mmol/l MgCl2. 420mmol/l NaCl, 0.2mmol/l 
EDTA, 0.5mmol/l DTT, 0.2mmol/l PMSF), incubated on ice for 20 minutes and centrifuged for 
2 minutes at 4°C and 15.000rpm. The supernatant containing nuclear proteins was 
immediately quickfrozen at -80°C. Protein concentration was determined according to 
Bradford using a BCA assay (Pierce, Ill. USA). 
Electrophoretic mobility shift assay (EMSA): For EMSA 10μg of nuclear proteins were 
used. Binding of NF-B to 1ng of 5’-radiolabelled NF-B consensus oligonucleotides (5’-AGT 
TGA GGG GAC TTT CCC AGG C-3’) was done for 20 minutes at room temperature in 
10mmol/l HEPES, pH7.5, 0.5mmol/l EDTA, 100mmol/l KCl, 2mmol/l DTT, 2% glycerol, 4% 
Ficoll, 0.25% NP-40, 1mg/ml BSA, and 0.1μg/μl poly d/dC by Pahl’s method (Pahl and 
Baeuerle, 1995). Protein-DNA complexes were separated from unbound DNA probe by 
electrophoresis through 5% native polyacrylamide gels containing 2.5% glycerol and 
0.5xTris-Borat-EDTA (TBE). Gels were dried under vacuum and exposed for 48 to 64 hours 
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to Amersham Hyperfilms (Amersham, Braunschweig, Germany) at -80°C with intensifying 
screens. Specificity of binding was ascertained by competition with a 160-fold molar excess 
of unlabelled consensus oligonucleotides and by characterization using specific antibodies 
for the NF-B subunits p65, p50, c-Rel and Rel B (Santa Cruz Biotechnology, Heidelberg, 
Germany). 
Semi-quantitative determination of NF-kBp65 binding activity: To quantify the NF-B 
signal obtained from isolated PBMCs, 2.5, 5.0, and 7.5μg recombinant NF-Bp65 (rNF-
Bp65) containing lysates were included in each EMSA on each gel. The resulting NF-B 
signals were quantified by densitometry (Bio-Rad, München, Germany) and used to establish 
a standard curve for each gel (Hofmann et al., 1998). The densitometric value for the NF-B 
signal of a given subject was converted into rNF-Bp65 equivalents by using the internal 
standard curve for rNF-Bp65 (Hofmann et al., 1998). 
4.4.3.4 Statistical Analysis 
Data were analyzed using the Statistical Package for the Social Science Version 
11.0.2 (SPSS Institute, Chicago, IL). All data were tested for normality prior to statistical 
analysis using the Kolmogorov-Smirnov test and Greenhouse-Geisser corrections for 
repeated measures were calculated where appropriate. Values of p<0.05 were considered 
significant. 
Various parameters, such as gender and age, are known to modulate endocrine 
stress responses (Barnes et al., 1982; Kirschbaum et al., 1992) and NF-B binding activity 
(Trebilcock and Ponnappan, 1996b) and were therefore initially included as covariates or 
predictors. As none of these variables changed results, they were no longer considered in 
the present analyses (section 4.4.4). 
4.4.3.4.1 Effects of disease, stress, and treatment on endocrine parameters 
Student’s t tests were applied for comparing baseline measures between patients and 
healthy subjects (AD vs. HS). To test for effects of stress and hydrocortisone injection 
(‘treatment’) on salivary cortisol levels, a repeated measures ANOVA was calculated. 
Additionally, maximum cortisol levels as well as increases in cortisol from pre-TSST to 
maximum levels were compared by univariate ANOVAs and subsequent Scheffé tests to 
confirm adequacy of hydrocortisone dose of 0.03mg/kg to mimic cortisol stress responses in 
patients with Addison’s disease. Repeated measures ANOVAs were also calculated for 
norepinephrine and epinephrine levels comparing the courses of healthy subjects and 
patients with Addison’s disease. No effects of hydrocortisone treatment were expected in 
these two parameters (Bornstein et al., 1995). 
RESULTS 171 
4.4.3.4.2 Effects of stress, disease, and treatment on NF-B binding activity 
 To test for effects of Addison’s disease and hydrocortisone treatment on NF-B 
binding activity, a set of three repeated measures ANOVAs was calculated: To test for 
effects of disease, first two between-group levels were included representing the groups AD-
NaCl and HS-NaCl (‘disease’). To test for effects of hydrocortisone treatment in patients with 
Addison’s disease, next the two groups AD-HC and AD-NaCl were included (‘treatment’). 
The third repeated measure ANOVA included all three groups (AD-HC, AD-NaCl, and HS-
NaCl) as between-subject factors. Since rather changes in NF-B binding activity than the 
degree of NF-B binding activity per se seem to be of clinical relevance (Bohrer et al., 1997), 
this set of ANOVAs was repeated with signal intensity of NF-B binding activity being 
transferred to percent change to baseline. 
4.4.3.4.3 Endocrine variables: indices of variation 
For later regression analyses, indices of variations in hormone levels (i.e. stress-
induced increases and subsequent decreases) were computed. Generally lower values were 
subtracted from higher values, i.e., for decreases the second value was subtracted from the 
first, while for increases the first values was subtracted from the second. In detail, increases 
in cortisol from pre-stress to maximum were calculated by subtraction of baseline levels from 
maximum cortisol levels (cort_incr1>3). Two decrease indices were calculated by subtraction 
of cortisol levels at 60 and 120 min after TSST from maximum cortisol levels (cort_decr3>7 
and cort_decr3>9, respectively). One increase (baseline subtracted from maximum) and one 
decrease index (maximum-levels at +10min) for each norepinephrine (NE_incr1>2, 
NE_decr2>3, respectively) and epinephrine were calculated (E_incr1>2, E_decr2>3, 
respectively). Univariate ANOVAs with subsequent Scheffè test were computed for 
comparison of cortisol indices between the three groups. Since no effects of hydrocortisone 
treatment are to be expected, for comparison of catecholamine indices between patients with 
Addison’s disease and healthy subjects Student’s t tests were computed. 
4.4.3.4.4 Predictors of NF-B binding activity variations 
In parallel to endocrine indices of variation, three indices of NF-B binding activity 
variations were computed (NF-B1>2: changes from pre-TSST to 10min post TSST; NF-
B2>3: changes from +10min to +60min; NF-B3>4: changes from +60min to +120 min). 
Next, each of the three indices were subjected to a stepwise regression analysis as 
dependent variable. As independent variables, the following parameters were included as 
predictors of NF-B1>2: cortisol, norepinephrine, and epinephrine levels at time-points -1min, 
+1min, and +10min, cort_incr1>3, NE_incr1>2, NE_decr2>3, E_incr1>2, and E_decr2>3. For 
NF-B2>3, additionally cortisol levels at time-points +20min, +30min, +45min, and +60min as 
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well as the variable cort_decr3>7 were included. No further norepinephrine and epinephrine 
concentrations were considered, as no variations in catecholamine levels are to be expected 
after time-point +10min. For NF-B3>4, also cortisol levels at +90min and +120min and the 
variable cort_decr3>9 were included as predictors. 
First, regression analyses were computed regarding all subjects. In these cases, the 
variable ‘group’ was included as an additional predictor. Next, regression analyses were 
calculated for each group separately, since in patients with Addison’s disease the altered 
endocrine status may cause other variables to influence NF-B binding activity trajectories 
than in healthy subjects. Due to the small numbers of subjects, these regression analyses 
are considered preliminary. Hence only regression analyses with an ANOVA of the 
respective model yielding a significant result (p<.05) will be presented. Adjusted R squares 
(R2) and standardized betas () will be given as indicators of model quality. 
4.4.4 Results 
4.4.4.1 Baseline Differences 
NF-B binding activity (t30=-0.90, p=.38) and norepinephrine levels (t30=0.99, p=.33) 
did not differ significantly between patients with Addison’s disease and healthy subjects, 
while in patients significantly lower free cortisol (t30=-5.04, p<.001) and epinephrine (t30=-
3.65, p=.001) levels were found compared to healthy subjects (see chapter 4.2). 
4.4.4.2 Salivary Free Cortisol Levels: Effects of Stress and Treatment  
In parallel to former results (see section 4.2), healthy subjects in the present subset 
showed significant increases in free cortisol levels in response to stress, while in patients 
with Addison’s disease, very low cortisol levels and no stress response was observed. 
Treatment of patients with hydrocortisone resulted in cortisol trajectories comparable to 
healthy subjects (repeated measures ANOVA: group: F2,29=19.92, p<.001; time: F8,232=56.32, 
p<.001; group-by-time: F16,232=16.15, p<.001). This was confirmed by univariate ANOVAs 
comparing free cortisol levels at time-point +10 and increases in free cortisol levels from 
time-point -1 to +10 between the three groups (cort+10: F2,31=27.30, p<.001; Scheffé tests: 
AD-HC vs. AD-NaCl: p<.001; AD-HC vs. HS-NaCl: p=.072; AD-NaCl vs. HS-NaCl: p<.001 – 
incr_cort1>3: F2,31=24.68, p<.001; Scheffé tests: AD-HC vs. AD-NaCl: p<.001; AD-HC vs. 
HS-NaCl: p=.99; AD-NaCl vs. HS-NaCl: p<.001). 
4.4.4.3 Catecholamine Levels: Effects of Stress 
In healthy subjects, stress additionally induced significant increases in norepinephrine 
and epinephrine. Patients with Addison’s disease showed norepinephrine levels comparable 
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to healthy subjects throughout the investigation, but significantly lower epinephrine levels and 
no epinephrine stress response (see section 4.2; repeated measures ANOVAs – 
norepinephrine: group: F1,30=0.82, p=.37; time: F8,240=9.59, p<.001; group-by-time: 
F8,240=0.88, p=.49; epinephrine: group F1,30=24.27, p<.001; time: F8,240=11.13, p<.001; group-
by-time: F8,240=6.35, p<.001). 
4.4.4.4 NF-B Binding Activity: Effects of Stress, Disease, and Treatment 
No group differences were found in NF-B binding activity trajectories: Neither did 
patients with Addison’s disease differ from healthy subjects, nor did hydrocortisone treatment 
have significant effects. Additionally, missing time effects indicate stress to not induce 
significant changes in NF-B binding activity. Table 4-9 summarizes the statistical results for 
both NF-B signal intensity and its transformation into percent change to baseline, while 
figures 4-17 and 4-18 depict the respective trajectories. 
Tab. 4-9: Results of repeated measures ANOVAs for NF-B signal intensity (1st row) and NF-B activity in percent 
change to baseline (2
nd
 row) with two between-group levels testing for group (column A) and treatment effects 
(column B), and with three levels comparing changes over time between all three groups (column C). 
  A: DISEASE 
AD-NaCl (n=11) /  
HS-NaCl (n=11) 
B: TREATMENT 
AD-HC (n=10) /  
AD-NaCl (n=11) 
C: DIS. x TREAT. 
AD-HC / AD-NaCl /  
HS-NaCl 
group: F1,20=0.57, p=.46 F1,19=0.01, p=.92 F2,29=0.53, p=.59 
time: F3,60=0.98, p=.40 F3,57=0.49, p=.65 F3,87=0.81, p=.48 
NF-B 
signal 
group x time: F3,60=2.19, p=.12 F3,57=0.64, p=.56 F6,87=0.79, p=.57 
group: F1,20=0.16, p=.69 F1,19=0.14, p=.72 F2,29=0.09, p=.92 
time: F3,60=0.61, p=.56 F3,57=0.17, p=.86 F3,87=0.50, p=.64 
NF-B 
% change 
group x time: F3,60=1.45, p=.25 F3,57=0.74, p=.50 F6,87=0.63, p=.67 
 
 
Fig. 4-17: NF-B-DNA binding activity (signal intensity) before and repeatedly after stress in patients (with and 
without hydrocortisone treatment) and healthy subjects. 
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Fig. 4-18: NF-B-DNA binding activity (% change to baseline) before and repeatedly after stress in patients (with 
and without hydrocortisone treatment) and healthy subjects. 
4.4.4.5 Endocrine Variables: Indices of Variation 
As expected, overall the groups did differ significantly in the degree cortisol levels 
increased in response to TSST (F2,31=24.68, p<.001). Thereby, patients showed no stress 
response and hence cortisol increases differed significantly from healthy controls (Scheffé 
test: p<.001). Hydrocortisone treatment resulted in cortisol increases comparable to 
increases in healthy subjects (Scheffé test: p=.99) and significantly different from untreated 
patients (Scheffé test: p<.001). In the subsequent decreases in cortisol levels, again 
significant group differences were found (cort_decr3>7: F2,31=19.71, p<.001; cort_decr3>9: 
F2,31=27.20, p<.001). Patients treated with hydrocortisone showed decreases comparable to 
healthy subjects (Scheffé tests; cort_decr3>7: p=.99; cort_decr3>9: p=.38), while decreases 
in cortisol levels differed significantly in both treated patients and healthy subjects from 
untreated patients (Scheffé tests; cort_decr3>7: AD-HC vs. AD-NaCl: p<.001; NaCl-AD vs. 
HS-NaCl: p<.001 – cort_decr3>9: AD-HC vs. AD-NaCl: p<.001; NaCl-AD vs. HS-NaCl: 
p<.001). Figures 4-19 depicts means and standard errors of changes in cortisol levels for 
each of the three groups separately. 
 
Fig. 4-19: Means and standard errors of stress-induced increases in cortisol levels from pre-TSST to +10min (incr. 
1>3), decreases from +10min to +60min (decr. 3>7), and decreases from +10min to +120min (decr. 3>9) in 
healthy subjects and patients with Addison’s disease with and without hydrocortisone treatment. 
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Regarding stress-induced norepinephrine changes, no significant differences 
between patients with Addison’s disease and healthy subjects were found (NE_incr1>2: t30=-
1.20, p=.24; NE_decr2>3: t30=-1.99, p=.056). Contrary, as patients with Addison’s disease 
showed very low epinephrine levels and no changes throughout the investigation, their 
changes in epinephrine levels differed significantly from healthy subjects (E_incr1>2: t30=-
4.17, p<.001; E_decr2>3: t30=-3.04, p=.005). Figure 4-20 depicts means and standard errors 
of changes in norepinephrine and epinephrine levels for patients with Addison’s disease and 
healthy subjects. 
 
Fig. 4-20: Means and standard errors of stress-induced changes in norepinephrine (NE, left) and epinephrine (E, 
right) levels from pre-TSST to +1min (incr. 1>2) and from +1min to +10min (decr. 2>3) in patients with Addison’s 
disease and healthy subjects. 
4.4.4.6 Regression Analyses: Predictors of NF-B Binding Activity Variations 
Based on the given NF-B trajectories (see fig. 4-18), the following indices of 
variations were calculated and included in regression analyses as dependent variable: 
decr.1>2 (=NF-B1–NF-B2), incr2>3 (=NF-B3–NF-B2), decr3>4 (=NF-B3–NF-B4). 
Out of 12 regression analyses with NF-B binding activity variations as dependent 
variables, only three yielded significant results. The free cortisol concentration immediately 
after TSST (+1min) was the only predictor of decreases in NF-B activity from pre-TSST to 
+10min after TSST (NF-kB_decr1>2) in healthy subjects, in that higher cortisol levels 
predicted more pronounced decreases in NF-B binding activity (R2=0.39, adjusted R2= 0.32, 
F1,10=5.66, p=.041, =0.62). Contrary, in patients with Addison’s disease more pronounced 
decreases in norepinephrine after TSST predicted attenuated decreases in NF-B binding 
activity (R2=0.41, adjusted R2= 0.35, F1,10=6.27, p=.034, =-0.64). In patients treated with 
hydrocortisone, steeper increases in cortisol levels in turn predicted less pronounced 
increases in NF-B binding activity from time-point +10min to +60min after TSST (R2=0.45, 
adjusted R2= 0.38, F1,9=6.57, p=.033, =-0.67). Scatterplots of these results (see figure 4-21) 
indicated that the third significant result is most probably caused by only one subject. 
Therefore this regression analysis was repeated excluding the respective patient and the 
regression no longer remained significant. 
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Fig. 2-21: Scatterplots summarizing the significant regression models regarding variations in NF-B binding 
activity. 
4.4.5 Conclusion 
The present findings are in line with previously reported endocrine stress responses 
in healthy subjects and patients with Addison’s disease (see section 4.2): While healthy 
subjects showed the expected significant increases in all endocrine parameters, i.e. free 
cortisol, norepinephrine, and epinephrine, patients with Addison’s disease responded to 
stress only with increases in norepinephrine. Furthermore, hydrocortisone treatment of 
patients with Addison’s disease resulted in post-TSST free cortisol levels as well as 
increases from pre- to post-TSST levels comparable to that found in healthy subjects. These 
findings provide the necessary basis for investigation of the role of glucocorticoids in NF-B 
activity with regard to stress by fulfilling the criteria of hormone subtraction (Addison’s 
disease) and replacement (hydrocortisone treatment). 
Interestingly, in the present study NF-B activity per se did statistically neither change 
in response to stress nor to hydrocortisone treatment and did not vary between patients with 
Addison’s disease and healthy subjects. This is in clear contrast to own previous findings of 
stress-associated increases in NF-B activity (Bierhaus et al., 2003). This contradictory 
findings may be explained, at least in part, by subjects in the present study being 
approximately 20 years older than in the previous. Nevertheless, considering age statistically 
did not change results and age did not reveal to be an important factor on its own (see 
above), but variation of age may also have been to low in the present study. Own preliminary 
data from a greater sample of 44 healthy subjects suggested that NF-B activity increases in 
response to stress only in younger subjects, while NF-B activity decreases in subjects older 
than 30 years (Wolf et al., 2005). In the present study just two 32 years old subjects came 
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close to this cut-off of 30 years. Consequently, the present NF-B trajectories, though not 
varying significantly in response to stress, mimicked more closely the courses found in older 
subjects. In parallel to these stress-induced decreases in NF-B activity, in vitro studies 
repeatedly found activity of NF-B in T-cells to decrease during aging (Trebilcock and 
Ponnappan, 1996a; Trebilcock and Ponnappan, 1996b), an effect most probably due to 
failure of full degradation of IB- and interpreted in the context of immunosenescence 
(Ponnappan et al., 2004; Ponnappan et al., 1999a; Ponnappan et al., 1999b; Trebilcock and 
Ponnappan, 1998). Contrary, in brains of aged mice and rats, DNA-binding activity of NF-B 
was found to be elevated (Korhonen et al., 1997; Toliver-Kinsky et al., 1997; Ye and 
Johnson, 2001). This is also true for nuclear extracts from other tissues including liver 
(Supakar et al., 1995; Walter and Sierra, 1998), heart (Helenius et al., 1996), and spleen 
(Poynter and Daynes, 1998). This points to tissue-specific age-related processes altering 
NF-B activity. It is therefore conceivable that age may also influence stress-associated 
changes in NF-B activity and that just the low number of subjects in the present study 
prevented its discovering. 
Furthermore, although no statistical significant differences in NF-B trajectories 
between healthy subjects and patients with and without hydrocortisone treatment were 
found, regression analyses revealed distinguishable influences of free cortisol and 
norepinephrine. In healthy subjects, free cortisol levels immediately after completion of TSST 
predicted decreases in NF-B activity from pre- to post-stress: With higher cortisol levels, this 
decrease in NF-B activity became more pronounced. This is in line with findings of 
glucocorticoids suppressing NF-B activity by interfering with its activation cascade, both via 
increasing IB- and via physical interaction between NF-B- and GR-DNA binding (Auphan 
et al., 1995; De Bosscher et al., 1997; De Bosscher et al., 2000b; Ray and Prefontaine, 
1994; Scheinman et al., 1995a). The fact that not maximum cortisol levels predicted NF-B 
decreases but the sample 10 minutes earlier suggests that intracellular cortisol signaling 
requires a certain time to cause changes in NF-B activity. In parallel to this finding, the 
same time lag of 10 minutes was found in NF-B response to infection (Naumann, 2000). It 
may be hypothesized that maximum stress-induced cortisol levels exert even more 
pronounced effects on NF-B activity at later time-points (i.e., 20 to 30 minutes after TSST) 
not considered in the present study. However, to our knowledge this is the first study 
showing glucocorticoids to inhibit NF-B activity in humans and also with regard to stress. 
These findings are further substantiated by data of patients with Addison’s disease. As 
patients with Addison’s disease can not respond to stress with increases in free cortisol 
levels, their NF-B trajectories were consequently not predicted from cortisol levels. Instead, 
associations between norepinephrine, the only hormone showing normal concentrations and 
stress responses in Addison’s disease, and NF-B activity were found. This finding points to 
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stress-induced norepinephrine also being an inhibitor of NF-B activity, as faster clearance of 
norepinephrine levels after stress predicted attenuated decreases or more pronounced 
increases in NF-B activity from pre- to post TSST. That norepinephrine inhibited NF-B 
activity suggests that in patients with Addison’s disease the cAMP/PKA pathway of 
catecholamine signal transduction may be involved, since as outline above, elevated levels 
of cAMP have repeatedly been shown to inhibit NF-B (Chen and Rothenberg, 1994; 
Neumann et al., 1995; Paliogianni et al., 1993; Parry and Mackman, 1997; Tsuruta et al., 
1995). Interestingly, former results in healthy subjects showed psychosocial stress to 
increase NF-B activity most probably by norepinephrine inducing the MAPK pathway 
(Bierhaus et al., 2003). But since patients with Addison’s disease do not secrete cortisol in 
response to stress, it may be hypothesized that norepinephrine inhibiting NF-B activity 
functions as a compensation of the missing inhibitory cortisol actions. 
Based on these results, glucocorticoid stress responses can not be regarded as 
necessary (and hence also not as sufficient) for suppressing NF-B activity. This conclusion 
is supported by free cortisol levels and stress-induced variations not predicting changes in 
NF-B activity in patients treated with hydrocortisone. However, norepinephrine as well did 
not predict changes in NF-B activity. It may be hypothesized that treatment with 
hydrocortisone represents an unusual situation in patients with Addison’s disease resulting in 
conflicting intracellular processes regarding (usual) catecholamine and (unusual) 
glucocorticoid signaling pathways interfering with the NF-B activation cascade. 
Nevertheless, treatment of patients resulted in NF-B trajectories phenomenologically similar 
to that found in healthy subjects. This especially concerns changes in NF-B activity from ten 
minutes to one hour after stress. Within this period, both healthy subjects and hydrocortisone 
treated patients showed increases in NF-B activity, while NF-B activity in untreated 
patients further declined (see figure 4.18). Unfortunately, none of the endocrine parameters 
appeared to be associated or to predict these later variations in NF-B activity. But as 
suppressed NFB activity implicates attenuated immune reactivity, prolonged decreased NF-
B activity subsequently to stress may put patients with Addison’s disease at a higher risk for 
infections during this period. However, studies with higher numbers of subjects will be 
needed to approve this hypothesis. 
In summary, the present study showed for the first time that stress-induced 
glucocorticoid concentrations inhibit NF-B activity in humans. Furthermore, findings in 
patients with Addison’s disease suggests that this immune-suppressive action of 
glucocorticoids is accomplishable also by norepinephrine, if glucocorticoid stress responses 
are missing in the long term. These results once more emphasize the need for studying 
complex and interrelated processes also in the human whole organism to allow for 
uncovering compensatory mechanisms. 
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5 SUMMARY, GENERAL DISCUSSION, AND OUTLOOK 
In the following, all results of the former sections will be briefly summarized and 
placed in perspective to the present literature (section 5.1) in order to discuss them 
subsequently in a greater context (section 5.2). Finally, an outlook regarding the role of 
Addison’s disease in PNI as well as the relevance of the findings for patients will be given. 
5.1 SUMMARY OF RESULTS 
The general aim of the present doctoral thesis was to scrutinize the method Addison’s 
disease with respect to its value as a complemental approach to decide on the relevance of 
psycho-neuro-immunological findings for human health and disease. In this regard, four 
specific problem formulations were investigated empirically, with two aiming at clarifying the 
endocrinological initial conditions of Addison’s disease and two representing applications of 
the method with respect to the immune system. The four problem formulations were: 
1) What are the initial basal endocrinological conditions in Addison’s disease? 
2) How are endocrine stress responses in Addison’s disease characterized? 
3) Does the immune system show influences from long-term altered endocrine stress 
responses? 
4) Does compensation of long-term altered endocrine stress responses occur intra-
cellularly at the level of NF-B? 
5.1.1 Initial Endocrinological Conditions in Addison’s Disease  
The first study shows salivary cortisol levels in patients with Addison’s disease to be 
notably elevated compared to standard values, which points to an over-replacement of 
patients already repeatedly reported by others (al-Shoumer et al., 1995; Florkowski et al., 
1994; Howlett, 1997; Lovas and Husebye, 2003; Peacey et al., 1997; Zelissen et al., 1994). 
Furthermore, on average 7 hours after the first replacement dose, free cortisol levels of 
patients with Addison’s disease fell below levels of healthy subjects, which is in line with data 
on pharmacokinetics and pharmacodynamics of cortisol (Howlett, 1997) and endorse 
recommendations of replacement regimens which allow for lower but more frequent doses 
(Howlett, 1997; Peacey et al., 1997). As in plasma cortisol, free cortisol trajectories of 
patients taking cortisone acetate are blunted and delayed compared to that of hydrocortisone 
(Feek et al., 1981). The missing linear association between hydrocortisone doses and 
resulting salivary cortisol levels supports findings showing no beneficial effects of 
hydrocortisone doses greater than 20mg a day (Wichers et al., 1999). 
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The second study revealed elevated general and physical fatigue scores in patients 
with Addison’s disease compared to healthy subjects, which is in accordance with former 
reports (Lovas et al., 2002). Contrary to subjective self-reports, no differences in mental 
fatigue, activity and motivation were found. Beside psychometric investigation of patients with 
Addison’s disease, the second study clearly focused on endocrine and cardiovascular stress 
responses. These stress-related endocrine as well as blood pressure findings are 
summarized in figure 5-1. 
 
Fig. 5-1: Summary of endocrine (cortisol: top row, norepinephrine and epinephrine: middle row) and blood 
pressure (bottom row) results. Data from healthy subjects are depicted in the left column, from patients with 
Addison’s disease in the middle column, and from patients treated with hydrocortisone in the right column. Please 
note that catecholamine responses in patients were not divided according to treatment vs. no treatment. 
Patients with Addison’s disease did not show stress-responses in free cortisol. 
Treatment of patients with 0.03mg/kg hydrocortisone resulted in stress-induced cortisol 
increases and maximum salivary cortisol levels mimicking those of healthy subjects. 
However, patients showed a more pronounced decrease in salivary cortisol levels thereafter. 
The findings of very low basal epinephrine levels accompanied by a trend to elevated basal 
norepinephrine levels are in line with prior findings, such as in patients with Addison’s 
disease (Bornstein et al., 1995), in experimental animals with reduced glucocorticoid 
synthesis (Wurtman, 1966), and after adrenalectomy (Eisenhofer et al., 1995; Merke et al., 
2000). The present minimal stress responses in epinephrine and slightly higher 
norepinephrine responses compared to healthy subjects in turn parallel findings in patients 
with isolated glucocorticoid deficiency (Zuckerman-Levin et al., 2001). As expected from 
studies showing glucocorticoid and mineralocorticoid replacement therapy to restore cardiac 
healthy subjects untreated patients HC-treated patients 
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functions (Fallo et al., 1999; Fallo et al., 1994), no significant differences in resting blood 
pressure or heart rate in patients with Addison’s disease compared to healthy subjects were 
observed. Additionally, hydrocortisone treatment did not influence the trajectories of both 
cardiovascular parameters suggesting permissive actions of cortisol (i.e., basal cortisol levels 
induced by replacement therapy) being sufficient for catecholamine stress effects on blood 
pressure and heart rate (Allolio et al., 1994). 
5.1.2 Effects of Altered Endocrine Stress Responses on the Immune System 
To investigate the effects of altered endocrine stress responses on related immune 
functions, percentages of blood cells, stimulated IL-6 production, stimulated cell proliferation, 
and NF-B activity were measured repeatedly over the course of the experiment. The main 
results are summarized in figure 5-2. 
 
Fig. 5-2: Summary of immune (white blood cells: top row, LPS-stimulated IL-6 production: 2
nd
 row, PHA-
stimulated cell proliferation: 3
rd
 row) and NF-B (bottom row) results. Data from healthy subjects are depicted in 
the left column, from patients with Addison’s disease in the middle column, and from patients treated with 
hydrocortisone in the right column. 
healthy subjects untreated patients HC-treated patients 
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5.1.2.1 Blood Cell Counts 
In detail, patients with Addison’s disease showed slow increases in numbers of white 
blood cells, while healthy subjects showed most pronounced increases between one and two 
hours after stress. This is due to the various changes in percentages in cell subtypes. While 
immediate stress responses in lymphocytes and granulocytes were comparable in patients 
and healthy controls, at one and two hours after stress differences in trajectories were found 
with patients showing a continuation of prior trends, i.e. lymphocytes continued increasing 
and granulocytes continued decreasing. These findings reflect the two phases typically found 
after catecholamine administration and emphasize the interpretation of early events being 
mediated by catecholamines (Benschop et al., 1996) and later time-points being influenced 
by glucocorticoids (Dhabhar et al., 1996). Nevertheless, hydrocortisone treatment of patients 
did not restore these patterns, as would have been suggested. 
5.1.2.2 LPS-Stimulated IL-6 Production and its Glucocorticoid Sensitivity 
In LPS-stimulated IL-6 production, no baseline differences could be found between 
healthy subjects and patients with Addison’s disease. However, stress-related trajectories of 
LPS-stimulated IL-6 production did vary: While healthy subjects showed decreases 
immediately after stress and slow increases during the following two hours, reaching levels 
above baseline at two hours after TSST, patients with Addison’s disease showed increases 
in LPS-stimulated IL-6 levels immediately after stress with little variations thereafter. 
Treatment of patients with hydrocortisone resulted in pronounced decreases in IL-6 
production ten minutes after TSST with a return to baseline 1 hour after TSST, thereby 
mimicking more closely the trajectories found in healthy subjects than in untreated patients. 
Unfortunately, just a few studies are available measuring stress-related LPS stimulated IL-6 
production in humans and in whole blood assays and these studies additionally report 
contradictory results. Thus, findings of Rohleder et al. exposing men (Rohleder et al., 2001) 
and young women in the luteal phase (Rohleder et al., 2003b) to the TSST and of Smits et 
al. investigating the effects of exercise in oarsmen (Smits et al., 1998) are in parallel with the 
present findings in healthy subjects. Contrary, the trajectories of LPS-stimulated IL-6 
production in patients with Addison’s disease reflect those found by Goebel et al. in healthy 
volunteers during an acute speech stress (Goebel et al., 2000), by Maes et al. investigating 
academic examination stress (Maes et al., 1998), and by Rohleder et al. exposing young 
women taking oral contraceptives to the TSST (Rohleder et al., 2003b). Studies in 
adrenalectomized animals are rare as well and procedures additionally differ too much from 
procedures in the present studies to compare results. For example, Meltzer et al. not only 
used iv LPS injection in adrenalectomized and intact rats, but also investigated the effects of 
footshock on splenic cytokine production (Meltzer et al., 2004), with spleen cells being known 
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to respond differently to glucocorticoids due to different expression levels of glucocorticoid 
receptors (Miller et al., 1998). The findings in humans suggest stress-related IL-6 production 
to be influenced by gender or sex hormones. However, no influence at least from gender was 
found in the present study.  
Regarding glucocorticoid sensitivity of IL-6 producing cells, no differences between 
healthy subjects and patients with Addison’s disease were found. Only hydrocortisone 
treatment resulted in pronounced decreases in glucocorticoid sensitivity, which appeared to 
be due to LPS-stimulated IL-6 levels being pronouncedly decreased after hydrocortisone-
treatment, thereby affecting IC50 calculation. Overall, the course of IL-6 IC50 slightly increased 
in response to stress, indicating attenuated glucocorticoid sensitivity immediately after stress. 
Own former studies suggest glucocorticoid sensitivity also to be influenced by gender or sex 
hormones: glucocorticoid sensitivity decreased in women and older men, increased in 
younger men and women using oral contraceptives, and did not change in women being in 
the luteal phase of their menstrual cycle (Rohleder et al., 2003a). But again, in the present 
study no influence of gender could be observed. 
5.1.2.3 PHA-Stimulated Cell Proliferation and its Glucocorticoid Sensitivity 
In PHA-stimulated cell proliferation, only significant time effects were found, indicating 
stress to result in increases in PHA-stimulated cell proliferation and decreases in 
glucocorticoid sensitivity. The latter was most pronounced two hours after stress. The finding 
of stress-induced increases in PHA-stimulated cell proliferation is in line with other data 
reporting of enhanced proliferation in response to a social stressor (Bohus et al., 1993) and 
five weeks of isolation and water scheduling in rats (Jessop et al., 1987). Contrary, 
suppressed PHA-stimulated proliferation was reported in humans in response to a Stroop 
test (Bachen et al., 1992), in peripheral T-cells (Connor et al., 1997) as well as in splenocytes 
(Ferry et al., 1991) in rats in response to a forced swim tests, and in juvenile squirrel 
monkeys two days after 3 hours of separation (Friedman et al., 1991). No changes in 
proliferation were observed in response to a difficult puzzle task (Brosschot et al., 1992) or in 
response to an electric shock with loud white noise (Weisse et al., 1990). Only a few studies 
measured sensitivity and again the results are contradictory. Comparable to the present 
study, decreases in glucocorticoid sensitivity in peripheral blood mononuclear cells (PBMCs) 
were found on days with academic examination stress (Sauer et al., 1995). On the other 
hand, acute stress did not induce any significant changes in glucocorticoid sensitivity of PHA-
stimulated splenocyte and blood lymphocyte proliferation in rats (Bauer et al., 2001), and our 
own laboratory found acute stress in healthy subjects to be associated with increased 
glucocorticoid sensitivity (Rohleder et al., 2005). However, in all the cited studies not only 
different types and durations of stressors, but also different tissues and PHA concentrations 
were employed, which hampers an integration of the present findings considerably. 
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Furthermore, no differences between patients with Addison’s disease and healthy subjects 
and no effect of hydrocortisone treatment in patients were found. These findings lead to the 
same conclusion as drawn by Keller et al. (Keller et al., 1983) that stress effects on 
lymphocyte function are glucocorticoid independent. 
5.1.2.4 NF-B Activity 
The fourth problem formulation concerned the role of the transcription factor NF-B 
as mediator of immune-suppressive glucocorticoid actions. In the present study, NF-B 
activity did neither change in response to stress nor to hydrocortisone treatment, and did 
further not vary between patients with Addison’s disease and healthy subjects. This is on the 
one hand in clear contrast to own previous findings of stress-associated increases in NF-B 
activity (Bierhaus et al., 2003). However, age differs in the two studies and is known to 
influence NF-B activity (Ponnappan et al., 2004; Trebilcock and Ponnappan, 1998). Thus, 
on the other hand the present NF-B trajectories, though not varying significantly in response 
to stress, mimicked more closely the courses previously found in older subjects (Wolf et al., 
2005). Contrary, in brain of aged mice and rats, DNA-binding activity of NF-B was found to 
be elevated (Korhonen et al., 1997; Toliver-Kinsky et al., 1997; Ye and Johnson, 2001) as it 
was the case in other tissues, such as liver (Supakar et al., 1995; Walter and Sierra, 1998), 
heart (Helenius et al., 1996), and spleen (Poynter and Daynes, 1998). This points to NF-B 
activity being not only age-dependent but also tissue specific. However, treatment of patients 
resulted in NF-B trajectories phenomenologically similar to that found in healthy subjects, 
with both healthy subjects and hydrocortisone treated patients showing increases in NF-B 
activity from ten minutes to one hour after stress, while NF-B activity in untreated patients 
further declined. 
Regression analyses revealed distinguishable influences of free cortisol and 
norepinephrine. In healthy subjects, higher cortisol levels immediately after completion of 
TSST predicted more pronounced decreases from pre- to post-stress in NF-B activity. This 
is in line with findings of glucocorticoids suppressing NF-B activity by interfering with its 
activation cascade (Auphan et al., 1995; De Bosscher et al., 1997; De Bosscher et al., 
2000b; Ray and Prefontaine, 1994; Scheinman et al., 1995a). In patients with Addison’s 
disease, faster clearance of norepinephrine subsequent to stress predicted attenuated 
decreases or more pronounced increases in NF-B activity from pre- to post TSST. This 
indirect finding of norepinephrine inhibiting NF-B activity is in accordance with studies 
showing elevated levels of cAMP to inhibit NF-B (Chen and Rothenberg, 1994; Neumann et 
al., 1995; Paliogianni et al., 1993; Parry and Mackman, 1997; Tsuruta et al., 1995). No 
predictors of NF-B variations were found for patients treated with hydrocortisone. 
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5.2 GENERAL DISCUSSION 
The first two of four problem formulations concerned the initial endocrinological 
conditions, which have to be taken into consideration when studying patients with Addison’s 
disease in order to decide on the relevance of psychoneuroimmunological findings for human 
health and disease. Thus, in the following the respective implications of these findings will be 
discussed to provide a framework for interpretation of the subsequent immunological 
findings. 
5.2.1 Initial Endocrinological Conditions 
5.2.1.1 Initial Basal Conditions 
Generally, measurement of salivary free cortisol in Addison’s patients has been 
shown to be a reliable method also applicable in further studies. Beyond that, the present 
results regarding the replacement of basal glucocorticoid levels in Addison’s disease clearly 
show patients to be over-treated. This questions the comparability of the basal hormonal 
situation in patients with Addison’s disease and healthy persons and hence also has 
implications for Addison’s disease as an alternative method in stress research. As outlined 
above (section 2.1.4), basal glucocorticoid levels exert permissive functions in stress 
responses, in that their cardiovascular, immunological, and cognitive effects as well as their 
effects on metabolism permissively help mediating the pending or ongoing stress-response 
(Sapolsky et al., 2000). This implies consequences to occur whether or not there is a stress-
induced increase in glucocorticoid concentrations (Ingle, 1952), but also that normal basal 
glucocorticoid levels have to be regarded as mandatory. Furthermore, in parallel to the 
concept of allostasis (i.e., ability to achieve stability through change) and allostatic load in 
stress research suggested by McEwen et al. (McEwen, 1998a), it can be argued that 
glucocorticoid replacement in patients with Addison’s disease produces pronounced 
activations of allostatic systems every day. This represents a challenge to allostatic systems 
of the organism and this wear and tear has a price, which McEwen et al. termed allostatic 
load. Allostatic load in turn was repeatedly associated with increased health risks, like 
elevated ambulatory blood pressure (Schnall et al., 1992), increased progression of 
atherosclerosis (Everson et al., 1997), atrophy of dendrites of pyramidal neurons in the 
hippocampus (McEwen et al., 1995; Uno et al., 1989), and changes in immune system 
responses (Cohen et al., 1991; Dhabhar and McEwen, 1997; Hadid et al., 1996). So far, it is 
largely unknown, which mechanisms in Addison’s disease are present to compensate the 
allostatic load produced by replacement therapy and on what long-term costs for health. 
Therefore, when investigating the effects of stress on immune parameter in patients with 
Addison’s disease, results have to be interpreted with caution. Distinctive features in patients 
SUMMARY, GENERAL DISCUSSION, AND OUTLOOK 186 
with Addison’s disease may not be ascribable solely to the missing cortisol stress response 
but rather to glucocorticoid (over-)treatment, which results in non-physiological high ‘basal’ 
glucocorticoid levels and evokes compensatory mechanisms in other bodily systems. 
The straightest implication of the present results for further investigations concerns 
the study design. For studying stress effects in patients with Addison’s disease in 
comparison to healthy controls, patients should avoid ingestion of glucocorticoid replacement 
several hours prior to study. Otherwise patients will already at baseline show cortisol levels 
far higher than those healthy subjects will show in response to a laboratory stressor. Again, 
this will hamper a comparison of patients and healthy subjects as well as the interpretation of 
results. For this reason, subjects in the second study were asked to postpone the second 
dose of glucocorticoid replacement at the day of investigation. Since in all patients the first 
saliva sample was collected at about 2p.m., this requirement resulted in baseline free cortisol 
levels even lower than those of healthy subjects. Given the free cortisol trajectories found in 
the first study, this actually was to be expected. Nevertheless, it raises a general 
methodological question: For satisfying the criterion of hormone subtraction in stress 
research, may a missing cortisol stress response or no cortisol at all be considered 
necessary? Basically, this concerns which actions of glucocorticoids one would like to 
differentiate. According to Sapolsky et al., elimination of stress-induced glucocorticoid levels 
is one criterion which allows for differentiation between stimulatory, suppressive, and 
preparative actions of glucocorticoids. Lack of glucocorticoids for several days before a 
stressor allows to decide whether permissive glucocorticoid actions are required (Sapolsky et 
al., 2000). As it is not tenable to ask patients for discontinuing of glucocorticoid replacement 
therapy for several days, we decided in favor of the outlined procedure. However, the 
rationale for the details were on the one hand related to the circadian rhythm of cortisol. Due 
to these variations, it is preferable to schedule investigations including measures of cortisol in 
the afternoon, at the time when cortisol levels show less variations (Kirschbaum and 
Hellhammer, 1989). On the other hand, patients with Addison’s disease take different doses 
of glucocorticoid replacement as well as different types of medication. Thus, free cortisol 
levels in patients would have been unpredictable starting the experiment at an earlier hour. 
The resulting variations in free cortisol levels between patients would have hampered not 
only the comparability between patients, but also rendered it impossible to utilize a defined 
dose of hydrocortisone for mimicking cortisol stress responses of healthy subjects. 
Nevertheless, it is important to keep in mind that investigation of patients with Addison’s 
disease may not be instrumental in deciding on permissive glucocorticoid actions, since other 
criteria (e.g., time-course, homeostasis) for determining whether a particular glucocorticoid 
action is permissive require basal levels of glucocorticoids. Which in turn raises an issue 
already discussed (see above). 
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5.2.1.2 Initial Stress-Related Conditions 
5.2.1.2.1 Stress-related free cortisol levels and hydrocortisone substitution 
Beside these considerations regarding basal cortisol levels, the chosen study design 
proved to be effectually concerning the investigation of stress-related distinctive features in 
Addison’s disease. The present study showed for the first time also empirically that no free 
cortisol stress response is to be observed in patients with Addison’s disease. Thereby, the 
method Addison’s disease fulfills the criterion of hormone subtraction. Furthermore, the 
observed low baseline cortisol levels in patients allow additionally for realization of the 
criterion of substitution by hydrocortisone injection. Because as outlined above, findings of an 
effect being associated with missing glucocorticoid stress responses only provide evidence 
of glucocorticoids being necessary for this effect. To establish that changes result specifically 
from lack of glucocorticoid activity, it has to be demonstrated that appropriate administration 
of exogenous glucocorticoids reverses these changes (Sapolsky et al., 2000). Therefore, we 
first determined a dose of 0.03mg/kg hydrocortisone iv in healthy subjects being appropriate 
in inducing stress-like free cortisol levels. Subsequently, half of the patients investigated in 
the second study were treated with this dose of hydrocortisone. The resulting free cortisol 
levels closely mimicked stress-induced increases and maximum concentrations of healthy 
subjects. Thus, for these early time-points the chosen study design turned out to be effective. 
Then again, for later time-points, a faster clearance of free cortisol in patients with Addison’s 
disease was observed. Hence, treatment of patients with a bolus injection is not appropriate 
to closely mimic the entire free cortisol trajectory found in healthy subjects. In healthy 
subjects, HPA-reactivity is adjusted to stress duration and this context-dependent HPA-
reactivity is controlled by a negative feedback circuit (Chrousos, 1998b; Dallman, 2000). To 
mimic these cortisol dynamics more closely, it might have been advantageous to administer 
hydrocortisone as an infusion rather than a bolus injection. Additionally, an infusion could 
have been applied already shortly before the onset of the stressor and thereby substitute 
also the increasing cortisol levels as the stressor continues. In the present study, such a 
procedure would have been not only unpleasant for the patients, but also it was practically 
not feasible without the disadvantages resulting from adjustments in the study protocol 
outweighing the disadvantages of a bolus injection. Nevertheless, the resulting differences in 
free cortisol trajectories between patients treated with hydrocortisone and healthy subjects is 
an issue to be taken into consideration regarding the interpretation of immune-related results. 
5.2.1.2.2 Stress-related catecholamine levels 
Regarding catecholamine stress responses, the findings of very low to absent 
epinephrine levels accompanied by slightly elevated norepinephrine levels are again in 
accordance with former findings (Bornstein et al., 1995; Eisenhofer et al., 1995; Merke et al., 
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2000; Wurtman, 1966), albeit to our knowledge this has not been demonstrated so far during 
stress and in humans contemporaneously. However, to which extent norepinephrine 
compensates nearly nonexistent epinephrine levels is debatably. Basically, norepinephrine 
and epinephrine differ in their binding affinity to adrenoceptors: While norepinephrine 
predominantly activates - and 1-adrenoceptors and is a weak stimulator of 2-
adrenoceptors, epinephrine is a strong stimulator of -adrenoceptors (Motulsky and Insel, 
1982). Adrenoceptors in turn are not uniformly distributed. For example, 2-adrenoceptors 
are not expressed on Th2 cells (Sanders et al., 1997). Theoretically, this might raise the 
question, if in cases of lacking high-affinity ligands (i.e. epinephrine) binding of a ligand with 
lower affinity (i.e. norepinephrine) to the respective receptor will in all circumstances induce 
the identical signal. Generally, if a ligand with higher receptor affinity is lacking, the ligand 
with the next lower affinity will bind preferentially to this respective receptor, thereby inducing 
the same signal as the high-affinity ligand. Adjustment of receptor expression and sensitivity 
may support this compensation (Elenkov et al., 2000). Further, since epinephrine is 
synthesized in the adrenal medulla by conversion of norepinephrine (Bornstein et al., 1995), 
it can be argued that without such conversion norepinephrine levels are slightly elevated, 
because they include the fraction to be converted to epinephrine. Thus, it is conceivable to 
assume that norepinephrine compensates lacking epinephrine not only at the receptor level 
with regard to signal induction, but also with regard to circulating levels. Hence, in the 
present thesis Addison’s disease will be primarily understood as a model for missing 
glucocorticoid stress responses. Nevertheless, regarding interpretation of immune-related 
results, lacking epinephrine levels will be considered where appropriate. 
5.2.1.2.3 Cardiovascular stress-response 
The present findings regarding cardiovascular parameters encourage the assumption 
of norepinephrine compensating lacking epinephrine levels, as no differences in blood 
pressure and heart rate trajectories were found between patients with Addison’s disease and 
healthy subjects and additionally hydrocortisone treatment revealed to be without any effect. 
Certainly the missing effect of hydrocortisone treatment may also be attributable to dosage 
and/or frequency being too low to exert effects. But the hydrocortisone dose utilized in the 
present study was more in a physiological range of cortisol levels than the doses used in 
studies observing hydrocortisone-induced increases in blood pressure (cf. Kelly et al., 1998; 
Whitworth et al., 1995). This points to glucocorticoids at physiological concentrations rather 
exerting permissive than stimulatory actions, an interpretation supported by findings of Allolio 
et al. demonstrating the importance of normal glucocorticoid levels for catecholamine 
responsiveness of 2-adrenoceptor in patients with Addison’s disease (Allolio et al., 1994). 
And in this regard, glucocorticoid and mineralocorticoid replacement therapy appears to be 
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successful, since it was previously shown to restore cardiac functions in patients with 
Addison’s disease (Fallo et al., 1999; Fallo et al., 1994). This is also suggested by the finding 
of missing differences in resting blood pressure and heart rate between patients with 
Addison’s disease and healthy subjects in the present study. 
5.2.1.2.4 Psychometric data 
In addition to endocrine and cardiovascular data, also psychometric data were 
collected in the present studies. These included stress-related questionnaires measuring 
perceived stress, chronic stress, and stress resistance, but also questionnaires measuring 
mood, fatigue, depressive symptoms, self-esteem, and anxiety. Interestingly, with the one 
exception of patients reporting more general and physical fatigue (Multidimensional Fatigue 
Inventory; Smets et al., 1995), patients with Addison’s disease did not differ in any of the 
questionnaires from healthy subjects and none of the questionnaires were related to any of 
the endocrine data (data not shown). Whereas the former is in clear contrast to oral 
information of, for example, reduced physical resilience or reduced stress resistance, the 
latter is a quite common phenomenon in stress research. In both cases it may only be 
speculated as for what reason data do not correspond. However, from a methodological 
point of view, missing distinctive features in Addison’s disease other than an altered 
endocrine state have to be regarded as advantageous for a stringent interpretation of results. 
5.2.1.2.5 Altered endocrine state and diseases 
Taken together, patients with Addison’s disease are characterized by elevated basal 
free cortisol levels at most times throughout the day accompanied by a lacking cortisol stress 
response. Beside understanding Addison’s disease as a method, this endocrine situation 
may as well be translated into basal hypercortisolism accompanied by stress-related HPA-
hyporeactivity, which from a patient’s point of view raises the question, what consequences 
for health and disease this combination implicates. To predict such consequences, first it 
would be necessary to determine which diseases are associated with basal and which with 
stress-related hypo- or hyperactivity and further, which diseases are characterized by a 
combination of these. For example in diabetes, basal hypersecretion has been found to be 
associated with impaired cortisol stress responsiveness (Chan et al., 2003). Next, cause and 
consequence have to be distinguished, but often processes are interrelated and no clear-cut 
distinction can be made, such as HPA dysregulation in diabetes involving impaired 
glucocorticoid negative feedback sensitivity and hypoinsulinemia, hyperglycemia and/or 
hypoleptinemia increasing central drive of the HPA axis (Chan et al., 2003). The picture 
becomes even more complicated by including short- vs. long-term effects: While 
hyperthyroidism is primarily associated with hypercortisolism, long-term experimentally-
induced hyperthyroidism is associated with diminished adrenal functional reserve (Johnson 
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et al., 2005). Furthermore, glucocorticoid concentrations are not directly related to 
glucocorticoid actions, as a wide range of factors (see section 2.3.4.2) modulate 
glucocorticoid sensitivities of target tissues (Bamberger et al., 1996). Unfortunately, this 
leads to the conclusion that not only in patients with Addison’s disease virtually every 
pathophysiological state may be predicted from or explained by the given endocrine 
situation, depending on which and how many factors will be considered or discounted. 
Wherewith one arrives at the starting point of the present thesis, which is to improve exactly 
this situation. 
Nevertheless, specifically in autoimmune Addison’s disease the components of 
autoimmune polyendocrine syndromes 1 (APS-1) and APS-2 tend to develop in a specific 
sequence. In APS-1, chronic mucocutaneous candidiasis is generally the first disease to 
appear, followed by hypoparathyroidism, which usually precedes Addison’s disease (Betterle 
et al., 1998). In APS-2, type 1 diabetes mellitus precedes Addison’s disease, with in turn 
mostly precedes chronic thyroiditis, whereas Graves’ disease/hyperthyroidism usually 
precedes and Hashimoto’s thyroiditis/hypothyroidism follows Addison’s disease (Betterle et 
al., 2004). However, both APS-1 and APS-2 are associated with further, more or less 
frequently occurring so-called minor diseases. Beside every component of APS-1 potentially 
being found as co-morbidity in APS-2 and the other way around, minor diseases are 
gastrointestinal diseases, such as chronic atrophic gastritis, pernicious anemia, and 
malabsorption, chronic active hepatitis, or autoimmune skin diseases, such as vitiligo and 
alopecia (Betterle et al., 1998; Betterle et al., 2004). Given the etiologies and 
immunogenetics of Addison’s disease (Betterle and Zanchetta, 2003; Peterson et al., 2000), 
it is certainly not assumed that preceding diseases cause later appearing diseases. But from 
a psychoneuroendocrinological and -immunological point of view it would be most interesting 
to longitudinally survey patients with Addison’s disease in order to reveal the impact of 
lacking glucocorticoids and various replacement regimens on the developmental pace and 
progress of following minor diseases not sharing a common immunogenetic cause with 
Addison’s disease. However, maybe due to the small number of patients and/or the cross-
sectional design, no associations between etiologies, disease durations, replacement 
regimens, time intervals between disease onsets, and number or types of co-morbidities 
were found in the present studies (data not shown). 
5.2.1.3 Summary 
In summary, patients with Addison’s disease show no cortisol stress response but 
elevated basal free cortisol levels at most times throughout the day. The lacking cortisol 
stress response thereby constitutes the primary requirement for the present thesis, with the 
findings regarding free cortisol levels resulting from glucocorticoid replacement therapy 
setting the specifics for study design. The almost inexistent epinephrine levels and stress 
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responses are regarded as unproblematic since norepinephrine is to be expected to 
compensate lacking epinephrine actions. No distinctive features in patients with Addison’s 
disease were found with respect to psychometric and cardiovascular data. Thus, they do not 
represent influencing factors mandatory to consider for further investigations and 
interpretation of subsequent results. Based on these findings, investigation of patients with 
Addison’s disease can be regarded as a valuable approach helping to reveal the relevance 
of a long-term altered endocrine stress response for health and disease. 
5.2.2 Effects of Altered Endocrine Stress Responses on the Immune System 
Beside empirically establishing the initial endocrinological conditions in Addison’s 
disease, the present thesis also aimed at applying this approach to 
psychoneuroimmunological problem formulations. In this regard, several immune parameters 
were measured before and repeatedly after stress: Numbers and percentages of blood cell 
subtypes, LPS-stimulated IL-6 production, PHA-stimulated cell proliferation, glucocorticoid 
sensitivities of the latter two, and NF-B activity. These parameters were chosen on behalf of 
their widespread use in PNI and/or the central role these parameters are playing in the 
immune system (see section 4.2 und 4.3). 
5.2.2.1 Baseline Differences 
Interestingly, in none of these parameters differences between patients with 
Addison’s disease and healthy subjects were found before stress onset. Considering the high 
free cortisol levels induced by replacement therapy, it certainly would have been reasonable 
to expect at least some distinctive features in patients with Addison’s disease. Especially, 
since the measure of glucocorticoid sensitivity of IL-6 production and cell proliferation not 
only involved stimulation of immune cells, but also inhibition by dexamethasone, and thus 
processes compensating for almost permanently elevated free cortisol levels – at least those 
not involving increased production of corticosteroid-binding globulin or 11-HSD2 – should 
have become apparent. But the dose-response curves in both parameters were virtually 
identically. Alternatively, it may have been argued that patients were asked to skip their 
second replacement dose and thus their free cortisol levels were atypical low. But again, 
immune parameters turned out to be unaffected by this altered endocrine state. Although 
these findings are rather surprising, from a patient’s point of view they may be regarded as 
advantageous, as well as from a methodological point of view, as they allow to focus on 
stress-related reactivity. Conversely, these results suggest that basal glucocorticoid activity 
per se does not alter immune states, but this assumption certainly has to be proven by future 
studies investigating additional immune parameters and functions. 
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5.2.2.2 Stress-Related Differences 
The measure of number and proportion of immune cells in the circulation can be 
regarded as the easiest way to gain insight into stress effects on immune system activation. 
Thereby, initially increasing cell numbers point to immune activation due to recruitment of 
cells, while subsequently decreasing numbers of cells point to redistribution of cells to 
inflammatory sites. The most pronounced differences in this stress-related immune cell 
trafficking between patients with Addison’s disease and healthy subjects were observed in 
the lymphocyte proportion. Comparing numbers and proportion of cell subtypes, changes in 
white blood cell numbers in healthy patients appear to be due to lymphocyte recruitment 
immediately after stress, followed by their redistribution one hour after stress and a 
recruitment of granulocytes between one and two hours after stress. In patients with 
Addison’s disease, the slow increase in white blood cell numbers over the course of the 
investigation is attributable solely to recruitment of lymphocytes. Both findings closely reflect 
previous findings in healthy subjects (Benschop et al., 1996) and adrenalectomized rats 
(Dhabhar et al., 1996), which additionally suggest catecholamines to be responsible for 
recruitment and glucocorticoids for redistribution. The present finding in patients with 
Addison’s disease supports this interpretation of glucocorticoids being important for 
lymphocyte redistribution. But while the processes in healthy subjects do make sense 
physiologically (see section 4.3.5), a recruitment of lymphocytes to peripheral blood without 
their subsequent migration to inflammatory sites cannot be regarded as immunological 
advantageous, since it attenuates the ability of the immune system to efficiently respond to 
local infections. Stress thus increases for several hours the risk of infections in patients with 
Addison’s disease. Interestingly, treatment of patients with hydrocortisone did not restore cell 
number trajectories. This may be explained on the one hand by the faster clearance of free 
cortisol levels in patients resulting in cortisol levels at later time-points being to low to provide 
for redistribution. Alternatively, over-treatment of patients with glucocorticoid replacement 
may have decreased the sensitivity of cells to regulatory actions of glucocorticoids regarding 
the expression of cell adhesion molecules (Cronstein et al., 1992; Pitzalis et al., 2002). 
However, findings in LPS-stimulated IL-6 production rather argue for the former 
interpretation, as patients do not show – at least in general – a reduced sensitivity of immune 
cells to glucocorticoid signaling. In fact, patients in the present study showed a very 
pronounced decrease in LPS-stimulated IL-6 production after hydrocortisone treatment 
suggesting a preserved sensitivity of peripheral blood mononuclear cells to inhibiting 
glucocorticoid action. The assumption of glucocorticoids suppressing IL-6 production is also 
supported by findings in healthy subjects, in which higher free cortisol levels were associated 
with lower LPS-stimulated IL-6 production and vice versa. Furthermore, untreated patients 
characterized by very low free cortisol levels showed increases in LPS-stimulated IL-6 levels 
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in response to stress without further variations in the subsequent two hours. Taken together, 
all these data clearly point to glucocorticoids suppressing IL-6 production. 
What causes the increase in LPS-stimulated IL-6 production after stress seen in 
patients with Addison’s disease? One self-evident candidate is norepinephrine, which is 
known to up-regulate IL-6 production (Maimone et al., 1993; Norris and Benveniste, 1993). 
Own previous findings support this assumption, as norepinephrine was shown to increase 
NF-B activity (Bierhaus et al., 2003) and increased NF-B activity in turn will result in 
increased cytokine production (McKay and Cidlowski, 1999). Unfortunately, in the present 
study NF-B activity in untreated patients decreased instead of increased in response to 
stress and again norepinephrine appeared to mediate this effect. This points to different 
signaling pathways by which norepinephrine may influence cytokine production. Thus, while 
suppressing NF-B activity for example by activating the cAMP/PKA pathway via -
adrenoceptor coupling to Gs-protein (Elenkov et al., 2000), norepinephrine may directly or 
indirectly increase cytokine production by another pathway. However initiated, increased IL-6 
production puts patients with Addison’s disease on risk of enhanced inflammatory responses 
during and several hours after stress. 
Another already mentioned conclusion to be drawn from these data is that peripheral 
blood mononuclear cells remain sensitive to glucocorticoid signaling despite long-term 
replacement therapy and despite long-term lacking glucocorticoid stress responses. 
Importantly, this conclusion is based on the trajectories of LPS-stimulated IL-6 production, 
not on the findings regarding glucocorticoid sensitivity measured by dexamethasone dose-
response curves. In these actual glucocorticoid sensitivity measures, no differences between 
healthy subjects and patients were found, just a slight decrease in sensitivity immediately 
and one hour after stress, respectively. Although glucocorticoid sensitivity in patients showed 
very pronounced decreases in response to hydrocortisone treatment, this effect was solely 
mediated by the pronounced effects of hydrocortisone on LPS-stimulated IL-6 production. 
Hence, it has to be concluded that the presently utilized assay was ill-suited to reflect 
glucocorticoid sensitivity properly due to a ceiling effect induced by hydrocortisone. If it would 
not have been for this ceiling effect, surely the use of dexamethasone as suppressant in the 
whole blood assay instead of the more obvious use of hydrocortisone would have to be 
discussed. But in the given situation, the use of dexamethasone – theoretically – even 
increased the change to detect differences in glucocorticoid sensitivity due to its higher 
receptor binding affinity and independence of CBG and 11-HSD2 levels. Nevertheless, in 
future studies it might be interesting to use both dexamethasone and hydrocortisone in 
parallel and compare their effects. However, beside these methodological considerations, the 
fact remains that patients with Addison’s disease respond surprisingly sensitive to 
glucocorticoid signaling. Since at most times throughout the day patients show pronouncedly 
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elevated instead of almost undetectable free cortisol levels, it may be hypothesized that this 
conserved glucocorticoid sensitivity will result in attenuated immune responses to challenge. 
This leaves patients not only with a higher risk for infections during times of stress (see 
above), but also with an impaired inflammatory response at most times of the day. 
Although not in the focus of the present thesis, the finding of free cortisol levels 
predicting NF-B activity in healthy subjects is worth to mention. It is well known that 
glucocorticoids repress NF-B activity und by this mechanism exert many of its suppressive 
actions (De Bosscher et al., 1997; De Bosscher et al., 2000b; Ray and Prefontaine, 1994; 
Scheinman et al., 1995a). But to the best of our knowledge, this is the first time that this was 
also shown in humans and for stress-related glucocorticoid levels. 
The last two parameters not addressed so far are PHA-stimulated cell proliferation 
and glucocorticoid sensitivity of PHA-stimulated cell proliferation. Here, neither untreated nor 
hydrocortisone treated patients show any differences compared to healthy subjects. 
Therefore it has to be concluded that cell proliferation appears to be uninfluenced by 
glucocorticoids. It may further be concluded that as soon as an immune response is initiated 
and the third line of immune defense, i.e. adaptive immunity comes into operation, 
glucocorticoids no longer interfere with these processes. But although proliferation of T-cells 
(which are predominantly stimulated by PHA) is centrally to an effective adaptive immune 
response, it reveals little about the functional capabilities of the effector cells T-cell 
differentiate into. These must be assessed by functional assays, such as cytotoxicity assays 
in the case of CTLs or assays measuring cytokines produced by Th1 and Th2 cells. 
Unfortunately, in the present study IL-4 and IFN- levels were not detectable in too many 
subjects to be statistically evaluated. However, glucocorticoids not only do influence immune 
responses at these later stages in causing a shift from cellular to humoral immunity (Daynes 
and Araneo, 1989; Elenkov, 2004; Tuckermann et al., 2005), but already interfered with 
these processes at very early stages by modulating the differentiation, maturation and 
function of antigen-presenting cells (Kitajima et al., 1996; Tuckermann et al., 2005). 
Therefore, physiologically it would not make sense to first direct an immune response and 
next to interfere with such a central step as proliferation of rare antigen-specific lymphocytes. 
Beside missing effects of disease and treatment, one to two hours after stress all 
subjects showed an increase in PHA-stimulated cell proliferation accompanied by a decrease 
in its glucocorticoid sensitivity. While the latter effect appeared to be mainly a consequence 
of the former (data not shown), the question arises what causes cell proliferation to increase. 
Despite stress-induced increases in norepinephrine being responsible for this rather late 
effect is unlikely, PHA-stimulated T-cell proliferation has repeatedly been shown to be 
inhibited and not stimulated by catecholamines or -adrenoceptor agonists (Chambers et al., 
1993; Hadden et al., 1970). The picture becomes even more complicated by findings of a 
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meta-analysis revealing acute laboratory stressors to decrease lymphocyte proliferation 
(Segerstrom and Miller, 2004). And since patients with Addison’s disease are lacking cortisol, 
findings of circadian variations in cortisol levels negatively correlating with lymphocyte 
proliferation (to tetanus toxoid) can not be considered as explanation (Hiemke et al., 1995). 
Hence, further studies are needed to confirm or disprove the present findings and – in the 
former case – to determine the mediators and mechanisms. 
5.2.3 Summary of General Discussion 
Taken together, the findings of the empirical studies presented in this thesis reveal 
investigation of patients with Addison’s disease to be a valuable approach for 
psychoneuroendocrinology and -immunology. As patients appear to be over-treated resulting 
in pronouncedly elevated free cortisol levels, it has to be recommended to investigate 
patients some hours after the last replacement intake to avoid high free cortisol levels 
interfering with parameters of interest. Furthermore, stress elicited only norepinephrine 
responses, while no stress response in free cortisol or epinephrine was found. As 
norepinephrine is expected to compensate lacking epinephrine, an assumption supported by 
the present cardiovascular data, missing cortisol stress responses remain the main 
characteristic of Addison’s disease, thus fulfilling the criteria of hormone subtraction. Bolus 
injection of 0.03mg/kg hydrocortisone revealed to be only to a limited degree appropriate to 
restore normal cortisol stress responses. While it was sufficient to produce pronounced 
effects in LPS-stimulated IL-6 production, regarding cell trafficking it is suggested that the 
faster clearance prevented its regulation of lymphocyte redistribution. Surprisingly, the 
immune system appeared to be rather unaffected by the endocrine state in Addison’s 
disease, as glucocorticoid replacement therapy did not induce generally altered immune 
functions, including the suggested decreased glucocorticoid sensitivity of immune cells. Quite 
the contrary was found, LPS-stimulated IL-6 production revealed to be distinctively sensitive 
to inhibitory glucocorticoid signals. Furthermore, immune-related findings in untreated 
patients suggest them being at an increased risk for infections during and after stress 
accompanied by an exacerbated inflammatory response once the immune system is 
activated. However, this situation may be reversed if findings are transferred to the daily free 
cortisol situation induced by glucocorticoid replacement therapy. Thus, without further 
investigations of the effects of daily replacement therapy on immune processes, additional 
glucocorticoid replacement of patients during times of stress cannot be recommended. The 
role of NF-B as mediator of immune-inhibitory glucocorticoid actions also regards further 
investigation. From the present data it can only be hypothesized that during stress 
norepinephrine may compensate missing glucocorticoid signaling by itself repressing NF-B 
activity. But such an interpretation is hampered by the missing association between 
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endocrine parameters and NF-B activity in hydrocortisone treated patients and the low 
overall numbers of subjects investigated in the present study. Nevertheless, the present – for 
the most part surprising – results clearly emphasize the need for studying complex and 
interrelated processes also in human whole organism to allow for uncovering compensatory 
mechanisms. 
5.3 OUTLOOK 
Although a large number of studies have investigated HPA axis function and 
abnormalities in human diseases, clear-cut evidence for the involvement of glucocorticoids in 
predisposing individuals to the development or exacerbations of specific diseases have so 
far predominantly been derived from animal studies or have been deduced from in vitro 
findings. This work introduced an additional approach, namely investigation of patients with 
Addison’s disease, to measure the effects of context-independently long-term altered 
glucocorticoid stress responses on the immune system. Studying such effects in patients 
with Addison’s disease may provide valuable insights in the interplay of endocrine stress 
systems in human whole organism, the extend to which an organisms is able to compensate 
dysregulations in these systems, and the clinical relevance of psychoneuroendocrinological 
and -immunological findings for health and disease. 
Based on the present findings, future studies certainly should extend the assay 
repertoire and investigate effects of missing endocrine stress responses also on other 
parameters of innate and adaptive immunity, such as natural killer cells or Th1/Th2 balance. 
Furthermore, it would be interesting to evaluate plasma cytokine levels instead of the 
stimulated levels measured in the present study. This would allow to directly get a picture of 
what is going on instead of what could happen. Additional valuable insights into 
glucocorticoid-immune interactions may be gained by investigating patients with Addison’s 
disease for influences of daily glucocorticoid replacement therapy on immune functions, 
disease progression, and co-morbidity development. Another interesting problem formulation 
for future studies concerns the immune-related role of augmented and sustained ACTH 
stress responses repeatedly found in association with adrenalectomy (Akana et al., 1988; 
Jacobson and Sapolsky, 1993). Treatment of patients with epinephrine in contrast to or in 
combination with hydrocortisone may further help to decide on the specificity of this stress 
mediator with regard to immune regulation in humans. It may further be advantageously to 
find a way to decelerate the clearance of hydrocortisone, so that free cortisol trajectories in 
patients with Addison’s disease more closely resemble stress-induced cortisol trajectories 
found in healthy subjects. 
Further efforts should also be undertaken to uncover the role of variables potentially 
mediating or moderating associations found between stress/glucocorticoids and immune 
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functions, such as gender or age. In this regard, the interplay between stress, age, NF-B 
activity, and stress-related immune alterations might be of special interest in relation to the 
well-known phenomenon of immune senescence. Furthermore, it will be of particular 
importance to evaluate in future studies to what extent serologic and immunogenetic states 
characterizing different etiologies of Addison’s disease (see section 2.2.6) influence stress-
related endocrine-immune associations. 
In summary, the results presented in this work show that investigation of patients with 
Addison’s disease is a promising approach to further elaborate in humans the role of 
glucocorticoid stress responses for health and disease. Employment of this approach in 
future studies will certainly contribute to clarify the clinical relevance of PNE and PNI 
findings. 
 
(Sartori et al., 1998) 
(Salkowski and Vogel, 1992a; Salkowski and Vogel, 1992b) 
(Diamond et al., 1992; Diamond et al., 1994) 
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